{"qid": "0", "sentence": "In <e2> T47D </e2> , <e1> Bax </e1> and Bad proteins were up-regulated; Bcl-2 protein is undetectable in these cells.", "e1": "Bax", "e2": "T47D", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 49, "rel_score": 4.72188, "prob_score": -0.2117822, "relevant": "1", "stops": "BAX - THAP11 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 4.60936, "prob_score": -0.21695219, "relevant": "1", "stops": "BAX - HSPA8 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 4.52694, "prob_score": -0.22090018, "relevant": "1", "stops": "BAX - GABARAP - Fulvestrant - Breast cancer stage IV", "reltypes": "COVARIES_GcG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 4.19727, "prob_score": -0.23825444, "relevant": "1", "stops": "BAX - breast cancer - Mitoxantrone - Breast cancer stage IV", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 32, "rel_score": 4.08797, "prob_score": -0.24461654, "relevant": "1", "stops": "BAX - PMAIP1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "2", "sentence": "Overexpression of <e1> TUBB3 protein </e1> was observed in 56 (85%) of the 66 <e2> ovarian cancers </e2> , and was significantly associated with aggressive tumor behavior (advanced stage, presence of ascites, suboptimal cytoreduction at surgery and presence of lymph node metastasis) (P<0.05).", "e1": "TUBB3 protein", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 2.13945, "prob_score": -0.46741286, "relevant": "1", "stops": "TUBB3 - Docetaxel - Ovarian cancer", "reltypes": "BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "3", "sentence": "Quantitative reverse transcription-PCR and Western blot analyses showed that GRB7 and <e1> GRB7v </e1> were frequently upregulated in <e2> ovarian cancer </e2> samples.", "e1": "GRB7v", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 11, "rel_score": 20.47502, "prob_score": -0.048839677, "relevant": "1", "stops": "GRB7 - ERBB2 - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 20.25111, "prob_score": -0.04938481, "relevant": "1", "stops": "GRB7 - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 18.92506, "prob_score": -0.052841537, "relevant": "1", "stops": "GRB7 - endometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 18, "rel_score": 18.04403, "prob_score": -0.05542332, "relevant": "1", "stops": "GRB7 - CAV1 - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "rel_score": 17.06485, "prob_score": -0.058602367, "relevant": "1", "stops": "GRB7 - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "4", "sentence": "Compared with <e2> BPH </e2> , the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of <e1> miR-96 </e1> , miR-182 and miR-183, with statistically significant differences between the two groups (P &lt; 0.05).", "e1": "miR-96", "e2": "BPH", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 7.26164, "prob_score": -0.13771017, "relevant": "1", "stops": "MARCH6 - Crizotinib - Infection - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 16, "rel_score": 7.18959, "prob_score": -0.13908944, "relevant": "1", "stops": "MARCH6 - central nervous system - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 6.62778, "prob_score": -0.1508829, "relevant": "1", "stops": "MARCH6 - blood - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 4, "rel_score": 6.22161, "prob_score": -0.16072631, "relevant": "1", "stops": "MARCH6 - bone marrow - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 11, "rel_score": 6.03719, "prob_score": -0.16564313, "relevant": "1", "stops": "MARCH6 - head - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "5", "sentence": "We therefore conclude that <e1> MUC18 </e1> expression is increased during <e2> prostate cancer </e2> initiation (high grade PIN) and progression to carcinoma, and in metastatic cell lines and metastatic carcinoma.", "e1": "MUC18", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 2.34935, "prob_score": -0.42565155, "relevant": "1", "stops": "MCAM - epithelium - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 2.08078, "prob_score": -0.48059496, "relevant": "1", "stops": "MCAM - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 44, "rel_score": 1.62731, "prob_score": -0.6145126, "relevant": "1", "stops": "MCAM - female gonad - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 1.54171, "prob_score": -0.64863473, "relevant": "1", "stops": "MCAM - lung - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 1.46628, "prob_score": -0.68199563, "relevant": "1", "stops": "MCAM - medulla oblongata - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "6", "sentence": "<e2> Ovarian carcinoma </e2> cells in effusions show up-regulation of Tn and <e1> Sialyl Tn </e1> , possibly representing a transient phenotypic alteration facilitating metastasis.", "e1": "Sialyl Tn", "e2": "Ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 28.71088, "prob_score": -0.034825254, "relevant": "1", "stops": "RALYL - BYSL - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "7", "sentence": "Administration of exogenous LTB4 (1-10 nmol/L) was able to stimulate the promoter activity of <e1> FASN </e1> in <e2> MCF-7 </e2> cells.", "e1": "FASN", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 11, "rel_score": 24.78315, "prob_score": -0.04035132, "relevant": "1", "stops": "FASN - Sirolimus - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 15, "rel_score": 19.78631, "prob_score": -0.050542332, "relevant": "1", "stops": "FASN - Mycophenolate mofetil - Pancreatitis - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 22, "rel_score": 18.48429, "prob_score": -0.054104734, "relevant": "1", "stops": "FASN - Mycophenolic acid - Rhinitis - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 35, "rel_score": 14.71454, "prob_score": -0.0679556, "relevant": "1", "stops": "FASN - Mycophenolate mofetil - Rhinitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 44, "rel_score": 14.21464, "prob_score": -0.07035331, "relevant": "1", "stops": "FASN - Sorafenib - Gynaecomastia - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "8", "sentence": "The elevated testosterone levels and the increased levels of insulin, IGF-I, and IGF-II that are seen in PCOS and abdominal obesity could favor the development of <e2> breast cancer </e2> in several ways, all of which have been demonstrated experimentally: binding of testosterone to cancer cells bearing testosterone receptors, with direct stimulation; intratissular aromatization of testosterone to estradiol, with stimulation of estrogen-sensitive cells; stimulation of the production of epithelial growth factor ( <e1> EGF </e1> ) by testosterone, with direct mitogenic effect of EGF on cancer cells; stimulation of aromatase by insulin and IGF-I; direct mitogenic stimulation of cancer cells by insulin, IGF-I, and IGF-II; and stimulation by IGF-I and IGF-II of the intratissular reduction of estrone to estradiol.", "e1": "EGF", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 42, "rel_score": -2.27873, "prob_score": -0.4388425, "relevant": "0", "stops": "EGFLAM - thyroid gland - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": -2.3146, "prob_score": -0.43203673, "relevant": "0", "stops": "EGFLAM - thyroid gland - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": -3.01987, "prob_score": -0.3311384, "relevant": "0", "stops": "EGFL6 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 38, "rel_score": -3.09991, "prob_score": -0.32258773, "relevant": "0", "stops": "EGFR - CASP7 - Memantine - Breast cancer female", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": -3.7733, "prob_score": -0.2650182, "relevant": "0", "stops": "EGFL7 - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "9", "sentence": "Our findings suggest that p <e1> Akt </e1> may be a useful predictor of resistance to endocrine therapy for <e2> breast cancer </e2> , while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.", "e1": "Akt", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 16, "rel_score": -6.46831, "prob_score": -0.15460132, "relevant": "0", "stops": "AKT3 - GPER1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 21, "rel_score": -6.54536, "prob_score": -0.15278265, "relevant": "0", "stops": "AKT3 - MAL - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": -6.60677, "prob_score": -0.15136068, "relevant": "0", "stops": "AKT3 - RPL22 - breast cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 42, "rel_score": -6.64055, "prob_score": -0.1505918, "relevant": "0", "stops": "AKT3 - STXBP1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": -6.88895, "prob_score": -0.145155, "relevant": "0", "stops": "AKT3 - IGFBP7 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "10", "sentence": "Expression level of vascular marker and <e1> HIF-1\u03b1 </e1> in <e2> OVCAR-3 </e2> increased in response to hCG treatment in a dose-dependent manner.", "e1": "HIF-1\u03b1", "e2": "OVCAR-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 16.56452, "prob_score": -0.060372945, "relevant": "1", "stops": "HIF1AN - NOLC1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 16.19958, "prob_score": -0.061725635, "relevant": "1", "stops": "HIF1AN - SLC35A1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 15.41782, "prob_score": -0.064858444, "relevant": "1", "stops": "HIF1AN - RPS4Y1 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 14.67567, "prob_score": -0.068137884, "relevant": "1", "stops": "HIF1AN - DRAP1 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 14.46759, "prob_score": -0.06911643, "relevant": "1", "stops": "HIF1AN - HOOK2 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "13", "sentence": "We report that transfection of insulin-like growth factor-binding protein-3 ( <e1> IGFBP-3 </e1> ) cDNA in human breast cancer cell lines expressing either mutant p53 ( <e2> T47D </e2> ) or wild-type p53 (MCF-7) induces apoptosis.", "e1": "IGFBP-3", "e2": "T47D", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 16, "rel_score": 26.90342, "prob_score": -0.03717205, "relevant": "1", "stops": "IGFBP3 - Estradiol - Breast cancer invasive NOS", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 25.4065, "prob_score": -0.039358873, "relevant": "1", "stops": "IGFBP3 - RRP12 - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 23.18572, "prob_score": -0.043128677, "relevant": "1", "stops": "IGFBP3 - Medrysone - Finasteride - Breast cancer male", "reltypes": "DOWNREGULATES_CdG - RESEMBLES_CrC - CAUSES_CcSE", "nodelabels": "Gene - Compound - Compound - SideEffect"}, {"pathid": 3, "rel_score": 22.77904, "prob_score": -0.0438961, "relevant": "1", "stops": "IGFBP3 - RRP12 - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 21.05706, "prob_score": -0.047491632, "relevant": "1", "stops": "IGFBP3 - RRP12 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "15", "sentence": "Artesunate treatment of human CCRF-CEM leukemia and <e2> MCF7 </e2> breast cancer cells induced ABCB6 expression but repressed <e1> ABCB7 </e1> expression.", "e1": "ABCB7", "e2": "MCF7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 43, "rel_score": 21.60294, "prob_score": -0.04629451, "relevant": "1", "stops": "ABCB7 - TMEM109 - Levonorgestrel - Breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 21.08815, "prob_score": -0.0474208, "relevant": "1", "stops": "ABCB7 - RPS4Y1 - Docetaxel - Breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 20.19386, "prob_score": -0.04952013, "relevant": "1", "stops": "ABCB7 - ICT1 - Everolimus - Breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 19.67729, "prob_score": -0.05082081, "relevant": "1", "stops": "ABCB7 - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 11, "rel_score": 16.11084, "prob_score": -0.06207088, "relevant": "1", "stops": "ABCB7 - MYC - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "16", "sentence": "Activated <e1> Src </e1> increases adhesion, survival and alpha2-integrin expression in human <e2> breast cancer </e2> cells.", "e1": "Src", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 44, "rel_score": 2.31417, "prob_score": -0.43212494, "relevant": "1", "stops": "SRCAP - cerebellum - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 2.13693, "prob_score": -0.467964, "relevant": "1", "stops": "SRCAP - sense organ - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 2.05799, "prob_score": -0.4859122, "relevant": "1", "stops": "SRCAP - sense organ - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 1.7225, "prob_score": -0.5805536, "relevant": "1", "stops": "SRCAP - cerebellum - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 30, "rel_score": 1.70873, "prob_score": -0.5852256, "relevant": "1", "stops": "SRCAP - endocrine gland - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}]}
{"qid": "17", "sentence": "These results show that CLDN3 and <e1> CLDN4 </e1> are frequently up-regulated in <e2> ovarian tumors </e2> and cell lines and may represent novel markers for this disease.", "e1": "CLDN4", "e2": "ovarian tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 20.67825, "prob_score": -0.0483558, "relevant": "1", "stops": "CLDN4 - RFC2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 20.27986, "prob_score": -0.04930597, "relevant": "1", "stops": "CLDN4 - SHBG - Estriol - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 19.63094, "prob_score": -0.050935775, "relevant": "1", "stops": "CLDN4 - SHBG - Progesterone - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 19.20123, "prob_score": -0.0520769, "relevant": "1", "stops": "CLDN4 - SHBG - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 15.05797, "prob_score": -0.06640751, "relevant": "1", "stops": "CLDN4 - decidua - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "18", "sentence": "Complete response of brain metastases from <e2> breast cancer </e2> overexpressing <e1> Her-2/neu </e1> to radiation and concurrent Lapatinib and Capecitabine.", "e1": "Her-2/neu", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 40, "rel_score": -5.96979, "prob_score": -0.16750605, "relevant": "0", "stops": "ERBB2IP - ERBB2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": -7.53466, "prob_score": -0.1327161, "relevant": "0", "stops": "ERBB2IP - SDHB - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": -8.35911, "prob_score": -0.11963409, "relevant": "0", "stops": "ERBB2IP - GRIN2B - Memantine - Breast cancer female", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": -12.4564, "prob_score": -0.08027556, "relevant": "0", "stops": "ERBB2IP - STAT3 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": -12.9887, "prob_score": -0.07699234, "relevant": "0", "stops": "ERBB2IP - SMAD4 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "19", "sentence": "In this study, while demonstrating suppressed levels of <e1> Tm1 </e1> in the prostate cancer cell lines LNCaP, <e2> PC3 </e2> , and DU-145 compared to normal prostate epithelial cell primary isolates (PrEC), a novel splice variant of the TPM2 gene was identified.", "e1": "Tm1", "e2": "PC3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 41, "rel_score": 7.4239, "prob_score": -0.13470149, "relevant": "1", "stops": "TOM1L1 - thyroid gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 6.97788, "prob_score": -0.14330599, "relevant": "1", "stops": "TOM1L1 - pituitary gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 6.72495, "prob_score": -0.14870146, "relevant": "1", "stops": "TOM1L1 - lung - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 6.3593, "prob_score": -0.15724659, "relevant": "1", "stops": "TOM1L1 - mammalian vulva - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 6.30279, "prob_score": -0.15866421, "relevant": "1", "stops": "TOM1L1 - female reproductive system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "20", "sentence": "A CpG island of another cell line showing faint expression of <e1> TUBB3 </e1> protein ( <e2> OVCAR-3 </e2> ), in which a significant gain of TUBB3 expression was induced by treatment with PBA but not with 5-Aza-CdR, was hypomethylated, similarly to a cell line (JHOC-5) showing constitutive expression of TUBB3.", "e1": "TUBB3", "e2": "OVCAR-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 10.55743, "prob_score": -0.094724946, "relevant": "1", "stops": "TUBB3 - Docetaxel - Ovarian cancer", "reltypes": "BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "21", "sentence": "The Src inhibitor, PP1, prevents hormone stimulation of <e1> Akt </e1> and PI3-kinase activities in <e2> MCF-7 </e2> cells.", "e1": "Akt", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 48, "rel_score": 10.248, "prob_score": -0.09757604, "relevant": "1", "stops": "AKT3 - embryo - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 30, "rel_score": 10.15228, "prob_score": -0.09849684, "relevant": "1", "stops": "AKT3 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 22, "rel_score": 9.21065, "prob_score": -0.10856646, "relevant": "1", "stops": "AKT3 - PCNA - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 8.91981, "prob_score": -0.112109415, "relevant": "1", "stops": "AKT3 - KLHL21 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 12, "rel_score": 8.64827, "prob_score": -0.11563043, "relevant": "1", "stops": "AKT3 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "25", "sentence": "In <e2> MCF-7 </e2> , an increase in <e1> Bad </e1> and Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed.", "e1": "Bad", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 9.67118, "prob_score": -0.103397146, "relevant": "1", "stops": "BAD - EIF2S2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 17, "rel_score": 8.76732, "prob_score": -0.11405645, "relevant": "1", "stops": "BAD - SNAI1 - breast cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "rel_score": 8.27335, "prob_score": -0.12087387, "relevant": "1", "stops": "BAD - RAF1 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 8.26241, "prob_score": -0.12103209, "relevant": "1", "stops": "BAD - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 21, "rel_score": 8.13405, "prob_score": -0.122944444, "relevant": "1", "stops": "BAD - CSF3 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "26", "sentence": "Using this approach we found an up-regulation of ubiquitin carboxyl extension protein 1 ( <e1> UBCEP-1 </e1> ) mRNA in <e2> prostate carcinoma </e2> cells compared to the normal glandular epithelium of the prostate proper.", "e1": "UBCEP-1", "e2": "prostate carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 43, "rel_score": 8.1182, "prob_score": -0.12317677, "relevant": "1", "stops": "UBLCP1 - cerebellum - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 7.6599, "prob_score": -0.13054997, "relevant": "1", "stops": "UBLCP1 - liver - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 7.15205, "prob_score": -0.13981567, "relevant": "1", "stops": "UBLCP1 - cardiac ventricle - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 7.122, "prob_score": -0.14040881, "relevant": "1", "stops": "UBLCP1 - saliva-secreting gland - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 6.22743, "prob_score": -0.16058148, "relevant": "1", "stops": "UBLCP1 - uterine cervix - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "27", "sentence": "Overexpression of IGFBP2 and <e1> IGFBP5 </e1> contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of <e2> breast cancer </e2> have not been investigated in detail.", "e1": "IGFBP5", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": 9.7229, "prob_score": -0.10284889, "relevant": "1", "stops": "IGFBP5 - PLK1 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 8.73668, "prob_score": -0.1144631, "relevant": "1", "stops": "IGFBP5 - PXN - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 8.6949, "prob_score": -0.115008116, "relevant": "1", "stops": "IGFBP5 - SCAND1 - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 8.14133, "prob_score": -0.12283364, "relevant": "1", "stops": "IGFBP5 - OXA1L - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 8.05607, "prob_score": -0.12412649, "relevant": "1", "stops": "IGFBP5 - OXA1L - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "28", "sentence": "Increased cellular activity of ornithine decarboxylase ( <e1> ODC </e1> ), the first and rate-limiting enzyme in polyamine (PA) synthesis, is an independent adverse prognostic factor for overall survival in human <e2> breast cancer </e2> , thus suggesting an important role for PA in tumor progression.", "e1": "ODC", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": 3.45244, "prob_score": -0.28964967, "relevant": "1", "stops": "ODC1 - NFKBIA - Memantine - Breast cancer female", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 3.09857, "prob_score": -0.32272512, "relevant": "1", "stops": "ODC1 - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 44, "rel_score": 2.83648, "prob_score": -0.35254958, "relevant": "1", "stops": "ODC1 - TIMM9 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 2.76855, "prob_score": -0.3612008, "relevant": "1", "stops": "ODC1 - EBF1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 8, "rel_score": 2.72272, "prob_score": -0.36728272, "relevant": "1", "stops": "ODC1 - LAMA3 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "29", "sentence": "Lewis y overexpression led to an increase in both mRNA and protein expression levels of cyclin A, cyclin D1 and cyclin E in <e2> ovarian cancer </e2> cells, decrease in both mRNA and protein expression levels of p16 and p21, and decrease of <e1> p27 </e1> at only the protein expression level without change in its mRNA level.", "e1": "p27", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 27, "rel_score": 6.72224, "prob_score": -0.14876066, "relevant": "1", "stops": "USP27X - modification-dependent macromolecule catabolic process - SKP2 - ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 29, "rel_score": 6.49351, "prob_score": -0.15400036, "relevant": "1", "stops": "USP27X - proteolysis involved in cellular protein catabolic process - SKP2 - ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 6, "rel_score": 5.6912, "prob_score": -0.17570657, "relevant": "1", "stops": "USP27X - chromatin organization - REST - ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_DdG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 36, "rel_score": 5.45048, "prob_score": -0.18347321, "relevant": "1", "stops": "USP27X - chromatin organization - RSF1 - ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 21, "rel_score": 5.3775, "prob_score": -0.18595514, "relevant": "1", "stops": "USP27X - UBC - SRSF6 - ovarian cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "30", "sentence": "Blocking of <e1> IL-1 alpha </e1> activity in <e2> HOC-7 </e2> cells with either IL-1 receptor antagonist (IL-1ra) or a neutralizing antibody directed against IL-1 alpha resulted in a dose-dependent decrease of IL-8 release by ATRA, TNF-alpha and IL-1 alpha treated HOC-7 cells.", "e1": "IL-1 alpha", "e2": "HOC-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 14, "rel_score": 11.38174, "prob_score": -0.0878585, "relevant": "1", "stops": "IL2 - breast cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 35, "rel_score": 10.69862, "prob_score": -0.093469754, "relevant": "1", "stops": "IL2 - ovarian cancer - Altretamine - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 33, "rel_score": 8.58148, "prob_score": -0.11652815, "relevant": "1", "stops": "IL2 - SHC1 - Estradiol - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 7.56372, "prob_score": -0.13220921, "relevant": "1", "stops": "IL2 - USP6NL - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 7.45935, "prob_score": -0.13405627, "relevant": "1", "stops": "IL2 - TXNDC9 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "32", "sentence": "In conclusion, physiological elevation of the <e1> bFGF </e1> during normal menstruation can influence the precise interpretation of the pathological elevation of the bFGF in pre-menopausal <e2> breast cancer </e2> patients.", "e1": "bFGF", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 7.29076, "prob_score": -0.13716124, "relevant": "1", "stops": "FGF16 - organ morphogenesis - PTEN - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 45, "rel_score": 6.8975, "prob_score": -0.14498287, "relevant": "1", "stops": "FGF16 - regulation of kinase activity - PTEN - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 36, "rel_score": 5.95664, "prob_score": -0.1678798, "relevant": "1", "stops": "FGF16 - positive regulation of protein phosphorylation - PTEN - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 26, "rel_score": 5.69022, "prob_score": -0.17573546, "relevant": "1", "stops": "FGF16 - phosphatidylinositol-mediated signaling - PTEN - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 5, "rel_score": 5.27204, "prob_score": -0.1896769, "relevant": "1", "stops": "FGF16 - positive regulation of protein phosphorylation - IQGAP3 - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_DuG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "33", "sentence": "No correlation could be seen between the histology of the <e2> ovarian tumours </e2> and the elevation of <e1> MMP-2/9 </e1> activity.", "e1": "MMP-2/9", "e2": "ovarian tumours", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 13, "rel_score": 43.85965, "prob_score": -0.022802226, "relevant": "1", "stops": "MMP20 - female gonad - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 41.94631, "prob_score": -0.023839155, "relevant": "1", "stops": "MMP20 - thyroid gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 41.20313, "prob_score": -0.024270307, "relevant": "1", "stops": "MMP20 - testis - SATB1 - Estriol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 34.78261, "prob_score": -0.028753418, "relevant": "1", "stops": "MMP20 - cerebellum - CYP2C19 - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 34.77052, "prob_score": -0.028761094, "relevant": "1", "stops": "MMP20 - cerebellum - CYP2C19 - Progesterone - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "34", "sentence": "In turn, stimulation of Src activity is abolished in ERalpha-expressing NIH 3T3 fibroblasts by co-transfection of the <e1> dominant-negative p85alpha </e1> and in <e2> MCF-7 </e2> cells by the PI3-kinase inhibitor, LY294002.", "e1": "dominant-negative p85alpha", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 30, "rel_score": 4.28357, "prob_score": -0.23344722, "relevant": "1", "stops": "MINA - thyroid gland - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 4.2452, "prob_score": -0.23555696, "relevant": "1", "stops": "MINA - mammary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 43, "rel_score": 4.0798, "prob_score": -0.2451098, "relevant": "1", "stops": "MINA - female gonad - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 3.89151, "prob_score": -0.25697297, "relevant": "1", "stops": "MINA - thyroid gland - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 3.51667, "prob_score": -0.28435543, "relevant": "1", "stops": "MINA - bone marrow - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "35", "sentence": "<e1> BRCA1 </e1> expression is decreased or absent in a significant proportion of sporadic breast and <e2> ovarian cancers </e2> , suggesting a wider role in these tumor types.", "e1": "BRCA1", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 2.97327, "prob_score": -0.3363345, "relevant": "1", "stops": "BRCA1 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "36", "sentence": "An in vitro internalization study showed that <e1> Av-G6Gd </e1> accumulated and was internalized into SHIN3 cells (a human <e2> ovarian cancer </e2> ) 50- and 3.5-fold greater than Gd-DTPA (Magnevist) and G6-(1B4M-Gd)(256) (G6Gd).", "e1": "Av-G6Gd", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 30, "rel_score": 7.07514, "prob_score": -0.14134263, "relevant": "1", "stops": "AVPR1B - Signaling Pathways - PSMB10 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Pathway - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 7.06364, "prob_score": -0.1415653, "relevant": "1", "stops": "AVPR1B - Desmopressin - Fluid retention - Docetaxel - Ovarian cancer", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 44, "rel_score": 7.06165, "prob_score": -0.14161468, "relevant": "1", "stops": "AVPR1B - metal ion homeostasis - WFS1 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 6.79209, "prob_score": -0.14722967, "relevant": "1", "stops": "AVPR1B - kinase binding - CCND1 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpMF - PARTICIPATES_GpMF - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - MolecularFunction - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 6.65868, "prob_score": -0.15017869, "relevant": "1", "stops": "AVPR1B - circulatory system process - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "37", "sentence": "<e1> Hyaluronan synthase 3 </e1> overexpression promotes the growth of TSU <e2> prostate cancer </e2> cells.", "e1": "Hyaluronan synthase 3", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 4, "rel_score": 15.04664, "prob_score": -0.066462636, "relevant": "1", "stops": "HAS3 - epithelium - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 43, "rel_score": 13.99776, "prob_score": -0.07144161, "relevant": "1", "stops": "HAS3 - UBC - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 12.55808, "prob_score": -0.079629466, "relevant": "1", "stops": "HAS3 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 45, "rel_score": 11.55268, "prob_score": -0.08655813, "relevant": "1", "stops": "HAS3 - saliva-secreting gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 10.75269, "prob_score": -0.09300314, "relevant": "1", "stops": "HAS3 - psoriasis - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_DuG - UPREGULATES_DuG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Disease - Gene - Compound - SideEffect"}]}
{"qid": "38", "sentence": "Overall, these results implicate inhibition of <e1> DNA-PK </e1> as a component of TLK286 cytotoxicity and provide a rationale for its use in the clinical management of cisplatin-resistant <e2> ovarian cancer </e2> .", "e1": "DNA-PK", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 45, "rel_score": -1.42986, "prob_score": -0.69936824, "relevant": "0", "stops": "DAPL1 - prostate gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": -1.54569, "prob_score": -0.64695793, "relevant": "0", "stops": "DAPL1 - thyroid gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": -1.59091, "prob_score": -0.6285696, "relevant": "0", "stops": "DAPL1 - digestive system - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": -1.64314, "prob_score": -0.6085926, "relevant": "0", "stops": "DAPL1 - trigeminal ganglion - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": -1.64558, "prob_score": -0.6076922, "relevant": "0", "stops": "DAPL1 - pituitary gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "39", "sentence": "NP manifested no immunoreactivity, whereas Pca and <e2> BPH </e2> showed significantly increased <e1> HIF-1alpha protein </e1> expression.", "e1": "HIF-1alpha protein", "e2": "BPH", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 10.37237, "prob_score": -0.09641456, "relevant": "1", "stops": "HINFP - central nervous system - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 9.9453, "prob_score": -0.10055127, "relevant": "1", "stops": "HINFP - tendon - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 9.00658, "prob_score": -0.11103155, "relevant": "1", "stops": "HINFP - brain - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 8.96459, "prob_score": -0.11155129, "relevant": "1", "stops": "HINFP - lung - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 8.30634, "prob_score": -0.12038894, "relevant": "1", "stops": "HINFP - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "40", "sentence": "By univariate survival analysis on the <e2> ovarian carcinoma </e2> cohorts, decreased <e1> TSLC1 </e1> protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P < 0.001).", "e1": "TSLC1", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 4.48049, "prob_score": -0.22319324, "relevant": "1", "stops": "TSC1 - ESR1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 4.11607, "prob_score": -0.24294944, "relevant": "1", "stops": "TSC1 - PPARG - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 3.88033, "prob_score": -0.25770614, "relevant": "1", "stops": "TSC1 - CCNB1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 3.84763, "prob_score": -0.25990343, "relevant": "1", "stops": "TSC1 - PMM2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 3.3857, "prob_score": -0.2953581, "relevant": "1", "stops": "TSC1 - ST3GAL5 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "41", "sentence": "These findings suggest that reduced expression of <e1> BRCA1 protein </e1> along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic <e2> ovarian carcinomas </e2> , particularly those of serous histology.", "e1": "BRCA1 protein", "e2": "ovarian carcinomas", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": -3.50349, "prob_score": -0.28543296, "relevant": "0", "stops": "BRCA1 - FOXO4 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": -3.50373, "prob_score": -0.285414, "relevant": "0", "stops": "BRCA1 - Tamoxifen - Clomifene - Ovarian carcinoma", "reltypes": "DOWNREGULATES_CdG - RESEMBLES_CrC - CAUSES_CcSE", "nodelabels": "Gene - Compound - Compound - SideEffect"}, {"pathid": 0, "rel_score": -4.01736, "prob_score": -0.24892056, "relevant": "0", "stops": "BRCA1 - CDK1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": -4.111, "prob_score": -0.24325143, "relevant": "0", "stops": "BRCA1 - DNAJA3 - Tolcapone - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": -4.60936, "prob_score": -0.21694624, "relevant": "0", "stops": "BRCA1 - CCNB1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "43", "sentence": "In <e2> MCF-7 </e2> , an increase in Bad and Bax protein expression and a decrease in Bcl-x(L) protein and <e1> Bcl-2 protein </e1> and mRNA were observed.", "e1": "Bcl-2 protein", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 20, "rel_score": 5.36251, "prob_score": -0.186479, "relevant": "1", "stops": "BCL2L2-PABPN1 - MLST8 - MIF - breast cancer", "reltypes": "COVARIES_GcG - REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 9, "rel_score": 5.34331, "prob_score": -0.18715298, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - SF3B4 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 3, "rel_score": 5.29493, "prob_score": -0.18886407, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - KCNN4 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 5.14827, "prob_score": -0.1942431, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - IQGAP3 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 30, "rel_score": 5.12033, "prob_score": -0.19529533, "relevant": "1", "stops": "BCL2L2-PABPN1 - HOOK2 - PDE4D - breast cancer", "reltypes": "COVARIES_GcG - REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "46", "sentence": "Up-regulation of AR by 1,25(OH)2D3 and of <e1> VDR </e1> by DHT provides evidence of cross-talk between 2 signaling pathways in <e2> OVCAR-3 </e2> cells.", "e1": "VDR", "e2": "OVCAR-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 25, "rel_score": 26.70227, "prob_score": -0.037447374, "relevant": "1", "stops": "VDR - MYC - Progesterone - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 24.37835, "prob_score": -0.041021146, "relevant": "1", "stops": "VDR - NR3C1 - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 22.58356, "prob_score": -0.04427778, "relevant": "1", "stops": "VDR - GNPDA1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 22.43158, "prob_score": -0.0445827, "relevant": "1", "stops": "VDR - VAT1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 21.43163, "prob_score": -0.04666387, "relevant": "1", "stops": "VDR - GNPDA1 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "47", "sentence": "Its stimulation on <e2> breast cancer </e2> cell lines induces <e1> \u03b21 integrin </e1> and promotes tumor invasiveness.", "e1": "\u03b21 integrin", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 21, "rel_score": -5.76302, "prob_score": -0.1735198, "relevant": "0", "stops": "C1D - uterus - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": -5.79609, "prob_score": -0.17252855, "relevant": "0", "stops": "C1D - gonad - MCM6 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -5.80788, "prob_score": -0.17218055, "relevant": "0", "stops": "C1D - lung - MCM6 - Paclitaxel - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": -6.05107, "prob_score": -0.16525768, "relevant": "0", "stops": "C1D - testis - MCM6 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": -6.73991, "prob_score": -0.14837, "relevant": "0", "stops": "C1D - female reproductive system - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "48", "sentence": "These results showed fisetin could inhibit the metastatic ability of <e2> PC-3 </e2> by reducing MMP-2 and <e1> MMP-9 </e1> expressions through suppressing phosphoinositide 3-kinase/Akt (PI3K/Akt) and JNK signaling pathways.", "e1": "MMP-9", "e2": "PC-3", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 39, "rel_score": 1.48708, "prob_score": -0.6724606, "relevant": "1", "stops": "MMP9 - FOS - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Gene - Disease - Compound - SideEffect"}, {"pathid": 44, "rel_score": 1.42765, "prob_score": -0.70045453, "relevant": "1", "stops": "MMP9 - JUND - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Gene - Disease - Compound - SideEffect"}, {"pathid": 14, "rel_score": -1.49045, "prob_score": -0.6709408, "relevant": "0", "stops": "MMP9 - female reproductive system - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": -1.5192, "prob_score": -0.65824425, "relevant": "0", "stops": "MMP9 - CXCL1 - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": -1.57038, "prob_score": -0.6367941, "relevant": "0", "stops": "MMP9 - Captopril - Agranulocytosis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "49", "sentence": "We now show that the MDA468 <e2> breast cancer </e2> cells express the mRNA for the EGF-like molecule, transforming growth factor-alpha (TGF-alpha), and demonstrate that TPA or EGF cause an accumulation of both EGF receptor and <e1> TGF-alpha mRNA </e1> .", "e1": "TGF-alpha mRNA", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": -2.08234, "prob_score": -0.48022977, "relevant": "0", "stops": "TGFA - pituitary gland - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 27, "rel_score": -2.12562, "prob_score": -0.4704486, "relevant": "0", "stops": "TGFA - NME1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 15, "rel_score": -2.18369, "prob_score": -0.45793995, "relevant": "0", "stops": "TGFA - NCOA3 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 26, "rel_score": -2.38447, "prob_score": -0.41938168, "relevant": "0", "stops": "TGFA - STXBP1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": -2.59094, "prob_score": -0.38596338, "relevant": "0", "stops": "TGFA - COL11A1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "50", "sentence": "Furthermore, elevated [Ca2+]o triggered activation of the <e1> Akt </e1> signaling pathway and enhanced <e2> PC-3 </e2> cell attachment.", "e1": "Akt", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 3.62319, "prob_score": -0.27599534, "relevant": "1", "stops": "AKT3 - bone marrow - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 2.96551, "prob_score": -0.3372146, "relevant": "1", "stops": "AKT3 - TOP2A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 45, "rel_score": 2.94768, "prob_score": -0.33924547, "relevant": "1", "stops": "AKT3 - MRPL12 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 2.91095, "prob_score": -0.3435327, "relevant": "1", "stops": "AKT3 - CSRP1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 26, "rel_score": 2.77847, "prob_score": -0.3599108, "relevant": "1", "stops": "AKT3 - ITGB1 - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "51", "sentence": "Here, we show that the developmental regulator <e1> Six1 </e1> is overexpressed in <e2> ovarian carcinoma </e2> cell lines (OCC) compared with normal ovarian surface epithelium.", "e1": "Six1", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 9.51837, "prob_score": -0.10506466, "relevant": "1", "stops": "SIX1 - brain - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 9.47059, "prob_score": -0.10559225, "relevant": "1", "stops": "SIX1 - nervous system - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 9.15667, "prob_score": -0.10921111, "relevant": "1", "stops": "SIX1 - bronchus - PHYH - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 8.95175, "prob_score": -0.111712046, "relevant": "1", "stops": "SIX1 - bronchus - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 7.3169, "prob_score": -0.13667089, "relevant": "1", "stops": "SIX1 - brain - ST6GALNAC2 - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "52", "sentence": "These findings suggest that the quinazoline-based doxazosin mediates <e2> prostate cancer </e2> apoptosis by initially inducing the expression of <e1> TGF-beta1 </e1> signalling effectors and subsequently I kappa B alpha.", "e1": "TGF-beta1", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 46, "rel_score": 2.95072, "prob_score": -0.33890104, "relevant": "1", "stops": "TGFB1 - PAFAH1B3 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 2.90183, "prob_score": -0.34461072, "relevant": "1", "stops": "TGFB1I1 - PTK2B - Riluzole - Prostate cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 2.73351, "prob_score": -0.3658296, "relevant": "1", "stops": "TGFB1 - SPAG4 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 2.39481, "prob_score": -0.41756666, "relevant": "1", "stops": "TGFB1 - SPAG4 - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": 1.75688, "prob_score": -0.56918514, "relevant": "1", "stops": "TGFB1 - Alzheimer's disease - Selegiline - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "53", "sentence": "Knockdown of HIF-1\u03b1 attenuated the increasing protein levels of both <e1> Btg2 </e1> and Ndrg1 by hypoxia or L-mimosine in <e2> LNCaP </e2> cells.", "e1": "Btg2", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 16, "rel_score": 14.87874, "prob_score": -0.06720876, "relevant": "1", "stops": "BTG2 - AKT1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 8, "rel_score": 12.45795, "prob_score": -0.08027385, "relevant": "1", "stops": "BTG2 - LDHB - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 35, "rel_score": 12.11387, "prob_score": -0.08255356, "relevant": "1", "stops": "BTG2 - MRPL12 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 11.85536, "prob_score": -0.08435151, "relevant": "1", "stops": "BTG2 - VIM - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 42, "rel_score": 11.42988, "prob_score": -0.087492585, "relevant": "1", "stops": "BTG2 - GPER1 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "54", "sentence": "Furthermore, E1 induced a twofold increase in connexin 43 (Cx43), whereas forskolin caused a 50% reduction in <e1> Cx32 </e1> expression in <e2> RWPE-1 </e2> cells.", "e1": "Cx32", "e2": "RWPE-1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 13.0039, "prob_score": -0.07690212, "relevant": "1", "stops": "CDX2 - MIF - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "rel_score": 12.86339, "prob_score": -0.077744074, "relevant": "1", "stops": "CDX2 - MYC - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 42, "rel_score": 10.23961, "prob_score": -0.09765894, "relevant": "1", "stops": "CDX2 - BIRC5 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 9.61631, "prob_score": -0.10399491, "relevant": "1", "stops": "CDX2 - CDC45 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 9.41265, "prob_score": -0.1062373, "relevant": "1", "stops": "CDX2 - CDC45 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "55", "sentence": "Although expressed at low levels in some normal human tissues, including the ovary, CLDN3 and <e1> CLDN4 </e1> are highly up-regulated in epithelial <e2> ovarian cancers </e2> of all subtypes.", "e1": "CLDN4", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 21, "rel_score": 7.01557, "prob_score": -0.14253956, "relevant": "1", "stops": "CLDN4 - breast cancer - ovarian cancer", "reltypes": "ASSOCIATES_DaG - RESEMBLES_DrD", "nodelabels": "Gene - Disease - Disease"}, {"pathid": 14, "rel_score": 4.6977, "prob_score": -0.21286601, "relevant": "1", "stops": "CLDN4 - breast cancer - Conjugated Estrogens - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 23, "rel_score": 4.52161, "prob_score": -0.22116241, "relevant": "1", "stops": "CLDN4 - myometrium - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 20, "rel_score": 3.90381, "prob_score": -0.25615618, "relevant": "1", "stops": "CLDN4 - uterine cervix - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 3.65217, "prob_score": -0.2738126, "relevant": "1", "stops": "CLDN4 - SHBG - Estradiol - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "56", "sentence": "Taken together, these studies suggest that IL-1 may kill ovarian NIH: <e2> OVCAR-3 </e2> tumor cells by inducing a blockade at G1/S of the cell cycle, down-regulating <e1> c-myc gene </e1> and inducing p53-dependent apoptosis.", "e1": "c-myc gene", "e2": "OVCAR-3", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 42, "rel_score": 1.43168, "prob_score": -0.69848, "relevant": "1", "stops": "CPEB3 - vagina - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": -1.41593, "prob_score": -0.7062497, "relevant": "0", "stops": "CPEB3 - nervous system - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -1.42029, "prob_score": -0.7040823, "relevant": "0", "stops": "CPEB3 - testis - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": -1.43779, "prob_score": -0.69551265, "relevant": "0", "stops": "CPEB3 - midbrain - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": -1.51874, "prob_score": -0.6584373, "relevant": "0", "stops": "CPEB3 - liver - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "57", "sentence": "We report that transfection of <e1> insulin-like growth factor-binding protein-3 </e1> (IGFBP-3) cDNA in human breast cancer cell lines expressing either mutant p53 ( <e2> T47D </e2> ) or wild-type p53 (MCF-7) induces apoptosis.", "e1": "insulin-like growth factor-binding protein-3", "e2": "T47D", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 48, "rel_score": 20.80732, "prob_score": -0.048055854, "relevant": "1", "stops": "INSL5 - head - NBN - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 10, "rel_score": 20.51703, "prob_score": -0.048739016, "relevant": "1", "stops": "INSL5 - brain - KCNN4 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 40, "rel_score": 19.66955, "prob_score": -0.050836463, "relevant": "1", "stops": "INSL5 - nervous system - SMUG1 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 30, "rel_score": 17.30104, "prob_score": -0.057802297, "relevant": "1", "stops": "INSL5 - nervous system - PTEN - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 29, "rel_score": 15.73812, "prob_score": -0.06353816, "relevant": "1", "stops": "INSL5 - digestive system - PTEN - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}]}
{"qid": "58", "sentence": "<e1> MTA1 </e1> overexpression correlates significantly with tumor grade and angiogenesis in human <e2> breast cancers </e2> .", "e1": "MTA1", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 15, "rel_score": -7.53636, "prob_score": -0.13268955, "relevant": "0", "stops": "MTA1 - MAL - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 39, "rel_score": -9.48677, "prob_score": -0.1054076, "relevant": "0", "stops": "MTA1 - ETS2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 21, "rel_score": -9.69086, "prob_score": -0.10319471, "relevant": "0", "stops": "MTA1 - HMOX1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": -9.70874, "prob_score": -0.102996886, "relevant": "0", "stops": "MTA1 - HIF1A - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 48, "rel_score": -10.92777, "prob_score": -0.09150761, "relevant": "0", "stops": "MTA1 - NFKBIA - Memantine - Breast cancer female", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "59", "sentence": "We found a correlation between ErbB2 expression and activation of Pak in estrogen receptor-positive human <e2> breast tumor </e2> samples and observed that in 3D cultures, activation of Rac-Pak1 pathway by ErbB2 homodimers induced growth factor-independent proliferation and promoted disruption of 3D mammary acinar-like structures through activation of the Erk and <e1> Akt </e1> pathways.", "e1": "Akt", "e2": "breast tumor", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 32, "rel_score": -1.64897, "prob_score": -0.606442, "relevant": "0", "stops": "AKT3 - endometrium - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 37, "rel_score": -1.80789, "prob_score": -0.553132, "relevant": "0", "stops": "AKT3 - bone marrow - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": -1.82266, "prob_score": -0.5486503, "relevant": "0", "stops": "AKT3 - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": -1.96769, "prob_score": -0.5082125, "relevant": "0", "stops": "AKT3 - KRT18 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 8, "rel_score": -2.0816, "prob_score": -0.4803998, "relevant": "0", "stops": "AKT3 - CEP55 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "60", "sentence": "<e1> PDLIM4 mRNA </e1> and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and <e2> PC3 </e2> prostate cancer cells.", "e1": "PDLIM4 mRNA", "e2": "PC3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 11.84694, "prob_score": -0.08440806, "relevant": "1", "stops": "PDLIM4 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 40, "rel_score": 10.99868, "prob_score": -0.09091739, "relevant": "1", "stops": "PDLIM4 - PIN1 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 10.48658, "prob_score": -0.09535956, "relevant": "1", "stops": "PDLIM4 - EDEM1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 10.33165, "prob_score": -0.09678827, "relevant": "1", "stops": "PDLIM4 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 19, "rel_score": 8.57927, "prob_score": -0.11655556, "relevant": "1", "stops": "PDLIM4 - EDEM1 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "62", "sentence": "<e1> NTN1 </e1> was found overexpressed in 76% of <e2> ovarian cancer </e2> specimens (13/17) as compared to normal (0/10, p<0.004)and benign (1/8, p<0.008) samples.", "e1": "NTN1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 7.16949, "prob_score": -0.13948183, "relevant": "1", "stops": "NTN1 - CDC20 - Clomifene - Ovarian cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 6.10389, "prob_score": -0.16383132, "relevant": "1", "stops": "NTN1 - female gonad - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 6.08347, "prob_score": -0.16437621, "relevant": "1", "stops": "NTN1 - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 5.95486, "prob_score": -0.16793497, "relevant": "1", "stops": "NTN1 - GCLM - ovarian cancer", "reltypes": "COVARIES_GcG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "rel_score": 5.70744, "prob_score": -0.17520666, "relevant": "1", "stops": "NTN1 - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "63", "sentence": "Transfection of HER2 in <e2> MCF7 </e2> breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of <e1> Akt </e1> , and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).", "e1": "Akt", "e2": "MCF7", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": -1.57441, "prob_score": -0.63516414, "relevant": "0", "stops": "AKT3 - CCT5 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 44, "rel_score": -1.61223, "prob_score": -0.6202596, "relevant": "0", "stops": "AKT3 - NME1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 45, "rel_score": -1.63784, "prob_score": -0.6105552, "relevant": "0", "stops": "AKT3 - CDKN1A - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 43, "rel_score": -1.65106, "prob_score": -0.6056656, "relevant": "0", "stops": "AKT3 - CSTF3 - breast cancer", "reltypes": "COVARIES_GcG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": -1.73656, "prob_score": -0.5758496, "relevant": "0", "stops": "AKT3 - HJURP - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "64", "sentence": "<e1> EPCR </e1> expression is up-regulated both at the mRNA and protein levels in invasive prostate DU-145 and <e2> PC-3 </e2> cells in comparison to normal prostate epithelial cells (PrEC) and less-invasive LNCaP cells.", "e1": "EPCR", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 40, "rel_score": 7.77545, "prob_score": -0.12860528, "relevant": "1", "stops": "PECR - SERPINA3 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 7.3346, "prob_score": -0.13633871, "relevant": "1", "stops": "PECR - PNRC1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 6.19886, "prob_score": -0.16131988, "relevant": "1", "stops": "PECR - MALT1 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 6.09422, "prob_score": -0.16408825, "relevant": "1", "stops": "PECR - ANXA4 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 15, "rel_score": 5.81294, "prob_score": -0.17203188, "relevant": "1", "stops": "PECR - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "65", "sentence": "The <e1> MMP-9 </e1> levels decreased in a time-dependent manner (3, 8, 24 h) and the addition of anti-IL-6 antibodies to <e2> SKOV-3 </e2> cell cultures significantly decreased their capacity to secrete MMP-9, particularly after 8 h of incubation.", "e1": "MMP-9", "e2": "SKOV-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 11, "rel_score": 7.94218, "prob_score": -0.12590604, "relevant": "1", "stops": "MMP9 - prostate cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 9, "rel_score": 6.48382, "prob_score": -0.1542313, "relevant": "1", "stops": "MMP9 - pancreatic cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 5, "rel_score": 4.78721, "prob_score": -0.20888633, "relevant": "1", "stops": "MMP9 - breast cancer - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 8, "rel_score": 3.62043, "prob_score": -0.27620772, "relevant": "1", "stops": "MMP9 - CXCL2 - Docetaxel - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 3.33923, "prob_score": -0.299469, "relevant": "1", "stops": "MMP9 - LCN2 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "66", "sentence": "Significantly decreased, or complete loss of, protein expression of the <e1> TSLC1 gene </e1> was observed in 59% <e2> ovarian carcinomas </e2> , 45% borderline tumors, and 7% cystadenomas, but in none of the normal ovaries (0%).", "e1": "TSLC1 gene", "e2": "ovarian carcinomas", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 1.55948, "prob_score": -0.6412375, "relevant": "1", "stops": "TSC1 - ESR1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": -1.47506, "prob_score": -0.67793506, "relevant": "0", "stops": "TSC1 - CDK1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": -1.53219, "prob_score": -0.6526619, "relevant": "0", "stops": "TSC1 - PMM2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": -1.70681, "prob_score": -0.5858884, "relevant": "0", "stops": "TSC1 - CCNB1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": -1.72111, "prob_score": -0.5810167, "relevant": "0", "stops": "TSC1 - PIK3C2B - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "67", "sentence": "Patients with <e2> breast cancer </e2> showed enhanced blood plasma concentrations of progesterone and estradiol, and enhanced tissue levels of ER and <e1> PGR </e1> associated with increased leptin levels.", "e1": "PGR", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 20, "rel_score": 2.19558, "prob_score": -0.4554641, "relevant": "1", "stops": "PGRMC1 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 31, "rel_score": 2.05897, "prob_score": -0.4856831, "relevant": "1", "stops": "PGRMC1 - PIM1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 49, "rel_score": 1.98606, "prob_score": -0.5035107, "relevant": "1", "stops": "PGRMC1 - SYNE1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 14, "rel_score": 1.93244, "prob_score": -0.5174805, "relevant": "1", "stops": "PGRMC1 - PYCR1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 15, "rel_score": 1.86022, "prob_score": -0.53757304, "relevant": "1", "stops": "PGRMC1 - WNT10B - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "69", "sentence": "Triple-negative (TN) <e2> breast cancers </e2> lack estrogen receptor ( <e1> ER </e1> ), progesterone receptor (PR), and HER2/neu amplification (HER2).", "e1": "ER", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": 2.67037, "prob_score": -0.3744823, "relevant": "1", "stops": "ERF - EPHB2 - Paclitaxel - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 2.55135, "prob_score": -0.3919503, "relevant": "1", "stops": "ERF - S100A13 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 2.44918, "prob_score": -0.40830478, "relevant": "1", "stops": "ERF - GOLT1B - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 2.4357, "prob_score": -0.4105603, "relevant": "1", "stops": "ERF - SLC25A4 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 2.13881, "prob_score": -0.46754798, "relevant": "1", "stops": "ERF - GOLT1B - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "70", "sentence": "We conclude that 13q34 amplification may be of relevance in tumor progression of basal-like <e2> breast cancers </e2> by inducing overexpression of <e1> CUL4A </e1> and TFDP1, which are both important in cell cycle regulation.", "e1": "CUL4A", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 39, "rel_score": -2.18613, "prob_score": -0.45742577, "relevant": "0", "stops": "CUL4A - RPL31 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": -2.19313, "prob_score": -0.45597142, "relevant": "0", "stops": "CUL4A - RPL11 - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": -2.23774, "prob_score": -0.44687828, "relevant": "0", "stops": "CUL4A - LRWD1 - breast cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": -2.2951, "prob_score": -0.43570653, "relevant": "0", "stops": "CUL4A - RPS8 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 23, "rel_score": -2.52436, "prob_score": -0.39613965, "relevant": "0", "stops": "CUL4A - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "71", "sentence": "Moreover, <e1> cav-1 </e1> expression was induced in <e2> IGROV1 </e2> cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression.", "e1": "cav-1", "e2": "IGROV1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 5.40482, "prob_score": -0.18502106, "relevant": "1", "stops": "CAV1 - KIF11 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 5.07563, "prob_score": -0.19701526, "relevant": "1", "stops": "CAV1 - ovarian cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 5, "rel_score": 4.80008, "prob_score": -0.20832528, "relevant": "1", "stops": "CAV1 - MCOLN1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 4.33802, "prob_score": -0.23052056, "relevant": "1", "stops": "CAV1 - CSK - Estradiol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 4.06967, "prob_score": -0.2457229, "relevant": "1", "stops": "CAV1 - MAL - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "72", "sentence": "<e2> Ovarian carcinoma </e2> cells in effusions show up-regulation of <e1> Tn </e1> and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis.", "e1": "Tn", "e2": "Ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 26.73082, "prob_score": -0.037405394, "relevant": "1", "stops": "TNC - retina - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 25.96054, "prob_score": -0.038522314, "relevant": "1", "stops": "TNC - spinal cord - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 25.76656, "prob_score": -0.03880733, "relevant": "1", "stops": "TNC - endometrium - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 23.49624, "prob_score": -0.042560685, "relevant": "1", "stops": "TNC - female gonad - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 23.10536, "prob_score": -0.04327632, "relevant": "1", "stops": "TNC - mammalian vulva - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "73", "sentence": "Transfection-mediated <e1> WWOX </e1> overexpression in <e2> DU145 </e2> cells suppressed colony growth (P = 0.0012), and WWOX overexpression by infection with Ad-WWOX virus induced apoptosis through a caspase-dependent mechanism and suppressed cell growth.", "e1": "WWOX", "e2": "DU145", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 35, "rel_score": 28.67795, "prob_score": -0.034866694, "relevant": "1", "stops": "WWOX - MRPL12 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 24.47981, "prob_score": -0.040850002, "relevant": "1", "stops": "WWOX - CHMP4A - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 20.02002, "prob_score": -0.04995228, "relevant": "1", "stops": "WWOX - SRC - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 10.96611, "prob_score": -0.09119045, "relevant": "1", "stops": "WWOX - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 30, "rel_score": 8.21963, "prob_score": -0.12166476, "relevant": "1", "stops": "WWOX - breast cancer - Testosterone - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "74", "sentence": "A higher increase of the expression and maximal pixel intensity of <e1> ICAM-1 </e1> , VCAM-1 and P-selectin was observed in endothelial cells cocultured with c-erbB2-positive <e2> breast carcinoma </e2> cells as compared to endothelial cells cocultured with c-erbB2-negative cell line.", "e1": "ICAM-1", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 27, "rel_score": 10.8003, "prob_score": -0.09259184, "relevant": "1", "stops": "ICAM1 - Irinotecan - breast cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 22, "rel_score": 8.85975, "prob_score": -0.112869084, "relevant": "1", "stops": "ICAM1 - HMOX1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 8.75887, "prob_score": -0.11416517, "relevant": "1", "stops": "ICAM1 - GPER1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": 8.45523, "prob_score": -0.11827348, "relevant": "1", "stops": "ICAM1 - TANK - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": 8.40548, "prob_score": -0.118968636, "relevant": "1", "stops": "ICAM1 - CEP55 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "76", "sentence": "Isolation and characterization of the major form of human <e1> MUC18 </e1> cDNA gene and correlation of MUC18 over-expression in <e2> prostate cancer </e2> cell lines and tissues with malignant progression.", "e1": "MUC18", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 1.55051, "prob_score": -0.64494735, "relevant": "1", "stops": "MCAM - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": -1.46381, "prob_score": -0.6831485, "relevant": "0", "stops": "MCAM - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 9, "rel_score": -2.06024, "prob_score": -0.4853771, "relevant": "0", "stops": "MCAM - endometrium - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": -2.17903, "prob_score": -0.4589151, "relevant": "0", "stops": "MCAM - nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": -2.28357, "prob_score": -0.43790618, "relevant": "0", "stops": "MCAM - cardiac ventricle - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "77", "sentence": "In 60% of <e2> breast cancers </e2> , the <e1> pp60(c-src) </e1> level was increased, the reaction intensity was elevated, and a positive reaction was seen in cytoplasma and in the nuclear area.", "e1": "pp60(c-src)", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 3.85356, "prob_score": -0.25949535, "relevant": "1", "stops": "PPIC - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 20, "rel_score": 3.56011, "prob_score": -0.28089276, "relevant": "1", "stops": "PPIC - PAK1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 3.36825, "prob_score": -0.29689127, "relevant": "1", "stops": "PPIC - HIST1H2BD - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 15, "rel_score": 3.08938, "prob_score": -0.32369155, "relevant": "1", "stops": "PPIC - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 40, "rel_score": 3.06082, "prob_score": -0.32670614, "relevant": "1", "stops": "PPIC - HIST1H2BH - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "81", "sentence": "Downregulation of <e1> protein kinase C </e1> suppresses induction of apoptosis in human <e2> prostatic carcinoma </e2> cells.", "e1": "protein kinase C", "e2": "prostatic carcinoma", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 26, "rel_score": -5.08725, "prob_score": -0.19656785, "relevant": "0", "stops": "POTEI - liver - IER3 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": -6.41601, "prob_score": -0.15586062, "relevant": "0", "stops": "POTEI - gonad - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -6.91133, "prob_score": -0.14468674, "relevant": "0", "stops": "POTEI - female reproductive system - GDF15 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": -6.96767, "prob_score": -0.14351526, "relevant": "0", "stops": "POTEI - female reproductive system - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": -7.47719, "prob_score": -0.13373989, "relevant": "0", "stops": "POTEI - testis - TNFSF11 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "82", "sentence": "<e1> uMtCK </e1> was up-regulated in AIPC cells and in human <e2> prostate cancer </e2> tissues at WHO grade III.", "e1": "uMtCK", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 11.00231, "prob_score": -0.09088809, "relevant": "1", "stops": "TMTC2 - female gonad - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 10.4526, "prob_score": -0.09566808, "relevant": "1", "stops": "TMTC2 - lymph node - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 8.63856, "prob_score": -0.11575506, "relevant": "1", "stops": "TMTC2 - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 8.57854, "prob_score": -0.11656583, "relevant": "1", "stops": "TMTC2 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": 8.42318, "prob_score": -0.118724436, "relevant": "1", "stops": "TMTC2 - bone marrow - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "83", "sentence": "<e1> Human folate receptor alpha </e1> (FRalpha) is a folate-binding protein that is selectively overexpressed in <e2> ovarian carcinoma </e2> and has been regarded as a suitable target antigen for immunotherapy purposes.", "e1": "Human folate receptor alpha", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 5.13057, "prob_score": -0.19490817, "relevant": "1", "stops": "NUMA1 - MRPL12 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 4.83022, "prob_score": -0.20703429, "relevant": "1", "stops": "NUMA1 - KIF20A - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 4.79893, "prob_score": -0.20837699, "relevant": "1", "stops": "NUMA1 - ATP1B1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 4.58568, "prob_score": -0.2180733, "relevant": "1", "stops": "NUMA1 - DNAJA3 - Tolcapone - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 4.52509, "prob_score": -0.22099145, "relevant": "1", "stops": "NUMA1 - DNAJA3 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "84", "sentence": "Our findings indicate that the activation of <e1> Akt </e1> in the downstream pathway of HER2 plays an important role in resistance to endocrine therapy for <e2> breast cancer </e2> .", "e1": "Akt", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 26, "rel_score": -4.88114, "prob_score": -0.20486619, "relevant": "0", "stops": "AKT3 - LOXL2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 23, "rel_score": -4.94584, "prob_score": -0.20219107, "relevant": "0", "stops": "AKT3 - ADRB2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 25, "rel_score": -5.09321, "prob_score": -0.19634424, "relevant": "0", "stops": "AKT3 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 15, "rel_score": -5.12715, "prob_score": -0.19503759, "relevant": "0", "stops": "AKT3 - MRPS28 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 21, "rel_score": -5.72607, "prob_score": -0.17463523, "relevant": "0", "stops": "AKT3 - MAL - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "86", "sentence": "We previously showed that the expressing level of FSH receptor ( <e1> FSHR </e1> ) increased from ovarian epithelial inclusions (OEIs) to benign <e2> ovarian epithelial tumors </e2> (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.", "e1": "FSHR", "e2": "ovarian epithelial tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 12.6968, "prob_score": -0.078755766, "relevant": "1", "stops": "FSHR - azoospermia - Clomifene - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 11, "rel_score": 7.9466, "prob_score": -0.12584335, "relevant": "1", "stops": "FSHR - female reproductive system - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 7.84437, "prob_score": -0.12747738, "relevant": "1", "stops": "FSHR - ovarian follicle - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": 7.17154, "prob_score": -0.13943726, "relevant": "1", "stops": "FSHR - TOP1 - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 6.99643, "prob_score": -0.14293452, "relevant": "1", "stops": "FSHR - lymph node - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "87", "sentence": "TIMP-2 or the generic MMP inhibitor-GM6001 inhibited both the activation of <e1> proMMP-2 </e1> and the increased invasion of <e2> DOV13 </e2> cells promoted by rhMMP-7.", "e1": "proMMP-2", "e2": "DOV13", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 23, "rel_score": 8.00961, "prob_score": -0.12485116, "relevant": "1", "stops": "PROM2 - saliva-secreting gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 7.2223, "prob_score": -0.13846053, "relevant": "1", "stops": "PROM2 - uterine cervix - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 6.73764, "prob_score": -0.1484175, "relevant": "1", "stops": "PROM2 - kidney - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 5.81497, "prob_score": -0.17197119, "relevant": "1", "stops": "PROM2 - vagina - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 5.72902, "prob_score": -0.17454912, "relevant": "1", "stops": "PROM2 - blood - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "88", "sentence": "Four out of the twelve cancer tissue specimens, one specimen of cancer ascites cells and the NIH: <e2> OVCAR-3 </e2> cancer cell line showed elevated amplification of <e1> c-Ki-ras </e1> , as compared to the human fibroblast cell line FS4 and normal ovarian tissues.", "e1": "c-Ki-ras", "e2": "OVCAR-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 4.3987, "prob_score": -0.2273384, "relevant": "1", "stops": "CPEB3 - endocrine gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 4.05301, "prob_score": -0.24673124, "relevant": "1", "stops": "CPEB3 - lymph node - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 4.03747, "prob_score": -0.24768123, "relevant": "1", "stops": "CPEB3 - thyroid gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 3.87567, "prob_score": -0.25801814, "relevant": "1", "stops": "CPEB3 - cerebellum - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 3.76676, "prob_score": -0.26548463, "relevant": "1", "stops": "CPEB3 - spinal cord - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "89", "sentence": "Neurofibromin 1 ( <e1> NF1 </e1> ) defects are common in human <e2> ovarian serous carcinomas </e2> and co-occur with TP53 mutations.", "e1": "NF1", "e2": "ovarian serous carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 3.74462, "prob_score": -0.26704967, "relevant": "1", "stops": "NF1 - INPP4B - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 3.53132, "prob_score": -0.28318438, "relevant": "1", "stops": "NF1 - TPI1 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 2.97274, "prob_score": -0.33639285, "relevant": "1", "stops": "NF1 - DNAJA3 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 2.80002, "prob_score": -0.3571437, "relevant": "1", "stops": "NF1 - USP22 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 2.74303, "prob_score": -0.36456126, "relevant": "1", "stops": "NF1 - ST6GALNAC2 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "90", "sentence": "Pak1, <e1> p-Pak1 </e1> and p-Pak2 were overexpressed in <e2> ovarian cancer </e2> cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts.", "e1": "p-Pak1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 5.05178, "prob_score": -0.1979491, "relevant": "1", "stops": "PAK1 - FOXO3 - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 4.85201, "prob_score": -0.20610327, "relevant": "1", "stops": "PAK1IP1 - EBNA1BP2 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 4.8452, "prob_score": -0.20639078, "relevant": "1", "stops": "PAK1 - CYP2C19 - Estradiol - Ovarian cancer", "reltypes": "COVARIES_GcG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 4.73889, "prob_score": -0.21101919, "relevant": "1", "stops": "PAK1 - DNAJA3 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 4.21923, "prob_score": -0.2370141, "relevant": "1", "stops": "PAK1 - DNAJA3 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "91", "sentence": "<e1> HER-2 </e1> over-expression was observed in 18.1% of Tunisian <e2> breast carcinoma </e2> affecting female patients.", "e1": "HER-2", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 6.60415, "prob_score": -0.15142424, "relevant": "1", "stops": "ERBB2IP - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 6.41849, "prob_score": -0.15579924, "relevant": "1", "stops": "ERBB2IP - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 27, "rel_score": 5.5273, "prob_score": -0.18091975, "relevant": "1", "stops": "ERBB2IP - APC - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 45, "rel_score": 5.48908, "prob_score": -0.18218175, "relevant": "1", "stops": "ERBB2 - PNKP - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 4.79317, "prob_score": -0.2086343, "relevant": "1", "stops": "ERBB2IP - PROS1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "92", "sentence": "Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with <e2> prostatic cancer </e2> prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in <e1> alpha 1-globulin </e1> from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.", "e1": "alpha 1-globulin", "e2": "prostatic cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 26, "rel_score": 14.44043, "prob_score": -0.069251984, "relevant": "1", "stops": "APH1A - pancreas - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 13.7193, "prob_score": -0.072887495, "relevant": "1", "stops": "APH1A - uterine cervix - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 13.39764, "prob_score": -0.074638434, "relevant": "1", "stops": "APH1A - urethra - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 8.22571, "prob_score": -0.12156957, "relevant": "1", "stops": "APH1A - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": 8.11557, "prob_score": -0.12321777, "relevant": "1", "stops": "APH1A - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "93", "sentence": "Our findings indicate that <e1> bcl-2 </e1> expression is augmented following androgen ablation and is correlated with the progression of <e2> prostate cancer </e2> from androgen dependence to androgen independence.", "e1": "bcl-2", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 45, "rel_score": 5.63603, "prob_score": -0.17742814, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - urethra - prostate cancer", "reltypes": "INTERACTS_GiG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 5.52029, "prob_score": -0.1811508, "relevant": "1", "stops": "BCL2L15 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 27, "rel_score": 5.27148, "prob_score": -0.18969671, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - MAEA - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 28, "rel_score": 5.19184, "prob_score": -0.19260639, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - SBDS - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 4.4609, "prob_score": -0.22417058, "relevant": "1", "stops": "BCL2L15 - NAT1 - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "94", "sentence": "Our findings suggest that LH/hCG influences the chemosensitivity of <e2> ovarian cancer </e2> cells through an apoptosis-inhibitory signal possibly via up-regulation of <e1> IGF-1 </e1> expression.", "e1": "IGF-1", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 15, "rel_score": 3.77872, "prob_score": -0.2646352, "relevant": "1", "stops": "IGF1R - DNAJA3 - Tolcapone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 3.57807, "prob_score": -0.27948487, "relevant": "1", "stops": "IGF1R - ST6GALNAC2 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 3.43395, "prob_score": -0.29121202, "relevant": "1", "stops": "IGF1R - PXN - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 3.39202, "prob_score": -0.29480872, "relevant": "1", "stops": "IGF1R - MCOLN1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 1.74265, "prob_score": -0.57384396, "relevant": "1", "stops": "IGF1R - Parkinson's disease - Pramipexole - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "95", "sentence": "We report that elevated expression of <e1> LPAAT-beta </e1> was associated with reduced survival in <e2> ovarian cancer </e2> and earlier progression of disease in ovarian and endometrial cancer.", "e1": "LPAAT-beta", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 43, "rel_score": 16.7364, "prob_score": -0.059754647, "relevant": "1", "stops": "LPAR3 - PCNA - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 14.9723, "prob_score": -0.06678617, "relevant": "1", "stops": "LPAR3 - ELAC2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 14.95886, "prob_score": -0.06684762, "relevant": "1", "stops": "LPAR5 - BACE2 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 14.87874, "prob_score": -0.06721035, "relevant": "1", "stops": "LPAR5 - RRP8 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 13.7931, "prob_score": -0.07249574, "relevant": "1", "stops": "LPAR5 - CDC20 - Progesterone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "96", "sentence": "It has been shown recently that 17beta-estradiol (E2) can stimulate the Src/p21ras/mitogen-activated protein kinase pathway in <e2> breast cancer </e2> cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the <e1> c-fos </e1> and c-jun early genes or of genes involved in cell cycle control.", "e1": "c-fos", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 9, "rel_score": -2.03674, "prob_score": -0.49098253, "relevant": "0", "stops": "FOSL1 - ADH5 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "rel_score": -2.09842, "prob_score": -0.4765528, "relevant": "0", "stops": "FOSL1 - TFAP2A - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": -2.23179, "prob_score": -0.4480678, "relevant": "0", "stops": "FOSL1 - ERBB3 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": -2.3075, "prob_score": -0.43336865, "relevant": "0", "stops": "FOSL1 - epithelium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 33, "rel_score": -2.3727, "prob_score": -0.42146474, "relevant": "0", "stops": "FOSL1 - FGFR1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "97", "sentence": "The gene array revealed decreased expression of ADAMTS1, <e1> ephrin-A5 </e1> , fibronectin 1, and neuropilin 1 in <e2> LNCaP </e2> -19 compared to LNCaP, while expression of midkine and VEGF were increased.", "e1": "ephrin-A5", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 6.71727, "prob_score": -0.14887175, "relevant": "1", "stops": "SERPINA5 - Levonorgestrel - Testosterone Propionate - Prostate cancer", "reltypes": "UPREGULATES_CuG - RESEMBLES_CrC - CAUSES_CcSE", "nodelabels": "Gene - Compound - Compound - SideEffect"}, {"pathid": 34, "rel_score": 6.36862, "prob_score": -0.157017, "relevant": "1", "stops": "SERPINA5 - GPER1 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 5.95167, "prob_score": -0.16801716, "relevant": "1", "stops": "SERPINA5 - EP300 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 37, "rel_score": 5.69055, "prob_score": -0.17572744, "relevant": "1", "stops": "SERPINA5 - PCNA - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 4.59707, "prob_score": -0.21752952, "relevant": "1", "stops": "SERPINA5 - EPRS - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "98", "sentence": "Knockdown of <e1> HIF-1\u03b1 </e1> attenuated the increasing protein levels of both Btg2 and Ndrg1 by hypoxia or L-mimosine in <e2> LNCaP </e2> cells.", "e1": "HIF-1\u03b1", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 10.59434, "prob_score": -0.094387755, "relevant": "1", "stops": "HIF1AN - SSR2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 41, "rel_score": 9.72101, "prob_score": -0.102869615, "relevant": "1", "stops": "HIF1AN - MEF2C - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 9.67399, "prob_score": -0.10337084, "relevant": "1", "stops": "HIF1AN - MRPL12 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 9.55201, "prob_score": -0.1046892, "relevant": "1", "stops": "HIF1AN - MRPL12 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 9.44109, "prob_score": -0.10592334, "relevant": "1", "stops": "HIF1AN - PUF60 - Riluzole - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "99", "sentence": "Here,we demonstrated that NTN1 may be involved in <e2> ovarian cancer </e2> as the expression of <e1> NTN1 mRNA </e1> is strongly upregulated in ovarian malignant tumors but not in benign tumors.", "e1": "NTN1 mRNA", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 10.05025, "prob_score": -0.09949515, "relevant": "1", "stops": "NTN1 - GCLM - ovarian cancer", "reltypes": "COVARIES_GcG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "rel_score": 9.46074, "prob_score": -0.10570351, "relevant": "1", "stops": "NTN1 - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 8.86839, "prob_score": -0.1127637, "relevant": "1", "stops": "NTN1 - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 8.12216, "prob_score": -0.12312407, "relevant": "1", "stops": "NTN1 - CDC20 - Raloxifene - Ovarian cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 7.68758, "prob_score": -0.13007572, "relevant": "1", "stops": "NTN1 - CDC20 - Clomifene - Ovarian cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "100", "sentence": "Transfection with GSK-3betaS9A to upregulate the GSK-3beta activity resulted in the increase of <e1> BrdU </e1> incorporation in <e2> SKOV3 </e2> cells compared with that in the control vector.", "e1": "BrdU", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 9.64227, "prob_score": -0.10371199, "relevant": "1", "stops": "BRD8 - Parkinson's disease - Pramipexole - Ovarian cancer", "reltypes": "UPREGULATES_DuG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 10, "rel_score": 5.43833, "prob_score": -0.1838827, "relevant": "1", "stops": "BRD8 - PPARG - Clomifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 5.23095, "prob_score": -0.19116737, "relevant": "1", "stops": "BRD8 - CCDC86 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 5.07769, "prob_score": -0.19693533, "relevant": "1", "stops": "BRD8 - LRP10 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 5.01404, "prob_score": -0.19944195, "relevant": "1", "stops": "BRD8 - CCNA2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "102", "sentence": "Arsenite induces HIF-1alpha and VEGF through PI3K, <e1> Akt </e1> and reactive oxygen species in <e2> DU145 </e2> human prostate carcinoma cells.", "e1": "Akt", "e2": "DU145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 1.4869, "prob_score": -0.6725355, "relevant": "1", "stops": "AKT3 - MEF2C - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": -1.53912, "prob_score": -0.6497249, "relevant": "0", "stops": "AKT3 - CASP3 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": -1.67684, "prob_score": -0.59635925, "relevant": "0", "stops": "AKT3 - GPX3 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 20, "rel_score": -1.70172, "prob_score": -0.5876427, "relevant": "0", "stops": "AKT3 - TYMS - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": -1.7113, "prob_score": -0.5843477, "relevant": "0", "stops": "AKT3 - TOP2A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "103", "sentence": "In vivid contrast, antisense oligodeoxynucleotides to <e1> L-FABP </e1> (overexpressed in <e2> prostate cancer </e2> ) decreased proliferation and caused apoptosis.", "e1": "L-FABP", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 24, "rel_score": 5.56019, "prob_score": -0.17985237, "relevant": "1", "stops": "FSBP - uterus - MIF - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 41, "rel_score": 5.52242, "prob_score": -0.18108143, "relevant": "1", "stops": "FSBP - uterus - PRNP - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 47, "rel_score": 5.29605, "prob_score": -0.18881907, "relevant": "1", "stops": "FSBP - uterus - OGG1 - prostate cancer", "reltypes": "EXPRESSES_AeG - UPREGULATES_AuG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 11, "rel_score": 5.13321, "prob_score": -0.19480619, "relevant": "1", "stops": "FSBP - rheumatoid arthritis - LILRA3 - prostate cancer", "reltypes": "DOWNREGULATES_DdG - UPREGULATES_DuG - ASSOCIATES_DaG", "nodelabels": "Gene - Disease - Gene - Disease"}, {"pathid": 15, "rel_score": 4.68099, "prob_score": -0.21362954, "relevant": "1", "stops": "FSBP - female reproductive system - KLK5 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}]}
{"qid": "106", "sentence": "We tested the in vivo effects of GSK690693 in Lck-Myr <e1> Akt </e1> 2 transgenic mice that develop lymphomas, heterozygous Pten(+/-) knockout mice that exhibit endometrial tumors, and TgMISIIR-TAg-DR26 mice that develop <e2> ovarian carcinomas </e2> , all of which exhibit hyperactivation of Akt.", "e1": "Akt", "e2": "ovarian carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 4.09216, "prob_score": -0.24436912, "relevant": "1", "stops": "AKT3 - SATB1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 3.73692, "prob_score": -0.26760384, "relevant": "1", "stops": "AKT3 - ST3GAL5 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 3.72856, "prob_score": -0.26819503, "relevant": "1", "stops": "AKT3 - MCOLN1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 3.55126, "prob_score": -0.28158775, "relevant": "1", "stops": "AKT3 - CDC20 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 3.1175, "prob_score": -0.32077432, "relevant": "1", "stops": "AKT3 - SYNE2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "107", "sentence": "Down-regulation of <e1> beta 1C integrin </e1> , an inhibitor of cell proliferation, in <e2> prostate carcinoma </e2> .", "e1": "beta 1C integrin", "e2": "prostate carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 3.67512, "prob_score": -0.27210367, "relevant": "1", "stops": "BET1L - COPB2 - Testosterone - Prostate carcinoma", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 3.60023, "prob_score": -0.27776065, "relevant": "1", "stops": "BET1 - HERPUD1 - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 3.31884, "prob_score": -0.3013138, "relevant": "1", "stops": "BET1 - TUBB6 - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "108", "sentence": "Low <e1> COX-2 </e1> expression in <e2> PC-3 </e2> was up-regulated by serum, and 15d-PGJ(2) blocked serum-induced COX-2 expression and activity in a dose-dependent manner.", "e1": "COX-2", "e2": "PC-3", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": -2.16403, "prob_score": -0.46210217, "relevant": "0", "stops": "COX2 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 21, "rel_score": -2.8001, "prob_score": -0.35712823, "relevant": "0", "stops": "COX2 - uterus - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -3.31049, "prob_score": -0.30207285, "relevant": "0", "stops": "COX2 - smooth muscle tissue - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": -3.47126, "prob_score": -0.28808275, "relevant": "0", "stops": "COX2 - renal system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": -3.63372, "prob_score": -0.27519917, "relevant": "0", "stops": "COX2 - endocrine gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "110", "sentence": "Dimethyloxalylglycine, a pan-prolyl hydroxylase inhibitor, also induced Btg2 and <e1> Ndrg1 protein </e1> expression in <e2> LNCaP </e2> cells.", "e1": "Ndrg1 protein", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": 12.46417, "prob_score": -0.08022918, "relevant": "1", "stops": "NDRG1 - IFRD2 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 12.41773, "prob_score": -0.080534235, "relevant": "1", "stops": "NDRG1 - COTL1 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 12.39926, "prob_score": -0.08065073, "relevant": "1", "stops": "NDRG1 - MCOLN1 - Ropinirole - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 11.40771, "prob_score": -0.087656245, "relevant": "1", "stops": "NDRG1 - POLR2I - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 10.54074, "prob_score": -0.09487211, "relevant": "1", "stops": "NDRG1 - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "111", "sentence": "<e1> Myosin II co-chaperone general cell UNC-45 </e1> overexpression is associated with <e2> ovarian cancer </e2> , rapid proliferation, and motility.", "e1": "Myosin II co-chaperone general cell UNC-45", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 2.30303, "prob_score": -0.43420744, "relevant": "1", "stops": "MOSPD2 - Niclosamide - Tolcapone - Ovarian cancer", "reltypes": "UPREGULATES_CuG - RESEMBLES_CrC - CAUSES_CcSE", "nodelabels": "Gene - Compound - Compound - SideEffect"}, {"pathid": 13, "rel_score": 2.10944, "prob_score": -0.47405803, "relevant": "1", "stops": "MOSPD1 - urethra - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - UPREGULATES_AuG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 1.98488, "prob_score": -0.5038118, "relevant": "1", "stops": "MOSPD1 - pituitary gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 1.89858, "prob_score": -0.526706, "relevant": "1", "stops": "MOS - TXNDC9 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 1.80969, "prob_score": -0.552583, "relevant": "1", "stops": "MOS - FAM63A - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "112", "sentence": "Patients with <e2> breast cancer </e2> showed enhanced blood plasma concentrations of progesterone and estradiol, and enhanced tissue levels of ER and PGR associated with increased <e1> leptin </e1> levels.", "e1": "leptin", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 23, "rel_score": 12.09921, "prob_score": -0.082648516, "relevant": "1", "stops": "LEPROT - Sirolimus - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 41, "rel_score": 11.05705, "prob_score": -0.090436414, "relevant": "1", "stops": "LEPROT - blood - CYP2C19 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 10.80847, "prob_score": -0.09252005, "relevant": "1", "stops": "LEPROT - Sirolimus - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 33, "rel_score": 10.5753, "prob_score": -0.09456473, "relevant": "1", "stops": "LEPROT - Sirolimus - Conjunctivitis - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 3, "rel_score": 9.07688, "prob_score": -0.110166185, "relevant": "1", "stops": "LEPROTL1 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "113", "sentence": "The expression of the p75 neurotrophin receptor ( <e1> p75NTR </e1> ) is diminished in epithelial cells during progression of <e2> prostate cancer </e2> in vivo and in vitro.", "e1": "p75NTR", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 7.99424, "prob_score": -0.1250916, "relevant": "1", "stops": "PCNT - Raloxifene - Neoplasm malignant - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 2, "rel_score": 6.9847, "prob_score": -0.14317432, "relevant": "1", "stops": "PCNT - Raloxifene - Muscle spasms - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 11, "rel_score": 6.42096, "prob_score": -0.15574493, "relevant": "1", "stops": "PCNT - head - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 5.973, "prob_score": -0.16741715, "relevant": "1", "stops": "PCNT - ALDH3B1 - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 4.75534, "prob_score": -0.21028624, "relevant": "1", "stops": "PCNT - Mebendazole - Dermatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "114", "sentence": "Interestingly, <e2> ovarian cancer </e2> patients (n = 42) with G-A/G-A homozygous genotype had increased expression of <e1> LTBP-1 </e1> and apparently poorer survival than those with other genotypes (P = 0.02).", "e1": "LTBP-1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 13, "rel_score": 5.79207, "prob_score": -0.17265294, "relevant": "1", "stops": "LTBP1 - AKT1 - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 5.46388, "prob_score": -0.18302494, "relevant": "1", "stops": "LTBP1 - HSPA8 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 5.29353, "prob_score": -0.18891482, "relevant": "1", "stops": "LTBP1 - CSNK1E - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 5.0421, "prob_score": -0.1983346, "relevant": "1", "stops": "LTBP1 - CEBPD - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 5.00375, "prob_score": -0.19984609, "relevant": "1", "stops": "LTBP1 - myometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "115", "sentence": "Together, our data suggest that strong <e1> Tiam1 </e1> overexpression relative to the corresponding benign epithelial cells is a new and independent predictor of decreased DFS for patients with <e2> prostate cancer </e2> .", "e1": "Tiam1", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 44, "rel_score": 3.21533, "prob_score": -0.31100568, "relevant": "1", "stops": "TIAM1 - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 25, "rel_score": 2.61445, "prob_score": -0.38249367, "relevant": "1", "stops": "TIAM1 - TP53 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 16, "rel_score": 2.5697, "prob_score": -0.38915077, "relevant": "1", "stops": "TIAM1 - Estradiol - prostate cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 18, "rel_score": 2.29043, "prob_score": -0.43659934, "relevant": "1", "stops": "TIAM1 - SRD5A1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "rel_score": 2.1259, "prob_score": -0.4703888, "relevant": "1", "stops": "TIAM1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "116", "sentence": "These findings indicate that <e1> FoxM1 </e1> depletion causes cell death due to mitotic catastrophe and that inhibiting FoxM1 represents a therapeutic strategy to target <e2> breast cancer </e2> .", "e1": "FoxM1", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 33, "rel_score": 251.88917, "prob_score": -0.0039687636, "relevant": "1", "stops": "FOXM1 - Paroxetine - Rhinitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 46, "rel_score": 238.6635, "prob_score": -0.004187281, "relevant": "1", "stops": "FOXM1 - Raloxifene - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 29, "rel_score": 232.01855, "prob_score": -0.004307962, "relevant": "1", "stops": "FOXM1 - Everolimus - Rhinitis - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 43, "rel_score": 217.86492, "prob_score": -0.0045860377, "relevant": "1", "stops": "FOXM1 - Irinotecan - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 49, "rel_score": 211.8644, "prob_score": -0.0047216644, "relevant": "1", "stops": "FOXM1 - Azacitidine - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "117", "sentence": "HGF induces <e1> Dgk </e1> activation in <e2> MDA-MB-231 </e2> cells that is required for cell invasiveness.", "e1": "Dgk", "e2": "MDA-MB-231", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 20, "rel_score": 1.52397, "prob_score": -0.65618455, "relevant": "1", "stops": "DGKK - CSF3 - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "COVARIES_GcG - REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": 1.49954, "prob_score": -0.6668655, "relevant": "1", "stops": "DGKK - SSBP4 - COTL1 - Escitalopram - Breast cancer female", "reltypes": "COVARIES_GcG - REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": -1.47111, "prob_score": -0.67975634, "relevant": "0", "stops": "DGKK - BUB1B - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "COVARIES_GcG - REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": -1.52309, "prob_score": -0.6565635, "relevant": "0", "stops": "DGKK - KDM3A - COTL1 - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -1.60604, "prob_score": -0.6226531, "relevant": "0", "stops": "DGKK - HOXA1 - COTL1 - Escitalopram - Breast cancer female", "reltypes": "COVARIES_GcG - REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}]}
{"qid": "118", "sentence": "Our findings suggest that the down-regulation of ICAM-1 in mammary epithelial cells may contribute both to the high expression of psoriasin seen in some high-grade <e2> DCIS </e2> tumors and to the induction of <e1> MUC1 </e1> .", "e1": "MUC1", "e2": "DCIS", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 25, "rel_score": 8.71612, "prob_score": -0.11473294, "relevant": "1", "stops": "MUC19 - MAB21L2 - central nervous system - Gilles de la Tourette syndrome - Tics", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Gene - Anatomy - Disease - Symptom"}, {"pathid": 45, "rel_score": 8.62069, "prob_score": -0.11600163, "relevant": "1", "stops": "MUC19 - MAB21L2 - nervous system - Gilles de la Tourette syndrome - Tics", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Gene - Anatomy - Disease - Symptom"}, {"pathid": 24, "rel_score": 7.75795, "prob_score": -0.12889937, "relevant": "1", "stops": "MUC19 - MRPL50 - nicotine dependence - attention deficit hyperactivity disorder - Tics", "reltypes": "COVARIES_GcG - UPREGULATES_DuG - RESEMBLES_DrD - PRESENTS_DpS", "nodelabels": "Gene - Gene - Disease - Disease - Symptom"}, {"pathid": 2, "rel_score": 7.75134, "prob_score": -0.1290078, "relevant": "1", "stops": "MUC1 - brain - Gilles de la Tourette syndrome - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}, {"pathid": 14, "rel_score": 5.45464, "prob_score": -0.18332998, "relevant": "1", "stops": "MUC16 - brain - Gilles de la Tourette syndrome - Tics", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}]}
{"qid": "119", "sentence": "In conclusion, HGF up-regulates the expression of the <e1> bone morphogenetic protein receptors </e1> , BMPR-IB and BMPR-II, in <e2> prostate cancer </e2> cells, both in vitro and in vivo.", "e1": "bone morphogenetic protein receptors", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 20, "rel_score": 3.37826, "prob_score": -0.29601023, "relevant": "1", "stops": "GNE - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 38, "rel_score": 3.20657, "prob_score": -0.31186345, "relevant": "1", "stops": "GNE - MBOAT7 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 3.14683, "prob_score": -0.31777647, "relevant": "1", "stops": "GNE - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": 3.13814, "prob_score": -0.31866267, "relevant": "1", "stops": "GNE - PRKCQ - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 2.99446, "prob_score": -0.33395177, "relevant": "1", "stops": "GNE - EPCAM - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "122", "sentence": "Adipocyte expression and circulating levels of <e1> leptin </e1> increase in both gynaecological and <e2> breast cancer </e2> patients.", "e1": "leptin", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 16.04621, "prob_score": -0.062322296, "relevant": "1", "stops": "LEPROT - Sirolimus - Rhinitis - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 30, "rel_score": 15.9821, "prob_score": -0.06257452, "relevant": "1", "stops": "LEPROT - Sirolimus - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 8, "rel_score": 15.97699, "prob_score": -0.06259002, "relevant": "1", "stops": "LEPROTL1 - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 15.67644, "prob_score": -0.06378813, "relevant": "1", "stops": "LEPROTL1 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 11, "rel_score": 14.40715, "prob_score": -0.06941158, "relevant": "1", "stops": "LEPROTL1 - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "123", "sentence": "Southern analysis of <e2> breast cancer </e2> profiling arrays revealed that 29 patients (group I) expressed an elevated <e1> LF </e1> , 10 patients (group II) showed decreased LF, and 8 patients (group III) had no change relative to the adjacent normal tissue.", "e1": "LF", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 10, "rel_score": 5.44307, "prob_score": -0.1837157, "relevant": "1", "stops": "LHFPL3 - PIK3CG - breast cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": 5.43922, "prob_score": -0.1838453, "relevant": "1", "stops": "LHFP - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 22, "rel_score": 5.35848, "prob_score": -0.18662155, "relevant": "1", "stops": "LHFPL2 - TUBB3 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 12, "rel_score": 4.94022, "prob_score": -0.20242374, "relevant": "1", "stops": "LHFPL3 - CLDN11 - breast cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 30, "rel_score": 4.90148, "prob_score": -0.20402339, "relevant": "1", "stops": "LHFPL1 - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "125", "sentence": "Methylseleninic acid enhances taxane drug efficacy against human <e2> prostate cancer </e2> and down-regulates antiapoptotic proteins <e1> Bcl-XL </e1> and survivin.", "e1": "Bcl-XL", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 13.68363, "prob_score": -0.07308359, "relevant": "1", "stops": "BCL9L - epithelium - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 20, "rel_score": 11.49954, "prob_score": -0.08695872, "relevant": "1", "stops": "BCL9L - nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 11.38822, "prob_score": -0.08781049, "relevant": "1", "stops": "BCL9L - endocrine gland - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 10.73077, "prob_score": -0.093189344, "relevant": "1", "stops": "BCL9L - prostate gland - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 10.67008, "prob_score": -0.09372345, "relevant": "1", "stops": "BCL9L - female gonad - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "127", "sentence": "Decreased <e1> p21Cip1 </e1> expression is related to several indicators of aggressiveness in <e2> ovarian adenocarcinomas </e2> and seems to be differentially regulated in LMP tumors and adenocarcinomas.", "e1": "p21Cip1", "e2": "ovarian adenocarcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 6.59283, "prob_score": -0.15168364, "relevant": "1", "stops": "PAIP1 - Raloxifene - Ovarian cancer", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 6.20117, "prob_score": -0.16125615, "relevant": "1", "stops": "PAIP1 - endometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": 5.88062, "prob_score": -0.17004885, "relevant": "1", "stops": "PAIP1 - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": 5.78704, "prob_score": -0.1727952, "relevant": "1", "stops": "PAIP1 - vagina - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 8, "rel_score": 5.64876, "prob_score": -0.1770255, "relevant": "1", "stops": "PAIP1 - bone marrow - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "128", "sentence": "<e1> ErbB2 </e1> overexpression in <e2> breast tumors </e2> results in increased metastasis and angiogenesis and reduced survival.", "e1": "ErbB2", "e2": "breast tumors", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 40, "rel_score": 27.21088, "prob_score": -0.0367494, "relevant": "1", "stops": "ERBB2IP - ERBB2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 24.99375, "prob_score": -0.04000598, "relevant": "1", "stops": "ERBB2IP - MAP4 - Paclitaxel - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 21.29472, "prob_score": -0.04696134, "relevant": "1", "stops": "ERBB2IP - TNIP1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 20.81599, "prob_score": -0.048036803, "relevant": "1", "stops": "ERBB2IP - AGTR2 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 28, "rel_score": 19.39488, "prob_score": -0.051560953, "relevant": "1", "stops": "ERBB2IP - SMAD3 - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "130", "sentence": "The differentiation-related gene 1, <e1> Drg1 </e1> , is markedly upregulated by androgens in <e2> LNCaP </e2> prostatic adenocarcinoma cells.", "e1": "Drg1", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 8.6103, "prob_score": -0.11614314, "relevant": "1", "stops": "DRG1 - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 8.49834, "prob_score": -0.11767081, "relevant": "1", "stops": "DRG1 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 8.1011, "prob_score": -0.123444915, "relevant": "1", "stops": "DRG1 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 33, "rel_score": 6.73854, "prob_score": -0.14839573, "relevant": "1", "stops": "DRG1 - blood - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 6.44662, "prob_score": -0.15511844, "relevant": "1", "stops": "DRG1 - midbrain - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "132", "sentence": "In keeping with our clinical data, activation of <e1> AR </e1> by dihydrotestosterone (DHT) potently activated GRP78 expression in both <e2> LNCaP </e2> and LNCaP-CR cells.", "e1": "AR", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 44, "rel_score": 5.04108, "prob_score": -0.19837056, "relevant": "1", "stops": "ARF4 - PSAT1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 39, "rel_score": 4.98455, "prob_score": -0.20062101, "relevant": "1", "stops": "ARF4 - GADD45A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 42, "rel_score": 4.64598, "prob_score": -0.21523544, "relevant": "1", "stops": "ARF4 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 27, "rel_score": 4.64576, "prob_score": -0.21525267, "relevant": "1", "stops": "ARF4 - HERPUD1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 35, "rel_score": 4.54669, "prob_score": -0.21994238, "relevant": "1", "stops": "ARF4 - MIF - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "133", "sentence": "Electronic profiling of publicly available expressed sequence tag databases identified a gene, cysteine-rich secretoryprotein-3 ( <e1> CRISP-3 </e1> ), that is up-regulated in <e2> prostate cancer </e2> , and of which the expression is relatively prostate-specific.", "e1": "CRISP-3", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 2.31305, "prob_score": -0.43233326, "relevant": "1", "stops": "CRISP3 - head - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 2.29158, "prob_score": -0.43637556, "relevant": "1", "stops": "CRISP3 - endocrine gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 2.21818, "prob_score": -0.45081505, "relevant": "1", "stops": "CRISP3 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 2.00469, "prob_score": -0.4988312, "relevant": "1", "stops": "CRISP3 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 15, "rel_score": 1.45939, "prob_score": -0.68522084, "relevant": "1", "stops": "CRISP3 - vagina - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "135", "sentence": "<e1> TAT </e1> and FDP were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with <e2> ovarian cancer </e2> .", "e1": "TAT", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 35, "rel_score": 13.80834, "prob_score": -0.072420835, "relevant": "1", "stops": "TATDN1 - testis - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 12.90156, "prob_score": -0.07750657, "relevant": "1", "stops": "TATDN1 - prostate gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 12.45485, "prob_score": -0.08028837, "relevant": "1", "stops": "TATDN1 - adrenal gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 12.4502, "prob_score": -0.080318436, "relevant": "1", "stops": "TATDN1 - female gonad - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 10.74807, "prob_score": -0.09304292, "relevant": "1", "stops": "TAT - GRN - Estriol - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "136", "sentence": "Oestrogen receptor-alpha ( <e1> ERalpha </e1> ) is an important prognostic marker in <e2> breast cancer </e2> and endocrine therapies are designed to inhibit or prevent ERalpha activity.", "e1": "ERalpha", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 7, "rel_score": 8.01025, "prob_score": -0.12483575, "relevant": "1", "stops": "ERAL1 - Everolimus - Conjunctivitis - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 19, "rel_score": 5.2173, "prob_score": -0.19167176, "relevant": "1", "stops": "ERAL1 - medulla oblongata - CYP2C19 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 4.86618, "prob_score": -0.2054972, "relevant": "1", "stops": "ERAL1 - testis - CYP2C19 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 4.72322, "prob_score": -0.21172489, "relevant": "1", "stops": "ERAL1 - spinal cord - CYP2C19 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 4.24268, "prob_score": -0.23570457, "relevant": "1", "stops": "ERAL1 - blood - CYP2C19 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "137", "sentence": "Increased expression of <e1> type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) </e1> and its relationship with androgen receptor in <e2> prostate carcinoma </e2> .", "e1": "type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3)", "e2": "prostate carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 4.01558, "prob_score": -0.24903332, "relevant": "1", "stops": "TYMP - endocrine gland - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 3.4626, "prob_score": -0.288796, "relevant": "1", "stops": "TYMP - mammary gland - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 3.38192, "prob_score": -0.29569474, "relevant": "1", "stops": "TYMP - midbrain - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 3.29001, "prob_score": -0.30395308, "relevant": "1", "stops": "TYMP - brain - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 3.16136, "prob_score": -0.31632018, "relevant": "1", "stops": "TYMP - saliva-secreting gland - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "141", "sentence": "Mutations of the tumor suppressor gene p53 have been identified in <e2> breast cancer </e2> cell lines, and some breast carcinomas are detectable by immunohistochemical assay because of <e1> p53 protein </e1> accumulation.", "e1": "p53 protein", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": -2.6521, "prob_score": -0.3770648, "relevant": "0", "stops": "TP53INP2 - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": -3.03868, "prob_score": -0.32909486, "relevant": "0", "stops": "TP53RK - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 48, "rel_score": -3.30589, "prob_score": -0.3024851, "relevant": "0", "stops": "TP53RK - GNAI1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 39, "rel_score": -3.52547, "prob_score": -0.28364804, "relevant": "0", "stops": "TP53RK - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 40, "rel_score": -3.82438, "prob_score": -0.2614757, "relevant": "0", "stops": "TP53RK - CCT5 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "143", "sentence": "Immunohistochemical analysis on <e2> ovarian cancer </e2> tissue array confirmed that the upregulated <e1> GRB7 </e1> was significantly correlated with high-grade ovarian cancer (P = 0.001).", "e1": "GRB7", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 10, "rel_score": 9.30579, "prob_score": -0.107455134, "relevant": "1", "stops": "GRB7 - breast cancer - ovarian cancer", "reltypes": "ASSOCIATES_DaG - RESEMBLES_DrD", "nodelabels": "Gene - Disease - Disease"}, {"pathid": 11, "rel_score": 8.90948, "prob_score": -0.11223915, "relevant": "1", "stops": "GRB7 - ERBB2 - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 7.54546, "prob_score": -0.13253343, "relevant": "1", "stops": "GRB7 - Tolcapone - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 6.77048, "prob_score": -0.14770068, "relevant": "1", "stops": "GRB7 - vagina - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 19, "rel_score": 6.72993, "prob_score": -0.14859478, "relevant": "1", "stops": "GRB7 - ANXA3 - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "145", "sentence": "<e1> OC </e1> expression is elevated in <e2> prostate tumor </e2> cells and in prostate and bone stromal cells interdigitating with both localized and metastatic prostate epithelium.", "e1": "OC", "e2": "prostate tumor", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 8.56311, "prob_score": -0.11677995, "relevant": "1", "stops": "OCM2 - female reproductive system - GNRH1 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 47, "rel_score": 8.47673, "prob_score": -0.11797188, "relevant": "1", "stops": "OCM2 - female reproductive system - ARMC2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 42, "rel_score": 7.97385, "prob_score": -0.12541087, "relevant": "1", "stops": "OCM2 - female reproductive system - ACE - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 14, "rel_score": 7.13521, "prob_score": -0.14015113, "relevant": "1", "stops": "OCM2 - calcium ion binding - PCDH11Y - prostate cancer", "reltypes": "PARTICIPATES_GpMF - PARTICIPATES_GpMF - ASSOCIATES_DaG", "nodelabels": "Gene - MolecularFunction - Gene - Disease"}, {"pathid": 29, "rel_score": 6.51466, "prob_score": -0.15350483, "relevant": "1", "stops": "OCM2 - TERF2IP - MYC - prostate cancer", "reltypes": "INTERACTS_GiG - REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "148", "sentence": "Increase in <e1> nitric oxide synthase </e1> activity might be related to the growth and malignant behavior of <e2> ovarian cancer </e2> .", "e1": "nitric oxide synthase", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 7, "rel_score": -8.39137, "prob_score": -0.11916791, "relevant": "0", "stops": "PITRM1 - TIPARP - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": -8.49762, "prob_score": -0.11768021, "relevant": "0", "stops": "PITRM1 - GBP2 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": -8.63409, "prob_score": -0.11581515, "relevant": "0", "stops": "PITRM1 - POP4 - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": -9.29282, "prob_score": -0.107607916, "relevant": "0", "stops": "PITRM1 - POP4 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": -9.7352, "prob_score": -0.102718905, "relevant": "0", "stops": "PITRM1 - TIPARP - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "149", "sentence": "Although <e1> EDD </e1> expression was not directly correlated with relative cisplatin sensitivity of <e2> ovarian cancer </e2> cell lines, sensitivity to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of EDD expression.", "e1": "EDD", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 24.20721, "prob_score": -0.041313812, "relevant": "1", "stops": "NEDD1 - ovarian cancer - Altretamine - Ovarian cancer", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 0, "rel_score": 24.06739, "prob_score": -0.041554406, "relevant": "1", "stops": "NEDD1 - ovarian cancer - Docetaxel - Ovarian cancer", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "150", "sentence": "We report that <e1> MMP-7 </e1> is overexpressed in <e2> ovarian cancer </e2> cell lines and EOC surgical specimens.", "e1": "MMP-7", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 8.17194, "prob_score": -0.1223677, "relevant": "1", "stops": "MMP7 - uterus - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 42, "rel_score": 7.55915, "prob_score": -0.13229182, "relevant": "1", "stops": "MMP7 - vagina - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 6.47878, "prob_score": -0.15435487, "relevant": "1", "stops": "MMP7 - LAMA3 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 6.40287, "prob_score": -0.15618473, "relevant": "1", "stops": "MMP7 - PLS1 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 5.32708, "prob_score": -0.18771975, "relevant": "1", "stops": "MMP7 - ABCC5 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "152", "sentence": "Our findings indicate that: (I) <e1> VDR </e1> expression is increased in <e2> ovarian carcinomas </e2> as compared to normal ovarian tissue.", "e1": "VDR", "e2": "ovarian carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 12.57862, "prob_score": -0.07949803, "relevant": "1", "stops": "VDR - TRAP1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 12.2429, "prob_score": -0.08167785, "relevant": "1", "stops": "VDR - LIPA - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 12.1862, "prob_score": -0.08205799, "relevant": "1", "stops": "VDR - CDK19 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 11.63873, "prob_score": -0.085921586, "relevant": "1", "stops": "VDR - ECH1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 10.58425, "prob_score": -0.094484225, "relevant": "1", "stops": "VDR - SLC2A6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "154", "sentence": "Transforming growth factor beta 1 can induce <e1> CIP1/WAF1 </e1> expression independent of the p53 pathway in <e2> ovarian cancer </e2> cells.", "e1": "CIP1/WAF1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 12.41773, "prob_score": -0.08053479, "relevant": "1", "stops": "CRIP1 - ITGAE - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 11.88213, "prob_score": -0.08416113, "relevant": "1", "stops": "CRIP1 - CCDC86 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 11.54468, "prob_score": -0.08662496, "relevant": "1", "stops": "CRIP1 - VAV3 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 11.50351, "prob_score": -0.086931325, "relevant": "1", "stops": "CRIP1 - PLOD3 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 11.41813, "prob_score": -0.0875829, "relevant": "1", "stops": "CRIP1 - CYP3A5 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "156", "sentence": "We found that <e1> IGF-IR </e1> overexpression markedly stimulated aggregation in E-cad-positive <e2> MCF-7 </e2> breast cancer cells, but not in E-cad-negative MDA-MB-231 cells.", "e1": "IGF-IR", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 2.42201, "prob_score": -0.41288045, "relevant": "1", "stops": "IGF1R - RRP1B - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 2.34434, "prob_score": -0.42655525, "relevant": "1", "stops": "IGF1R - SLC2A6 - Estradiol - Breast cancer invasive NOS", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 2.32266, "prob_score": -0.430535, "relevant": "1", "stops": "IGF1R - NUP93 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 2.212, "prob_score": -0.45208126, "relevant": "1", "stops": "IGF1R - CES1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 2.20284, "prob_score": -0.45395935, "relevant": "1", "stops": "IGF1R - PCNA - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "157", "sentence": "All three interferons and TPA enhanced the expression of the Mr 180,000 carcinoembryonic antigen ( <e1> CEA </e1> ) and CEA-related TAA recognized by monoclonal antibody B1.1 in both <e2> T47D </e2> and MCF-7 human breast carcinoma cell lines.", "e1": "CEA", "e2": "T47D", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 7.32333, "prob_score": -0.13654989, "relevant": "1", "stops": "CELA1 - CYP3A4 - Docetaxel - Breast cancer", "reltypes": "COVARIES_GcG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 6.79625, "prob_score": -0.14713612, "relevant": "1", "stops": "CELA1 - CYP3A4 - Dutasteride - Breast cancer", "reltypes": "COVARIES_GcG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 6.01685, "prob_score": -0.16620184, "relevant": "1", "stops": "CELA1 - SERPINA3 - Levonorgestrel - Breast cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 5.74251, "prob_score": -0.17413516, "relevant": "1", "stops": "CELA1 - CYP3A4 - Estrone - Breast cancer", "reltypes": "COVARIES_GcG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 5.46597, "prob_score": -0.18294965, "relevant": "1", "stops": "CELA1 - SERPINA3 - Estradiol - Breast cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "158", "sentence": "Out of seven isoforms of gal8, the proto isoform gal8e and our newly discovered proto isoform <e1> gal8g </e1> were upregulated in <e2> LNCaP </e2> cells compared to PrEC, whereas the two tandem-repeat isoforms gal8a and gal8b were equally expressed in these cells.", "e1": "gal8g", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 10.43297, "prob_score": -0.0958488, "relevant": "1", "stops": "GALP - brain - KLK5 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 3, "rel_score": 10.04117, "prob_score": -0.09959039, "relevant": "1", "stops": "GALP - brain - EFEMP2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 40, "rel_score": 9.78857, "prob_score": -0.102155864, "relevant": "1", "stops": "GALP - endocrine gland - KLK5 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 32, "rel_score": 9.42596, "prob_score": -0.10609062, "relevant": "1", "stops": "GALP - endocrine gland - ADAM9 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 42, "rel_score": 9.32314, "prob_score": -0.10726115, "relevant": "1", "stops": "GALP - brain - HBG2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}]}
{"qid": "161", "sentence": "RT-PCR and Western blot showed that the expressions of only c-Met and <e1> STAT3 </e1> decreased obviously in colon and <e2> breast cancer </e2> cells exposed to LS-7.", "e1": "STAT3", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 6.02156, "prob_score": -0.1660681, "relevant": "1", "stops": "STAT3 - PRKCD - Memantine - Breast cancer female", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 5.32255, "prob_score": -0.18787636, "relevant": "1", "stops": "STAT3 - TXLNA - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 5.24054, "prob_score": -0.1908203, "relevant": "1", "stops": "STAT3 - CCND1 - Fulvestrant - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 5.19076, "prob_score": -0.19265385, "relevant": "1", "stops": "STAT3 - PNKP - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 4.80538, "prob_score": -0.20810272, "relevant": "1", "stops": "STAT3 - RNH1 - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "162", "sentence": "Conversely, enforced expression of <e1> MKP3 </e1> in MKP3-deficient <e2> ovarian cancer </e2> cells significantly reduced ERK1/2 activity and inhibited cell proliferation, anchorage-independent growth ability and tumor development in nude mice.", "e1": "MKP3", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 0, "rel_score": 26.55337, "prob_score": -0.037655197, "relevant": "1", "stops": "PKP3 - RNH1 - Estrone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 21.38123, "prob_score": -0.04677415, "relevant": "1", "stops": "PKP3 - NSDHL - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 19.86097, "prob_score": -0.050348286, "relevant": "1", "stops": "PKP3 - prostate cancer - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 6, "rel_score": 15.78781, "prob_score": -0.06333894, "relevant": "1", "stops": "PKP3 - prostate cancer - Estradiol - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 10, "rel_score": 15.006, "prob_score": -0.066643834, "relevant": "1", "stops": "PKP3 - uterine cervix - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "163", "sentence": "This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of AKT and <e1> p70S6K1 </e1> in human <e2> ovarian cancer </e2> cells.", "e1": "p70S6K1", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 11, "rel_score": -1.7066, "prob_score": -0.5859647, "relevant": "0", "stops": "PCSK1 - myometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 23, "rel_score": -1.81048, "prob_score": -0.5523355, "relevant": "0", "stops": "PCSK1N - uterus - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 14, "rel_score": -1.83036, "prob_score": -0.5463362, "relevant": "0", "stops": "PCSK1N - endometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": -1.96843, "prob_score": -0.5080229, "relevant": "0", "stops": "PCSK1 - CTNNB1 - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": -2.21567, "prob_score": -0.45132983, "relevant": "0", "stops": "PCSK1N - TIPARP - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "164", "sentence": "Artesunate treatment of human CCRF-CEM leukemia and <e2> MCF7 </e2> breast cancer cells induced <e1> ABCB6 </e1> expression but repressed ABCB7 expression.", "e1": "ABCB6", "e2": "MCF7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 14, "rel_score": 11.48237, "prob_score": -0.08708987, "relevant": "1", "stops": "ABCB6 - CDKN3 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 11.14703, "prob_score": -0.08970959, "relevant": "1", "stops": "ABCB6 - TGM2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "rel_score": 10.93135, "prob_score": -0.09148224, "relevant": "1", "stops": "ABCB6 - CCNB2 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": 10.55743, "prob_score": -0.09472281, "relevant": "1", "stops": "ABCB6 - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 18, "rel_score": 9.67961, "prob_score": -0.103308335, "relevant": "1", "stops": "ABCB6 - PIN1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "165", "sentence": "By immunohistochemical analysis, we have found that <e1> PTOV1 </e1> is overexpressed in 71% of 38 <e2> prostate carcinomas </e2> and in 80% of samples with prostate intraepithelial neoplasia.", "e1": "PTOV1", "e2": "prostate carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 11.12842, "prob_score": -0.089858145, "relevant": "1", "stops": "PTOV1 - POLR2I - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 11.01928, "prob_score": -0.090746574, "relevant": "1", "stops": "PTOV1 - POLR2I - Riluzole - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 9.45537, "prob_score": -0.10575867, "relevant": "1", "stops": "PTOV1 - POLR2I - Testosterone - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 9.29454, "prob_score": -0.10758536, "relevant": "1", "stops": "PTOV1 - POLR2I - Testosterone Propionate - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "166", "sentence": "Out of seven isoforms of gal8, the proto isoform <e1> gal8e </e1> and our newly discovered proto isoform gal8g were upregulated in <e2> LNCaP </e2> cells compared to PrEC, whereas the two tandem-repeat isoforms gal8a and gal8b were equally expressed in these cells.", "e1": "gal8e", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 13, "rel_score": 15.18142, "prob_score": -0.06587497, "relevant": "1", "stops": "GALE - GTF2A2 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 20, "rel_score": 14.77978, "prob_score": -0.06765794, "relevant": "1", "stops": "GALE - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 41, "rel_score": 14.36782, "prob_score": -0.06960019, "relevant": "1", "stops": "GALE - IGF1R - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": 13.46983, "prob_score": -0.0742419, "relevant": "1", "stops": "GALE - SSBP2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 13.02592, "prob_score": -0.07676595, "relevant": "1", "stops": "GALE - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "167", "sentence": "<e1> CSF-1 </e1> overexpression in <e2> Hey </e2> cells was found to associate with increased invasiveness, motility, urokinase activity, and virulence of tumorigenicity, compared with NOSE.1 cells, which expressed little CSF-1.", "e1": "CSF-1", "e2": "Hey", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": -1.50218, "prob_score": -0.6656983, "relevant": "0", "stops": "CSF1R - breast cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 45, "rel_score": -1.52453, "prob_score": -0.6559397, "relevant": "0", "stops": "CSF1 - MEST - Estradiol - Ovarian cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": -1.56375, "prob_score": -0.63949054, "relevant": "0", "stops": "CSF1R - CEBPB - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": -1.62752, "prob_score": -0.61443, "relevant": "0", "stops": "CSF1R - SRC - Estradiol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": -1.76233, "prob_score": -0.5674275, "relevant": "0", "stops": "CSF1R - PIH1D1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "168", "sentence": "Arsenite induces HIF-1alpha and <e1> VEGF </e1> through PI3K, Akt and reactive oxygen species in <e2> DU145 </e2> human prostate carcinoma cells.", "e1": "VEGF", "e2": "DU145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 41, "rel_score": 2.1994, "prob_score": -0.45467418, "relevant": "1", "stops": "VEGFA - amyotrophic lateral sclerosis - Riluzole - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 36, "rel_score": 1.9713, "prob_score": -0.50727725, "relevant": "1", "stops": "VEGFA - chronic obstructive pulmonary disease - Roflumilast - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 14, "rel_score": 1.96329, "prob_score": -0.5093471, "relevant": "1", "stops": "VEGFA - breast cancer - Testosterone Propionate - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 49, "rel_score": 1.87822, "prob_score": -0.53241926, "relevant": "1", "stops": "VEGFA - PHKG2 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 1.674, "prob_score": -0.59737116, "relevant": "1", "stops": "VEGFA - TERF2IP - Riluzole - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "169", "sentence": "<e1> p53 </e1> overexpression, identified by immunohistochemistry, and p53 mutations, identified by single-strand conformational polymorphism (SSCP) and DNA sequencing, have been described in <e2> ovarian cancers </e2> .", "e1": "p53", "e2": "ovarian cancers", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": -2.10686, "prob_score": -0.47463843, "relevant": "0", "stops": "TP53RK - MCOLN1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": -2.13904, "prob_score": -0.46749657, "relevant": "0", "stops": "TP53RK - ITGAE - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": -2.17099, "prob_score": -0.46061528, "relevant": "0", "stops": "TP53RK - FIS1 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": -2.37203, "prob_score": -0.42158, "relevant": "0", "stops": "TP53RK - CXCL2 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": -2.91248, "prob_score": -0.34335348, "relevant": "0", "stops": "TP53RK - C2CD2 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "170", "sentence": "We propose that, in the <e2> ovarian tumour </e2> microenvironment, interaction between tumour cells and fibroblasts may enhance fibroblast production of the proMMP-2 and <e1> TIMP-2 </e1> .", "e1": "TIMP-2", "e2": "ovarian tumour", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 10, "rel_score": 14.38228, "prob_score": -0.06952908, "relevant": "1", "stops": "TIMP2 - FDPS - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 12.59446, "prob_score": -0.079403676, "relevant": "1", "stops": "TIMP2 - CCNB2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 12.51095, "prob_score": -0.07993238, "relevant": "1", "stops": "TIMP2 - MTHFD2 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 12.49844, "prob_score": -0.080009416, "relevant": "1", "stops": "TIMP2 - TNFRSF21 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 12.07729, "prob_score": -0.08280248, "relevant": "1", "stops": "TIMP2 - AKR7A2 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "171", "sentence": "<e1> Six1 </e1> was overexpressed in 50% of the early-stage (stage I) and 63% of the late-stage (stages II, III, and IV) <e2> ovarian carcinomas </e2> examined, with late-stage carcinomas expressing approximately 3-fold higher Six1 mRNA levels on average compared with early-stage tumors.", "e1": "Six1", "e2": "ovarian carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 19.1681, "prob_score": -0.05217114, "relevant": "1", "stops": "SIX1 - nervous system - PHYH - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 18.71608, "prob_score": -0.053425863, "relevant": "1", "stops": "SIX1 - brain - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 18.66716, "prob_score": -0.05356749, "relevant": "1", "stops": "SIX1 - bronchus - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 16.34788, "prob_score": -0.06117236, "relevant": "1", "stops": "SIX1 - head - PHYH - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 16.03849, "prob_score": -0.062347356, "relevant": "1", "stops": "SIX1 - female reproductive system - ABCE1 - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "172", "sentence": "Elevated expression of <e1> Met </e1> has been shown in advanced cases of <e2> carcinoma of the prostate </e2> , stomach, pancreas, and thyroid.", "e1": "Met", "e2": "carcinoma of the prostate", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 10.9517, "prob_score": -0.09130596, "relevant": "1", "stops": "METTL7A - central nervous system - PAH - Tetrahydrobiopterin - Carcinoma testes", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 9.93049, "prob_score": -0.100695744, "relevant": "1", "stops": "METTL7A - central nervous system - BAG3 - Tetrahydrobiopterin - Carcinoma testes", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 9.90688, "prob_score": -0.10094267, "relevant": "1", "stops": "METTL7A - rheumatoid arthritis - NOS3 - Tetrahydrobiopterin - Carcinoma testes", "reltypes": "DOWNREGULATES_DdG - ASSOCIATES_DaG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Disease - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 9.86096, "prob_score": -0.101414256, "relevant": "1", "stops": "METTL7A - central nervous system - NOS3 - Tetrahydrobiopterin - Carcinoma testes", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 9.22679, "prob_score": -0.108380385, "relevant": "1", "stops": "METTL7A - central nervous system - SATB1 - Tetrahydrobiopterin - Carcinoma testes", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "173", "sentence": "These results suggest a novel mechanism of CDDP's anti-tumor activity in <e2> ovarian cancer </e2> cells via HIF-1 expression and <e1> VEGF </e1> transcriptional activation.", "e1": "VEGF", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 0, "rel_score": -1.52683, "prob_score": -0.6549458, "relevant": "0", "stops": "VEGFA - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "174", "sentence": "Decreased expression of <e1> miR-342 </e1> in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis <e2> breast cancer </e2> , but that it could also present an attractive target for therapeutic intervention.", "e1": "miR-342", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 46, "rel_score": 4.91135, "prob_score": -0.20360643, "relevant": "1", "stops": "MRPL42 - Everolimus - Candida infection - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 41, "rel_score": 4.75579, "prob_score": -0.2102745, "relevant": "1", "stops": "MRPL42 - Everolimus - Acne - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 43, "rel_score": 4.59031, "prob_score": -0.21785109, "relevant": "1", "stops": "MRPL42 - Simvastatin - Nightmare - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 37, "rel_score": 4.49802, "prob_score": -0.22232333, "relevant": "1", "stops": "MRPL42 - Simvastatin - CYP2C19 - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - BINDS_CbG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Compound - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 3.71651, "prob_score": -0.26907098, "relevant": "1", "stops": "MRPL42 - Gemcitabine - breast cancer", "reltypes": "DOWNREGULATES_CdG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}]}
{"qid": "175", "sentence": "It has been shown recently that 17beta-estradiol (E2) can stimulate the Src/p21ras/mitogen-activated protein kinase pathway in <e2> breast cancer </e2> cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the c-fos and <e1> c-jun early genes </e1> or of genes involved in cell cycle control.", "e1": "c-jun early genes", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 48, "rel_score": -3.0012, "prob_score": -0.33319888, "relevant": "0", "stops": "CPXM1 - female gonad - breast cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": -3.05409, "prob_score": -0.3274287, "relevant": "0", "stops": "CPEB3 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 45, "rel_score": -3.10357, "prob_score": -0.32220957, "relevant": "0", "stops": "CPXM1 - adipose tissue - breast cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 33, "rel_score": -3.34202, "prob_score": -0.29921857, "relevant": "0", "stops": "CPSF1 - AGR2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": -3.36939, "prob_score": -0.2967926, "relevant": "0", "stops": "CPOX - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "176", "sentence": "Activation of <e1> PI3K/Akt </e1> signaling and hormone resistance in <e2> breast cancer </e2> .", "e1": "PI3K/Akt", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 1.7207, "prob_score": -0.58116496, "relevant": "1", "stops": "PI3 - endocrine gland - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 1.47667, "prob_score": -0.6771968, "relevant": "1", "stops": "PI3 - adipose tissue - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 1.4688, "prob_score": -0.6808277, "relevant": "1", "stops": "PI3 - brain - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": -1.44417, "prob_score": -0.692438, "relevant": "0", "stops": "PI3 - trachea - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": -1.95825, "prob_score": -0.5106598, "relevant": "0", "stops": "PI3 - respiratory system - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "177", "sentence": "In addition, the higher <e2> PA1 </e2> cell responsiveness to endogenous compared with exogenous <e1> activin </e1> , suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor.", "e1": "activin", "e2": "PA1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 25, "rel_score": 4.01542, "prob_score": -0.2490364, "relevant": "1", "stops": "ATMIN - FAS - Decitabine - Pain in extremity", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 3.87192, "prob_score": -0.25826898, "relevant": "1", "stops": "ATMIN - RRP8 - Lovastatin - Pain in extremity", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 3.82834, "prob_score": -0.261211, "relevant": "1", "stops": "ATMIN - RRP8 - Bortezomib - Pain in extremity", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 3.78587, "prob_score": -0.26413897, "relevant": "1", "stops": "ATMIN - RRP8 - Tretinoin - Pain in extremity", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 3.39974, "prob_score": -0.29413593, "relevant": "1", "stops": "ATMIN - CRIP1 - Trametinib - Pain in extremity", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "178", "sentence": "[Antitumor effect of endothelial progenitor cells with <e1> TRAIL gene </e1> transfection on <e2> ovarian carcinoma </e2> xenografts in nude mice].", "e1": "TRAIL gene", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 4.99301, "prob_score": -0.20028134, "relevant": "1", "stops": "TRIL - positive regulation of immune system process - DUSP4 - Clomifene - Ovarian carcinoma", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 4.80862, "prob_score": -0.20795819, "relevant": "1", "stops": "TRIL - immune response-activating signal transduction - DUSP4 - Clomifene - Ovarian carcinoma", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 4.78492, "prob_score": -0.20898594, "relevant": "1", "stops": "TRIL - innate immune response-activating signal transduction - DUSP4 - Clomifene - Ovarian carcinoma", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 4.7515, "prob_score": -0.21045586, "relevant": "1", "stops": "TRIL - positive regulation of defense response - DUSP4 - Clomifene - Ovarian carcinoma", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 4.52919, "prob_score": -0.22079225, "relevant": "1", "stops": "TRIL - regulation of defense response - DNAJA3 - Tolcapone - Ovarian carcinoma", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "179", "sentence": "Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of <e2> prostate cancer </e2> cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated <e1> RAR-beta </e1> , RXR-alpha, and RXR-beta.", "e1": "RAR-beta", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 2.45507, "prob_score": -0.4073207, "relevant": "1", "stops": "RARB - Tretinoin - Candida infection - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 28, "rel_score": 2.38271, "prob_score": -0.4196939, "relevant": "1", "stops": "RARB - Acitretin - Dysuria - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 40, "rel_score": 2.31965, "prob_score": -0.4310961, "relevant": "1", "stops": "RARB - Alitretinoin - Dermatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 38, "rel_score": 2.31374, "prob_score": -0.43219593, "relevant": "1", "stops": "RARB - Tazarotene - Dermatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 15, "rel_score": 2.29106, "prob_score": -0.43648002, "relevant": "1", "stops": "RARB - Acitretin - Rhinitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "180", "sentence": "Decreased expression of <e1> miR-342 </e1> in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis <e2> breast cancer </e2> , but that it could also present an attractive target for therapeutic intervention.", "e1": "miR-342", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 4.58295, "prob_score": -0.21820454, "relevant": "1", "stops": "MRPL42 - Simvastatin - Nightmare - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 47, "rel_score": 4.54752, "prob_score": -0.21990404, "relevant": "1", "stops": "MRPL42 - Everolimus - Candida infection - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 25, "rel_score": 3.83995, "prob_score": -0.2604153, "relevant": "1", "stops": "MRPL42 - Everolimus - Conjunctivitis - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 6, "rel_score": 3.66233, "prob_score": -0.27304554, "relevant": "1", "stops": "MRPL42 - KRAS - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": 3.14574, "prob_score": -0.31788936, "relevant": "1", "stops": "MRPL42 - KLF11 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "181", "sentence": "P1, a <e1> high mobility group-like protein </e1> is depressed in human <e2> breast adenocarcinoma </e2> .", "e1": "high mobility group-like protein", "e2": "breast adenocarcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": 9.15416, "prob_score": -0.10924297, "relevant": "1", "stops": "IGH - Immune System - DUSP6 - breast cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - DOWNREGULATES_DdG", "nodelabels": "Gene - Pathway - Gene - Disease"}, {"pathid": 28, "rel_score": 8.33333, "prob_score": -0.1199982, "relevant": "1", "stops": "IGH - Immune System - AKT1 - breast cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - ASSOCIATES_DaG", "nodelabels": "Gene - Pathway - Gene - Disease"}, {"pathid": 35, "rel_score": 8.29531, "prob_score": -0.12055247, "relevant": "1", "stops": "IGH - Innate Immune System - DUSP6 - breast cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - DOWNREGULATES_DdG", "nodelabels": "Gene - Pathway - Gene - Disease"}, {"pathid": 18, "rel_score": 7.97067, "prob_score": -0.12546027, "relevant": "1", "stops": "IGH - Immune System - CTSB - breast cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - UPREGULATES_DuG", "nodelabels": "Gene - Pathway - Gene - Disease"}, {"pathid": 43, "rel_score": 5.98695, "prob_score": -0.16702574, "relevant": "1", "stops": "IGH - Fcgamma receptor (FCGR) dependent phagocytosis - PAK1 - breast cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - ASSOCIATES_DaG", "nodelabels": "Gene - Pathway - Gene - Disease"}]}
{"qid": "183", "sentence": "GSK3 inhibition using 6-bromoindirubin-3'-oxime suppressed <e1> hTERT </e1> expression, telomerase activity and telomere length in several cancer cell lines and growth and hTERT expression in <e2> ovarian cancer </e2> xenografts.", "e1": "hTERT", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 4.58905, "prob_score": -0.21790883, "relevant": "1", "stops": "TERT - breast cancer - Raloxifene - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 1, "rel_score": 3.50828, "prob_score": -0.2850438, "relevant": "1", "stops": "TERT - ZFAND6 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 3.36485, "prob_score": -0.2971878, "relevant": "1", "stops": "TERT - ESR2 - Estrone - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 3.08119, "prob_score": -0.3245521, "relevant": "1", "stops": "TERT - ESR2 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 2.98534, "prob_score": -0.33497232, "relevant": "1", "stops": "TERT - ovarian cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "184", "sentence": "<e1> Smad3 </e1> is overexpressed in advanced human <e2> prostate cancer </e2> and necessary for progressive growth of prostate cancer cells in nude mice.", "e1": "Smad3", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 21, "rel_score": 28.28054, "prob_score": -0.035358805, "relevant": "1", "stops": "SMAD3 - urethra - prostate cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 32, "rel_score": 26.04167, "prob_score": -0.038402475, "relevant": "1", "stops": "SMAD3 - TLR4 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 11, "rel_score": 25.66735, "prob_score": -0.038961716, "relevant": "1", "stops": "SMAD3 - AKT1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 27, "rel_score": 23.4852, "prob_score": -0.042579383, "relevant": "1", "stops": "SMAD3 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 19.24557, "prob_score": -0.0519586, "relevant": "1", "stops": "SMAD3 - Dexamethasone - prostate cancer", "reltypes": "DOWNREGULATES_CdG - PALLIATES_CpD", "nodelabels": "Gene - Compound - Disease"}]}
{"qid": "185", "sentence": "IFN-alpha increased the cell surface expression of <e1> DR antigen </e1> only in <e2> ZR-75-1 </e2> cells.", "e1": "DR antigen", "e2": "ZR-75-1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 5.73756, "prob_score": -0.17428957, "relevant": "1", "stops": "DR1 - ERBB2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 46, "rel_score": 4.42008, "prob_score": -0.22623952, "relevant": "1", "stops": "DR1 - ZNF589 - Paroxetine - Breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 4.40373, "prob_score": -0.22707848, "relevant": "1", "stops": "DR1 - GADD45A - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 3.69413, "prob_score": -0.2706976, "relevant": "1", "stops": "DR1 - HOOK2 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 3.67972, "prob_score": -0.2717601, "relevant": "1", "stops": "DR1 - WIF1 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "187", "sentence": "In addition, even a transient, siRNA-mediated <e1> p21 </e1> suppression in fibroblasts sufficiently stimulates <e2> MCF7 </e2> and MDA-MB-231 growth in vivo.", "e1": "p21", "e2": "MCF7", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 49, "rel_score": -2.53158, "prob_score": -0.39500925, "relevant": "0", "stops": "PHF21B - SSBP2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": -2.68868, "prob_score": -0.37192923, "relevant": "0", "stops": "PHF21B - COTL1 - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": -2.72591, "prob_score": -0.36684766, "relevant": "0", "stops": "PHF21B - CES1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": -2.98954, "prob_score": -0.33449772, "relevant": "0", "stops": "PHF21B - NME1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": -3.10713, "prob_score": -0.32183704, "relevant": "0", "stops": "PHF21B - S100A11 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "188", "sentence": "Loss of this 42-bp sequence was associated with increased <e1> ERCC1 mRNA </e1> expression, in an assessment of 121 <e2> ovarian cancer </e2> specimens (p2<10(-6)).", "e1": "ERCC1 mRNA", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 13, "rel_score": 5.22575, "prob_score": -0.19135657, "relevant": "1", "stops": "ERCC1 - RRP8 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 4.85578, "prob_score": -0.20593673, "relevant": "1", "stops": "ERCC1 - PNKP - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 4.71032, "prob_score": -0.21229997, "relevant": "1", "stops": "ERCC1 - SMARCD2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 4.58253, "prob_score": -0.21821705, "relevant": "1", "stops": "ERCC1 - NUP85 - Progesterone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 4.52202, "prob_score": -0.2211354, "relevant": "1", "stops": "ERCC1 - TIPARP - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "189", "sentence": "<e2> DU145 </e2> human prostate carcinoma cells were transfected with the cDNA for manganese superoxide dismutase ( <e1> MnSOD </e1> ), and two clones overexpressing MnSOD activity were subsequently characterized by comparison with parental and plasmid control-transfected cells.", "e1": "MnSOD", "e2": "DU145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 2.12775, "prob_score": -0.46997693, "relevant": "1", "stops": "MNS1 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 49, "rel_score": 1.89254, "prob_score": -0.5283871, "relevant": "1", "stops": "MNS1 - endocrine gland - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 1.82189, "prob_score": -0.5488843, "relevant": "1", "stops": "MNS1 - IRS1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 1.75445, "prob_score": -0.56998163, "relevant": "1", "stops": "MNS1 - bone marrow - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 13, "rel_score": 1.56311, "prob_score": -0.6397545, "relevant": "1", "stops": "MNS1 - female reproductive system - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "190", "sentence": "Treatment with the oxidizing agents H2O2 and menadione produced an increase in <e1> gamma-glutamyl transpeptidase </e1> activity in <e2> LNCaP </e2> cells, whereas treatment with the antioxidant compound ascorbic acid (100 mM) reduced the oxidative stress produced in LNCaP cells by 1 nM R1881 and completely blocked the gamma-glutamyl transpeptidase activity.", "e1": "gamma-glutamyl transpeptidase", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 15.65435, "prob_score": -0.06387898, "relevant": "1", "stops": "GALM - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 14.26533, "prob_score": -0.07010443, "relevant": "1", "stops": "GALM - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 22, "rel_score": 13.37256, "prob_score": -0.07478001, "relevant": "1", "stops": "GALM - bronchus - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 13.1406, "prob_score": -0.076098904, "relevant": "1", "stops": "GALM - cerebellum - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 12.91156, "prob_score": -0.07744612, "relevant": "1", "stops": "GALM - spinal cord - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "191", "sentence": "Response to bicalutamide in <e2> LNCaP </e2> cells was represented by downregulation of androgen-regulated genes, activation of the p53 pathway and inhibition of telomerase, which was associated with downregulation of v-myc avian myelocytomatosis viral oncogene homologue (MYC) and <e1> telomerase reverse transcriptase subunit </e1> .", "e1": "telomerase reverse transcriptase subunit", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 3.64737, "prob_score": -0.27417275, "relevant": "1", "stops": "EOMES - multiple sclerosis - Pregabalin - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 5, "rel_score": 3.45554, "prob_score": -0.28939232, "relevant": "1", "stops": "EOMES - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 7, "rel_score": 3.43548, "prob_score": -0.2910826, "relevant": "1", "stops": "EOMES - hematologic cancer - Ruxolitinib - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 0, "rel_score": 3.02471, "prob_score": -0.3306111, "relevant": "1", "stops": "EOMES - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 2.94811, "prob_score": -0.33920404, "relevant": "1", "stops": "EOMES - TGFB1 - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "192", "sentence": "Accumulation of <e1> p53 tumor suppressor gene protein </e1> : an independent marker of prognosis in <e2> breast cancers </e2> .", "e1": "p53 tumor suppressor gene protein", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 11, "rel_score": 5.01203, "prob_score": -0.19952114, "relevant": "1", "stops": "TP53INP2 - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 33, "rel_score": 4.50532, "prob_score": -0.2219623, "relevant": "1", "stops": "TP53RK - MAL - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": 4.41112, "prob_score": -0.22669585, "relevant": "1", "stops": "TP53INP2 - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 19, "rel_score": 4.39947, "prob_score": -0.22730222, "relevant": "1", "stops": "TP53RK - HSP90AA1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 3.87327, "prob_score": -0.2581781, "relevant": "1", "stops": "TP53RK - GPER1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "193", "sentence": "These results suggest that TMS may inhibit the cell cycle through induction of <e1> p27 </e1> (kip1), leading to apoptotic cell death in <e2> PC-3 </e2> prostate cancer cells.", "e1": "p27", "e2": "PC-3", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 12, "rel_score": 11.9976, "prob_score": -0.08334836, "relevant": "1", "stops": "USP27X - UBC - NBN - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 11.83432, "prob_score": -0.0844962, "relevant": "1", "stops": "USP27X - protein catabolic process - CTSB - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 48, "rel_score": 10.34447, "prob_score": -0.09667068, "relevant": "1", "stops": "USP27X - protein catabolic process - KLHL3 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_DuG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 41, "rel_score": 10.12556, "prob_score": -0.09875962, "relevant": "1", "stops": "USP27X - cellular macromolecule catabolic process - KLHL3 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_DuG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 20, "rel_score": 8.89047, "prob_score": -0.11248058, "relevant": "1", "stops": "USP27X - proteolysis involved in cellular protein catabolic process - CTSB - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "194", "sentence": "In contrast with the hypothesis that <e1> CLU </e1> is a positive modulator of <e2> prostate cancer </e2> , we and others have observed that CLU is downregulated during human prostate cancer progression.", "e1": "CLU", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": 47.84689, "prob_score": -0.020903386, "relevant": "1", "stops": "CLUAP1 - head - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 45.08566, "prob_score": -0.022177784, "relevant": "1", "stops": "CLUAP1 - bronchus - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 43.59198, "prob_score": -0.022938205, "relevant": "1", "stops": "CLUAP1 - mammary gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 39.0625, "prob_score": -0.025601514, "relevant": "1", "stops": "CLUAP1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 23, "rel_score": 38.66976, "prob_score": -0.025859855, "relevant": "1", "stops": "CLUL1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "197", "sentence": "Three recent articles support a model in which, in the absence of mutations in the <e1> Hh </e1> pathway, Hh ligands expressed by a subset of epithelial cancers, including colon, pancreatic, and <e2> ovarian cancer </e2> , promote tumor growth indirectly by activating Hh signaling in the surrounding stroma, which, in turn, provides a more favorable environment for tumor growth.", "e1": "Hh", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 1, "rel_score": -16.51528, "prob_score": -0.060550105, "relevant": "0", "stops": "HRH3 - DRD1 - Pramipexole - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": -17.06776, "prob_score": -0.058594685, "relevant": "0", "stops": "HRH3 - blood - REST - ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_DdG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 44, "rel_score": -18.36885, "prob_score": -0.05444349, "relevant": "0", "stops": "HRH3 - adrenal gland - MCM6 - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_DuG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 10, "rel_score": -18.81468, "prob_score": -0.053151894, "relevant": "0", "stops": "HRH3 - nervous system - REST - ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_DdG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 23, "rel_score": -19.79022, "prob_score": -0.050530758, "relevant": "0", "stops": "HRH3 - negative regulation of transport - REST - ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_DdG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "198", "sentence": "Furthermore, by using <e2> ovarian cancer </e2> cell lines expressing dominant-negative <e1> CHK2 </e1> and CHK2-knockout HCT116 cells, we found that CHK2 activation contributes to the control of S and G2/M cell cycle arrests, but not chemosensitivity to irofulven.", "e1": "CHK2", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 5.97193, "prob_score": -0.16744657, "relevant": "1", "stops": "CHEK2 - Docetaxel - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 5.21376, "prob_score": -0.19179744, "relevant": "1", "stops": "CHEK2 - Estradiol - Ovarian cancer", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 4.66548, "prob_score": -0.21434292, "relevant": "1", "stops": "CHEK2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "199", "sentence": "The cellular retinol binding protein I gene ( <e1> CRBP </e1> ) is downregulated in a subset of human <e2> breast cancers </e2> and in MMTV-Myc induced mouse mammary tumors.", "e1": "CRBP", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 6.86012, "prob_score": -0.14576761, "relevant": "1", "stops": "CIRBP - MEOX2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 9, "rel_score": 6.53595, "prob_score": -0.1529978, "relevant": "1", "stops": "CIRBP - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": 6.01142, "prob_score": -0.16635332, "relevant": "1", "stops": "CIRBP - COPB2 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 5.93401, "prob_score": -0.1685244, "relevant": "1", "stops": "CIRBP - RANBP9 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 14, "rel_score": 5.71233, "prob_score": -0.17506057, "relevant": "1", "stops": "CIRBP - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "201", "sentence": "NSAIDs exert their anti-inflammatory effects by inhibiting cyclooxygenase ( <e1> COX </e1> ) activity; however, evidence suggests that COX-independent mechanisms mediate decreased <e2> prostate cancer </e2> cell survival.", "e1": "COX", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 24.43793, "prob_score": -0.0409156, "relevant": "1", "stops": "CPOX - adrenal cortex - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 24.3843, "prob_score": -0.04100523, "relevant": "1", "stops": "CPOX - female gonad - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 23.14815, "prob_score": -0.043197524, "relevant": "1", "stops": "CPOX - testis - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 21.78175, "prob_score": -0.045914933, "relevant": "1", "stops": "CPOX - nipple - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 21.43623, "prob_score": -0.046649486, "relevant": "1", "stops": "CPOX - bone marrow - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "202", "sentence": "Evaluation of differential gene expression in drug-sensitive ( <e2> A2780 </e2> ) and drug-resistant (A2780cp) ovarian carcinoma cell lines exposed to 0.1 microg/ml HMN-176 up to 48 h using cDNA microarrays with 1,154 known human genes revealed significant drug effects on tumor associated genes, including upregulation of tissue inhibitor matrix metalloproteinases gene ( <e1> TIMP </e1> ) in both cell lines, suggesting that HMN-176 could potentially overcome tumor drug resistance.", "e1": "TIMP", "e2": "A2780", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 43, "rel_score": 4.12541, "prob_score": -0.24240308, "relevant": "1", "stops": "TIMP1 - ESR1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 3.75305, "prob_score": -0.2664462, "relevant": "1", "stops": "TIMP1 - MRPL12 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 3.72634, "prob_score": -0.2683557, "relevant": "1", "stops": "TIMP1 - AR - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 3.57539, "prob_score": -0.2796906, "relevant": "1", "stops": "TIMP1 - BZW2 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 2.9529, "prob_score": -0.33865333, "relevant": "1", "stops": "TIMP1 - MCOLN1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "203", "sentence": "This study demonstrates a novel mechanism of EGF-induced VEGF and HIF-1alpha expression through production of H2O2 and activation of <e1> AKT </e1> and p70S6K1 in human <e2> ovarian cancer </e2> cells.", "e1": "AKT", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": -4.42752, "prob_score": -0.22585763, "relevant": "0", "stops": "AKT3 - MAL - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": -4.62942, "prob_score": -0.21601434, "relevant": "0", "stops": "AKT3 - ATF6 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": -4.73619, "prob_score": -0.21114075, "relevant": "0", "stops": "AKT3 - KLHL21 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": -5.40424, "prob_score": -0.1850446, "relevant": "0", "stops": "AKT3 - ST3GAL5 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": -5.42623, "prob_score": -0.18429014, "relevant": "0", "stops": "AKT3 - UBQLN2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "204", "sentence": "MDA-MB231 cell membranes induced <e1> plasmin </e1> generation in a time-dependent manner while those from <e2> MCF-7 </e2> cells failed to convert plasminogen to plasmin.", "e1": "plasmin", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 23, "rel_score": 17.8031, "prob_score": -0.056165185, "relevant": "1", "stops": "ATMIN - ERBB2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 30, "rel_score": 16.33453, "prob_score": -0.061224137, "relevant": "1", "stops": "ATMIN - SMAD3 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 14, "rel_score": 16.17338, "prob_score": -0.061830055, "relevant": "1", "stops": "ATMIN - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": 15.75051, "prob_score": -0.063487016, "relevant": "1", "stops": "ATMIN - mammary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 29, "rel_score": 15.65925, "prob_score": -0.063856006, "relevant": "1", "stops": "ATMIN - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "205", "sentence": "Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells ( <e2> PC-3 </e2> ) are associated with increase in <e1> p21 </e1> and hypophosphorylated retinoblastoma proteins expression.", "e1": "p21", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 4.07847, "prob_score": -0.24519326, "relevant": "1", "stops": "PHF21B - DYNLT1 - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 37, "rel_score": 3.21895, "prob_score": -0.31066343, "relevant": "1", "stops": "PHF21B - PAK4 - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 3.17329, "prob_score": -0.31512555, "relevant": "1", "stops": "PHF21B - PHKG2 - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 3.10482, "prob_score": -0.3220832, "relevant": "1", "stops": "PHF21B - PRKAR2B - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 3.06993, "prob_score": -0.32574126, "relevant": "1", "stops": "PHF21B - head - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "206", "sentence": "Functionally, short hairpin RNA knock down of endogenous MKP3 resulted in increased <e1> ERK1/2 </e1> activity, cell proliferation rate, anchorage-independent growth ability and resistance to cisplatin in <e2> ovarian cancer </e2> cells.", "e1": "ERK1/2", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 40, "rel_score": -2.29011, "prob_score": -0.4366614, "relevant": "0", "stops": "ERVV-2 - brain - PPRC1 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": -2.3388, "prob_score": -0.42757028, "relevant": "0", "stops": "ERVV-2 - brain - MRPL12 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": -2.33885, "prob_score": -0.4275625, "relevant": "0", "stops": "ERVV-2 - brain - ACADVL - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": -2.37818, "prob_score": -0.4204892, "relevant": "0", "stops": "ERVV-2 - brain - MTHFD2 - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": -2.61568, "prob_score": -0.38230708, "relevant": "0", "stops": "ERVV-2 - brain - ALB - Estropipate - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "207", "sentence": "When the <e1> epidermal growth factor-receptor </e1> (EGFR) tyrosine kinase activity was inhibited by the use of its inhibitor AG1478, Ang II was still able to induce ERK1/2 phosphorylation and c-fos expression, therefore proving that the transactivation of EGFR was not required for these Ang II effects in <e2> MCF-7 </e2> cells.", "e1": "epidermal growth factor-receptor", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 46, "rel_score": 50.32713, "prob_score": -0.0198652, "relevant": "1", "stops": "EGFR - PRKCD - Fulvestrant - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 46.49001, "prob_score": -0.02150513, "relevant": "1", "stops": "EGFR - TMEM109 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 46.27487, "prob_score": -0.021606768, "relevant": "1", "stops": "EGFR - MRPL12 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 43.64906, "prob_score": -0.022908177, "relevant": "1", "stops": "EGFR - PIK3R3 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 41.94631, "prob_score": -0.023843559, "relevant": "1", "stops": "EGFR - MEF2C - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "208", "sentence": "For example, some studies showed that <e1> CLU </e1> expression is increased in advanced stages of <e2> prostate cancer </e2> and that suppression of CLU expression sensitizes prostate cancer cells to chemotherapeutic drugs killing.", "e1": "CLU", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 21, "rel_score": 5.74779, "prob_score": -0.17397968, "relevant": "1", "stops": "CLUH - HIST1H2BG - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 43, "rel_score": 4.84966, "prob_score": -0.20619826, "relevant": "1", "stops": "CLUAP1 - kidney - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 4.7918, "prob_score": -0.20868811, "relevant": "1", "stops": "CLUAP1 - nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 4.54422, "prob_score": -0.22005942, "relevant": "1", "stops": "CLUL1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 26, "rel_score": 4.24178, "prob_score": -0.23574637, "relevant": "1", "stops": "CLUAP1 - blood - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "209", "sentence": "Estradiol stimulates cell growth and secretion of <e1> procathepsin D </e1> and a 120-kilodalton protein in the human ovarian cancer cell line <e2> BG-1 </e2> .", "e1": "procathepsin D", "e2": "BG-1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 4.58695, "prob_score": -0.21800615, "relevant": "1", "stops": "CTSD - breast cancer - ovarian cancer", "reltypes": "ASSOCIATES_DaG - RESEMBLES_DrD", "nodelabels": "Gene - Disease - Disease"}, {"pathid": 12, "rel_score": 4.0093, "prob_score": -0.24941933, "relevant": "1", "stops": "CTSD - oviduct - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 11, "rel_score": 3.99361, "prob_score": -0.2504022, "relevant": "1", "stops": "CTSD - uterine cervix - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": 3.98184, "prob_score": -0.25114012, "relevant": "1", "stops": "CTSD - KIAA0753 - ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 3.00499, "prob_score": -0.33278173, "relevant": "1", "stops": "CTSD - PPIE - ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "210", "sentence": "Overexpression of <e1> clusterin </e1> in <e2> LNCaP </e2> cells confers resistance to both androgen ablation and chemotherapy.", "e1": "clusterin", "e2": "LNCaP", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 3, "rel_score": 2.24648, "prob_score": -0.44513503, "relevant": "1", "stops": "CLUAP1 - CLU - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 25, "rel_score": 2.11171, "prob_score": -0.47355363, "relevant": "1", "stops": "CLUL1 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": 1.68512, "prob_score": -0.593429, "relevant": "1", "stops": "CLUAP1 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "rel_score": 1.68101, "prob_score": -0.5948833, "relevant": "1", "stops": "CLUH - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 22, "rel_score": 1.56747, "prob_score": -0.63797015, "relevant": "1", "stops": "CLUH - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "212", "sentence": "Compared with <e2> BPH </e2> , the PCa patients showed decreased expressions of miR-98, let-7d and let-7g, and decreased expressions of miR-96, <e1> miR-182 </e1> and miR-183, with statistically significant differences between the two groups (P &lt; 0.05).", "e1": "miR-182", "e2": "BPH", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 6.68941, "prob_score": -0.14949293, "relevant": "1", "stops": "GPR182 - hypertension - GNRH1 - prostate cancer", "reltypes": "ASSOCIATES_DaG - ASSOCIATES_DaG - ASSOCIATES_DaG", "nodelabels": "Gene - Disease - Gene - Disease"}, {"pathid": 21, "rel_score": 6.4156, "prob_score": -0.15586874, "relevant": "1", "stops": "GPR182 - Myometrial Relaxation and Contraction Pathways - PDE4D - prostate cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - ASSOCIATES_DaG", "nodelabels": "Gene - Pathway - Gene - Disease"}, {"pathid": 15, "rel_score": 5.80383, "prob_score": -0.1722963, "relevant": "1", "stops": "GPR182 - digestive system - CTSB - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 9, "rel_score": 5.59284, "prob_score": -0.17880462, "relevant": "1", "stops": "GPR182 - digestive system - ADAM9 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 47, "rel_score": 5.56545, "prob_score": -0.17968303, "relevant": "1", "stops": "GPR182 - digestive system - MAEA - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}]}
{"qid": "213", "sentence": "Correlation with clinicopathological data showed, however, that the loss of one <e1> H-ras-1 allele </e1> in <e2> breast carcinoma </e2> DNAs is significantly linked to histological Grade III tumors, the lack of estrogen and/or progesterone receptors, and the subsequent occurrence of distal metastasis.", "e1": "H-ras-1 allele", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 13.34579, "prob_score": -0.07492655, "relevant": "1", "stops": "HPRT1 - KRT18 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": 13.04461, "prob_score": -0.076663636, "relevant": "1", "stops": "HPRT1 - CHEK2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 41, "rel_score": 11.63467, "prob_score": -0.08594965, "relevant": "1", "stops": "HPRT1 - SDC1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": 10.30078, "prob_score": -0.097077124, "relevant": "1", "stops": "HPRT1 - HRAS - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 17, "rel_score": 10.25746, "prob_score": -0.0974893, "relevant": "1", "stops": "HPRT1 - HIST1H2BK - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "214", "sentence": "<e1> AGR2 </e1> knockdown induced cell death in <e2> ZR-75-1 </e2> and T47 D cells, and also downregulated survivin and c-Myc.", "e1": "AGR2", "e2": "ZR-75-1", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 20, "rel_score": -1.64422, "prob_score": -0.6081864, "relevant": "0", "stops": "AGR2 - SPAG4 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": -1.7094, "prob_score": -0.58499825, "relevant": "0", "stops": "AGR2 - HERC6 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": -1.75303, "prob_score": -0.5704438, "relevant": "0", "stops": "AGR2 - MCOLN1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": -1.78881, "prob_score": -0.5590275, "relevant": "0", "stops": "AGR2 - TMEM109 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": -1.95088, "prob_score": -0.5125918, "relevant": "0", "stops": "AGR2 - EED - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "215", "sentence": "In both <e2> PC-3 </e2> and PC-3U cells, TGF-beta 1 was found to stimulate the induction of fibronectin and plasminogen activator inhibitor-1 and the expression of <e1> junB mRNA </e1> , and PMA did not affect these responses.", "e1": "junB mRNA", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 13.39944, "prob_score": -0.07462577, "relevant": "1", "stops": "JUNB - LSM6 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 13.30849, "prob_score": -0.07513691, "relevant": "1", "stops": "JUNB - TSPAN4 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 10.83189, "prob_score": -0.09231826, "relevant": "1", "stops": "JUNB - BRCA1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": 9.89413, "prob_score": -0.10107491, "relevant": "1", "stops": "JUNB - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 16, "rel_score": 8.89601, "prob_score": -0.11240699, "relevant": "1", "stops": "JUNB - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "216", "sentence": "We also found that the expression of <e1> tumour necrosis factor receptor 2 and death receptor 3 </e1> (DR3) was increased in <e2> PC3 </e2> cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.", "e1": "tumour necrosis factor receptor 2 and death receptor 3", "e2": "PC3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 20, "rel_score": 5.34988, "prob_score": -0.18692057, "relevant": "1", "stops": "MTOR - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 4.99376, "prob_score": -0.20024966, "relevant": "1", "stops": "MTOR - SIRT1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": 4.939, "prob_score": -0.20247363, "relevant": "1", "stops": "MTOR - TYMS - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": 4.79088, "prob_score": -0.20873381, "relevant": "1", "stops": "MTOR - PHGDH - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 25, "rel_score": 4.55913, "prob_score": -0.2193387, "relevant": "1", "stops": "MTOR - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "217", "sentence": "These results suggest that down-regulation of <e1> PRA </e1> is associated with the development of <e2> ovarian epithelial carcinoma </e2> .", "e1": "PRA", "e2": "ovarian epithelial carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 19.08397, "prob_score": -0.052396093, "relevant": "1", "stops": "PURA - RPS4Y1 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 18.73712, "prob_score": -0.053373575, "relevant": "1", "stops": "PURA - KIAA0196 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 17.42464, "prob_score": -0.057390686, "relevant": "1", "stops": "PURA - DPH2 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 16.79825, "prob_score": -0.059532262, "relevant": "1", "stops": "PURA - RPS4Y1 - Estrone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 15.56905, "prob_score": -0.064231426, "relevant": "1", "stops": "PURA - CSRP1 - Estrone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "218", "sentence": "L-mimosine enhanced expression of Btg2 and <e1> Ndrg1 </e1> , which attenuated cell proliferation of the <e2> PC-3 </e2> and LNCaP prostate carcinoma cells.", "e1": "Ndrg1", "e2": "PC-3", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 9, "rel_score": -8.28432, "prob_score": -0.12071009, "relevant": "0", "stops": "NDRG1 - RRP8 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": -8.87469, "prob_score": -0.11268141, "relevant": "0", "stops": "NDRG1 - HOMER2 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": -9.56755, "prob_score": -0.104516104, "relevant": "0", "stops": "NDRG1 - NNT - Ropinirole - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": -9.56938, "prob_score": -0.10449906, "relevant": "0", "stops": "NDRG1 - MAOA - Selegiline - Prostate cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": -9.71628, "prob_score": -0.10291744, "relevant": "0", "stops": "NDRG1 - MAOA - Testosterone - Prostate cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "219", "sentence": "Compared with primary <e2> prostate tumors </e2> , castration-resistant metastases displayed alterations in genes encoding steroidogenic enzymes, including up-regulated expression of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and UGT2B17 and down-regulated expression of <e1> SRD5A2 </e1> (P < 0.001 for all).", "e1": "SRD5A2", "e2": "prostate tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 44, "rel_score": 4.13274, "prob_score": -0.24197158, "relevant": "1", "stops": "SRD5A2 - response to drug - TGFBR2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 3.69181, "prob_score": -0.27087325, "relevant": "1", "stops": "SRD5A2 - Finasteride - Pruritus - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 37, "rel_score": 3.64259, "prob_score": -0.27453417, "relevant": "1", "stops": "SRD5A2 - Finasteride - Hypersensitivity - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 45, "rel_score": 2.77354, "prob_score": -0.36055306, "relevant": "1", "stops": "SRD5A2 - skeletal system development - TGFBR2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 2.65231, "prob_score": -0.3770336, "relevant": "1", "stops": "SRD5A2 - prostate cancer - TNFSF11 - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - ASSOCIATES_DaG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Disease - Gene - Compound - SideEffect"}]}
{"qid": "220", "sentence": "ErbB2 increases <e1> vascular endothelial growth factor protein </e1> synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human <e2> breast cancer </e2> cells.", "e1": "vascular endothelial growth factor protein", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 10, "rel_score": 32.64773, "prob_score": -0.030634863, "relevant": "1", "stops": "VEGFA - ALDOC - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 30.98853, "prob_score": -0.032271374, "relevant": "1", "stops": "VEGFA - LGMN - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 26.63116, "prob_score": -0.037547294, "relevant": "1", "stops": "VEGFA - ADAM10 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 19.79414, "prob_score": -0.050517052, "relevant": "1", "stops": "VEGFA - PRKCD - Memantine - Breast cancer female", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 19.5122, "prob_score": -0.051246215, "relevant": "1", "stops": "VEGFA - SCAND1 - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "221", "sentence": "In patients with recurrence of <e2> ovary tumor </e2> , the <e1> IAP </e1> levels was increased to compare with the health women (P < 0.01), the incidence of the abnormal value was 100%.", "e1": "IAP", "e2": "ovary tumor", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": -1.8206, "prob_score": -0.54926664, "relevant": "0", "stops": "XIAP - NUP85 - Progesterone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": -1.83803, "prob_score": -0.54406047, "relevant": "0", "stops": "XIAP - BLMH - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": -2.93902, "prob_score": -0.34025037, "relevant": "0", "stops": "XIAP - BZW2 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": -3.0077, "prob_score": -0.33248052, "relevant": "0", "stops": "XIAP - TXLNA - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": -3.01978, "prob_score": -0.3311515, "relevant": "0", "stops": "XIAP - MRPL12 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "222", "sentence": "We have also shown that expression of activated <e1> Src </e1> in <e2> breast cancer </e2> cells increased the expression of alpha2-integrin and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.", "e1": "Src", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": -1.51451, "prob_score": -0.6602848, "relevant": "0", "stops": "SRCAP - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": -1.53905, "prob_score": -0.6497501, "relevant": "0", "stops": "SRCAP - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 30, "rel_score": -1.55451, "prob_score": -0.6432864, "relevant": "0", "stops": "SRCAP - endocrine gland - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 27, "rel_score": -1.64758, "prob_score": -0.6069475, "relevant": "0", "stops": "SRCAP - testis - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 38, "rel_score": -2.16642, "prob_score": -0.4615942, "relevant": "0", "stops": "SRCAP - hematopoietic system - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "223", "sentence": "Furthermore, siRNA knockdown of the p38 mitogen-activated protein kinase (MAPK) protein prevented induction of <e1> p75 </e1> (NTR) by DIM in the <e2> PC-3 </e2> prostate cell line.", "e1": "p75", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 6.46371, "prob_score": -0.15471299, "relevant": "1", "stops": "GPR75-ASB3 - CUL5 - TOP2A - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 17, "rel_score": 5.95203, "prob_score": -0.1680089, "relevant": "1", "stops": "GPR75-ASB3 - HSP90AA1 - STAT3 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 43, "rel_score": 5.86235, "prob_score": -0.17057733, "relevant": "1", "stops": "GPR75-ASB3 - HSP90AA1 - PDGFRB - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 45, "rel_score": 5.54109, "prob_score": -0.18046553, "relevant": "1", "stops": "GPR75-ASB3 - HSP90AA1 - ESR1 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 27, "rel_score": 5.39782, "prob_score": -0.1852613, "relevant": "1", "stops": "GPR75-ASB3 - HSP90AA1 - ATF3 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "224", "sentence": "Arsenite induces <e1> p70S6K1 </e1> activation and HIF-1alpha expression in <e2> prostate cancer </e2> cells.", "e1": "p70S6K1", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 14, "rel_score": 8.54628, "prob_score": -0.117013656, "relevant": "1", "stops": "PCSK1 - trachea - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 8.46453, "prob_score": -0.11813967, "relevant": "1", "stops": "PCSK1 - spinal cord - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 8.13273, "prob_score": -0.122958735, "relevant": "1", "stops": "PCSK1 - brain - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 7.93714, "prob_score": -0.12599447, "relevant": "1", "stops": "PCSK1N - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 7.88706, "prob_score": -0.12678643, "relevant": "1", "stops": "PCSK1N - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "225", "sentence": "Established miR-21 targets PTEN and <e1> PDCD4 </e1> were reduced in ERalpha46-transfected, E(2)-treated <e2> MCF-7 </e2> cells.", "e1": "PDCD4", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 20.59732, "prob_score": -0.048552383, "relevant": "1", "stops": "PDCD4 - colon cancer - breast cancer", "reltypes": "DOWNREGULATES_DdG - RESEMBLES_DrD", "nodelabels": "Gene - Disease - Disease"}, {"pathid": 22, "rel_score": 15.29754, "prob_score": -0.065371655, "relevant": "1", "stops": "PDCD4 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 34, "rel_score": 13.26788, "prob_score": -0.075371414, "relevant": "1", "stops": "PDCD4 - Sirolimus - Conjunctivitis - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 44, "rel_score": 12.32286, "prob_score": -0.08115329, "relevant": "1", "stops": "PDCD4 - medulla oblongata - CYP2C19 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 11.57273, "prob_score": -0.08640548, "relevant": "1", "stops": "PDCD4 - medulla oblongata - CYP2C19 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "226", "sentence": "Androgens repress <e1> Bcl-2 </e1> expression via activation of the retinoblastoma (RB) protein in <e2> prostate cancer </e2> cells.", "e1": "Bcl-2", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": 14.09245, "prob_score": -0.0709562, "relevant": "1", "stops": "BCL2L2-PABPN1 - ZNF580 - epithelium - prostate cancer", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 19, "rel_score": 12.1862, "prob_score": -0.082063496, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - SLC39A1 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 21, "rel_score": 10.92896, "prob_score": -0.09150191, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - MYC - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 10.81081, "prob_score": -0.092495084, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - MYEOV - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 8, "rel_score": 10.75153, "prob_score": -0.09301307, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - ADAM9 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "227", "sentence": "The overexpression of the <e1> colony-stimulating factor-1 </e1> (CSF-1) by epithelial <e2> ovarian cancer </e2> cells enhances invasiveness and metastatic properties, contributing to the poor prognosis of the patients.", "e1": "colony-stimulating factor-1", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 4, "rel_score": 15.13546, "prob_score": -0.06607359, "relevant": "1", "stops": "OCLN - breast cancer - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 17, "rel_score": 12.8866, "prob_score": -0.07759838, "relevant": "1", "stops": "OCLN - epithelium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 9.20895, "prob_score": -0.10859356, "relevant": "1", "stops": "OCLN - breast cancer - Estradiol - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 12, "rel_score": 7.17206, "prob_score": -0.13942926, "relevant": "1", "stops": "OCLN - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": 5.78202, "prob_score": -0.17295463, "relevant": "1", "stops": "OCLN - breast cancer - ovarian cancer", "reltypes": "ASSOCIATES_DaG - RESEMBLES_DrD", "nodelabels": "Gene - Disease - Disease"}]}
{"qid": "228", "sentence": "The multidrug transporter <e2> breast cancer </e2> resistance protein ( <e1> BCRP/ABCG2 </e1> ) is strongly induced in the mammary gland during pregnancy and lactation.", "e1": "BCRP/ABCG2", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 40, "rel_score": 10.91941, "prob_score": -0.09157677, "relevant": "1", "stops": "CRP - blood - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 10.64396, "prob_score": -0.09394724, "relevant": "1", "stops": "CRP - respiratory system - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 9.90688, "prob_score": -0.10093963, "relevant": "1", "stops": "CRP - liver - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 8.55066, "prob_score": -0.11695185, "relevant": "1", "stops": "CRP - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 8.39983, "prob_score": -0.1190547, "relevant": "1", "stops": "CRP - heart - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "229", "sentence": "Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and <e1> P70S6K1 </e1> in human <e2> ovarian cancer </e2> cells.", "e1": "P70S6K1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 26, "rel_score": 4.14353, "prob_score": -0.2413442, "relevant": "1", "stops": "PCSK1N - vagina - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 23, "rel_score": 4.0818, "prob_score": -0.24499364, "relevant": "1", "stops": "PCSK1N - uterus - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 30, "rel_score": 3.96637, "prob_score": -0.2521187, "relevant": "1", "stops": "PCSK1N - myometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 3.71209, "prob_score": -0.2693871, "relevant": "1", "stops": "PCSK1N - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 9, "rel_score": 3.19091, "prob_score": -0.31339437, "relevant": "1", "stops": "PCSK1N - TIPARP - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "230", "sentence": "Furthermore, a 100-fold reduction in the transcription efficiency of the <e1> Cdc6 promoter-luciferase construct </e1> was noted in the metastatic <e2> PC3 </e2> cells compared with that in BPH-1 cells.", "e1": "Cdc6 promoter-luciferase construct", "e2": "PC3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 13.96648, "prob_score": -0.07160256, "relevant": "1", "stops": "CDC6 - Sunitinib - Pancreatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 22, "rel_score": 13.47709, "prob_score": -0.07419888, "relevant": "1", "stops": "CDC6 - Simvastatin - Gynaecomastia - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 49, "rel_score": 11.90193, "prob_score": -0.0840173, "relevant": "1", "stops": "CDC6 - Afatinib - Infestation - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 32, "rel_score": 10.85776, "prob_score": -0.09210309, "relevant": "1", "stops": "CDC6 - Sirolimus - Conjunctivitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 5, "rel_score": 9.3633, "prob_score": -0.10679554, "relevant": "1", "stops": "CDC6 - KLF6 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "231", "sentence": "The <e1> EphA2 receptor tyrosine kinase </e1> is frequently overexpressed in invasive <e2> breast cancer </e2> cells.", "e1": "EphA2 receptor tyrosine kinase", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 3.56405, "prob_score": -0.280576, "relevant": "1", "stops": "EPHA2 - SNAI2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 43, "rel_score": 2.88775, "prob_score": -0.34628546, "relevant": "1", "stops": "EPHA2 - COPB2 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 44, "rel_score": 2.87728, "prob_score": -0.34755406, "relevant": "1", "stops": "EPHA2 - COL7A1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 2.82526, "prob_score": -0.35395303, "relevant": "1", "stops": "EPHA2 - ADH5 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": 2.78652, "prob_score": -0.35886827, "relevant": "1", "stops": "EPHA2 - GALE - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "232", "sentence": "Activated <e1> STAT3 </e1> correlated with elevated cyclin D1 protein in primary <e2> breast tumors </e2> and breast cancer-derived cell lines.", "e1": "STAT3", "e2": "breast tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 23, "rel_score": 9.9226, "prob_score": -0.100781925, "relevant": "1", "stops": "STAT3 - CEP55 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 9.56938, "prob_score": -0.10450186, "relevant": "1", "stops": "STAT3 - GSTM2 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 8.81057, "prob_score": -0.11350495, "relevant": "1", "stops": "STAT3 - FOXO3 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 8.80049, "prob_score": -0.11362888, "relevant": "1", "stops": "STAT3 - DECR1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 8.73515, "prob_score": -0.11447687, "relevant": "1", "stops": "STAT3 - DRAP1 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "233", "sentence": "From these 23 patients, 18 pts were referred for suspected recurrence of <e2> ovarian carcinoma </e2> : occult recurrence (OR) defined by an increase in serum <e1> CA-125 </e1> levels with negative conventional imaging (13 pts) or equivocal aspect at conventional imaging (5 pts).", "e1": "CA-125", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 3.16787, "prob_score": -0.3156715, "relevant": "1", "stops": "CA12 - SLC35B1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 3.14881, "prob_score": -0.31757995, "relevant": "1", "stops": "CA12 - MRPL12 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 3.09799, "prob_score": -0.32279417, "relevant": "1", "stops": "CA12 - ZDHHC6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 3.06288, "prob_score": -0.32648745, "relevant": "1", "stops": "CA12 - DPH2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 3.0292, "prob_score": -0.33011597, "relevant": "1", "stops": "CA12 - PWP2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "234", "sentence": "Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins ( <e1> albumin </e1> , alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with <e2> prostatic cancer </e2> prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.", "e1": "albumin", "e2": "prostatic cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 25, "rel_score": 17.44896, "prob_score": -0.057308115, "relevant": "1", "stops": "ATMIN - Parkinson's disease - Pramipexole - Prostate cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 9, "rel_score": 13.7779, "prob_score": -0.072578646, "relevant": "1", "stops": "ATMIN - ERBB2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": 13.20481, "prob_score": -0.0757339, "relevant": "1", "stops": "ATMIN - RPS6KA1 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 8.26515, "prob_score": -0.12098687, "relevant": "1", "stops": "ATMIN - HPGD - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 17, "rel_score": 7.33084, "prob_score": -0.13640921, "relevant": "1", "stops": "ATMIN - SLC35A1 - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "236", "sentence": "<e1> Epidermal growth factor </e1> (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of <e2> ovarian cancer </e2> by activating autocrine pathways.", "e1": "Epidermal growth factor", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 46, "rel_score": -1.5658, "prob_score": -0.6386524, "relevant": "0", "stops": "EGFL6 - telencephalon - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": -1.73699, "prob_score": -0.5757063, "relevant": "0", "stops": "EGFL6 - central nervous system - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": -1.76457, "prob_score": -0.5667097, "relevant": "0", "stops": "EGFL6 - blood - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -1.85319, "prob_score": -0.5396109, "relevant": "0", "stops": "EGFL6 - prostate gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": -3.22872, "prob_score": -0.3097164, "relevant": "0", "stops": "EGFR - Docetaxel - Ovarian cancer", "reltypes": "BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "237", "sentence": "Here we show that heterozygous inactivation of the tumor suppressor gene <e1> Pten </e1> leads to the formation of basal-like mammary tumors in mice, and that loss of PTEN expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary <e2> breast cancers </e2> .", "e1": "Pten", "e2": "breast cancers", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 23, "rel_score": 23.86065, "prob_score": -0.04190969, "relevant": "1", "stops": "PTEN - POLD4 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 20.57613, "prob_score": -0.048603103, "relevant": "1", "stops": "PTEN - P4HTM - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 16.2022, "prob_score": -0.06171696, "relevant": "1", "stops": "PTEN - MCOLN1 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 13.44628, "prob_score": -0.07437428, "relevant": "1", "stops": "PTEN - CES1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 12.40849, "prob_score": -0.08059081, "relevant": "1", "stops": "PTEN - ADO - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "238", "sentence": "With the treatment of 9-cis RA, the <e1> NKX3.1 </e1> promoter activity was increased in reporter gene assay and NKX3.1 expression was enhanced at both mRNA and protein levels in <e2> LNCaP </e2> cells.", "e1": "NKX3.1", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 4.23083, "prob_score": -0.2363648, "relevant": "1", "stops": "NKX3-1 - hematologic cancer - Ruxolitinib - Prostate cancer", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 4, "rel_score": 3.7853, "prob_score": -0.2641781, "relevant": "1", "stops": "NKX3-1 - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 2, "rel_score": 3.27643, "prob_score": -0.30521047, "relevant": "1", "stops": "NKX3-1 - MNAT1 - Ruxolitinib - Prostate cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 3.14238, "prob_score": -0.3182293, "relevant": "1", "stops": "NKX3-1 - HIPK2 - Ruxolitinib - Prostate cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 2.6356, "prob_score": -0.3794162, "relevant": "1", "stops": "NKX3-1 - SPDEF - Testosterone - Prostate cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "239", "sentence": "Consistently, <e1> PI3-kinase </e1> inhibition with a dominant-negative mutant or MAPK/ERK activation with a gain-of-function mutant reduced MMP-9 levels and prevented migration and invasion in wild-type <e2> PC-3 </e2> cells.", "e1": "PI3-kinase", "e2": "PC-3", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 5, "rel_score": -2.22752, "prob_score": -0.44892555, "relevant": "0", "stops": "PI3 - lung - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": -2.24442, "prob_score": -0.44555017, "relevant": "0", "stops": "PI3 - prostate gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": -2.32169, "prob_score": -0.43071863, "relevant": "0", "stops": "PI3 - bone marrow - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": -2.62281, "prob_score": -0.38126808, "relevant": "0", "stops": "PI3 - lymphoid tissue - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": -2.88792, "prob_score": -0.3462719, "relevant": "0", "stops": "PI3 - respiratory system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "240", "sentence": "This new modified antisense oligonucleotides targeting <e1> VEGF-A </e1> can decrease VEGF-A expression and inhibit cell migration in <e2> SKOV3 </e2> ovarian cancer cells.", "e1": "VEGF-A", "e2": "SKOV3", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": -3.49969, "prob_score": -0.28574073, "relevant": "0", "stops": "VEGFA - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "243", "sentence": "<e1> CBX7 </e1> overexpression in <e2> LNCaP </e2> cells resulted in a slight growth advantage in both androgen-dependent and -independent conditions.", "e1": "CBX7", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 37, "rel_score": -10.52299, "prob_score": -0.095026515, "relevant": "0", "stops": "CBX7 - VAPB - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": -11.48237, "prob_score": -0.087089956, "relevant": "0", "stops": "CBX7 - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": -12.2489, "prob_score": -0.081639916, "relevant": "0", "stops": "CBX7 - NPDC1 - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": -12.66464, "prob_score": -0.07895797, "relevant": "0", "stops": "CBX7 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": -13.21702, "prob_score": -0.075664155, "relevant": "0", "stops": "CBX7 - AGR2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "244", "sentence": "<e2> Ovarian carcinoma </e2> and breast carcinoma cells which are multiply drug resistant due to overexpression of <e1> P-glycoprotein </e1> are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol.", "e1": "P-glycoprotein", "e2": "Ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 5.26011, "prob_score": -0.19011146, "relevant": "1", "stops": "PCDHA7 - central nervous system - CYP19A1 - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 4.2517, "prob_score": -0.23520194, "relevant": "1", "stops": "PCDHA7 - head - PHYH - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 3.60477, "prob_score": -0.27741325, "relevant": "1", "stops": "PCDHA7 - central nervous system - FDPS - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 3.50054, "prob_score": -0.2856719, "relevant": "1", "stops": "PCDHA7 - CRK - MCOLN1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 3.10463, "prob_score": -0.32209986, "relevant": "1", "stops": "PCDHA7 - brain - SPAG4 - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "245", "sentence": "We have also shown that expression of activated Src in <e2> breast cancer </e2> cells increased the expression of <e1> alpha2-integrin </e1> and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.", "e1": "alpha2-integrin", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 1.73022, "prob_score": -0.57795817, "relevant": "1", "stops": "ALDH3A2 - ADH5 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 1.71945, "prob_score": -0.5815785, "relevant": "1", "stops": "ALDH3A2 - breast cancer - Paclitaxel - Breast cancer stage IV", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 6, "rel_score": 1.65717, "prob_score": -0.6034434, "relevant": "1", "stops": "ALDH3A2 - breast cancer - Fulvestrant - Breast cancer stage IV", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 7, "rel_score": 1.60182, "prob_score": -0.62428695, "relevant": "1", "stops": "ALDH3A2 - breast cancer - Mitoxantrone - Breast cancer stage IV", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 18, "rel_score": -1.43715, "prob_score": -0.69581836, "relevant": "0", "stops": "ALDH3A2 - SUPV3L1 - Estradiol valerate/Dienogest - Breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "246", "sentence": "We found a correlation between ErbB2 expression and activation of Pak in estrogen receptor-positive human <e2> breast tumor </e2> samples and observed that in 3D cultures, activation of Rac-Pak1 pathway by ErbB2 homodimers induced growth factor-independent proliferation and promoted disruption of 3D mammary acinar-like structures through activation of the <e1> Erk </e1> and Akt pathways.", "e1": "Erk", "e2": "breast tumor", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 10, "rel_score": 1.96082, "prob_score": -0.50998634, "relevant": "1", "stops": "CERK - colon cancer - breast cancer", "reltypes": "DOWNREGULATES_DdG - RESEMBLES_DrD", "nodelabels": "Gene - Disease - Disease"}, {"pathid": 23, "rel_score": -1.62986, "prob_score": -0.6135465, "relevant": "0", "stops": "CERK - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 33, "rel_score": -1.96487, "prob_score": -0.50893706, "relevant": "0", "stops": "CERK - Mitoxantrone - breast cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 15, "rel_score": -2.19833, "prob_score": -0.4548877, "relevant": "0", "stops": "CERK - PCNA - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 48, "rel_score": -2.48515, "prob_score": -0.40239492, "relevant": "0", "stops": "CERK - NFKBIA - Memantine - Breast cancer female", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "248", "sentence": "Specific inhibition of <e1> AKT2 </e1> by RNA interference results in reduction of <e2> ovarian cancer </e2> cell proliferation: increased expression of AKT in advanced ovarian cancer.", "e1": "AKT2", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 13, "rel_score": 3.61233, "prob_score": -0.27683112, "relevant": "1", "stops": "AKT2 - MRPL12 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 3.50152, "prob_score": -0.28559417, "relevant": "1", "stops": "AKT2 - CCDC86 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 3.45125, "prob_score": -0.2897533, "relevant": "1", "stops": "AKT2 - DNAJA3 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 2.69993, "prob_score": -0.37038246, "relevant": "1", "stops": "AKT2 - DNAJA3 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 2.2025, "prob_score": -0.45402506, "relevant": "1", "stops": "AKT2 - PFN1 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "252", "sentence": "We observed that re-expression of AR in the AR-negative cells <e2> PC3 </e2> decreases anchorage-independent growth and Matrigel invasiveness of PC3-AR cells where plasma membrane interaction between AR and <e1> EGFR </e1> led to an interference with downstream signalling and internalization of activated EGFR.", "e1": "EGFR", "e2": "PC3", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 49, "rel_score": -1.61095, "prob_score": -0.62075204, "relevant": "0", "stops": "EGFR - chronic obstructive pulmonary disease - Roflumilast - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 11, "rel_score": -4.6594, "prob_score": -0.21462083, "relevant": "0", "stops": "EGFR - MEF2C - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": -4.78904, "prob_score": -0.20880917, "relevant": "0", "stops": "EGFR - PNP - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": -4.94511, "prob_score": -0.20222208, "relevant": "0", "stops": "EGFR - MRPS16 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": -4.94535, "prob_score": -0.2022058, "relevant": "0", "stops": "EGFR - CSTA - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "253", "sentence": "Strikingly, IFN-gamma-induced apoptosis and growth inhibition of <e2> M12 </e2> cells were associated with persistent suppression of the constitutive tyrosine-phosphorylated <e1> STAT3 </e1> (pY-STAT3).", "e1": "STAT3", "e2": "M12", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 5.39084, "prob_score": -0.18550336, "relevant": "1", "stops": "STAT3 - brain - Gilles de la Tourette syndrome - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}, {"pathid": 5, "rel_score": 4.85508, "prob_score": -0.20596756, "relevant": "1", "stops": "STAT3 - forebrain - attention deficit hyperactivity disorder - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}, {"pathid": 3, "rel_score": 4.16095, "prob_score": -0.24032679, "relevant": "1", "stops": "STAT3 - central nervous system - Gilles de la Tourette syndrome - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}, {"pathid": 16, "rel_score": 2.56023, "prob_score": -0.39059234, "relevant": "1", "stops": "STAT3 - chemical homeostasis - CARTPT - Amphetamine - Tic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 2.05977, "prob_score": -0.4854906, "relevant": "1", "stops": "STAT3 - endometrium - SLC18A2 - Amphetamine - Tic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "256", "sentence": "<e1> GRB7 protein </e1> over-expression and clinical outcome in <e2> breast cancer </e2> .", "e1": "GRB7 protein", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 45, "rel_score": 2.25825, "prob_score": -0.44282395, "relevant": "1", "stops": "GRB7 - CSK - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 2.14133, "prob_score": -0.4669984, "relevant": "1", "stops": "GRB7 - TIMM9 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 2.13156, "prob_score": -0.46913704, "relevant": "1", "stops": "GRB7 - ACKR3 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 2.09947, "prob_score": -0.4763104, "relevant": "1", "stops": "GRB7 - TLE1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 1.96402, "prob_score": -0.509156, "relevant": "1", "stops": "GRB7 - ATP6V0B - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "257", "sentence": "When the epidermal growth factor-receptor (EGFR) tyrosine kinase activity was inhibited by the use of its inhibitor AG1478, Ang II was still able to induce ERK1/2 phosphorylation and <e1> c-fos </e1> expression, therefore proving that the transactivation of EGFR was not required for these Ang II effects in <e2> MCF-7 </e2> cells.", "e1": "c-fos", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 23, "rel_score": 15.42972, "prob_score": -0.064812176, "relevant": "1", "stops": "FOSL1 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "rel_score": 13.837, "prob_score": -0.0722723, "relevant": "1", "stops": "FOSL1 - female gonad - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 34, "rel_score": 12.30618, "prob_score": -0.08125773, "relevant": "1", "stops": "FOSL1 - ALK - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 12.30012, "prob_score": -0.08130329, "relevant": "1", "stops": "FOSL1 - RANBP9 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": 11.84413, "prob_score": -0.084425144, "relevant": "1", "stops": "FOSL1 - AR - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "260", "sentence": "By using 5' deletion mutant constructs of <e1> MMP-2 promoter </e1> , we showed that deletion of the region containing activator protein-1 (AP-1) site caused the greatest reduction of MMP-2 promoter activity both in MKK6- and H-Ras-activated <e2> MCF10A </e2> cells, suggesting that the AP-1 binding site is critical for the MMP-2 promoter activation.", "e1": "MMP-2 promoter", "e2": "MCF10A", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 11.75641, "prob_score": -0.08506167, "relevant": "1", "stops": "MMP21 - tendon - EEF1A1 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_DdG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 39, "rel_score": 7.85361, "prob_score": -0.12733054, "relevant": "1", "stops": "MMP21 - tendon - TK1 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_DuG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 47, "rel_score": 7.24375, "prob_score": -0.13804705, "relevant": "1", "stops": "MMP21 - circulatory system development - PTEN - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 37, "rel_score": 6.98812, "prob_score": -0.14310408, "relevant": "1", "stops": "MMP28 - adipose tissue - breast cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 6.668, "prob_score": -0.14997311, "relevant": "1", "stops": "MMP26 - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "261", "sentence": "Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, <e1> BMPR-IB </e1> and BMPR-II, in human <e2> prostate cancer </e2> cells.", "e1": "BMPR-IB", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 14, "rel_score": 11.68497, "prob_score": -0.08557756, "relevant": "1", "stops": "BMPR1B - Dasatinib - Infestation - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 29, "rel_score": 11.07788, "prob_score": -0.09027433, "relevant": "1", "stops": "BMPR1B - endocrine gland - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 10.60221, "prob_score": -0.094316706, "relevant": "1", "stops": "BMPR1B - Vandetanib - Pancreatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 27, "rel_score": 10.36592, "prob_score": -0.09647022, "relevant": "1", "stops": "BMPR1B - prostate gland - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 10.06644, "prob_score": -0.09933814, "relevant": "1", "stops": "BMPR1B - testis - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "263", "sentence": "These data suggest that GAPDH binding to <e1> CSF-1 </e1> ARE sequence prevents CSF-1 mRNA decay and subsequent down-regulation of CSF-1 protein translation, leading to CSF-1 overexpression and increased metastatic properties seen in <e2> ovarian cancer </e2> .", "e1": "CSF-1", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 37, "rel_score": -6.66489, "prob_score": -0.15004124, "relevant": "0", "stops": "CSF1 - breast cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 41, "rel_score": -7.24113, "prob_score": -0.13810417, "relevant": "0", "stops": "CSF1 - breast cancer - Estradiol - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 15, "rel_score": -7.9233, "prob_score": -0.12621424, "relevant": "0", "stops": "CSF1R - breast cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 26, "rel_score": -12.05691, "prob_score": -0.082944214, "relevant": "0", "stops": "CSF1R - STAP2 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": -12.45951, "prob_score": -0.08025517, "relevant": "0", "stops": "CSF1R - CEBPD - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "264", "sentence": "<e1> HER2 </e1> overexpression/amplification, which is an early event in <e2> breast cancer </e2> development, is associated with a poor prognosis and may predict response to therapy.", "e1": "HER2", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 1.64166, "prob_score": -0.6091409, "relevant": "1", "stops": "ERBB2IP - HRAS - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 44, "rel_score": 1.56052, "prob_score": -0.6408132, "relevant": "1", "stops": "ERBB2IP - TIMP2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 1.55044, "prob_score": -0.64497787, "relevant": "1", "stops": "ERBB2IP - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 31, "rel_score": -1.63854, "prob_score": -0.61029756, "relevant": "0", "stops": "ERBB2IP - GRIN2B - Memantine - Breast cancer female", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -1.7135, "prob_score": -0.583602, "relevant": "0", "stops": "ERBB2 - Fulvestrant - Breast cancer stage IV", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "265", "sentence": "Thus, <e1> FGF6 </e1> is increased in PIN and <e2> prostate cancer </e2> and can promote the proliferation of the transformed prostatic epithelial cells via paracrine and autocrine mechanisms.", "e1": "FGF6", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 2, "rel_score": 14.72104, "prob_score": -0.06792651, "relevant": "1", "stops": "FGF6 - tendon - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 14.46759, "prob_score": -0.069119714, "relevant": "1", "stops": "FGF6 - MAPK cascade - TNFSF11 - Lenalidomide - Prostate cancer metastatic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 13.63698, "prob_score": -0.07333073, "relevant": "1", "stops": "FGF6 - cell proliferation - TNFSF11 - Lenalidomide - Prostate cancer metastatic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 12.51878, "prob_score": -0.07988007, "relevant": "1", "stops": "FGF6 - regulation of protein serine/threonine kinase activity - TNFSF11 - Lenalidomide - Prostate cancer metastatic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 11.70823, "prob_score": -0.08540519, "relevant": "1", "stops": "FGF6 - vasculature development - PTGS2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "266", "sentence": "Epidermal growth factor ( <e1> EGF </e1> ) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of <e2> ovarian cancer </e2> by activating autocrine pathways.", "e1": "EGF", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 5, "rel_score": -1.97523, "prob_score": -0.5062675, "relevant": "0", "stops": "EGFLAM - breast cancer - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 19, "rel_score": -2.01865, "prob_score": -0.49538028, "relevant": "0", "stops": "EGFL6 - female reproductive system - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": -2.0642, "prob_score": -0.484449, "relevant": "0", "stops": "EGFL6 - female gonad - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": -2.12571, "prob_score": -0.47042614, "relevant": "0", "stops": "EGFL6 - liver - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": -2.21921, "prob_score": -0.45061415, "relevant": "0", "stops": "EGFL6 - blood - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "267", "sentence": "Single-chain antibody-mediated inhibition of <e1> Bcl-2 </e1> in <e2> SKOV3 </e2> cells was associated with increased growth rates and more rapid cell cycle progression.", "e1": "Bcl-2", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 13, "rel_score": -3.27547, "prob_score": -0.3052987, "relevant": "0", "stops": "BCL2L15 - digestive system - SATB1 - Estriol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": -3.91298, "prob_score": -0.25556043, "relevant": "0", "stops": "BCL2L15 - digestive system - CCND1 - Estradiol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": -4.21053, "prob_score": -0.23750286, "relevant": "0", "stops": "BCL2L15 - digestive system - PUF60 - Clomifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": -4.28284, "prob_score": -0.23349412, "relevant": "0", "stops": "BCL2L15 - renal system - BZW2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -4.38673, "prob_score": -0.22795968, "relevant": "0", "stops": "BCL2L15 - renal system - SMARCD2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "268", "sentence": "Expression of BRCA1 protein in benign, borderline, and malignant epithelial <e2> ovarian neoplasms </e2> and its relationship to methylation and allelic loss of the <e1> BRCA1 gene </e1> .", "e1": "BRCA1 gene", "e2": "ovarian neoplasms", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": -1.44688, "prob_score": -0.6911412, "relevant": "0", "stops": "BRCA1 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "269", "sentence": "Those patients that progressed to <e2> breast cancer </e2> (cases) showed significantly higher <e1> ER-alpha </e1> [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-alpha median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and <0.001).", "e1": "ER-alpha", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": 2.86714, "prob_score": -0.3487799, "relevant": "1", "stops": "ERF - RNH1 - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 2.62247, "prob_score": -0.38132223, "relevant": "1", "stops": "ERF - S100A13 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 2.51357, "prob_score": -0.3978353, "relevant": "1", "stops": "ERF - SLC25A20 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 2.45393, "prob_score": -0.40750596, "relevant": "1", "stops": "ERF - CYCS - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 2.29896, "prob_score": -0.43497673, "relevant": "1", "stops": "ERF - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "270", "sentence": "In vitro and in vivo xenograft experiments in NOD/SCID mice further demonstrated that SOX2 increased the apoptosis-resistant properties of <e2> DU145 </e2> cells with decreased function of store-operated Ca(2+) entry and reduced expression of <e1> Orai1 </e1> at both mRNA and protein levels, suggesting a potential mechanism that contributes to the anti-apoptotic property of SOX2.", "e1": "Orai1", "e2": "DU145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 6.8465, "prob_score": -0.14606223, "relevant": "1", "stops": "ORAI1 - hematopoietic system - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 6.52443, "prob_score": -0.1532701, "relevant": "1", "stops": "ORAI1 - endocrine gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 5.83294, "prob_score": -0.17144403, "relevant": "1", "stops": "ORAI1 - prostate gland - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 5.65323, "prob_score": -0.17688815, "relevant": "1", "stops": "ORAI1 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 5.49541, "prob_score": -0.18197112, "relevant": "1", "stops": "ORAI1 - female gonad - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "271", "sentence": "Specific inhibition of <e1> AKT </e1> 2 by RNA interference results in reduction of <e2> ovarian cancer </e2> cell proliferation: increased expression of AKT in advanced ovarian cancer.", "e1": "AKT", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": -2.48034, "prob_score": -0.40316653, "relevant": "0", "stops": "AKT3 - NUP85 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": -2.54557, "prob_score": -0.39284343, "relevant": "0", "stops": "AKT3 - MCOLN1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": -2.60892, "prob_score": -0.383301, "relevant": "0", "stops": "AKT3 - HIST1H2BK - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": -2.6244, "prob_score": -0.38103962, "relevant": "0", "stops": "AKT3 - GPER1 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": -2.73224, "prob_score": -0.36599812, "relevant": "0", "stops": "AKT3 - HIST1H2BK - Progesterone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "272", "sentence": "The gene array revealed decreased expression of <e1> ADAMTS1 </e1> , ephrin-A5, fibronectin 1, and neuropilin 1 in <e2> LNCaP </e2> -19 compared to LNCaP, while expression of midkine and VEGF were increased.", "e1": "ADAMTS1", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 9.29973, "prob_score": -0.10752644, "relevant": "1", "stops": "ADAMTS19 - endometrium - PLEK2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 29, "rel_score": 8.50847, "prob_score": -0.117526636, "relevant": "1", "stops": "ADAMTS19 - myometrium - EFEMP2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 33, "rel_score": 7.8235, "prob_score": -0.12782434, "relevant": "1", "stops": "ADAMTS19 - adrenal gland - EFEMP2 - prostate cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 5, "rel_score": 6.70062, "prob_score": -0.14924414, "relevant": "1", "stops": "ADAMTS13 - epithelium - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": 6.26802, "prob_score": -0.15953785, "relevant": "1", "stops": "ADAMTS19 - proteinaceous extracellular matrix - EFEMP2 - prostate cancer", "reltypes": "PARTICIPATES_GpCC - PARTICIPATES_GpCC - ASSOCIATES_DaG", "nodelabels": "Gene - CellularComponent - Gene - Disease"}]}
{"qid": "273", "sentence": "In conclusion, our results demonstrate that growth inhibition of <e2> LNCaP </e2> cells by 1,25-(OH)2D3 and 9-cis RA is mediated by an AR-dependent mechanism and preceded by the induction of <e1> AR gene </e1> expression.", "e1": "AR gene", "e2": "LNCaP", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": -10.19784, "prob_score": -0.0980584, "relevant": "0", "stops": "ARFGEF2 - prostate gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": -10.33165, "prob_score": -0.09679227, "relevant": "0", "stops": "ARFGEF2 - blood - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": -10.67692, "prob_score": -0.0936563, "relevant": "0", "stops": "ARFGEF2 - head - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": -11.13586, "prob_score": -0.08979515, "relevant": "0", "stops": "ARFGEF2 - thyroid gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": -11.58212, "prob_score": -0.08634029, "relevant": "0", "stops": "ARFGEF2 - nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "274", "sentence": "Knockdown of <e1> GC UNC-45 </e1> reduced the spreading ability of <e2> ovarian cancer </e2> cells whereas it was enhanced by GC UNC-45 overexpression.", "e1": "GC UNC-45", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 48, "rel_score": 2.79197, "prob_score": -0.3581694, "relevant": "1", "stops": "GCLC - SNX6 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 2.19529, "prob_score": -0.45552316, "relevant": "1", "stops": "GCLC - LAGE3 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 2.17075, "prob_score": -0.46067452, "relevant": "1", "stops": "GCLC - STUB1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": -2.07551, "prob_score": -0.4818091, "relevant": "0", "stops": "GCLC - SERPINA3 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -2.14957, "prob_score": -0.4652101, "relevant": "0", "stops": "GCLC - PMM2 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "276", "sentence": "<e1> Src </e1> is an attractive target because it is overexpressed in a number of malignancies, including <e2> ovarian cancer </e2> .", "e1": "Src", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 14, "rel_score": 5.93014, "prob_score": -0.1686252, "relevant": "1", "stops": "SRCAP - embryo - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 16, "rel_score": 5.24576, "prob_score": -0.19062825, "relevant": "1", "stops": "SRCAP - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 23, "rel_score": 4.35939, "prob_score": -0.22938848, "relevant": "1", "stops": "SRCIN1 - regulation of cell development - REST - ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_DdG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 7, "rel_score": 4.33764, "prob_score": -0.23053706, "relevant": "1", "stops": "SRCIN1 - SRC - Estradiol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 3.92249, "prob_score": -0.2549439, "relevant": "1", "stops": "SRCIN1 - positive regulation of protein phosphorylation - PTEN - ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "277", "sentence": "Eighteen (37%) of the <e2> ovarian carcinomas </e2> had germline or somatic <e1> BRCA1 </e1> mutations, or epigenetic loss of BRCA1.", "e1": "BRCA1", "e2": "ovarian carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 1.65505, "prob_score": -0.60420835, "relevant": "1", "stops": "BRCA1 - MCOLN1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 1.61319, "prob_score": -0.619892, "relevant": "1", "stops": "BRCA1 - ZDHHC6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 1.52655, "prob_score": -0.65506727, "relevant": "1", "stops": "BRCA1 - FAM63A - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 1.43521, "prob_score": -0.6967588, "relevant": "1", "stops": "BRCA1 - GOLT1B - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 1.42625, "prob_score": -0.7011371, "relevant": "1", "stops": "BRCA1 - SPAG4 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "278", "sentence": "Quercetin-induced growth inhibition and cell death in prostatic carcinoma cells ( <e2> PC-3 </e2> ) are associated with increase in <e1> p21 </e1> and hypophosphorylated retinoblastoma proteins expression.", "e1": "p21", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": 4.03845, "prob_score": -0.2476176, "relevant": "1", "stops": "PHF21B - APEX1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 9, "rel_score": 4.02026, "prob_score": -0.24873573, "relevant": "1", "stops": "PHF21B - RPN1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 3.31466, "prob_score": -0.3016905, "relevant": "1", "stops": "PHF21B - central nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 3.26328, "prob_score": -0.3064359, "relevant": "1", "stops": "PHF21B - GNAI1 - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 3.02572, "prob_score": -0.33049744, "relevant": "1", "stops": "PHF21B - PEX11A - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}]}
{"qid": "279", "sentence": "The antisense oligonucleotides targeting VEGF-A significantly decreased <e1> VEGF-A protein and mRNA </e1> expression and inhibited cell migration in <e2> SKOV3 </e2> ovarian cancer cells.", "e1": "VEGF-A protein and mRNA", "e2": "SKOV3", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": -5.07511, "prob_score": -0.1970396, "relevant": "0", "stops": "VEGFA - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "280", "sentence": "<e2> Prostate cancer </e2> bony metastases show increased expression of the <e1> PTH receptor </e1> (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.", "e1": "PTH receptor", "e2": "Prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 4, "rel_score": 38.66976, "prob_score": -0.02585636, "relevant": "1", "stops": "PTH - testis - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 18, "rel_score": 34.95281, "prob_score": -0.02860683, "relevant": "1", "stops": "PTH2 - head - EFEMP2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 20, "rel_score": 34.80682, "prob_score": -0.028733196, "relevant": "1", "stops": "PTH2 - brain - EFEMP2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 5, "rel_score": 33.42246, "prob_score": -0.029922614, "relevant": "1", "stops": "PTH1R - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 26, "rel_score": 32.48863, "prob_score": -0.030777784, "relevant": "1", "stops": "PTH2 - Signaling Pathways - CCND1 - prostate cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - ASSOCIATES_DaG", "nodelabels": "Gene - Pathway - Gene - Disease"}]}
{"qid": "281", "sentence": "Our results strongly suggest that the induction of <e1> Cx26 protein </e1> observed in human <e2> breast cancer </e2> s, reported previously, may not be very relevant to the development of breast cancers, and that Cx26 can function as a tumor suppressor in breast cancer cells.", "e1": "Cx26 protein", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 26.0078, "prob_score": -0.038453337, "relevant": "1", "stops": "CDX2 - CCNB2 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 26, "rel_score": 25.77984, "prob_score": -0.038792633, "relevant": "1", "stops": "CDX2 - RAI14 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 35, "rel_score": 25.60164, "prob_score": -0.03905669, "relevant": "1", "stops": "CDX2 - CENPA - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": 22.14839, "prob_score": -0.045154236, "relevant": "1", "stops": "CDX2 - MTHFD2 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 20.76412, "prob_score": -0.048163153, "relevant": "1", "stops": "CDX2 - OXA1L - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "282", "sentence": "The proliferation of certain human HER2-positive <e2> breast cancer </e2> lines also requires HSF1, as its knockdown led to upregulation of <e1> p21 </e1> and/or decrease in survivin, precipitating growth arrest.", "e1": "p21", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 43, "rel_score": 2.45658, "prob_score": -0.4070692, "relevant": "1", "stops": "PHF21B - MEF2C - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 2.29933, "prob_score": -0.43491387, "relevant": "1", "stops": "PHF21B - CES1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 2.19284, "prob_score": -0.45602933, "relevant": "1", "stops": "PHF21B - CUL5 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": 2.11144, "prob_score": -0.47360778, "relevant": "1", "stops": "PHF21B - SRPX - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 20, "rel_score": 1.93293, "prob_score": -0.5173535, "relevant": "1", "stops": "PHF21B - MYC - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "283", "sentence": "AMACR was the best single marker of <e2> prostate cancer </e2> but in 7 of the 59 total cases the expression of AMACR was not significantly elevated while <e1> PSGR </e1> and/or PSGR2 were substantially elevated.", "e1": "PSGR", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 20, "rel_score": 8.48464, "prob_score": -0.11786381, "relevant": "1", "stops": "PGRMC2 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 47, "rel_score": 8.27678, "prob_score": -0.120821856, "relevant": "1", "stops": "PGR - Medroxyprogesterone Acetate - Infestation - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 36, "rel_score": 8.15395, "prob_score": -0.12264383, "relevant": "1", "stops": "PGR - Dexamethasone - Conjunctivitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 6, "rel_score": 7.74773, "prob_score": -0.12906687, "relevant": "1", "stops": "PGR - epithelium - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 7.31422, "prob_score": -0.13671711, "relevant": "1", "stops": "PGR - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "284", "sentence": "In <e2> MDA-MB-231 </e2> , TGF-beta1 had no effect on cell proliferation but increased <e1> uPA </e1> activity and PAI-1 antigen level; sodium butyrate inhibited both cell proliferation and uPA activity but had no effect on PAI-1 level.", "e1": "uPA", "e2": "MDA-MB-231", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 10, "rel_score": 8.79198, "prob_score": -0.113742806, "relevant": "1", "stops": "LPAR5 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 16, "rel_score": 8.55725, "prob_score": -0.11686267, "relevant": "1", "stops": "LPAR3 - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 8.47458, "prob_score": -0.11799763, "relevant": "1", "stops": "LPAR5 - SDC1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": 8.17127, "prob_score": -0.122383, "relevant": "1", "stops": "LPAR6 - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 21, "rel_score": 8.08669, "prob_score": -0.123662904, "relevant": "1", "stops": "LPAR3 - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "286", "sentence": "After glioma pathogenesis-related protein 1 ( <e1> GLIPR1 </e1> /Glipr1) was identified, the expression of GLIPR1 was shown to be down-regulated in human <e2> prostate cancer </e2> , owing in part to methylation in the regulatory region of this gene in prostate cancer cells.", "e1": "GLIPR1", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 9.16086, "prob_score": -0.10915559, "relevant": "1", "stops": "GLIPR1 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 8.83236, "prob_score": -0.11322072, "relevant": "1", "stops": "GLIPR1 - CREG1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 6.99594, "prob_score": -0.14294276, "relevant": "1", "stops": "GLIPR1L1 - medulla oblongata - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 6.8018, "prob_score": -0.14701867, "relevant": "1", "stops": "GLIPR1L1 - testis - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 6.68941, "prob_score": -0.14949325, "relevant": "1", "stops": "GLIPR1L1 - testis - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "287", "sentence": "These findings therefore suggest that <e1> Akt </e1> activation induces endocrine resistance in metastatic <e2> breast cancer </e2> , irrespective of the kind of endocrine agents that were administered.", "e1": "Akt", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 17, "rel_score": -1.9887, "prob_score": -0.5028432, "relevant": "0", "stops": "AKT3 - CASP3 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": -2.01377, "prob_score": -0.49657866, "relevant": "0", "stops": "AKT3 - TOP2A - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": -2.09578, "prob_score": -0.47715008, "relevant": "0", "stops": "AKT3 - TYMS - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 37, "rel_score": -2.11914, "prob_score": -0.4718925, "relevant": "0", "stops": "AKT3 - bone marrow - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": -2.25606, "prob_score": -0.4432505, "relevant": "0", "stops": "AKT3 - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "288", "sentence": "<e1> BCSG1 </e1> -siRNA down-regulates the expression of BCSG1 and inhibits effectively growth of the transplaned human <e2> breast cancer </e2> cell line in nude mice.", "e1": "BCSG1", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 28, "rel_score": -3.1295, "prob_score": -0.3195398, "relevant": "0", "stops": "CSAG1 - testis - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 32, "rel_score": -5.49058, "prob_score": -0.18212904, "relevant": "0", "stops": "CSAG1 - brain - GRIN1 - Memantine - Breast cancer female", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": -7.28491, "prob_score": -0.13726832, "relevant": "0", "stops": "CSAG1 - lung - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": -7.5861, "prob_score": -0.13182327, "relevant": "0", "stops": "CSAG1 - heart - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -8.73286, "prob_score": -0.11451292, "relevant": "0", "stops": "CSAG1 - female gonad - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "289", "sentence": "The non-receptor PTK termed <e2> breast tumor </e2> kinase ( <e1> Brk/PTK6 </e1> ) is overexpressed in approximately 86% of human breast tumors.", "e1": "Brk/PTK6", "e2": "breast tumor", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 12.43317, "prob_score": -0.08043202, "relevant": "1", "stops": "BRK1 - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 11.52074, "prob_score": -0.08679565, "relevant": "1", "stops": "BRK1 - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 11.25366, "prob_score": -0.0888565, "relevant": "1", "stops": "BRK1 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 10.91227, "prob_score": -0.09164193, "relevant": "1", "stops": "BRK1 - bone marrow - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 23, "rel_score": 7.83269, "prob_score": -0.1276706, "relevant": "1", "stops": "BRK1 - cerebellum - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}]}
{"qid": "290", "sentence": "Here we show that heterozygous inactivation of the tumor suppressor gene Pten leads to the formation of basal-like mammary tumors in mice, and that loss of <e1> PTEN </e1> expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary <e2> breast cancers </e2> .", "e1": "PTEN", "e2": "breast cancers", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": -13.75327, "prob_score": -0.07270827, "relevant": "0", "stops": "PTEN - MLLT11 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -13.81597, "prob_score": -0.072377264, "relevant": "0", "stops": "PTEN - TXNDC9 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": -14.61775, "prob_score": -0.0684056, "relevant": "0", "stops": "PTEN - P4HTM - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": -17.0911, "prob_score": -0.05851006, "relevant": "0", "stops": "PTEN - P4HTM - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -20.22654, "prob_score": -0.049437057, "relevant": "0", "stops": "PTEN - PXN - Fulvestrant - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "294", "sentence": "L-mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and <e1> N-myc downstream regulated gene 1 </e1> in <e2> prostate carcinoma </e2> cells.", "e1": "N-myc downstream regulated gene 1", "e2": "prostate carcinoma", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 5, "rel_score": 2.1889, "prob_score": -0.4568459, "relevant": "1", "stops": "TP73 - MYC - Testosterone - Prostate carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 1.93184, "prob_score": -0.5176409, "relevant": "1", "stops": "TMEM14C - uterine cervix - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 1.86543, "prob_score": -0.53606933, "relevant": "1", "stops": "TP73 - IKBKB - Paroxetine - Prostate carcinoma", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 1.74954, "prob_score": -0.5715821, "relevant": "1", "stops": "TMEM14C - pituitary gland - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 1.74578, "prob_score": -0.5728073, "relevant": "1", "stops": "TMEM14C - cardiac ventricle - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "296", "sentence": "Overexpression of the enhancer of zeste homolog 2 ( <e1> EZH2 </e1> ) protein, a known repressor of gene transcription, has been reported to be associated with biological malignancy of <e2> prostate cancer </e2> and several other cancers.", "e1": "EZH2", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 1.67434, "prob_score": -0.5972532, "relevant": "1", "stops": "EZH2 - Paroxetine - Prostate cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": -1.49786, "prob_score": -0.66762304, "relevant": "0", "stops": "EZH2 - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 3, "rel_score": -1.53513, "prob_score": -0.65140676, "relevant": "0", "stops": "EZH2 - CRBN - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -1.63824, "prob_score": -0.6104074, "relevant": "0", "stops": "EZH2 - TNFSF11 - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": -1.68413, "prob_score": -0.59378076, "relevant": "0", "stops": "EZH2 - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "298", "sentence": "AGR2 knockdown induced cell death in <e2> ZR-75-1 </e2> and T47 D cells, and also downregulated survivin and <e1> c-Myc </e1> .", "e1": "c-Myc", "e2": "ZR-75-1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 49, "rel_score": 2.70893, "prob_score": -0.36914754, "relevant": "1", "stops": "MYCT1 - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 44, "rel_score": 2.64901, "prob_score": -0.37750155, "relevant": "1", "stops": "MYCT1 - pituitary gland - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 24, "rel_score": 2.59289, "prob_score": -0.3856747, "relevant": "1", "stops": "MYCN - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": 2.45906, "prob_score": -0.40666378, "relevant": "1", "stops": "MYCN - PCNA - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": 2.39017, "prob_score": -0.41837615, "relevant": "1", "stops": "MYCN - PRC1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "299", "sentence": "IL-1-alpha induced a moderate level of HLA class I antigen in ZR-75-1, <e2> BT-20 </e2> and MDA-MB-468 cells, and <e1> HLA class II (DR) </e1> expression only in ZR-75-1 cells.", "e1": "HLA class II (DR)", "e2": "BT-20", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 9.91965, "prob_score": -0.10081012, "relevant": "1", "stops": "HHLA1 - RBBP8NL - female reproductive system - breast cancer", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 9.70591, "prob_score": -0.10303086, "relevant": "1", "stops": "HHLA1 - RBBP8NL - hematologic cancer - Gemcitabine - Breast cancer", "reltypes": "COVARIES_GcG - UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Gene - Disease - Compound - SideEffect"}, {"pathid": 0, "rel_score": 9.36856, "prob_score": -0.10674265, "relevant": "1", "stops": "HHLA1 - RBBP8NL - adipose tissue - breast cancer", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 8.48033, "prob_score": -0.117923, "relevant": "1", "stops": "HHLA1 - RBBP8NL - hematologic cancer - Mitoxantrone - Breast cancer stage IV", "reltypes": "COVARIES_GcG - UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Gene - Disease - Compound - SideEffect"}]}
{"qid": "300", "sentence": "<e1> CCBE1 </e1> is expressed in normal ovary, but is reduced in <e2> ovarian cancer </e2> cell lines and primary carcinomas.", "e1": "CCBE1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 18.32845, "prob_score": -0.054560214, "relevant": "1", "stops": "CCBE1 - CEP55 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 17.66472, "prob_score": -0.05661055, "relevant": "1", "stops": "CCBE1 - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 16.70286, "prob_score": -0.05987029, "relevant": "1", "stops": "CCBE1 - vagina - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 14.92983, "prob_score": -0.06697512, "relevant": "1", "stops": "CCBE1 - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": 14.26533, "prob_score": -0.0700952, "relevant": "1", "stops": "CCBE1 - uterine cervix - ovarian cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "301", "sentence": "Amplification or overexpression of the <e1> c-erbB-2 oncogene </e1> (also known as HER-2, neu) is a frequent event in many types of human cancer including 20-30% of <e2> ovarian cancers </e2> where it characterizes a group of patients with poor prognosis (1,2).", "e1": "c-erbB-2 oncogene", "e2": "ovarian cancers", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": -2.22351, "prob_score": -0.44973865, "relevant": "0", "stops": "CPEB3 - head - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": -2.5599, "prob_score": -0.39063814, "relevant": "0", "stops": "CPEB3 - liver - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": -2.59707, "prob_score": -0.38504693, "relevant": "0", "stops": "CPEB3 - lung - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -3.12607, "prob_score": -0.31989405, "relevant": "0", "stops": "CPEB3 - pituitary gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": -3.35683, "prob_score": -0.29790366, "relevant": "0", "stops": "CPEB3 - trigeminal ganglion - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "302", "sentence": "We have also shown that arsenite specifically induces <e1> HIF-1alpha </e1> , but not HIF-1beta, protein levels in <e2> prostate cancer </e2> cells in a mTOR-dependent manner.", "e1": "HIF-1alpha", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 2.52729, "prob_score": -0.3956842, "relevant": "1", "stops": "HIF1AN - TMEM5 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 2.51168, "prob_score": -0.3981358, "relevant": "1", "stops": "HIF1AN - GDF15 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 2.44846, "prob_score": -0.4084227, "relevant": "1", "stops": "HIF1AN - PCNA - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "rel_score": 2.43748, "prob_score": -0.41025698, "relevant": "1", "stops": "HIF1AN - ELAC2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 25, "rel_score": 2.43185, "prob_score": -0.41121328, "relevant": "1", "stops": "HIF1AN - APEX1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "304", "sentence": "Immunoblotting analysis demonstrated that <e1> PRB protein </e1> expression was markedly up-regulated in <e2> OVCAR-3 </e2> , whereas the PRA and PRB isoforms both appeared to be increased in NOV-31.", "e1": "PRB protein", "e2": "OVCAR-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 7.02839, "prob_score": -0.14228275, "relevant": "1", "stops": "PREB - Estradiol - Ovarian cancer", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 6.56556, "prob_score": -0.15230523, "relevant": "1", "stops": "PREB - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 9, "rel_score": 5.98982, "prob_score": -0.16695221, "relevant": "1", "stops": "PREB - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": 5.97229, "prob_score": -0.16743699, "relevant": "1", "stops": "PREB - gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 5.5063, "prob_score": -0.18161437, "relevant": "1", "stops": "PREB - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "305", "sentence": "First, a comprehensive serial immunohistochemical analysis of primary and metastatic <e2> prostate cancer </e2> samples showed increased stage-specific expression of <e1> IL-11Ralpha </e1> during disease progression.", "e1": "IL-11Ralpha", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 8.93575, "prob_score": -0.11191242, "relevant": "1", "stops": "IL1RAPL2 - liver - PTEN - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 10, "rel_score": 8.85818, "prob_score": -0.11288736, "relevant": "1", "stops": "IL1RAPL2 - endocrine gland - EFEMP2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 26, "rel_score": 8.69263, "prob_score": -0.115041904, "relevant": "1", "stops": "IL1RAPL2 - brain - CCND1 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 2, "rel_score": 8.66927, "prob_score": -0.1153508, "relevant": "1", "stops": "IL1RAPL2 - endocrine gland - PLEK2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 5, "rel_score": 8.65127, "prob_score": -0.11559216, "relevant": "1", "stops": "IL1RAPL2 - brain - EFEMP2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}]}
{"qid": "306", "sentence": "L-mimosine blocks cell proliferation via upregulation of <e1> B-cell translocation gene 2 </e1> and N-myc downstream regulated gene 1 in <e2> prostate carcinoma </e2> cells.", "e1": "B-cell translocation gene 2", "e2": "prostate carcinoma", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 3, "rel_score": -1.74663, "prob_score": -0.5725348, "relevant": "0", "stops": "MBOAT7 - TMEM109 - Testosterone - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": -1.75762, "prob_score": -0.5689544, "relevant": "0", "stops": "MBOAT2 - BIRC5 - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": -1.88615, "prob_score": -0.53018475, "relevant": "0", "stops": "MBOAT7 - RPIA - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": -1.88708, "prob_score": -0.5299239, "relevant": "0", "stops": "MBOAT7 - HIST2H2BE - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": -1.92341, "prob_score": -0.51990914, "relevant": "0", "stops": "MBOAT7 - ARID5B - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "307", "sentence": "One of these kinases, Erk5, has been found to reside in the nucleus of <e2> breast cancer </e2> cells that overexpress the <e1> ErbB2 receptor </e1> .", "e1": "ErbB2 receptor", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 44, "rel_score": -3.16506, "prob_score": -0.31594545, "relevant": "0", "stops": "ERBB2IP - TIMP2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": -3.4229, "prob_score": -0.29215217, "relevant": "0", "stops": "ERBB2IP - TNIP1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": -3.51556, "prob_score": -0.28445333, "relevant": "0", "stops": "ERBB2IP - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": -3.74448, "prob_score": -0.26705834, "relevant": "0", "stops": "ERBB2 - RPS4Y1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -4.06918, "prob_score": -0.24575454, "relevant": "0", "stops": "ERBB2IP - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "309", "sentence": "Thus, even when C2GnT1 is expressed, the O-glycans added to MUC1 become core 1-dominated structures, provided expression of <e1> ST3Gal-I </e1> is increased as it is in <e2> breast cancer </e2> .", "e1": "ST3Gal-I", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 2.28446, "prob_score": -0.43774194, "relevant": "1", "stops": "ST3GAL6 - tendon - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 2.19848, "prob_score": -0.4548559, "relevant": "1", "stops": "ST3GAL6 - telencephalon - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 2.11573, "prob_score": -0.47265008, "relevant": "1", "stops": "ST3GAL6 - female reproductive system - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 1.94624, "prob_score": -0.5138074, "relevant": "1", "stops": "ST3GAL6 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 1.80986, "prob_score": -0.55252576, "relevant": "1", "stops": "ST3GAL6 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "310", "sentence": "Loss of <e1> c-kit </e1> expression has been reported in 80-90% of <e2> breast cancer </e2> specimens, suggesting a possible role in the development of tumors.", "e1": "c-kit", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": 6.79948, "prob_score": -0.14706637, "relevant": "1", "stops": "CITED1 - uterus - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 8, "rel_score": 6.62296, "prob_score": -0.15098503, "relevant": "1", "stops": "CITED2 - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 27, "rel_score": 6.62164, "prob_score": -0.15102105, "relevant": "1", "stops": "CITED1 - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": 6.51042, "prob_score": -0.15360269, "relevant": "1", "stops": "CITED2 - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": 6.11023, "prob_score": -0.16365555, "relevant": "1", "stops": "CITED4 - TFAP2A - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "312", "sentence": "Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with <e2> prostatic cancer </e2> prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and <e1> alpha 2-globulin </e1> and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.", "e1": "alpha 2-globulin", "e2": "prostatic cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 26, "rel_score": 7.87836, "prob_score": -0.12693083, "relevant": "1", "stops": "APH1A - pancreas - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 7.48279, "prob_score": -0.13364217, "relevant": "1", "stops": "APH1A - prostate gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 7.43494, "prob_score": -0.13450368, "relevant": "1", "stops": "APH1A - lung - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 4.84027, "prob_score": -0.20660467, "relevant": "1", "stops": "APH1A - TNFRSF21 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 4.7808, "prob_score": -0.20917131, "relevant": "1", "stops": "APH1A - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "313", "sentence": "The overexpressed <e1> GRB7 </e1> (P = 0.009) and GRB7v (P = 0.017) were significantly correlated with high-grade <e2> ovarian cancer </e2> .", "e1": "GRB7", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 13, "rel_score": 8.42247, "prob_score": -0.11872651, "relevant": "1", "stops": "GRB7 - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 20, "rel_score": 8.07168, "prob_score": -0.1238855, "relevant": "1", "stops": "GRB7 - POT1 - ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": 7.81372, "prob_score": -0.12797928, "relevant": "1", "stops": "GRB7 - MLH1 - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 7.39317, "prob_score": -0.13525596, "relevant": "1", "stops": "GRB7 - CAV1 - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "rel_score": 7.22387, "prob_score": -0.13842697, "relevant": "1", "stops": "GRB7 - endometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "314", "sentence": "Interestingly, <e2> MDA-MB-231 </e2> cells showed dramatic enrichment of VASP at their leading edge when <e1> Pfn1 </e1> expression was downregulated and this observation was also reproducible in other cell types including human mammary epithelial cells and vascular endothelial cells.", "e1": "Pfn1", "e2": "MDA-MB-231", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 44, "rel_score": 8.59845, "prob_score": -0.11630445, "relevant": "1", "stops": "PFN1 - NOTCH2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 7.85176, "prob_score": -0.12736389, "relevant": "1", "stops": "PFN1 - HIST1H2BK - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 13, "rel_score": 7.4173, "prob_score": -0.13481884, "relevant": "1", "stops": "PFN1 - BCL2L1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 7.31797, "prob_score": -0.13664807, "relevant": "1", "stops": "PFN1 - GNAI1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 6.97204, "prob_score": -0.14342824, "relevant": "1", "stops": "PFN1 - TK1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "316", "sentence": "<e1> p53 </e1> accumulation in <e2> ovarian carcinomas </e2> and its prognostic implications.", "e1": "p53", "e2": "ovarian carcinomas", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": -11.83572, "prob_score": -0.08448651, "relevant": "0", "stops": "TP53INP2 - endocrine gland - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": -12.84192, "prob_score": -0.077873215, "relevant": "0", "stops": "TP53INP2 - bronchus - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": -13.43183, "prob_score": -0.07444887, "relevant": "0", "stops": "TP53INP2 - spinal cord - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": -13.85233, "prob_score": -0.07219444, "relevant": "0", "stops": "TP53INP2 - uterine cervix - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": -15.88058, "prob_score": -0.062968284, "relevant": "0", "stops": "TP53INP2 - retina - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "317", "sentence": "The drug-resistant cell lines include <e2> ovarian cancer </e2> cell lines resistant to cisplatin, topotecan, adriamycin and paclitaxel overexpressing <e1> class III beta-tubulin </e1> , A2780TC1 and A2780TC3.", "e1": "class III beta-tubulin", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 3.47222, "prob_score": -0.28800157, "relevant": "1", "stops": "CASS4 - brain - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 3.44804, "prob_score": -0.29001778, "relevant": "1", "stops": "CASS4 - blood - CYP2C19 - Estradiol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 3.3687, "prob_score": -0.29685426, "relevant": "1", "stops": "CASS4 - blood - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 2.84325, "prob_score": -0.35171232, "relevant": "1", "stops": "CASS4 - prostate gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 2.79291, "prob_score": -0.35804608, "relevant": "1", "stops": "CASS4 - prostate gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "318", "sentence": "<e1> CTEN (C-terminal tensin-like) </e1> , a novel oncogene overexpressed in invasive <e2> breast carcinoma </e2> of poor prognosis.", "e1": "CTEN (C-terminal tensin-like)", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 37, "rel_score": 1.49238, "prob_score": -0.6700696, "relevant": "1", "stops": "CETN1 - calcium ion binding - GRIN1 - Memantine - Breast cancer female", "reltypes": "PARTICIPATES_GpMF - PARTICIPATES_GpMF - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - MolecularFunction - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": -1.77756, "prob_score": -0.56256574, "relevant": "0", "stops": "CETN1 - cerebellum - GRIN1 - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": -2.12373, "prob_score": -0.47087407, "relevant": "0", "stops": "CETN1 - testis - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 30, "rel_score": -2.26285, "prob_score": -0.44192195, "relevant": "0", "stops": "CETN1 - protein complex binding - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "PARTICIPATES_GpMF - PARTICIPATES_GpMF - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - MolecularFunction - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": -3.4571, "prob_score": -0.28926495, "relevant": "0", "stops": "CETN1 - cerebellum - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}]}
{"qid": "319", "sentence": "The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in <e2> LNCaP </e2> -19 compared to LNCaP, while expression of midkine and <e1> VEGF </e1> were increased.", "e1": "VEGF", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 5.60821, "prob_score": -0.17831212, "relevant": "1", "stops": "VEGFA - NNT - Ropinirole - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 5.04337, "prob_score": -0.19827874, "relevant": "1", "stops": "VEGFA - INPP1 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 4.93316, "prob_score": -0.20271476, "relevant": "1", "stops": "VEGFA - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 21, "rel_score": 4.71676, "prob_score": -0.21200836, "relevant": "1", "stops": "VEGFA - CHMP4A - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 4.57477, "prob_score": -0.21858916, "relevant": "1", "stops": "VEGFA - ALDOC - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "320", "sentence": "In summary, in patients with primary <e2> ovarian cancer </e2> , overexpression of <e1> MRP1 </e1> is an adverse marker for patient outcome and cancer aggressiveness.", "e1": "MRP1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 15.19064, "prob_score": -0.06582595, "relevant": "1", "stops": "MRPL1 - saliva-secreting gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 13.07531, "prob_score": -0.076476, "relevant": "1", "stops": "MRPL1 - endometrium - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - UPREGULATES_AuG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 12.47972, "prob_score": -0.080133826, "relevant": "1", "stops": "MRPL13 - CCNB1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 12.28954, "prob_score": -0.08137233, "relevant": "1", "stops": "MRPL13 - PBXIP1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 12.27747, "prob_score": -0.08144955, "relevant": "1", "stops": "MRPL1 - uterine cervix - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "321", "sentence": "Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in <e2> ovarian cancer </e2> cells: possible role of up-regulation of <e1> insulin-like growth factor-1 </e1> by hCG.", "e1": "insulin-like growth factor-1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 30, "rel_score": -6.20887, "prob_score": -0.16106203, "relevant": "0", "stops": "INSL5 - nervous system - SATB1 - Estriol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": -6.66178, "prob_score": -0.15010688, "relevant": "0", "stops": "INSL5 - vagina - CYP2C19 - Estradiol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": -6.80457, "prob_score": -0.14696123, "relevant": "0", "stops": "INSL5 - central nervous system - SATB1 - Clomifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -6.87711, "prob_score": -0.14541136, "relevant": "0", "stops": "INSL5 - nervous system - MTHFD2 - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": -7.15154, "prob_score": -0.1398328, "relevant": "0", "stops": "INSL5 - digestive system - CYP2C19 - Estradiol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "322", "sentence": "<e1> Polycomb-group oncogenes EZH2 </e1> , BMI1, and RING1 are overexpressed in <e2> prostate cancer </e2> with adverse pathologic and clinical features.", "e1": "Polycomb-group oncogenes EZH2", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 1.86442, "prob_score": -0.5363644, "relevant": "1", "stops": "POLM - seminal vesicle - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 1.84128, "prob_score": -0.5431029, "relevant": "1", "stops": "POLM - female reproductive system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 1.59829, "prob_score": -0.62567085, "relevant": "1", "stops": "POLM - respiratory system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 1.5723, "prob_score": -0.63601166, "relevant": "1", "stops": "POLM - digestive system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 1.5277, "prob_score": -0.65458083, "relevant": "1", "stops": "POLM - renal system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "323", "sentence": "<e2> SKOV3 </e2> , but not two alphaFR-negative non-ovarian cell lines, exhibited down-regulation of cav-1 expression following stable <e1> alphaFR cDNA </e1> transfection.", "e1": "alphaFR cDNA", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 45, "rel_score": 5.80754, "prob_score": -0.17219356, "relevant": "1", "stops": "SPHAR - cardiovascular system - MYC - Progesterone - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 5.46986, "prob_score": -0.18281715, "relevant": "1", "stops": "SPHAR - cardiovascular system - ETS1 - Estradiol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 5.34759, "prob_score": -0.18699902, "relevant": "1", "stops": "SPHAR - blood vessel - ABCB1 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 5.06355, "prob_score": -0.19748561, "relevant": "1", "stops": "SPHAR - DNA replication - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 4.54236, "prob_score": -0.22015113, "relevant": "1", "stops": "SPHAR - DNA metabolic process - CSNK1E - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "324", "sentence": "In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and <e1> BMPR-II </e1> , in <e2> prostate cancer </e2> cells, both in vitro and in vivo.", "e1": "BMPR-II", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 4.48109, "prob_score": -0.22315659, "relevant": "1", "stops": "MPRIP - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 16, "rel_score": 3.55038, "prob_score": -0.2816584, "relevant": "1", "stops": "MPRIP - nervous system - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 3.4644, "prob_score": -0.28864866, "relevant": "1", "stops": "MPRIP - Afatinib - Unspecified disorder of skin and subcutaneous tissue - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 45, "rel_score": 3.26413, "prob_score": -0.30636376, "relevant": "1", "stops": "MPRIP - Afatinib - Alopecia - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 37, "rel_score": 3.21543, "prob_score": -0.3109952, "relevant": "1", "stops": "MPRIP - lung - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}]}
{"qid": "326", "sentence": "We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 ( <e1> DR3 </e1> ) was increased in <e2> PC3 </e2> cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.", "e1": "DR3", "e2": "PC3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 46, "rel_score": 3.79046, "prob_score": -0.26381588, "relevant": "1", "stops": "WDR31 - JADE2 - RNASE4 - prostate cancer", "reltypes": "COVARIES_GcG - REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 44, "rel_score": 3.59092, "prob_score": -0.27848345, "relevant": "1", "stops": "WDR31 - JADE2 - ETV1 - prostate cancer", "reltypes": "COVARIES_GcG - REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 13, "rel_score": 3.37678, "prob_score": -0.2961403, "relevant": "1", "stops": "WDR36 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 32, "rel_score": 3.21069, "prob_score": -0.31146118, "relevant": "1", "stops": "WDR37 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "rel_score": 2.97921, "prob_score": -0.33566123, "relevant": "1", "stops": "WDR36 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "327", "sentence": "In <e2> MCF-7 </e2> , an increase in <e1> Bad </e1> and Bax protein expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed.", "e1": "Bad", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 9.67118, "prob_score": -0.103397146, "relevant": "1", "stops": "BAD - EIF2S2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 9.10747, "prob_score": -0.10980122, "relevant": "1", "stops": "BAD - TP53 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": 9.09008, "prob_score": -0.110013634, "relevant": "1", "stops": "BAD - PIM1 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 8.26241, "prob_score": -0.12103209, "relevant": "1", "stops": "BAD - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 8.17595, "prob_score": -0.1223109, "relevant": "1", "stops": "BAD - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "328", "sentence": "In contrast to previous findings by others, <e1> PPAR-gamma </e1> ligands did not induce PPAR-gamma expression in EC or <e2> PC-3 </e2> .", "e1": "PPAR-gamma", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 42.8449, "prob_score": -0.023335677, "relevant": "1", "stops": "PPARA - MAL - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 42.44482, "prob_score": -0.023563463, "relevant": "1", "stops": "PPARA - DERA - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 41.73623, "prob_score": -0.023963198, "relevant": "1", "stops": "PPARA - CYTH1 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 41.61465, "prob_score": -0.024030162, "relevant": "1", "stops": "PPARA - PFN1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 39.21569, "prob_score": -0.025497831, "relevant": "1", "stops": "PPARA - SATB1 - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "329", "sentence": "The data also show that LY294002 directly inhibits vascular endothelial growth factor ( <e1> VEGF </e1> ) protein expression and release from <e2> ovarian carcinoma </e2> and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.", "e1": "VEGF", "e2": "ovarian carcinoma", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": -7.10379, "prob_score": -0.14077093, "relevant": "0", "stops": "VEGFA - THAP11 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": -7.1144, "prob_score": -0.14055856, "relevant": "0", "stops": "VEGFA - MSRA - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": -7.13012, "prob_score": -0.14025462, "relevant": "0", "stops": "VEGFA - CCDC86 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": -7.81739, "prob_score": -0.12792443, "relevant": "0", "stops": "VEGFA - ZDHHC6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": -7.88457, "prob_score": -0.1268293, "relevant": "0", "stops": "VEGFA - LOXL1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "330", "sentence": "Response to bicalutamide in <e2> LNCaP </e2> cells was represented by downregulation of androgen-regulated genes, activation of the <e1> p53 </e1> pathway and inhibition of telomerase, which was associated with downregulation of v-myc avian myelocytomatosis viral oncogene homologue (MYC) and telomerase reverse transcriptase subunit.", "e1": "p53", "e2": "LNCaP", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": 1.44976, "prob_score": -0.6897699, "relevant": "1", "stops": "TP53RK - SMNDC1 - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": -1.42422, "prob_score": -0.7021361, "relevant": "0", "stops": "TP53INP2 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 19, "rel_score": -1.44848, "prob_score": -0.69038045, "relevant": "0", "stops": "TP53RK - CSRP1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": -1.52121, "prob_score": -0.65736604, "relevant": "0", "stops": "TP53RK - ADRB2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 20, "rel_score": -1.52147, "prob_score": -0.65725946, "relevant": "0", "stops": "TP53RK - GADD45A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "331", "sentence": "In <e2> MDA-MB-231 </e2> breast carcinoma cells, Taxo did not interfere with the re-activation of E-cadherin and <e1> maspin genes </e1> by 5-AZA-CdR.", "e1": "maspin genes", "e2": "MDA-MB-231", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 27, "rel_score": 34.12969, "prob_score": -0.029303592, "relevant": "1", "stops": "ASPN - endocrine gland - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 31.69572, "prob_score": -0.03154707, "relevant": "1", "stops": "ASPN - decidua - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 29.48113, "prob_score": -0.03392374, "relevant": "1", "stops": "ASPN - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 28.73563, "prob_score": -0.03479894, "relevant": "1", "stops": "ASPN - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 8, "rel_score": 24.63054, "prob_score": -0.04059749, "relevant": "1", "stops": "ASPN - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "332", "sentence": "In a murine prostate tumour model, infusion of recombinant HGF resulted in an increase in the levels of both BMPR-IB and <e1> BMPR-II transcript </e1> in <e2> prostate tumours </e2> .", "e1": "BMPR-II transcript", "e2": "prostate tumours", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 17, "rel_score": 4.28302, "prob_score": -0.23347817, "relevant": "1", "stops": "BMPER - brain - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 4.15766, "prob_score": -0.24052103, "relevant": "1", "stops": "BMPER - nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 4.05219, "prob_score": -0.24678248, "relevant": "1", "stops": "BMPER - lung - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 4.04989, "prob_score": -0.24692489, "relevant": "1", "stops": "BMPER - testis - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 3.66797, "prob_score": -0.27262646, "relevant": "1", "stops": "BMPER - adrenal gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "333", "sentence": "[Overexpression of <e1> p53 protein </e1> in <e2> ovarian carcinomas </e2> : correlation with histopathologic data and clinical course].", "e1": "p53 protein", "e2": "ovarian carcinomas", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": -2.42401, "prob_score": -0.4125351, "relevant": "0", "stops": "TP53INP2 - endocrine gland - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": -2.4564, "prob_score": -0.4070952, "relevant": "0", "stops": "TP53INP2 - pituitary gland - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": -2.53152, "prob_score": -0.3950179, "relevant": "0", "stops": "TP53INP2 - islet of Langerhans - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": -2.61458, "prob_score": -0.38247117, "relevant": "0", "stops": "TP53INP2 - thyroid gland - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": -3.10897, "prob_score": -0.32165208, "relevant": "0", "stops": "TP53INP2 - uterine cervix - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "334", "sentence": "DPPIV reexpression in <e2> prostate cancer </e2> cells blocks nuclear localization of <e1> bFGF </e1> , reduces bFGF levels, inhibits mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK)1/2 activation, and decreases levels of urokinase-type plasminogen activator, known downstream effectors of bFGF signaling pathway.", "e1": "bFGF", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": 4.32919, "prob_score": -0.23098987, "relevant": "1", "stops": "FGF16 - neuron projection morphogenesis - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 39, "rel_score": 4.15697, "prob_score": -0.24056427, "relevant": "1", "stops": "FGF16 - cell part morphogenesis - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 44, "rel_score": 3.9681, "prob_score": -0.2520093, "relevant": "1", "stops": "FGF16 - Signaling by NGF - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - ASSOCIATES_DaG", "nodelabels": "Gene - Pathway - Gene - Disease"}, {"pathid": 16, "rel_score": 3.57462, "prob_score": -0.27974898, "relevant": "1", "stops": "FGF16 - positive regulation of MAPK cascade - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 10, "rel_score": 3.39075, "prob_score": -0.29492453, "relevant": "1", "stops": "FGF16 - positive regulation of cell proliferation - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "336", "sentence": "Expression and overexpression of the epidermal growth factor receptor ( <e1> EGFR </e1> ) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and <e2> ovarian cancers </e2> .", "e1": "EGFR", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 7.68344, "prob_score": -0.13015367, "relevant": "1", "stops": "EGFR - Docetaxel - Ovarian cancer", "reltypes": "BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "337", "sentence": "Moreover, cav-1 expression was induced in <e2> IGROV1 </e2> cells by transfection with intracellular anti- <e1> alphaFR </e1> antibodies to downmodulate alphaFR expression.", "e1": "alphaFR", "e2": "IGROV1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 5.74284, "prob_score": -0.17413142, "relevant": "1", "stops": "SPHAR - cardiovascular system - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 5.46568, "prob_score": -0.18296109, "relevant": "1", "stops": "SPHAR - cardiovascular system - CCND1 - Estradiol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 5.3516, "prob_score": -0.18685816, "relevant": "1", "stops": "SPHAR - cardiovascular system - ABCB1 - Conjugated Estrogens - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 4.88591, "prob_score": -0.20467076, "relevant": "1", "stops": "SPHAR - blood vessel - ABCB1 - Estriol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 4.66244, "prob_score": -0.21447983, "relevant": "1", "stops": "SPHAR - DNA replication - POLD1 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "338", "sentence": "Our results support ongoing therapeutic attempts of <e1> EGFR </e1> inhibition in subgroups of patients with <e2> prostate cancer </e2> .", "e1": "EGFR", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 28, "rel_score": 2.75209, "prob_score": -0.36336127, "relevant": "1", "stops": "EGFR - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 46, "rel_score": 2.75058, "prob_score": -0.36356437, "relevant": "1", "stops": "EGFR - Parkinson's disease - Tolcapone - Prostate cancer", "reltypes": "UPREGULATES_DuG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 33, "rel_score": 1.93892, "prob_score": -0.5157486, "relevant": "1", "stops": "EGFR - CSTA - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 1.89122, "prob_score": -0.52875614, "relevant": "1", "stops": "EGFR - POLR2I - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 1.62135, "prob_score": -0.6167685, "relevant": "1", "stops": "EGFR - PUF60 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "339", "sentence": "Sustained increase of the <e1> c-myc gene product </e1> was detectable in <e2> PC-3 </e2> but not in DU-145 cells.", "e1": "c-myc gene product", "e2": "PC-3", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": -1.46841, "prob_score": -0.6810134, "relevant": "0", "stops": "MYCN - GJA1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "rel_score": -1.48122, "prob_score": -0.6751207, "relevant": "0", "stops": "MYCN - CD82 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 35, "rel_score": -1.68996, "prob_score": -0.5917305, "relevant": "0", "stops": "MYCBP - FBXO11 - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 31, "rel_score": -1.77585, "prob_score": -0.5631133, "relevant": "0", "stops": "MYCBP - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 33, "rel_score": -1.77781, "prob_score": -0.56248975, "relevant": "0", "stops": "MYCBP - MYC - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "341", "sentence": "<e2> Prostate cancer </e2> bony metastases show increased expression of the <e1> PTH </e1> receptor (PTH-IR) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.", "e1": "PTH", "e2": "Prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 10, "rel_score": 31.0559, "prob_score": -0.032203916, "relevant": "1", "stops": "PTH1R - PTHLH - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 14, "rel_score": 26.13696, "prob_score": -0.038263462, "relevant": "1", "stops": "PTH2R - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 40, "rel_score": 22.6142, "prob_score": -0.044223655, "relevant": "1", "stops": "PTH2 - brain - KLK5 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 26, "rel_score": 22.51745, "prob_score": -0.044411678, "relevant": "1", "stops": "PTH2 - Signaling Pathways - CCND1 - prostate cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - ASSOCIATES_DaG", "nodelabels": "Gene - Pathway - Gene - Disease"}, {"pathid": 2, "rel_score": 17.7683, "prob_score": -0.056283403, "relevant": "1", "stops": "PTH - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "342", "sentence": "The overexpression of <e1> HER II </e1> is also positively correlated with other markers of prognosis of <e2> breast cancer </e2> such as cathepsin expression.", "e1": "HER II", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 2.07727, "prob_score": -0.48140353, "relevant": "1", "stops": "ERBB2IP - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": 1.99001, "prob_score": -0.5025124, "relevant": "1", "stops": "ERBB2IP - CTNNB1 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": 1.90942, "prob_score": -0.52372396, "relevant": "1", "stops": "ERBB2IP - VEGFA - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 41, "rel_score": -1.44867, "prob_score": -0.6902881, "relevant": "0", "stops": "ERBB2IP - NSDHL - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": -1.49539, "prob_score": -0.6687175, "relevant": "0", "stops": "ERBB2IP - SDHB - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "343", "sentence": "Induction of <e1> ErbB-3 </e1> expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative <e2> breast carcinomas </e2> .", "e1": "ErbB-3", "e2": "breast carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 30, "rel_score": 16.27869, "prob_score": -0.06142816, "relevant": "1", "stops": "ERBB3 - PNP - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 14.41753, "prob_score": -0.06935944, "relevant": "1", "stops": "ERBB3 - UBE2C - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 14.2511, "prob_score": -0.07017365, "relevant": "1", "stops": "ERBB3 - RRS1 - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 14.15428, "prob_score": -0.07065278, "relevant": "1", "stops": "ERBB3 - CCNB1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 13.79691, "prob_score": -0.07248033, "relevant": "1", "stops": "ERBB3 - MRPL12 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "344", "sentence": "The study suggests that <e1> IGF-II </e1> has a role in regulating AR expression in <e2> prostate cancer </e2> cells, and that the action of anti-androgens is mediated partly by an ability to suppress IGF-II expression.", "e1": "IGF-II", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 8.17996, "prob_score": -0.12224684, "relevant": "1", "stops": "IGFL2 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 7.50244, "prob_score": -0.13328889, "relevant": "1", "stops": "IGFL2 - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 1, "rel_score": 6.72948, "prob_score": -0.14859743, "relevant": "1", "stops": "IGFL2 - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 4, "rel_score": 6.17017, "prob_score": -0.16207339, "relevant": "1", "stops": "IGFL2 - hematologic cancer - Ruxolitinib - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 2, "rel_score": 4.38866, "prob_score": -0.22786482, "relevant": "1", "stops": "IGFL2 - chronic obstructive pulmonary disease - Roflumilast - Prostate cancer", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "345", "sentence": "Finally, androgen treatment of <e2> LNCaP </e2> cells upregulated specifically levels of the cyclin-dependent kinase inhibitors (CDKIs) p15INK4B and <e1> p27KIP1 </e1> .", "e1": "p27KIP1", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 3.94773, "prob_score": -0.25331125, "relevant": "1", "stops": "PDZK1IP1 - female gonad - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 3.94353, "prob_score": -0.2535803, "relevant": "1", "stops": "PDZK1IP1 - pancreas - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 3.93329, "prob_score": -0.25424224, "relevant": "1", "stops": "PDZK1IP1 - nephron tubule - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 3.89241, "prob_score": -0.2569072, "relevant": "1", "stops": "PDZK1IP1 - mammalian vulva - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 3.71195, "prob_score": -0.26940283, "relevant": "1", "stops": "PDZK1IP1 - hematopoietic system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "346", "sentence": "<e1> IGFBP2 </e1> and IGFBP5 overexpression correlates with the lymph node metastasis in T1 <e2> breast carcinomas </e2> .", "e1": "IGFBP2", "e2": "breast carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 13.83892, "prob_score": -0.07225666, "relevant": "1", "stops": "IGFBP2 - CDKN1A - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 13, "rel_score": 13.10616, "prob_score": -0.076298356, "relevant": "1", "stops": "IGFBP2 - TTK - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 12.27144, "prob_score": -0.0814913, "relevant": "1", "stops": "IGFBP2 - TK1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 43, "rel_score": 11.69864, "prob_score": -0.08547768, "relevant": "1", "stops": "IGFBP2 - SMC4 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": 11.25239, "prob_score": -0.08886799, "relevant": "1", "stops": "IGFBP2 - TRIP13 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "347", "sentence": "Moreover, we examined the putative impact of <e1> p53 </e1> MspI 1798G>A, which is completely linked to p53PIN3, a 16 bp insertion/duplication that has been associated with reduced p53 expression, on familial <e2> breast cancer </e2> risk.", "e1": "p53", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": -5.86613, "prob_score": -0.17046735, "relevant": "0", "stops": "TP53INP2 - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 38, "rel_score": -7.00722, "prob_score": -0.14271447, "relevant": "0", "stops": "TP53RK - GINS1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": -7.58725, "prob_score": -0.13180283, "relevant": "0", "stops": "TP53RK - HSP90AA1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "rel_score": -8.77501, "prob_score": -0.11395888, "relevant": "0", "stops": "TP53INP2 - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 39, "rel_score": -12.13592, "prob_score": -0.082398154, "relevant": "0", "stops": "TP53RK - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "348", "sentence": "Knockdown of HIF-1\u03b1 attenuated the increasing protein levels of both Btg2 and <e1> Ndrg1 </e1> by hypoxia or L-mimosine in <e2> LNCaP </e2> cells.", "e1": "Ndrg1", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 10.11225, "prob_score": -0.09889491, "relevant": "1", "stops": "NDRG1 - MCOLN1 - Ropinirole - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 10.07252, "prob_score": -0.09927963, "relevant": "1", "stops": "NDRG1 - MAOA - Testosterone - Prostate cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 9.47149, "prob_score": -0.10557586, "relevant": "1", "stops": "NDRG1 - ITGAE - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 9.25241, "prob_score": -0.10807613, "relevant": "1", "stops": "NDRG1 - CDC20 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 9.04977, "prob_score": -0.11049963, "relevant": "1", "stops": "NDRG1 - CDC20 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "349", "sentence": "Those patients that progressed to <e2> breast cancer </e2> (cases) showed significantly higher <e1> ER-alpha </e1> [median, 57.00% of cells within individual HUT foci; interquartile range (IQ), 33.48 to 67.78] and Ki-67 (median, 3.82%; IQ, 0.85 to 11.28) expression in their HUT foci compared with controls (ER-alpha median, 30.27%; IQ, 19.75 to 52.50 and Ki-67 median, 0.77%; IQ, 0.0458 to 1.72, P = 0.008 and <0.001).", "e1": "ER-alpha", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 3.00327, "prob_score": -0.33297116, "relevant": "1", "stops": "ERF - IL1B - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": 2.66588, "prob_score": -0.3751068, "relevant": "1", "stops": "ERF - DLD - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 2.48201, "prob_score": -0.40290058, "relevant": "1", "stops": "ERF - GNAI1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 39, "rel_score": 2.24125, "prob_score": -0.4461808, "relevant": "1", "stops": "ERF - CYCS - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 1.89761, "prob_score": -0.5269807, "relevant": "1", "stops": "ERF - CYCS - Clomifene - Breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "350", "sentence": "Exogenous uMtCK in <e2> LNCaP </e2> cells surprisingly contributed to overproduction of <e1> ROS </e1> , activation of Akt signaling pathway and more aggressive phenotypes including androgen independence development.", "e1": "ROS", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 1.81861, "prob_score": -0.54987043, "relevant": "1", "stops": "ROS1 - Crizotinib - Neuropathy - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 34, "rel_score": 1.7411, "prob_score": -0.574349, "relevant": "1", "stops": "ROS1 - Crizotinib - Infestation - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 30, "rel_score": 1.7381, "prob_score": -0.57534254, "relevant": "1", "stops": "ROS1 - bone marrow - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 0, "rel_score": 1.5571, "prob_score": -0.6422171, "relevant": "1", "stops": "ROS1 - PTPN11 - prostate cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": 1.53158, "prob_score": -0.65291864, "relevant": "1", "stops": "ROS1 - Crizotinib - Unspecified disorder of skin and subcutaneous tissue - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "352", "sentence": "The insLQ polymorphism increases <e1> LHR </e1> activity, thereby shortening <e2> breast cancer </e2> disease-free survival, probably by increasing estrogen exposure in female carriers.", "e1": "LHR", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 20, "rel_score": -2.22094, "prob_score": -0.45026428, "relevant": "0", "stops": "AHR - SCAND1 - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": -2.28066, "prob_score": -0.43846887, "relevant": "0", "stops": "AHR - VAT1 - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": -2.48182, "prob_score": -0.40292856, "relevant": "0", "stops": "AHRR - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 23, "rel_score": -2.5492, "prob_score": -0.39228263, "relevant": "0", "stops": "AHR - RNH1 - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": -2.56502, "prob_score": -0.38985604, "relevant": "0", "stops": "AHRR - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "354", "sentence": "In addition, <e1> Ang-2 </e1> levels were significantly higher in patients with ovarian carcinoma compared with patients with benign (P < 0.0005) or borderline <e2> ovarian tumors </e2> (P = 0.011).", "e1": "Ang-2", "e2": "ovarian tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 2.45014, "prob_score": -0.40814286, "relevant": "1", "stops": "ANGPT1 - IARS2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 2.34979, "prob_score": -0.42557332, "relevant": "1", "stops": "ANGPT1 - RPIA - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 2.22965, "prob_score": -0.44850212, "relevant": "1", "stops": "ANGPT1 - PDHX - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 2.2168, "prob_score": -0.45110086, "relevant": "1", "stops": "ANGPT1 - STUB1 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 2.01939, "prob_score": -0.4951959, "relevant": "1", "stops": "ANGPT1 - KIAA0753 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "356", "sentence": "Patients with invasive <e2> ovarian cancer </e2> were found to have significantly higher median <e1> c-erbB-2 oncoprotein </e1> expression than patients with either benign ovarian cyst (P = 0.002) or control groups (P = 0.001).", "e1": "c-erbB-2 oncoprotein", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": -1.48956, "prob_score": -0.6713441, "relevant": "0", "stops": "CPEB3 - parotid gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": -1.50618, "prob_score": -0.6639271, "relevant": "0", "stops": "CPEB3 - bronchus - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": -1.50912, "prob_score": -0.66263616, "relevant": "0", "stops": "CPEB3 - adrenal gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": -1.60326, "prob_score": -0.62373215, "relevant": "0", "stops": "CPEB3 - vagina - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": -1.60715, "prob_score": -0.62222147, "relevant": "0", "stops": "CPEB3 - brain - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "357", "sentence": "Elevation of <e1> GC UNC-45 </e1> levels by ectopic expression enhanced the rate of <e2> ovarian cancer </e2> cell proliferation, whereas siRNA knockdown of GC UNC-45 suppressed proliferation without altering myosin II levels.", "e1": "GC UNC-45", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 3, "rel_score": 2.85739, "prob_score": -0.34996656, "relevant": "1", "stops": "GCLC - RPS4Y1 - Estrone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 2.81476, "prob_score": -0.35527238, "relevant": "1", "stops": "GCLC - LAGE3 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 2.65668, "prob_score": -0.37640813, "relevant": "1", "stops": "GCLC - SUZ12 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 2.56292, "prob_score": -0.39017665, "relevant": "1", "stops": "GCK - ST6GALNAC2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 2.53627, "prob_score": -0.39428258, "relevant": "1", "stops": "GCLC - SCAND1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "358", "sentence": "Moreover, <e1> cav-1 </e1> expression was induced in <e2> IGROV1 </e2> cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression.", "e1": "cav-1", "e2": "IGROV1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 5.09087, "prob_score": -0.19643147, "relevant": "1", "stops": "CAV1 - breast cancer - Estrone - Ovarian cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 45, "rel_score": 4.78583, "prob_score": -0.20895089, "relevant": "1", "stops": "CAV1 - TXNRD1 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 4.76077, "prob_score": -0.21004786, "relevant": "1", "stops": "CAV1 - ILK - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 4.5977, "prob_score": -0.21750328, "relevant": "1", "stops": "CAV1 - NUP85 - Progesterone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 4.06967, "prob_score": -0.2457229, "relevant": "1", "stops": "CAV1 - MAL - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "359", "sentence": "We have previously shown that the E3 ubiquitin ligase, <e1> EDD </e1> , a regulator of DNA damage responses, is amplified and overexpressed in serous <e2> ovarian carcinoma </e2> .", "e1": "EDD", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 1.77911, "prob_score": -0.5620769, "relevant": "1", "stops": "NEDD1 - tendon - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 1.72167, "prob_score": -0.58082557, "relevant": "1", "stops": "NEDD1 - urethra - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 1.71883, "prob_score": -0.58179384, "relevant": "1", "stops": "NEDD1 - endocrine gland - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 1.70815, "prob_score": -0.58542526, "relevant": "1", "stops": "NEDD1 - tendon - ST6GALNAC2 - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 1.6942, "prob_score": -0.5902462, "relevant": "1", "stops": "NEDD1 - female gonad - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "360", "sentence": "These results support the hypothesis that <e1> EMSY </e1> overexpression can play a role in the genesis of human <e2> breast cancer </e2> .", "e1": "EMSY", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 1, "rel_score": 2.73441, "prob_score": -0.3657124, "relevant": "1", "stops": "EFS - SRC - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 27, "rel_score": 2.68197, "prob_score": -0.37286428, "relevant": "1", "stops": "EFS - Treprostinil - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 23, "rel_score": 2.34984, "prob_score": -0.4255614, "relevant": "1", "stops": "EFS - Dabrafenib - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 22, "rel_score": 2.23844, "prob_score": -0.44673905, "relevant": "1", "stops": "EFS - Dabrafenib - Pancreatitis - Memantine - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 45, "rel_score": 2.21126, "prob_score": -0.4522331, "relevant": "1", "stops": "EFS - liver - CYP2C19 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "361", "sentence": "We also observed a reduction of <e1> UBR1 protein </e1> levels in geldanamycin-treated mouse embryonic fibroblasts and human <e2> breast cancer </e2> cells, suggesting that UBR1 is an Hsp90 client.", "e1": "UBR1 protein", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 6.47584, "prob_score": -0.1544225, "relevant": "1", "stops": "UBR1 - ZNF432 - breast cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "rel_score": 6.18276, "prob_score": -0.16173726, "relevant": "1", "stops": "UBR1 - P3H2 - breast cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "rel_score": 6.15839, "prob_score": -0.16238295, "relevant": "1", "stops": "UBR1 - bone marrow - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 29, "rel_score": 5.45792, "prob_score": -0.18322162, "relevant": "1", "stops": "UBR1 - blood - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 4.10324, "prob_score": -0.24371463, "relevant": "1", "stops": "UBR1 - thyroid gland - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "362", "sentence": "In <e2> MDA-MB-231 </e2> , TGF-beta1 had no effect on cell proliferation but increased uPA activity and <e1> PAI-1 antigen </e1> level; sodium butyrate inhibited both cell proliferation and uPA activity but had no effect on PAI-1 level.", "e1": "PAI-1 antigen", "e2": "MDA-MB-231", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 16.16292, "prob_score": -0.06186585, "relevant": "1", "stops": "PAIP1 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 37, "rel_score": 15.08296, "prob_score": -0.06629527, "relevant": "1", "stops": "PAIP1 - endometrium - ST6GALNAC2 - Tamoxifen - Breast cancer male", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 15.07841, "prob_score": -0.066322826, "relevant": "1", "stops": "PAIP1 - bone marrow - ST6GALNAC2 - Tamoxifen - Breast cancer male", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 14.01149, "prob_score": -0.0713666, "relevant": "1", "stops": "PAIP1 - lymph node - ST6GALNAC2 - Tamoxifen - Breast cancer male", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 13.7893, "prob_score": -0.07251755, "relevant": "1", "stops": "PAIP1 - adrenal cortex - ST6GALNAC2 - Tamoxifen - Breast cancer male", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "364", "sentence": "In addition, <e1> Six1 </e1> overexpression renders OCC resistant to tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis, and Six1 knockdown in the TRAIL-resistant <e2> SKOV3 </e2> ovarian carcinoma line dramatically sensitizes the cells to TRAIL.", "e1": "Six1", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 10, "rel_score": 1.43125, "prob_score": -0.6986921, "relevant": "1", "stops": "SIX1 - bronchus - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -1.62046, "prob_score": -0.617107, "relevant": "0", "stops": "SIX1 - urogenital system development - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": -1.72357, "prob_score": -0.5801901, "relevant": "0", "stops": "SIX1 - embryo development - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": -1.75, "prob_score": -0.57143354, "relevant": "0", "stops": "SIX1 - striated muscle tissue development - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": -2.04847, "prob_score": -0.4881748, "relevant": "0", "stops": "SIX1 - embryonic organ morphogenesis - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "365", "sentence": "In conclusion, we provide an explanation for telomerase inhibition after androgen receptor blockade in LNCaP cells and we also report activation of the <e1> p53 </e1> pathway in LNCaP cells and in-vitro sensitivity to bicalutamide of low confluent androgen-insensitive <e2> DU145 </e2> cells.", "e1": "p53", "e2": "DU145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 31, "rel_score": 7.02839, "prob_score": -0.14227764, "relevant": "1", "stops": "TP53RK - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": 6.92377, "prob_score": -0.14443478, "relevant": "1", "stops": "TP53RK - TIMP4 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 49, "rel_score": 6.71321, "prob_score": -0.14896008, "relevant": "1", "stops": "TP53I3 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 6.57808, "prob_score": -0.15202093, "relevant": "1", "stops": "TP53RK - ELAC2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 16, "rel_score": 6.52997, "prob_score": -0.15313709, "relevant": "1", "stops": "TP53RK - MIF - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "366", "sentence": "These results show that <e1> CLDN3 </e1> and CLDN4 are frequently up-regulated in <e2> ovarian tumors </e2> and cell lines and may represent novel markers for this disease.", "e1": "CLDN3", "e2": "ovarian tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": 29.13753, "prob_score": -0.034316357, "relevant": "1", "stops": "CLDN34 - bicellular tight junction - ATP7B - ovarian cancer", "reltypes": "PARTICIPATES_GpCC - PARTICIPATES_GpCC - ASSOCIATES_DaG", "nodelabels": "Gene - CellularComponent - Gene - Disease"}, {"pathid": 35, "rel_score": 28.50627, "prob_score": -0.035076175, "relevant": "1", "stops": "CLDN34 - cell-cell junction - ATP7B - ovarian cancer", "reltypes": "PARTICIPATES_GpCC - PARTICIPATES_GpCC - ASSOCIATES_DaG", "nodelabels": "Gene - CellularComponent - Gene - Disease"}, {"pathid": 19, "rel_score": 26.91066, "prob_score": -0.037164196, "relevant": "1", "stops": "CLDN34 - occluding junction - CCND1 - ovarian cancer", "reltypes": "PARTICIPATES_GpCC - PARTICIPATES_GpCC - ASSOCIATES_DaG", "nodelabels": "Gene - CellularComponent - Gene - Disease"}, {"pathid": 2, "rel_score": 24.667, "prob_score": -0.040536568, "relevant": "1", "stops": "CLDN3 - prostate cancer - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 10, "rel_score": 20.3666, "prob_score": -0.049101107, "relevant": "1", "stops": "CLDN3 - uterine cervix - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "369", "sentence": "The drop in PCho levels following <e1> FASN </e1> inhibition was confirmed in SKOV-3 ovarian cancer cells treated with Orlistat and in <e2> MCF-7 </e2> breast cancer cells treated with Orlistat as well as cerulenin.", "e1": "FASN", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 20.9205, "prob_score": -0.047799967, "relevant": "1", "stops": "FASN - Mycophenolate mofetil - Pancreatitis - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 8, "rel_score": 18.69508, "prob_score": -0.05349487, "relevant": "1", "stops": "FASN - Irinotecan - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 10, "rel_score": 17.73993, "prob_score": -0.056366716, "relevant": "1", "stops": "FASN - Sirolimus - Pancreatitis - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 2, "rel_score": 16.82935, "prob_score": -0.05942036, "relevant": "1", "stops": "FASN - Sorafenib - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 43, "rel_score": 10.36162, "prob_score": -0.09651211, "relevant": "1", "stops": "FASN - Sorafenib - Gynaecomastia - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "370", "sentence": "In <e2> breast cancer </e2> cells overexpressing <e1> ErbB2 </e1> , Erk5 dual phosphorylation required ErbB2 tyrosine kinase activity; however, Erk5 nuclear residency did not require ErbB2 activity.", "e1": "ErbB2", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 1.88253, "prob_score": -0.5312027, "relevant": "1", "stops": "ERBB2IP - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 1.78591, "prob_score": -0.5599372, "relevant": "1", "stops": "ERBB2IP - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 22, "rel_score": 1.77828, "prob_score": -0.5623412, "relevant": "1", "stops": "ERBB2IP - PROS1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": -1.46301, "prob_score": -0.6835169, "relevant": "0", "stops": "ERBB2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": -1.50509, "prob_score": -0.6644117, "relevant": "0", "stops": "ERBB2IP - TIMP2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "371", "sentence": "Functional studies suggest that <e1> CRBP </e1> downregulation contributes to <e2> breast tumor </e2> progression.", "e1": "CRBP", "e2": "breast tumor", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 12, "rel_score": 3.82599, "prob_score": -0.2613676, "relevant": "1", "stops": "CIRBP - CFL2 - breast cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 14, "rel_score": 3.52684, "prob_score": -0.28354147, "relevant": "1", "stops": "CIRBP - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 3.44744, "prob_score": -0.29006505, "relevant": "1", "stops": "CIRBP - DPYSL2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 46, "rel_score": 3.25935, "prob_score": -0.3068105, "relevant": "1", "stops": "CIRBP - ADCK3 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 3.02517, "prob_score": -0.3305644, "relevant": "1", "stops": "CIRBP - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "372", "sentence": "The interaction between FADD and caspase-8 was inhibited, but abrogation of JNK activity or <e1> HIPK3 </e1> expression was found to restore this interaction and increased the sensitivity of <e2> DU 145 </e2> cells to Fas receptor-mediated apoptosis.", "e1": "HIPK3", "e2": "DU 145", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 17, "rel_score": -2.91894, "prob_score": -0.3425853, "relevant": "0", "stops": "HIPK3 - thyroid gland - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": -2.94533, "prob_score": -0.339516, "relevant": "0", "stops": "HIPK3 - Sorafenib - Gynaecomastia - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 26, "rel_score": -3.05689, "prob_score": -0.32713145, "relevant": "0", "stops": "HIPK3 - vagina - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": -3.11993, "prob_score": -0.32051906, "relevant": "0", "stops": "HIPK3 - Sorafenib - Alopecia - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 1, "rel_score": -3.91267, "prob_score": -0.2555846, "relevant": "0", "stops": "HIPK3 - Sorafenib - Pancreatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "373", "sentence": "Overexpression of <e1> IL-4 </e1> increases the sensitivity of androgen-sensitive <e2> LNCaP </e2> prostate cancer cells in response to androgen stimulation and enhances the growth of LNCaP cells both in the presence and absence of androgen in vitro and in vivo.", "e1": "IL-4", "e2": "LNCaP", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 4, "rel_score": 12.47349, "prob_score": -0.08016649, "relevant": "1", "stops": "IL4R - PTPN11 - prostate cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 23, "rel_score": 12.39311, "prob_score": -0.08069113, "relevant": "1", "stops": "IL4R - Doxorubicin - prostate cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 47, "rel_score": 12.35941, "prob_score": -0.0809137, "relevant": "1", "stops": "IL4R - TNFRSF21 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 8, "rel_score": 11.03631, "prob_score": -0.0906102, "relevant": "1", "stops": "IL4R - WRN - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": 8.84877, "prob_score": -0.11301221, "relevant": "1", "stops": "IL4R - BAD - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "374", "sentence": "Our findings indicate a significant reduction in <e1> p27Kip1 </e1> immunoreactivity in HGPIN (P&lt;0.0001) and <e2> prostate cancer </e2> (P&lt;0.0001) compared with the benign tissue.", "e1": "p27Kip1", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 2.03153, "prob_score": -0.49224332, "relevant": "1", "stops": "PDZK1IP1 - bone marrow - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 2.01345, "prob_score": -0.4966596, "relevant": "1", "stops": "PDZK1IP1 - decidua - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 1.94462, "prob_score": -0.5142373, "relevant": "1", "stops": "PDZK1IP1 - testis - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 1.92894, "prob_score": -0.5184221, "relevant": "1", "stops": "PDZK1IP1 - urethra - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 1.81264, "prob_score": -0.5516763, "relevant": "1", "stops": "PDZK1IP1 - lung - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "375", "sentence": "Both elevated protein-tyrosine kinase activity of <e1> pp60(c-src) </e1> and the association of its high activity with a short disease-free period have been reported in patients with human <e2> breast cancer </e2> .", "e1": "pp60(c-src)", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 3.19285, "prob_score": -0.3132013, "relevant": "1", "stops": "PPIC - PTEN - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": 3.09033, "prob_score": -0.32359222, "relevant": "1", "stops": "PPIC - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 41, "rel_score": 2.83054, "prob_score": -0.3532909, "relevant": "1", "stops": "PPIC - KIF2C - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": 2.75512, "prob_score": -0.3629638, "relevant": "1", "stops": "PPIC - PDIA4 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": 2.7202, "prob_score": -0.36761528, "relevant": "1", "stops": "PPIC - CDC20 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "376", "sentence": "Reactivation of androgen receptor-regulated TMPRSS2: <e1> ERG gene </e1> expression in castration-resistant <e2> prostate cancer </e2> .", "e1": "ERG gene", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": -3.728, "prob_score": -0.26824003, "relevant": "0", "stops": "ERGIC1 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": -3.78129, "prob_score": -0.26446202, "relevant": "0", "stops": "ERGIC1 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": -4.51345, "prob_score": -0.22155693, "relevant": "0", "stops": "ERGIC1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": -4.55415, "prob_score": -0.21958159, "relevant": "0", "stops": "ERGIC3 - CDK2AP2 - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 45, "rel_score": -5.27287, "prob_score": -0.1896478, "relevant": "0", "stops": "ERG - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "377", "sentence": "We have found that <e1> Cdc6 </e1> expression is down-regulated in <e2> prostate cancer </e2> as detected by semiquantitative reverse transcriptase-PCR of prostate cell lines and laser-captured microdissected prostate tissues.", "e1": "Cdc6", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 14.25517, "prob_score": -0.07014856, "relevant": "1", "stops": "CDC6 - CDKN1A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "rel_score": 13.53363, "prob_score": -0.073887005, "relevant": "1", "stops": "CDC6 - TPI1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 17, "rel_score": 10.49869, "prob_score": -0.09525147, "relevant": "1", "stops": "CDC6 - Temsirolimus - Rhinitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 31, "rel_score": 9.86096, "prob_score": -0.101409, "relevant": "1", "stops": "CDC6 - Paroxetine - Conjunctivitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 19, "rel_score": 9.44733, "prob_score": -0.105848916, "relevant": "1", "stops": "CDC6 - Paroxetine - Rhinitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "379", "sentence": "In <e2> MCF-7 </e2> , mimicking E2, T3 stimulated growth in a dose-dependent (10(10) M - 10(-8) M) manner, induced the expression of progesterone receptor and growth factor TGFalpha mRNAs and inhibited that of TGFbeta mRNA; T3 also increased progesterone binding and <e1> LDH5 isozyme </e1> activities.", "e1": "LDH5 isozyme", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 13.09415, "prob_score": -0.076373994, "relevant": "1", "stops": "ALDH5A1 - CDC25A - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 12.33046, "prob_score": -0.08109943, "relevant": "1", "stops": "ALDH5A1 - MRPS16 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 11.97175, "prob_score": -0.08353299, "relevant": "1", "stops": "ALDH5A1 - Doxorubicin - breast cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 28, "rel_score": 11.64551, "prob_score": -0.08586977, "relevant": "1", "stops": "ALDH5A1 - COTL1 - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 10.38853, "prob_score": -0.09626398, "relevant": "1", "stops": "ALDH5A1 - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "380", "sentence": "Furthermore, siRNA knockdown of the p38 mitogen-activated protein kinase (MAPK) protein prevented induction of p75( <e1> NTR </e1> ) by DIM in the <e2> PC-3 </e2> prostate cell line.", "e1": "NTR", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 18.1061, "prob_score": -0.05522681, "relevant": "1", "stops": "NKTR - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 12.8238, "prob_score": -0.077979855, "relevant": "1", "stops": "NKTR - female reproductive system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 11.60227, "prob_score": -0.08619004, "relevant": "1", "stops": "NKTR - thyroid gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 11.22334, "prob_score": -0.08909837, "relevant": "1", "stops": "NKTR - female gonad - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 9.97705, "prob_score": -0.10023367, "relevant": "1", "stops": "NKTR - heart - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "382", "sentence": "Immunoblot assays indicated that hypoxia and L-mimosine stabilized hypoxia-inducible factor-1 \u03b1 (HIF-1\u03b1) and induced Btg2 and <e1> Ndrg1 protein </e1> expression, but downregulated protein levels of cyclin A in both <e2> PC-3 </e2> and LNCaP cells.", "e1": "Ndrg1 protein", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 7.01557, "prob_score": -0.14253934, "relevant": "1", "stops": "NDRG1 - MAOA - Selegiline - Prostate cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 6.77323, "prob_score": -0.14764224, "relevant": "1", "stops": "NDRG1 - POLR2I - Riluzole - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 6.48046, "prob_score": -0.15431184, "relevant": "1", "stops": "NDRG1 - COPB2 - Testosterone - Prostate cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 6.44912, "prob_score": -0.15505572, "relevant": "1", "stops": "NDRG1 - C2CD5 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 6.25743, "prob_score": -0.159809, "relevant": "1", "stops": "NDRG1 - breast cancer - Testosterone Propionate - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "383", "sentence": "We previously showed that the expressing level of FSH receptor ( <e1> FSHR </e1> ) increased from ovarian epithelial inclusions (OEIs) to benign <e2> ovarian epithelial tumors </e2> (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.", "e1": "FSHR", "e2": "ovarian epithelial tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 12.6968, "prob_score": -0.078755766, "relevant": "1", "stops": "FSHR - azoospermia - Clomifene - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 11, "rel_score": 7.9466, "prob_score": -0.12584335, "relevant": "1", "stops": "FSHR - female reproductive system - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 7.82656, "prob_score": -0.12776531, "relevant": "1", "stops": "FSHR - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 9, "rel_score": 7.36214, "prob_score": -0.13582721, "relevant": "1", "stops": "FSHR - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 6.99643, "prob_score": -0.14293452, "relevant": "1", "stops": "FSHR - lymph node - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "384", "sentence": "<e1> Scavenger receptor class A, member 3 </e1> (SCARA3) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with <e2> breast carcinoma </e2> effusions by global gene expression analysis.", "e1": "Scavenger receptor class A, member 3", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 7.06764, "prob_score": -0.14149237, "relevant": "1", "stops": "SCARA3 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 44, "rel_score": 7.06165, "prob_score": -0.14161111, "relevant": "1", "stops": "SCARA3 - spinal cord - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 7.05368, "prob_score": -0.14176632, "relevant": "1", "stops": "SCARA3 - brain - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 6.90942, "prob_score": -0.14473486, "relevant": "1", "stops": "SCARA3 - nervous system - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 5.9891, "prob_score": -0.16697489, "relevant": "1", "stops": "SCARA3 - uterine cervix - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "385", "sentence": "A broad spectrum of tumor derived cell lines, from varied tissue sources and blood samples from patients having confirmed <e2> prostate carcinoma </e2> , all scored positive for expression of <e1> PTI-1 </e1> , while corresponding normal tissues or blood samples were negative.", "e1": "PTI-1", "e2": "prostate carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 4.7019, "prob_score": -0.21267849, "relevant": "1", "stops": "TPI1 - Paroxetine - Prostate carcinoma", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "386", "sentence": "<e1> Pak1 </e1> , p-Pak1 and p-Pak2 were overexpressed in <e2> ovarian cancer </e2> cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts.", "e1": "Pak1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 6.74354, "prob_score": -0.14829046, "relevant": "1", "stops": "PAK1IP1 - melanoma - Docetaxel - Ovarian cancer", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 20, "rel_score": 6.31752, "prob_score": -0.15829234, "relevant": "1", "stops": "PAK1 - CYP2C19 - Estradiol - Ovarian cancer", "reltypes": "COVARIES_GcG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 6.22704, "prob_score": -0.16059066, "relevant": "1", "stops": "PAK1IP1 - DIMT1 - Estradiol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 6.00312, "prob_score": -0.16658191, "relevant": "1", "stops": "PAK1IP1 - NCL - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 5.42005, "prob_score": -0.1844988, "relevant": "1", "stops": "PAK1IP1 - TEX10 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "387", "sentence": "In the adjacent <e2> prostate adenocarcinoma </e2> glands, the <e1> beta 1C variant </e1> was dramatically down-regulated in 27 of 34 (79%) analyzed cases, whereas the expression and distribution of its wild-type counterpart, beta 1A, remained unchanged.", "e1": "beta 1C variant", "e2": "prostate adenocarcinoma", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 43, "rel_score": 1.68172, "prob_score": -0.5946265, "relevant": "1", "stops": "BET1L - nervous system - HTR2B - Ropinirole - Adenocarcinoma of prostate", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 1.48203, "prob_score": -0.6747534, "relevant": "1", "stops": "BET1L - brain - MCOLN1 - Ropinirole - Adenocarcinoma of prostate", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 1.47338, "prob_score": -0.678706, "relevant": "1", "stops": "BET1L - decidua - MCOLN1 - Ropinirole - Adenocarcinoma of prostate", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": -1.56497, "prob_score": -0.63899046, "relevant": "0", "stops": "BET1L - thyroid gland - MCOLN1 - Ropinirole - Adenocarcinoma of prostate", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -1.65123, "prob_score": -0.6056135, "relevant": "0", "stops": "BET1L - APP - MCOLN1 - Ropinirole - Adenocarcinoma of prostate", "reltypes": "INTERACTS_GiG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}]}
{"qid": "389", "sentence": "Transfection with the kinase-inactive mutant of Akt or TM of FKHRL1 induced the activity of the <e1> Fas ligand promoter </e1> in <e2> Caov-3 </e2> cells.", "e1": "Fas ligand promoter", "e2": "Caov-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": 13.70802, "prob_score": -0.072946675, "relevant": "1", "stops": "FASTKD5 - NPC1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 12.16989, "prob_score": -0.08216629, "relevant": "1", "stops": "FASTKD3 - COG2 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 11.98466, "prob_score": -0.08344371, "relevant": "1", "stops": "FASTKD5 - PLCB3 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 11.9289, "prob_score": -0.083831824, "relevant": "1", "stops": "FASTKD5 - NT5DC2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 10.84952, "prob_score": -0.09216771, "relevant": "1", "stops": "FASTKD5 - TOMM70A - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "390", "sentence": "Treatment of <e2> HOSE </e2> or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and <e1> PR-B mRNA </e1> and protein expression, with the regulation primarily controlled at the transcriptional level.", "e1": "PR-B mRNA", "e2": "HOSE", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 9.75324, "prob_score": -0.10253075, "relevant": "1", "stops": "PRLH - tendon - gout - Allopurinol - Gout attack", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 48, "rel_score": 7.15154, "prob_score": -0.13983417, "relevant": "1", "stops": "PRLH - brain - GMPPA - Cyclosporine - Gout attack", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 6.94059, "prob_score": -0.14407742, "relevant": "1", "stops": "PRLH - central nervous system - EED - Cyclosporine - Gout attack", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 6.49477, "prob_score": -0.15397248, "relevant": "1", "stops": "PRLH - pituitary gland - MCM6 - Cyclosporine - Gout attack", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 6.37877, "prob_score": -0.15676951, "relevant": "1", "stops": "PRLH - endocrine gland - GMPPA - Cyclosporine - Gout attack", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "391", "sentence": "Our data indicate the utility of the new compounds for inhibition of <e1> <e2> breast cancer </e2> cell estrone sulfatase </e1> activity.", "e1": "<e2> breast cancer </e2> cell estrone sulfatase", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 7.37572, "prob_score": -0.13558444, "relevant": "1", "stops": "ME2 - EGR1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 6.00781, "prob_score": -0.1664474, "relevant": "1", "stops": "ME2 - PABPC1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 13, "rel_score": 5.23834, "prob_score": -0.19090196, "relevant": "1", "stops": "ME2 - COL11A1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "rel_score": 5.05587, "prob_score": -0.19779095, "relevant": "1", "stops": "ME2 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 4.14405, "prob_score": -0.24130636, "relevant": "1", "stops": "ME2 - Epirubicin - breast cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}]}
{"qid": "392", "sentence": "Stimulation of <e2> SKBR3 </e2> cells and HCII RI#11 mouse mammary epithelial cells expressing the human erbB-2 with EGF led to an increase in scFv( <e1> FRP5 </e1> )-ETA activity, showing that the EGF-induced activation of erbB-2 can potentiate the action of the erbB-2-directed toxin.", "e1": "FRP5", "e2": "SKBR3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 4.44444, "prob_score": -0.22499722, "relevant": "1", "stops": "SFRP5 - mammalian vulva - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 4.38577, "prob_score": -0.2280115, "relevant": "1", "stops": "SFRP5 - pituitary gland - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 4.29479, "prob_score": -0.23284425, "relevant": "1", "stops": "SFRP5 - mammalian vulva - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 3.60464, "prob_score": -0.27741948, "relevant": "1", "stops": "SFRP5 - myometrium - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 3.59557, "prob_score": -0.2781174, "relevant": "1", "stops": "SFRP5 - myometrium - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "393", "sentence": "Here, we defined a new mechanism for IMC-C225 that cross-links integrins with EGFR, leading to activation of <e1> RhoA </e1> and inhibition of <e2> breast cancer </e2> cell invasion irrespective of the level of EGFR in the cells, thus providing a rationale for using IMC-C225 in the metastatic setting independent of the levels of EGFR.", "e1": "RhoA", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 2.7574, "prob_score": -0.36266315, "relevant": "1", "stops": "RHOA - NTRK2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 16, "rel_score": 2.25489, "prob_score": -0.44348222, "relevant": "1", "stops": "RHOA - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 2.17751, "prob_score": -0.4592382, "relevant": "1", "stops": "RHOA - IFNB1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 2.10899, "prob_score": -0.4741632, "relevant": "1", "stops": "RHOA - NME1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 20, "rel_score": 1.8809, "prob_score": -0.53166306, "relevant": "1", "stops": "RHOA - MPRIP - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "394", "sentence": "Dimethyloxalylglycine, a pan-prolyl hydroxylase inhibitor, also induced <e1> Btg2 </e1> and Ndrg1 protein expression in <e2> LNCaP </e2> cells.", "e1": "Btg2", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 30, "rel_score": 19.79414, "prob_score": -0.050518937, "relevant": "1", "stops": "BTG2 - SCAND1 - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 19.65023, "prob_score": -0.050885983, "relevant": "1", "stops": "BTG2 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 15, "rel_score": 18.94657, "prob_score": -0.052782174, "relevant": "1", "stops": "BTG2 - VIM - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 14, "rel_score": 18.52538, "prob_score": -0.053978812, "relevant": "1", "stops": "BTG2 - MIF - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 28, "rel_score": 16.31854, "prob_score": -0.061278284, "relevant": "1", "stops": "BTG2 - HSD17B10 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "395", "sentence": "Pharmacological demethylation/deacetylation in <e2> ovarian cancer </e2> cell lines re-induced <e1> CCBE1 </e1> expression, indicating that epigenetic mechanisms contribute to its silencing in cancer.", "e1": "CCBE1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 6.84182, "prob_score": -0.1461646, "relevant": "1", "stops": "CCBE1 - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 5.85583, "prob_score": -0.17077269, "relevant": "1", "stops": "CCBE1 - CEP55 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 5.84522, "prob_score": -0.17107596, "relevant": "1", "stops": "CCBE1 - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 5.64239, "prob_score": -0.17722884, "relevant": "1", "stops": "CCBE1 - endometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": 5.03499, "prob_score": -0.19860683, "relevant": "1", "stops": "CCBE1 - uterine cervix - ovarian cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "396", "sentence": "Our results suggest novel mechanisms by which <e1> MnSOD </e1> overexpression may modulate the malignant phenotype, with potential applications in developing new therapies for <e2> prostate cancer </e2> .", "e1": "MnSOD", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 9.75229, "prob_score": -0.10253518, "relevant": "1", "stops": "MNS1 - bone marrow - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 15, "rel_score": 8.89442, "prob_score": -0.112430245, "relevant": "1", "stops": "MNS1 - liver - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 8.15328, "prob_score": -0.12264874, "relevant": "1", "stops": "MNS1 - medulla oblongata - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 7.75494, "prob_score": -0.12894547, "relevant": "1", "stops": "MNS1 - cortex of kidney - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 7.10126, "prob_score": -0.14081621, "relevant": "1", "stops": "MNS1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "398", "sentence": "<e1> MEK5 </e1> overexpression is associated with metastatic <e2> prostate cancer </e2> , and stimulates proliferation, MMP-9 expression and invasion.", "e1": "MEK5", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 17, "rel_score": 3.22165, "prob_score": -0.31039712, "relevant": "1", "stops": "NEK5 - liver - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 2.955, "prob_score": -0.33840856, "relevant": "1", "stops": "NEK5 - brain - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 2.85356, "prob_score": -0.35043767, "relevant": "1", "stops": "NEK5 - lymph node - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 2.77909, "prob_score": -0.35982785, "relevant": "1", "stops": "NEK5 - testis - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 2.44499, "prob_score": -0.4089978, "relevant": "1", "stops": "NEK5 - thyroid gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "399", "sentence": "Activation of <e1> ATF2 </e1> , which depended on p38 activity, was crucial for MMP-2 promoter activity as well as induction of invasive and migrative phenotypes in <e2> MCF10A </e2> cells.", "e1": "ATF2", "e2": "MCF10A", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 25, "rel_score": 4.15386, "prob_score": -0.24074452, "relevant": "1", "stops": "ATF2 - ATM - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 39, "rel_score": 3.66663, "prob_score": -0.2727311, "relevant": "1", "stops": "ATF2 - HADHA - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 30, "rel_score": 3.61677, "prob_score": -0.2764907, "relevant": "1", "stops": "ATF2 - ANXA3 - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 35, "rel_score": 3.56748, "prob_score": -0.28030565, "relevant": "1", "stops": "ATF2 - PDIA4 - breast cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 2.60783, "prob_score": -0.3834637, "relevant": "1", "stops": "ATF2 - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "400", "sentence": "Treatment with the oxidizing agents H2O2 and menadione produced an increase in <e1> gamma-glutamyl transpeptidase </e1> activity in <e2> LNCaP </e2> cells, whereas treatment with the antioxidant compound ascorbic acid (100 mM) reduced the oxidative stress produced in LNCaP cells by 1 nM R1881 and completely blocked the gamma-glutamyl transpeptidase activity.", "e1": "gamma-glutamyl transpeptidase", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 14.35956, "prob_score": -0.06963938, "relevant": "1", "stops": "GALM - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 14.26533, "prob_score": -0.07010443, "relevant": "1", "stops": "GALM - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 13.71178, "prob_score": -0.07293115, "relevant": "1", "stops": "GALM - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 13.19261, "prob_score": -0.075802736, "relevant": "1", "stops": "GALM - myocardium - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 11.79523, "prob_score": -0.0847767, "relevant": "1", "stops": "GALM - cortex of kidney - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "401", "sentence": "By univariate survival analysis on the <e2> ovarian carcinoma </e2> cohorts, decreased <e1> TSLC1 protein </e1> expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P < 0.001).", "e1": "TSLC1 protein", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 3.87822, "prob_score": -0.25785193, "relevant": "1", "stops": "TSC1 - SPP1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 3.83642, "prob_score": -0.26066113, "relevant": "1", "stops": "TSC1 - PPARG - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 3.80981, "prob_score": -0.26247507, "relevant": "1", "stops": "TSC1 - CDK1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 3.76719, "prob_score": -0.26545346, "relevant": "1", "stops": "TSC1 - PMM2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 3.38972, "prob_score": -0.2950126, "relevant": "1", "stops": "TSC1 - RUVBL1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "402", "sentence": "We have previously reported that glucocorticoids markedly increase and anti-glucocorticoids (such as RU-486) block <e1> c-fms RNA </e1> and protein expression in some <e2> breast cancer </e2> cell lines, but not in others, and that this increase is the consequence of increased transcription from the first, epithelial cell-specific promoter of the c-fms gene (encoding CSF-1R, macrophage colony-stimulating factor receptor).", "e1": "c-fms RNA", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 31, "rel_score": 18.80406, "prob_score": -0.05318042, "relevant": "1", "stops": "CPSF1 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 18.72659, "prob_score": -0.05339839, "relevant": "1", "stops": "CPOX - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 33, "rel_score": 17.99856, "prob_score": -0.055558562, "relevant": "1", "stops": "CPSF1 - AGR2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": 17.32202, "prob_score": -0.05772646, "relevant": "1", "stops": "CPSF1 - PCNA - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 44, "rel_score": 16.9837, "prob_score": -0.058884673, "relevant": "1", "stops": "CPXM1 - MAPK3 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "403", "sentence": "In nuclear run-on assays, 17beta-estradiol (E2) increased the rate of <e1> Tf gene </e1> expression approximately 3-fold within 1 h after treatment and reporter gene activity was also induced in <e2> MCF-7 </e2> cells transfected with a construct containing a -3600 to +39 Tf gene promoter insert.", "e1": "Tf gene", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 5.81531, "prob_score": -0.17196102, "relevant": "1", "stops": "TFCP2 - IGFBP7 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 37, "rel_score": 5.70548, "prob_score": -0.17526507, "relevant": "1", "stops": "TFCP2 - KRT8 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 27, "rel_score": 5.69995, "prob_score": -0.1754445, "relevant": "1", "stops": "TFCP2 - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 49, "rel_score": 5.41155, "prob_score": -0.18478969, "relevant": "1", "stops": "TFCP2 - HADH - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": 5.11378, "prob_score": -0.19554715, "relevant": "1", "stops": "TFCP2 - SOCS2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "404", "sentence": "In addition, Cd enhanced DNA synthesis and <e1> pS2 mRNA </e1> levels in estrogen (10 pM estradiol) treated <e2> T47D </e2> cells.", "e1": "pS2 mRNA", "e2": "T47D", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 12.30164, "prob_score": -0.08128634, "relevant": "1", "stops": "GPS2 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 8.83939, "prob_score": -0.11312589, "relevant": "1", "stops": "GPS2 - endocrine gland - CYP2C19 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 8.29531, "prob_score": -0.120545216, "relevant": "1", "stops": "GPS2 - Mycophenolic acid - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 23, "rel_score": 7.88581, "prob_score": -0.12680887, "relevant": "1", "stops": "GPS2 - Mycophenolic acid - Arthropathy - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 48, "rel_score": 6.34156, "prob_score": -0.15768705, "relevant": "1", "stops": "GPS2 - cerebellum - CYP2C19 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "405", "sentence": "The expression of <e1> programmed cell death 6 </e1> (PDCD6) is known to be down-regulated in cancer cell lines and <e2> ovarian cancer </e2> tissues compared to normal cells and tissues.", "e1": "programmed cell death 6", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 7.6929, "prob_score": -0.1299861, "relevant": "1", "stops": "PRAME - lung cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 32, "rel_score": 7.0028, "prob_score": -0.14279571, "relevant": "1", "stops": "PRAMEF25 - negative regulation of cell death - CAT - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 6.87758, "prob_score": -0.14539616, "relevant": "1", "stops": "PRAMEF25 - negative regulation of developmental process - CCND1 - Estradiol - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 6.77507, "prob_score": -0.14760214, "relevant": "1", "stops": "PRAMEF25 - negative regulation of developmental process - CCND1 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 6.59196, "prob_score": -0.15170044, "relevant": "1", "stops": "PRAMEF25 - negative regulation of cell death - HTR2B - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "406", "sentence": "Selective inhibition of <e1> human 3\u03b2-hydroxysteroid dehydrogenase type 1 </e1> as a potential treatment for <e2> breast cancer </e2> .", "e1": "human 3\u03b2-hydroxysteroid dehydrogenase type 1", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 13, "rel_score": 1.74234, "prob_score": -0.57394123, "relevant": "1", "stops": "NUMA1 - HJURP - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 45, "rel_score": 1.6619, "prob_score": -0.60171866, "relevant": "1", "stops": "NUMA1 - KIFC1 - breast cancer", "reltypes": "COVARIES_GcG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 15, "rel_score": 1.62174, "prob_score": -0.6166194, "relevant": "1", "stops": "NUMA1 - TPX2 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": 1.52996, "prob_score": -0.6536116, "relevant": "1", "stops": "NUMA1 - CCNB2 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "rel_score": 1.49401, "prob_score": -0.66933596, "relevant": "1", "stops": "NUMA1 - AKT1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "407", "sentence": "The observed relationship between the down-regulation of <e1> Bcl-2 </e1> and induction of apoptosis was not causal because stable overexpression of Bcl-2 resulted in protection of <e2> MCF-7 </e2> cells from the cytotoxic morphological changes and growth-inhibitory effects of butyrate (15% growth inhibition compared to 60% growth inhibition in the parental cells).", "e1": "Bcl-2", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 29.76191, "prob_score": -0.033600513, "relevant": "1", "stops": "BCL2L2-PABPN1 - HOOK2 - COL11A1 - breast cancer", "reltypes": "COVARIES_GcG - REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 41, "rel_score": 28.67795, "prob_score": -0.034870964, "relevant": "1", "stops": "BCL2L2-PABPN1 - FKBP8 - endometrium - breast cancer", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": 28.53067, "prob_score": -0.035053607, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - endometrium - breast cancer", "reltypes": "INTERACTS_GiG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 19, "rel_score": 27.7855, "prob_score": -0.035985988, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - ADGRL3 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 27.76235, "prob_score": -0.036019698, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - PDE4D - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "408", "sentence": "We showed, for the first time, that knockdown of PDI in <e2> MCF-7 </e2> human breast cancer cells with RNA interference down-regulates ERalpha protein but up-regulates <e1> ERbeta protein </e1> , resulting in a drastic increase in ERbeta/ERalpha ratio, which is a crucial determinant of different cellular responses to estrogens.", "e1": "ERbeta protein", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 25, "rel_score": 8.25627, "prob_score": -0.121118024, "relevant": "1", "stops": "BET1 - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "rel_score": 7.95861, "prob_score": -0.12565438, "relevant": "1", "stops": "BET1 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 23, "rel_score": 7.91703, "prob_score": -0.12631305, "relevant": "1", "stops": "BET1 - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 35, "rel_score": 7.36269, "prob_score": -0.13582407, "relevant": "1", "stops": "BET1L - central nervous system - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 34, "rel_score": 7.15461, "prob_score": -0.13977057, "relevant": "1", "stops": "BET1L - testis - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}]}
{"qid": "409", "sentence": "The expression of programmed cell death 6 ( <e1> PDCD6 </e1> ) is known to be down-regulated in cancer cell lines and <e2> ovarian cancer </e2> tissues compared to normal cells and tissues.", "e1": "PDCD6", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 10.43188, "prob_score": -0.095856585, "relevant": "1", "stops": "PDCD6 - ANXA11 - ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 23, "rel_score": 10.33058, "prob_score": -0.09679673, "relevant": "1", "stops": "PDCD6IP - bone marrow - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 40, "rel_score": 10.06948, "prob_score": -0.09930968, "relevant": "1", "stops": "PDCD6IP - TIPARP - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": 9.95818, "prob_score": -0.10041723, "relevant": "1", "stops": "PDCD6IP - uterus - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 9.91375, "prob_score": -0.10087028, "relevant": "1", "stops": "PDCD6IP - CHMP4C - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "410", "sentence": "Here we demonstrate that arsenite induces the expression of HIF-1alpha but not <e1> HIF-1beta subunit </e1> in <e2> DU145 </e2> human prostate carcinoma cells.", "e1": "HIF-1beta subunit", "e2": "DU145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 34.39973, "prob_score": -0.029074797, "relevant": "1", "stops": "HINFP - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 43, "rel_score": 34.03676, "prob_score": -0.029380843, "relevant": "1", "stops": "HINFP - lung - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 31.36763, "prob_score": -0.031881105, "relevant": "1", "stops": "HINFP - respiratory system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 29.9222, "prob_score": -0.033423435, "relevant": "1", "stops": "HINFP - TRAF2 - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 26.75943, "prob_score": -0.037372757, "relevant": "1", "stops": "HINFP - central nervous system - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "411", "sentence": "In a pivotal phase III trial, the addition of trastuzumab to chemotherapy significantly improved response rate, time to disease progression, and overall survival in women with <e1> HER2 </e1> overexpressing metastatic <e2> breast cancer </e2> .", "e1": "HER2", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 31, "rel_score": -62.5, "prob_score": -0.01599568, "relevant": "0", "stops": "ERBB2IP - GRIN2B - Memantine - Breast cancer female", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": -71.07321, "prob_score": -0.01406575, "relevant": "0", "stops": "ERBB2IP - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 14, "rel_score": -73.58352, "prob_score": -0.013587061, "relevant": "0", "stops": "ERBB2IP - mammary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": -76.92308, "prob_score": -0.013001891, "relevant": "0", "stops": "ERBB2IP - DST - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 46, "rel_score": -92.50694, "prob_score": -0.010813766, "relevant": "0", "stops": "ERBB2 - RPS4Y1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "413", "sentence": "Arsenite induces HIF-1alpha and VEGF through <e1> PI3K </e1> , Akt and reactive oxygen species in <e2> DU145 </e2> human prostate carcinoma cells.", "e1": "PI3K", "e2": "DU145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 2.44517, "prob_score": -0.40896714, "relevant": "1", "stops": "PI3 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 14, "rel_score": 2.25038, "prob_score": -0.44437125, "relevant": "1", "stops": "PI3 - lymphoid tissue - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 2.18799, "prob_score": -0.4570377, "relevant": "1", "stops": "PI3 - head - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 2.07727, "prob_score": -0.48139653, "relevant": "1", "stops": "PI3 - vagina - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 1.87031, "prob_score": -0.53466797, "relevant": "1", "stops": "PI3 - islet of Langerhans - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "414", "sentence": "Northern blot analysis of mRNA from normal and <e2> BPH </e2> stromal cells demonstrated a 5-fold decrease in <e1> IGFBP-2 mRNA </e1> (P &lt; 0.001) and a 4-fold increase in IGFBP-5 mRNA (P &lt; 0.01) in BPH compared to normal cells.", "e1": "IGFBP-2 mRNA", "e2": "BPH", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 48, "rel_score": 19.83733, "prob_score": -0.050410733, "relevant": "1", "stops": "IGFBP2 - TMEM109 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 14.69076, "prob_score": -0.06807038, "relevant": "1", "stops": "IGFBP2 - TMEM109 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 12.96008, "prob_score": -0.07715994, "relevant": "1", "stops": "IGFBP2 - GDF15 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 35, "rel_score": 12.64862, "prob_score": -0.07906011, "relevant": "1", "stops": "IGFBP2 - CDKN1A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 11.78967, "prob_score": -0.084815316, "relevant": "1", "stops": "IGFBP2 - GJA1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "415", "sentence": "<e1> Intercellular adhesion molecule 1 (ICAM-1) </e1> was down-regulated in <e2> MCF10A </e2> cells using short hairpin RNA.", "e1": "Intercellular adhesion molecule 1 (ICAM-1)", "e2": "MCF10A", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 5.78536, "prob_score": -0.17284618, "relevant": "1", "stops": "ICAM1 - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 5.62905, "prob_score": -0.17765465, "relevant": "1", "stops": "ICAM1 - CDKN1A - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 5.36769, "prob_score": -0.18629858, "relevant": "1", "stops": "ICAM1 - GPER1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 42, "rel_score": 5.23259, "prob_score": -0.19110999, "relevant": "1", "stops": "ICAM1 - umbilical vein - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 4.38154, "prob_score": -0.22823063, "relevant": "1", "stops": "ICAM1 - FOS - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "417", "sentence": "Cisplatin decreased <e1> XIAP protein </e1> levels and induced Akt cleavage and apoptosis in chemosensitive, but not in resistant, <e2> ovarian cancer </e2> cells.", "e1": "XIAP protein", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 4.23352, "prob_score": -0.23620522, "relevant": "1", "stops": "XIAP - MYC - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 3.88818, "prob_score": -0.25718677, "relevant": "1", "stops": "XIAP - IKBKE - Estriol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 3.66126, "prob_score": -0.27312836, "relevant": "1", "stops": "XIAP - BRCA1 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 3.35233, "prob_score": -0.29830423, "relevant": "1", "stops": "XIAP - STAMBP - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 3.25616, "prob_score": -0.30711162, "relevant": "1", "stops": "XIAP - CASP10 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "418", "sentence": "Treatment of the androgen-independent human prostate cancer cells <e2> PC-3 </e2> with doxazosin resulted in a strong <e1> caspase-3 </e1> activation within 24 h, whereas tamsulosin, a sulphonamide-based alpha 1-adrenoceptor antagonist, had no significant apoptotic effect against prostate cancer cells.", "e1": "caspase-3", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 4.37771, "prob_score": -0.22843066, "relevant": "1", "stops": "ASPA - Dabrafenib - Mental disorder - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 17, "rel_score": 4.03861, "prob_score": -0.24760593, "relevant": "1", "stops": "ASPA - nervous system - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 4.02966, "prob_score": -0.24815828, "relevant": "1", "stops": "ASPA - renal system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 4.01542, "prob_score": -0.24904124, "relevant": "1", "stops": "ASPA - Dabrafenib - Pancreatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 39, "rel_score": 3.98708, "prob_score": -0.2508117, "relevant": "1", "stops": "ASPA - Dabrafenib - Rigors - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "421", "sentence": "These results demonstrate that in a sequence-specific manner, RIalpha antisense, via efficient depletion of the <e1> growth stimulatory molecule RIalpha </e1> , induces growth inhibition, apoptosis, and phenotypic (cell morphology) changes, providing an innovative approach to combat hormone-insensitive <e2> prostate cancer </e2> cell growth.", "e1": "growth stimulatory molecule RIalpha", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 48, "rel_score": 7.0492, "prob_score": -0.14185913, "relevant": "1", "stops": "GOT1L1 - medulla oblongata - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 6.51636, "prob_score": -0.15346356, "relevant": "1", "stops": "GOT1L1 - spinal cord - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 6.06024, "prob_score": -0.1650122, "relevant": "1", "stops": "GOT1L1 - testis - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 5.29521, "prob_score": -0.18884775, "relevant": "1", "stops": "GOT1 - epithelium - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 16, "rel_score": 4.61936, "prob_score": -0.21647544, "relevant": "1", "stops": "GOT1 - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "422", "sentence": "In 2 cell lines with weak expression of <e1> TUBB3 </e1> protein ( <e2> OVCAR-3 </e2> and JHOC-8), TUBB3 induction was independently induced by treatment with 5-Aza-CdR (JHOC-8) or PBA (OVCAR-3), while neither agent markedly altered TUBB3 mRNA/protein expression in a strongly TUBB3-expressing cell line (JHOC-5).", "e1": "TUBB3", "e2": "OVCAR-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 13.44086, "prob_score": -0.07440362, "relevant": "1", "stops": "TUBB3 - Docetaxel - Ovarian cancer", "reltypes": "BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "424", "sentence": "<e1> ZEB2 </e1> expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma <e2> SKOV3 </e2> cells resulted in an increase in CDH1 expression.", "e1": "ZEB2", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 16, "rel_score": 2.82287, "prob_score": -0.35424894, "relevant": "1", "stops": "ZEB2 - breast cancer - Estradiol - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 23, "rel_score": 2.76962, "prob_score": -0.36105523, "relevant": "1", "stops": "ZEB2 - endometrium - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 31, "rel_score": 2.76472, "prob_score": -0.36170205, "relevant": "1", "stops": "ZEB2 - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 2.67208, "prob_score": -0.37423915, "relevant": "1", "stops": "ZEB2 - female reproductive system - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 2.29516, "prob_score": -0.4356969, "relevant": "1", "stops": "ZEB2 - RAB4A - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "425", "sentence": "Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial <e2> ovarian carcinoma </e2> : evidence of up-regulated <e1> Tn </e1> and Sialyl Tn antigen expression in effusions.", "e1": "Tn", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 11, "rel_score": 4.56142, "prob_score": -0.21922745, "relevant": "1", "stops": "TNC - heart - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 4.42772, "prob_score": -0.22585276, "relevant": "1", "stops": "TNC - trigeminal ganglion - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": 4.32283, "prob_score": -0.23133273, "relevant": "1", "stops": "TNC - retina - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 4.04793, "prob_score": -0.2470395, "relevant": "1", "stops": "TNC - cardiac atrium - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 3.95804, "prob_score": -0.2526467, "relevant": "1", "stops": "TNC - liver - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "426", "sentence": "IL-1 and CDDP treatment induced <e1> p53 protein </e1> in NIH: <e2> OVCAR-3 </e2> tumor cells.", "e1": "p53 protein", "e2": "OVCAR-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 23, "rel_score": 5.90912, "prob_score": -0.1692314, "relevant": "1", "stops": "TP53RK - MRPL12 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 5.82479, "prob_score": -0.17167608, "relevant": "1", "stops": "TP53RK - DNAJA3 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": 5.30504, "prob_score": -0.1884971, "relevant": "1", "stops": "TP53RK - P4HTM - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 5.22302, "prob_score": -0.19145843, "relevant": "1", "stops": "TP53RK - MCOLN1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 4.98182, "prob_score": -0.200726, "relevant": "1", "stops": "TP53RK - PSRC1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "427", "sentence": "Furthermore, E1 induced a twofold increase in connexin 43 ( <e1> Cx43 </e1> ), whereas forskolin caused a 50% reduction in Cx32 expression in <e2> RWPE-1 </e2> cells.", "e1": "Cx43", "e2": "RWPE-1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 8.80049, "prob_score": -0.11362952, "relevant": "1", "stops": "CDX4 - embryo development - NAGLU - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 46, "rel_score": 8.49113, "prob_score": -0.11777186, "relevant": "1", "stops": "CDX4 - blood vessel development - CLIC4 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 31, "rel_score": 8.32432, "prob_score": -0.12012905, "relevant": "1", "stops": "CDX4 - reproductive structure development - ICAM1 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 30, "rel_score": 7.94029, "prob_score": -0.125943, "relevant": "1", "stops": "CDX4 - developmental process involved in reproduction - ICAM1 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 48, "rel_score": 7.64526, "prob_score": -0.13079557, "relevant": "1", "stops": "CDX4 - circulatory system development - CLIC4 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "428", "sentence": "Compared with <e2> BPH </e2> , the PCa patients showed decreased expressions of <e1> miR-98 </e1> , let-7d and let-7g, and decreased expressions of miR-96, miR-182 and miR-183, with statistically significant differences between the two groups (P &lt; 0.05).", "e1": "miR-98", "e2": "BPH", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 48, "rel_score": 10.0634, "prob_score": -0.09937427, "relevant": "1", "stops": "IRF9 - Sirolimus - Infestation - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 23, "rel_score": 10.04621, "prob_score": -0.09954264, "relevant": "1", "stops": "IRF9 - Sirolimus - Pancreatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 37, "rel_score": 9.86291, "prob_score": -0.10139156, "relevant": "1", "stops": "IRF9 - Simvastatin - Gynaecomastia - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 13, "rel_score": 9.19794, "prob_score": -0.10872353, "relevant": "1", "stops": "IRF9 - KDR - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": 8.33264, "prob_score": -0.12000521, "relevant": "1", "stops": "IRF9 - NCOA3 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "430", "sentence": "In this study, using in vitro model system we show that DPPIV loss is associated with increased <e1> bFGF </e1> production in metastatic <e2> prostate cancer </e2> cells.", "e1": "bFGF", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 12.79427, "prob_score": -0.078157336, "relevant": "1", "stops": "FGF16 - regulation of response to external stimulus - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 1, "rel_score": 12.40695, "prob_score": -0.080601044, "relevant": "1", "stops": "FGF16 - growth factor receptor binding - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpMF - PARTICIPATES_GpMF - ASSOCIATES_DaG", "nodelabels": "Gene - MolecularFunction - Gene - Disease"}, {"pathid": 27, "rel_score": 12.16249, "prob_score": -0.08222311, "relevant": "1", "stops": "FGF16 - regulation of cell motility - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 34, "rel_score": 11.45082, "prob_score": -0.08733229, "relevant": "1", "stops": "FGF16 - Fc receptor signaling pathway - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 42, "rel_score": 11.42204, "prob_score": -0.0875478, "relevant": "1", "stops": "FGF16 - regulation of locomotion - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "431", "sentence": "The epidermal growth factor (EGF) and <e1> EGF receptor </e1> (EGFR) family are often overexpressed in various human cancers including <e2> ovarian cancer </e2> .", "e1": "EGF receptor", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 7.93084, "prob_score": -0.12608825, "relevant": "1", "stops": "EGFL6 - blood - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 7.73515, "prob_score": -0.12928434, "relevant": "1", "stops": "EGFL6 - prostate gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 7.36052, "prob_score": -0.13585539, "relevant": "1", "stops": "EGFL6 - lymph node - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 7.32977, "prob_score": -0.13643077, "relevant": "1", "stops": "EGFL6 - prostate gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 7.18494, "prob_score": -0.13918167, "relevant": "1", "stops": "EGFL6 - pituitary gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "434", "sentence": "Coordinate up-regulation of <e1> TMEM97 </e1> and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of <e2> ovarian cancer </e2> .", "e1": "TMEM97", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 4.28302, "prob_score": -0.23348382, "relevant": "1", "stops": "TMEM97 - myometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 9, "rel_score": 4.23837, "prob_score": -0.23593749, "relevant": "1", "stops": "TMEM97 - MYC - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 17, "rel_score": 3.85788, "prob_score": -0.259211, "relevant": "1", "stops": "TMEM97 - uterine cervix - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 3.65177, "prob_score": -0.27383605, "relevant": "1", "stops": "TMEM97 - RAF1 - ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 15, "rel_score": 3.53845, "prob_score": -0.28261024, "relevant": "1", "stops": "TMEM97 - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "435", "sentence": "We have previously described the increased expression of two prostate-specific G-protein coupled receptors ( <e1> PSGR </e1> and PSGR2) in human <e2> prostate cancer </e2> .", "e1": "PSGR", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 26, "rel_score": 8.34028, "prob_score": -0.11989712, "relevant": "1", "stops": "PGRMC2 - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": 8.31117, "prob_score": -0.120315954, "relevant": "1", "stops": "PGR - Levonorgestrel - Infestation - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 47, "rel_score": 8.18398, "prob_score": -0.12219175, "relevant": "1", "stops": "PGR - Medroxyprogesterone Acetate - Infestation - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 7, "rel_score": 7.65521, "prob_score": -0.13063498, "relevant": "1", "stops": "PGR - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": 6.99594, "prob_score": -0.14293608, "relevant": "1", "stops": "PGR - NCOA3 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "436", "sentence": "<e1> TSPO </e1> expression is increased in prostatic intraepithelial neoplasia, primary <e2> prostate cancer </e2> , and metastases compared with normal prostate tissue and benign prostatic hyperplasia.", "e1": "TSPO", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": 3.82614, "prob_score": -0.2613637, "relevant": "1", "stops": "TSPO - Zopiclone - Dysuria - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 47, "rel_score": 3.66744, "prob_score": -0.2726734, "relevant": "1", "stops": "TSPO - Clorazepate - Dermatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 33, "rel_score": 3.59932, "prob_score": -0.27783418, "relevant": "1", "stops": "TSPO - Triazolam - Dysuria - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 26, "rel_score": 3.49101, "prob_score": -0.28644848, "relevant": "1", "stops": "TSPO - Eszopiclone - Gynaecomastia - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 6, "rel_score": 3.07673, "prob_score": -0.32501647, "relevant": "1", "stops": "TSPO - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "437", "sentence": "Our results suggest that in <e2> MCF-7 </e2> cells Ang II activates multiple signalling pathways involving PKC-zeta, PI3K and MAPK; of these pathways only PKC-zeta appears responsible for the induction of <e1> c-fos </e1> .", "e1": "c-fos", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 35, "rel_score": 4.54298, "prob_score": -0.22012483, "relevant": "1", "stops": "FOSL1 - CKS2 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 13, "rel_score": 3.93918, "prob_score": -0.25386405, "relevant": "1", "stops": "FOSL1 - Lapatinib - breast cancer", "reltypes": "DOWNREGULATES_CdG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 1, "rel_score": 3.85208, "prob_score": -0.2596001, "relevant": "1", "stops": "FOSL1 - HEY2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 3.79752, "prob_score": -0.2633279, "relevant": "1", "stops": "FOSL1 - Mitoxantrone - breast cancer", "reltypes": "DOWNREGULATES_CdG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 21, "rel_score": 3.7843, "prob_score": -0.26425236, "relevant": "1", "stops": "FOSL1 - Vinblastine - breast cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}]}
{"qid": "438", "sentence": "It has been shown recently that 17beta-estradiol (E2) can stimulate the <e1> Src/p21ras/mitogen-activated protein kinase </e1> pathway in <e2> breast cancer </e2> cells, and this effect is supposed to mediate the E2-induced stimulation of breast cancer cell proliferation, possibly via activation of the c-fos and c-jun early genes or of genes involved in cell cycle control.", "e1": "Src/p21ras/mitogen-activated protein kinase", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 43, "rel_score": 1.54214, "prob_score": -0.64845175, "relevant": "1", "stops": "SRCAP - respiratory system - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": -1.67721, "prob_score": -0.5962268, "relevant": "0", "stops": "SRCAP - female gonad - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": -2.13415, "prob_score": -0.4685726, "relevant": "0", "stops": "SRCAP - central nervous system - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 32, "rel_score": -2.41633, "prob_score": -0.41384557, "relevant": "0", "stops": "SRCAP - liver - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 26, "rel_score": -2.513, "prob_score": -0.39793417, "relevant": "0", "stops": "SRCAP - gonad - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}]}
{"qid": "439", "sentence": "Our studies implicate that the overexpressed GRB7 and <e1> GRB7v </e1> are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in <e2> ovarian cancer </e2> cells.", "e1": "GRB7v", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 21, "rel_score": 5.28513, "prob_score": -0.18921249, "relevant": "1", "stops": "GRB7 - vagina - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 20, "rel_score": 4.57122, "prob_score": -0.21876426, "relevant": "1", "stops": "GRB7 - POT1 - ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 4.53556, "prob_score": -0.22048214, "relevant": "1", "stops": "GRB7 - CAV1 - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "rel_score": 4.52325, "prob_score": -0.22108445, "relevant": "1", "stops": "GRB7 - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 19, "rel_score": 4.42537, "prob_score": -0.22597364, "relevant": "1", "stops": "GRB7 - ANXA3 - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "440", "sentence": "Overexpression of <e1> IGFBP2 </e1> and IGFBP5 contributes to the invasiveness and progression of several human cancers, but their roles in the metastasis of <e2> breast cancer </e2> have not been investigated in detail.", "e1": "IGFBP2", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 11.5088, "prob_score": -0.08688906, "relevant": "1", "stops": "IGFBP2 - ADH5 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 11, "rel_score": 10.92419, "prob_score": -0.091536455, "relevant": "1", "stops": "IGFBP2 - MIF - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 45, "rel_score": 10.85423, "prob_score": -0.092126, "relevant": "1", "stops": "IGFBP2 - PRAF2 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 10.71467, "prob_score": -0.09333372, "relevant": "1", "stops": "IGFBP2 - TK1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 21, "rel_score": 10.52853, "prob_score": -0.09498229, "relevant": "1", "stops": "IGFBP2 - KRT18 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "441", "sentence": "L-mimosine enhanced expression of <e1> Btg2 </e1> and Ndrg1, which attenuated cell proliferation of the <e2> PC-3 </e2> and LNCaP prostate carcinoma cells.", "e1": "Btg2", "e2": "PC-3", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 13, "rel_score": -7.83269, "prob_score": -0.12767199, "relevant": "0", "stops": "BTG2 - SSBP2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": -8.21963, "prob_score": -0.121655375, "relevant": "0", "stops": "BTG2 - VAV3 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 35, "rel_score": -10.32311, "prob_score": -0.09686802, "relevant": "0", "stops": "BTG2 - MRPL12 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": -10.53408, "prob_score": -0.094927415, "relevant": "0", "stops": "BTG2 - GPER1 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": -11.14827, "prob_score": -0.08969757, "relevant": "0", "stops": "BTG2 - ACAT2 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "442", "sentence": "In <e2> T-47D </e2> cells, <e1> PRG1 mRNA </e1> was rapidly and transiently induced by progestins, expression peaking between 2 and 4 h and returning to control levels by 12 h.", "e1": "PRG1 mRNA", "e2": "T-47D", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 30, "rel_score": 19.74724, "prob_score": -0.05063831, "relevant": "1", "stops": "TPRG1 - female reproductive system - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 18.06358, "prob_score": -0.055355012, "relevant": "1", "stops": "TPRG1L - bone marrow - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 24, "rel_score": 17.80627, "prob_score": -0.05615819, "relevant": "1", "stops": "TPRG1 - brain - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 17.7305, "prob_score": -0.056396652, "relevant": "1", "stops": "TPRG1 - mammary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 15, "rel_score": 14.69508, "prob_score": -0.06804733, "relevant": "1", "stops": "TPRG1L - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "443", "sentence": "Arsenite induces <e1> HIF-1alpha </e1> and VEGF through PI3K, Akt and reactive oxygen species in <e2> DU145 </e2> human prostate carcinoma cells.", "e1": "HIF-1alpha", "e2": "DU145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 2.09477, "prob_score": -0.4773769, "relevant": "1", "stops": "HIF1AN - COX6A1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 27, "rel_score": 2.03587, "prob_score": -0.49119318, "relevant": "1", "stops": "HIF1AN - TMEM50A - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 37, "rel_score": 1.94681, "prob_score": -0.5136635, "relevant": "1", "stops": "HIF1AN - SPAG4 - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 1.93032, "prob_score": -0.51805294, "relevant": "1", "stops": "HIF1AN - MEF2C - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 1.9263, "prob_score": -0.519134, "relevant": "1", "stops": "HIF1AN - PARP1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "444", "sentence": "Our findings suggest that the down-regulation of <e1> ICAM-1 </e1> in mammary epithelial cells may contribute both to the high expression of psoriasin seen in some high-grade <e2> DCIS </e2> tumors and to the induction of MUC1.", "e1": "ICAM-1", "e2": "DCIS", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 7.40412, "prob_score": -0.13506377, "relevant": "1", "stops": "ICAM1 - nervous system - Gilles de la Tourette syndrome - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}, {"pathid": 4, "rel_score": 6.93866, "prob_score": -0.14411817, "relevant": "1", "stops": "ICAM1 - central nervous system - Gilles de la Tourette syndrome - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}, {"pathid": 9, "rel_score": 6.51848, "prob_score": -0.15341398, "relevant": "1", "stops": "ICAM1 - nervous system - attention deficit hyperactivity disorder - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}, {"pathid": 7, "rel_score": 5.92136, "prob_score": -0.16888063, "relevant": "1", "stops": "ICAM1 - STUB1 - attention deficit hyperactivity disorder - Tics", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG - PRESENTS_DpS", "nodelabels": "Gene - Gene - Disease - Symptom"}, {"pathid": 10, "rel_score": 5.29605, "prob_score": -0.18881536, "relevant": "1", "stops": "ICAM1 - cardiovascular system - attention deficit hyperactivity disorder - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}]}
{"qid": "445", "sentence": "Up-regulated expression of <e1> AR </e1> and GRP78 expression in untreated <e2> prostate cancer </e2> predicts a less favourable outcome.", "e1": "AR", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 6.2027, "prob_score": -0.16122393, "relevant": "1", "stops": "ARL2BP - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "rel_score": 6.19771, "prob_score": -0.16135064, "relevant": "1", "stops": "ARHGEF35 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": 6.15915, "prob_score": -0.16236305, "relevant": "1", "stops": "ARF4 - CHEK2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": 5.85995, "prob_score": -0.17065383, "relevant": "1", "stops": "ARF4 - PRKCQ - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 5.6815, "prob_score": -0.17601116, "relevant": "1", "stops": "ARHGAP15 - PRNP - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "446", "sentence": "Resveratrol- and EGCG-induced apoptosis is associated with a significant down-regulation of <e1> CK2 </e1> activity and protein expression in both the ALVA-41 and <e2> PC-3 </e2> cells.", "e1": "CK2", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 8.66476, "prob_score": -0.11541237, "relevant": "1", "stops": "CDK2 - ETV1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 8.4868, "prob_score": -0.11782695, "relevant": "1", "stops": "CDK2 - GSTP1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 41, "rel_score": 8.17862, "prob_score": -0.1222675, "relevant": "1", "stops": "CDK2 - BRCA2 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 7.98085, "prob_score": -0.125301, "relevant": "1", "stops": "CDK2 - LPL - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 43, "rel_score": 7.85484, "prob_score": -0.12730956, "relevant": "1", "stops": "CDK2 - RPL12 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "447", "sentence": "Adipocyte expression and circulating levels of <e1> leptin </e1> increase in both gynaecological and <e2> breast cancer </e2> patients.", "e1": "leptin", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 16.5071, "prob_score": -0.060580786, "relevant": "1", "stops": "LEPROTL1 - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 30, "rel_score": 15.9821, "prob_score": -0.06257452, "relevant": "1", "stops": "LEPROT - Sirolimus - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 40, "rel_score": 15.76044, "prob_score": -0.06344575, "relevant": "1", "stops": "LEPROT - blood - CYP2C19 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 15.65435, "prob_score": -0.063879944, "relevant": "1", "stops": "LEPROTL1 - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": 15.53519, "prob_score": -0.0643697, "relevant": "1", "stops": "LEPROT - liver - CYP2C19 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "448", "sentence": "Scavenger receptor class A, member 3 ( <e1> SCARA3 </e1> ) was previously found to be overexpressed in ovarian/primary peritoneal carcinoma (OC/PPC) compared with <e2> breast carcinoma </e2> effusions by global gene expression analysis.", "e1": "SCARA3", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 17, "rel_score": 15.57875, "prob_score": -0.06419055, "relevant": "1", "stops": "SCARA3 - head - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 13.89468, "prob_score": -0.07196574, "relevant": "1", "stops": "SCARA3 - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": 13.46439, "prob_score": -0.074266605, "relevant": "1", "stops": "SCARA3 - myometrium - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 11.76194, "prob_score": -0.08502233, "relevant": "1", "stops": "SCARA3 - nipple - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 35, "rel_score": 11.71097, "prob_score": -0.085392594, "relevant": "1", "stops": "SCARA3 - telencephalon - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "450", "sentence": "Consistently, loss of <e1> CD95 </e1> in mouse models of <e2> ovarian cancer </e2> and liver cancer reduces cancer incidence as well as the size of the tumours.", "e1": "CD95", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 25, "rel_score": -1.67822, "prob_score": -0.59587455, "relevant": "0", "stops": "CD5L - telencephalon - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": -1.71541, "prob_score": -0.5829542, "relevant": "0", "stops": "CD5L - brain - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": -1.79051, "prob_score": -0.5585031, "relevant": "0", "stops": "CD5L - liver - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": -1.86651, "prob_score": -0.53576493, "relevant": "0", "stops": "CD5L - cerebellum - CYP2C19 - Progesterone - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -2.41354, "prob_score": -0.41432875, "relevant": "0", "stops": "CD53 - Parkinson's disease - Pramipexole - Ovarian cancer", "reltypes": "UPREGULATES_DuG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "451", "sentence": "KTI treatment may also be beneficial for <e2> ovarian cancer </e2> patients with or at risk for peritoneal disseminated metastasis; it greatly reduces tumor burden in part by inhibiting phosphorylation of MAP kinase and PI3 kinase, leading to suppression of <e1> uPA </e1> expression.", "e1": "uPA", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 40, "rel_score": -2.9036, "prob_score": -0.34439546, "relevant": "0", "stops": "LPAR3 - ACAT2 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": -3.05157, "prob_score": -0.3277022, "relevant": "0", "stops": "LPAR5 - CDC20 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": -3.16366, "prob_score": -0.3160924, "relevant": "0", "stops": "LPAR3 - TRAP1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": -3.29381, "prob_score": -0.30359873, "relevant": "0", "stops": "LPAR5 - PRSS23 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": -3.51358, "prob_score": -0.284611, "relevant": "0", "stops": "LPAR5 - ZDHHC6 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "452", "sentence": "We conclude that <e1> c-erbB-2 protein </e1> overexpression assessed by IHC is a superior prognostic indicator in operable <e2> breast cancer </e2> compared to c-erbB-2 gene amplification analysed by the dot-blot technique.", "e1": "c-erbB-2 protein", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": -1.55618, "prob_score": -0.64259636, "relevant": "0", "stops": "CPSF1 - AGR2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 11, "rel_score": -1.61044, "prob_score": -0.62095207, "relevant": "0", "stops": "CPOX - bone marrow - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": -1.61257, "prob_score": -0.62013113, "relevant": "0", "stops": "CPOX - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": -1.62174, "prob_score": -0.61662084, "relevant": "0", "stops": "CPOX - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 38, "rel_score": -1.64606, "prob_score": -0.6075093, "relevant": "0", "stops": "CPSF1 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "453", "sentence": "Pronounced increases in the concentration of an <e2> ovarian tumor </e2> marker, <e1> CA-125 </e1> , in serum of a healthy subject during menstruation.", "e1": "CA-125", "e2": "ovarian tumor", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 11, "rel_score": 4.17781, "prob_score": -0.23936187, "relevant": "1", "stops": "CA12 - GNPDA1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 3.82336, "prob_score": -0.2615512, "relevant": "1", "stops": "CA12 - TIMM9 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 3.36055, "prob_score": -0.2975662, "relevant": "1", "stops": "CA12 - RPS4Y1 - Estrone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 3.03573, "prob_score": -0.32940805, "relevant": "1", "stops": "CA12 - VAT1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 3.01405, "prob_score": -0.33177984, "relevant": "1", "stops": "CA12 - FABP5 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "454", "sentence": "Our previous studies have shown that sublines of human ovarian carcinoma cell line <e2> A2780 </e2> , which exhibited low levels of resistance to oxaliplatin, showed elevated steady state levels of mRNA and activity of <e1> gamma-glutamyl transpeptidase </e1> (gamma-GT, EC 2.3.2.2), but not of gamma-glutamylcysteine synthetase (gamma-GCS, EC 6.3.2.2) [El-akawi et al., Cancer Lett. 105:5-14; 1966].", "e1": "gamma-glutamyl transpeptidase", "e2": "A2780", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": 8.27746, "prob_score": -0.120807566, "relevant": "1", "stops": "GALM - female gonad - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 8.2352, "prob_score": -0.12143011, "relevant": "1", "stops": "GALM - cerebellum - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 7.84991, "prob_score": -0.12739418, "relevant": "1", "stops": "GALM - medulla oblongata - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 7.57978, "prob_score": -0.13193233, "relevant": "1", "stops": "GALM - midbrain - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 7.54432, "prob_score": -0.13255323, "relevant": "1", "stops": "GALM - brain - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "455", "sentence": "Under normoxic conditions, treatment of both <e2> ovarian cancer </e2> cell lines with dmPGE(2) resulted in a significant increase in <e1> VEGF </e1> expression but had no effect on HIF-1alpha.", "e1": "VEGF", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 9.21829, "prob_score": -0.1084784, "relevant": "1", "stops": "VEGFA - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "457", "sentence": "<e2> OVCA420 </e2> , a cell line that is dramatically growth inhibited by TGF beta 1, significantly induced <e1> CIP1 </e1> expression in response to TGF beta 1.", "e1": "CIP1", "e2": "OVCA420", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 6.14251, "prob_score": -0.16279821, "relevant": "1", "stops": "CRIP1 - CYP3A5 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 6.12933, "prob_score": -0.16315119, "relevant": "1", "stops": "CRIP1 - AKR7A2 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 5.91891, "prob_score": -0.1689549, "relevant": "1", "stops": "CRIP1 - CDK6 - Estrone - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 5.89136, "prob_score": -0.1697449, "relevant": "1", "stops": "CRIP1 - FAM57A - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 5.72803, "prob_score": -0.17457578, "relevant": "1", "stops": "CRIP1 - FAM57A - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "458", "sentence": "TAT and <e1> FDP </e1> were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with <e2> ovarian cancer </e2> .", "e1": "FDP", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 11.27777, "prob_score": -0.08866806, "relevant": "1", "stops": "FDPS - Raloxifene - Ovarian cancer", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 10.93613, "prob_score": -0.09143532, "relevant": "1", "stops": "FDPS - Clomifene - Ovarian cancer", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 10.8672, "prob_score": -0.09201502, "relevant": "1", "stops": "FDPS - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 10.62473, "prob_score": -0.09411879, "relevant": "1", "stops": "FDPS - decidua - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 10.47559, "prob_score": -0.09545933, "relevant": "1", "stops": "FDPS - HDAC2 - ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "459", "sentence": "These results indicate that the overexpression of <e1> H-ras </e1> in human <e2> breast tumors </e2> is not correlated with alteration of the protooncogene.", "e1": "H-ras", "e2": "breast tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 47.61905, "prob_score": -0.020995319, "relevant": "1", "stops": "HRASLS5 - prostate gland - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 47.23666, "prob_score": -0.021167884, "relevant": "1", "stops": "HRASLS5 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 34, "rel_score": 44.50378, "prob_score": -0.022472067, "relevant": "1", "stops": "HRASLS5 - brain - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 44.11116, "prob_score": -0.022666158, "relevant": "1", "stops": "HRASLS5 - heart - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 42.35494, "prob_score": -0.023609752, "relevant": "1", "stops": "HRASLS - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "460", "sentence": "Human folate receptor alpha ( <e1> FRalpha </e1> ) is a folate-binding protein that is selectively overexpressed in <e2> ovarian carcinoma </e2> and has been regarded as a suitable target antigen for immunotherapy purposes.", "e1": "FRalpha", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 6.58458, "prob_score": -0.15186548, "relevant": "1", "stops": "RALA - CDC20 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 6.54836, "prob_score": -0.15270615, "relevant": "1", "stops": "RALA - PCNA - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 6.38937, "prob_score": -0.15650652, "relevant": "1", "stops": "RALA - TIMELESS - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 6.10426, "prob_score": -0.16381748, "relevant": "1", "stops": "RALA - POLR2I - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 5.65355, "prob_score": -0.17688237, "relevant": "1", "stops": "RALA - ST3GAL5 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "462", "sentence": "Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and <e1> VEGF </e1> in <e2> prostate cancer </e2> cells.", "e1": "VEGF", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 5.003, "prob_score": -0.19987945, "relevant": "1", "stops": "VEGFA - BRCA1 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 4.584, "prob_score": -0.21815383, "relevant": "1", "stops": "VEGFA - CCDC86 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 4.51896, "prob_score": -0.22129168, "relevant": "1", "stops": "VEGFA - DECR1 - Ropinirole - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 4.03372, "prob_score": -0.24791256, "relevant": "1", "stops": "VEGFA - Alzheimer's disease - Selegiline - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 36, "rel_score": 3.94789, "prob_score": -0.2533017, "relevant": "1", "stops": "VEGFA - chronic obstructive pulmonary disease - Roflumilast - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "463", "sentence": "LPA increased <e1> COX-2 protein </e1> expression in a time- and concentration-dependent manner in two of three immortalized borderline ovarian epithelial cells as well as in four of six <e2> ovarian cancer </e2> cell lines.", "e1": "COX-2 protein", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 6.51848, "prob_score": -0.15340973, "relevant": "1", "stops": "CPOX - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 14, "rel_score": 6.21929, "prob_score": -0.16079335, "relevant": "1", "stops": "CPOX - decidua - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": 6.12933, "prob_score": -0.16315103, "relevant": "1", "stops": "CPOX - female reproductive system - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 5.94071, "prob_score": -0.16833393, "relevant": "1", "stops": "CPOX - bone marrow - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 5.36538, "prob_score": -0.18637706, "relevant": "1", "stops": "CPOX - STAMBP - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "464", "sentence": "We critically review the recent advances in <e2> prostate cancer </e2> immunohistochemistry, including the introduction of newer basal cell markers such as p63 and the discovery of the overexpression of <e1> alpha-methylacyl coenzyme A racemase </e1> (AMACR) in prostate cancer.", "e1": "alpha-methylacyl coenzyme A racemase", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 6.70466, "prob_score": -0.1491479, "relevant": "1", "stops": "APH1A - testis - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 6.46371, "prob_score": -0.15470845, "relevant": "1", "stops": "APH1A - telencephalon - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 6.18659, "prob_score": -0.16164416, "relevant": "1", "stops": "APH1A - TNFRSF21 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 6.17322, "prob_score": -0.16198736, "relevant": "1", "stops": "APH1A - endometrium - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 6.00962, "prob_score": -0.16640042, "relevant": "1", "stops": "APH1A - cerebellum - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "465", "sentence": "In clinical <e2> prostate cancer </e2> specimens from patients with varying grades of disease, the stained tissue sections showed high levels of <e1> SREBP-1 protein </e1> compared with noncancerous prostate tissue.", "e1": "SREBP-1 protein", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 5.24082, "prob_score": -0.1908114, "relevant": "1", "stops": "SERBP1 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": 5.09866, "prob_score": -0.19613329, "relevant": "1", "stops": "SERBP1 - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 35, "rel_score": 2.87977, "prob_score": -0.34725463, "relevant": "1", "stops": "SERBP1 - lung - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 26, "rel_score": 2.78629, "prob_score": -0.35890034, "relevant": "1", "stops": "SERBP1 - central nervous system - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 2.69165, "prob_score": -0.37151954, "relevant": "1", "stops": "SERBP1 - ISG15 - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Gene - Disease - Compound - SideEffect"}]}
{"qid": "466", "sentence": "Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line <e2> LNCaP </e2> observed in response to hormone withdrawal is further augmented by TNF-alpha treatment, and this effect is abated by inhibitors of <e1> NF-kappa B </e1> .", "e1": "NF-kappa B", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 1.70462, "prob_score": -0.5866426, "relevant": "1", "stops": "NF1 - PCNA - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": -1.59398, "prob_score": -0.62735796, "relevant": "0", "stops": "NF1 - TYMS - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": -1.5989, "prob_score": -0.6254308, "relevant": "0", "stops": "NF1 - PCNA - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": -1.62012, "prob_score": -0.61724, "relevant": "0", "stops": "NF1 - FAM57A - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": -1.67009, "prob_score": -0.5987655, "relevant": "0", "stops": "NF1 - RPS4Y1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "467", "sentence": "Herein, we demonstrate that loss of <e1> Pfn1 </e1> expression leads to slower but more stable lamellipodial protrusion thereby enhancing the net protrusion rate and the overall motility of <e2> MDA-MB-231 </e2> breast cancer cells.", "e1": "Pfn1", "e2": "MDA-MB-231", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 35, "rel_score": 3.3162, "prob_score": -0.3015479, "relevant": "1", "stops": "PFN1 - STX1A - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": 3.23185, "prob_score": -0.30941916, "relevant": "1", "stops": "PFN1 - TAB2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 2.5888, "prob_score": -0.38628283, "relevant": "1", "stops": "PFN1 - CDK2 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": 2.09754, "prob_score": -0.4767522, "relevant": "1", "stops": "PFN1 - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 48, "rel_score": -1.77952, "prob_score": -0.5619512, "relevant": "0", "stops": "PFN1 - Docetaxel - breast cancer", "reltypes": "DOWNREGULATES_CdG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}]}
{"qid": "468", "sentence": "Thus, pharmacologically-induced metabolic restriction (via treatment with glycolysis inhibitors) may be a promising new therapeutic strategy for <e2> breast cancer </e2> patients that lack stromal <e1> Cav-1 </e1> expression.", "e1": "Cav-1", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 21, "rel_score": 3.91711, "prob_score": -0.25529036, "relevant": "1", "stops": "CAV1 - CDK6 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 3.87792, "prob_score": -0.257873, "relevant": "1", "stops": "CAV1 - RHOA - Paclitaxel - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 3.50594, "prob_score": -0.2852256, "relevant": "1", "stops": "CAV1 - MCOLN1 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 3.47017, "prob_score": -0.28816774, "relevant": "1", "stops": "CAV1 - CSK - Mitoxantrone - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 3.23562, "prob_score": -0.3090605, "relevant": "1", "stops": "CAV1 - breast cancer - Mitoxantrone - Breast cancer stage IV", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "469", "sentence": "These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the <e1> SRD5A2 locus </e1> in <e2> prostate cancer </e2> progression, in a subset of patients.", "e1": "SRD5A2 locus", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": -2.37164, "prob_score": -0.4216526, "relevant": "0", "stops": "SRD5A2 - Dutasteride - Gynaecomastia - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 25, "rel_score": -2.38675, "prob_score": -0.41897908, "relevant": "0", "stops": "SRD5A2 - Finasteride - Urticaria - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 46, "rel_score": -2.6448, "prob_score": -0.37809533, "relevant": "0", "stops": "SRD5A2 - response to lipid - TGFBR2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": -3.17078, "prob_score": -0.31538194, "relevant": "0", "stops": "SRD5A2 - cell-cell signaling - GDF15 - Lenalidomide - Prostate cancer metastatic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -3.8962, "prob_score": -0.25665575, "relevant": "0", "stops": "SRD5A2 - prostate cancer - GDF15 - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - ASSOCIATES_DaG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Disease - Gene - Compound - SideEffect"}]}
{"qid": "470", "sentence": "<e2> DOV13 </e2> cells incubated with active rhMMP-7 significantly increased cellular invasion and <e1> proMMP-2 </e1> activation.", "e1": "proMMP-2", "e2": "DOV13", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 4.28908, "prob_score": -0.23314717, "relevant": "1", "stops": "PROM2 - tendon - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 4.23334, "prob_score": -0.2362205, "relevant": "1", "stops": "PROM2 - thyroid gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 3.80735, "prob_score": -0.26264906, "relevant": "1", "stops": "PROM2 - trachea - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 3.66059, "prob_score": -0.27318096, "relevant": "1", "stops": "PROM2 - nipple - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 3.46464, "prob_score": -0.28863034, "relevant": "1", "stops": "PROM2 - blood - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "471", "sentence": "Kaplan-Meier survival analysis confirmed increased <e1> RPL19 </e1> expression to be highly predictive of shorter patient survival (P &lt; 0.05), revealing RPL19 to be a sensitive predictor of <e2> prostate cancer </e2> progression.", "e1": "RPL19", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 2.2426, "prob_score": -0.44590625, "relevant": "1", "stops": "RPL19 - GTF3C4 - Ruxolitinib - Prostate cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 2.12766, "prob_score": -0.46999964, "relevant": "1", "stops": "RPL19 - PTGS2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 2.0819, "prob_score": -0.48033005, "relevant": "1", "stops": "RPL19 - MRPS16 - Riluzole - Prostate cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 2.05973, "prob_score": -0.48549676, "relevant": "1", "stops": "RPL19 - RPL10 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 37, "rel_score": 1.96371, "prob_score": -0.509236, "relevant": "1", "stops": "RPL19 - MRPS2 - Testosterone Propionate - Prostate cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "472", "sentence": "We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 ( <e1> DR3 </e1> ) was increased in <e2> PC3 </e2> cells, and the expression of FAS and DR3 was increased in SW620 cells by co-culture with NK-92 cells.", "e1": "DR3", "e2": "PC3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 3.59454, "prob_score": -0.27820134, "relevant": "1", "stops": "WDR37 - ERBB2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 3.54862, "prob_score": -0.28180027, "relevant": "1", "stops": "WDR3 - SUMO2 - prostate cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 21, "rel_score": 3.53195, "prob_score": -0.28312573, "relevant": "1", "stops": "WDR3 - KLF6 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 41, "rel_score": 3.52908, "prob_score": -0.2833637, "relevant": "1", "stops": "WDR31 - JADE2 - Dexamethasone - prostate cancer", "reltypes": "COVARIES_GcG - UPREGULATES_CuG - PALLIATES_CpD", "nodelabels": "Gene - Gene - Compound - Disease"}, {"pathid": 5, "rel_score": 3.25531, "prob_score": -0.30719492, "relevant": "1", "stops": "WDR35 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "473", "sentence": "Hence, R-flurbiprofen and ibuprofen selectively induce p75(NTR)-dependent decreased survival of <e2> prostate cancer </e2> cells independently of <e1> COX </e1> inhibition.", "e1": "COX", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": 6.39264, "prob_score": -0.15643233, "relevant": "1", "stops": "CPOX - nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 5.89206, "prob_score": -0.16972093, "relevant": "1", "stops": "CPOX - nipple - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 5.72639, "prob_score": -0.17463498, "relevant": "1", "stops": "CPOX - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 11, "rel_score": 5.58285, "prob_score": -0.17912284, "relevant": "1", "stops": "CPOX - cerebellum - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 5.50449, "prob_score": -0.18166971, "relevant": "1", "stops": "CPOX - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "476", "sentence": "<e1> PTOV1 </e1> was recently identified as a novel gene and protein during a differential display screening for genes overexpressed in <e2> prostate cancer </e2> .", "e1": "PTOV1", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 8.59697, "prob_score": -0.11631758, "relevant": "1", "stops": "PTOV1 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 40, "rel_score": 7.47887, "prob_score": -0.13371204, "relevant": "1", "stops": "PTOV1 - nipple - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 7.44048, "prob_score": -0.13439552, "relevant": "1", "stops": "PTOV1 - adipose tissue - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 6.62383, "prob_score": -0.1509736, "relevant": "1", "stops": "PTOV1 - CLDN7 - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 20, "rel_score": 6.29644, "prob_score": -0.15881918, "relevant": "1", "stops": "PTOV1 - cortex of kidney - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "477", "sentence": "Increased expression of <e1> CD146 </e1> , a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and <e2> ovarian cancer </e2> .", "e1": "CD146", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 40, "rel_score": 15.05117, "prob_score": -0.06644384, "relevant": "1", "stops": "CD46 - Topotecan - ovarian cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 5, "rel_score": 12.87333, "prob_score": -0.07767987, "relevant": "1", "stops": "CD46 - SRC - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 12.64223, "prob_score": -0.079103366, "relevant": "1", "stops": "CD46 - PDHX - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 11.40251, "prob_score": -0.08770118, "relevant": "1", "stops": "CD46 - PUF60 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 11.22965, "prob_score": -0.089052394, "relevant": "1", "stops": "CD46 - ABCC5 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "479", "sentence": "The fact that increased <e1> NTN1 </e1> is specifically observed in cancerous tissues indicates that NTN1 may represent a novel candidate biomarker for <e2> ovarian cancer </e2> .", "e1": "NTN1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 10.51193, "prob_score": -0.09512735, "relevant": "1", "stops": "NTN1 - CDC20 - Raloxifene - Ovarian cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 9.96214, "prob_score": -0.10038425, "relevant": "1", "stops": "NTN1 - CDC20 - Clomifene - Ovarian cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 9.47867, "prob_score": -0.10550269, "relevant": "1", "stops": "NTN1 - female gonad - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": 9.40822, "prob_score": -0.106288016, "relevant": "1", "stops": "NTN1 - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 6.36699, "prob_score": -0.15706168, "relevant": "1", "stops": "NTN1 - uterine fibroid - ovarian cancer", "reltypes": "UPREGULATES_DuG - RESEMBLES_DrD", "nodelabels": "Gene - Disease - Disease"}]}
{"qid": "480", "sentence": "<e1> IL-18 </e1> and FGF-2 proteins were significantly elevated in tumor tissues (p<0.04) and sera (p<0.05) from patients with <e2> ovarian cancer </e2> .", "e1": "IL-18", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 12.444, "prob_score": -0.08036011, "relevant": "1", "stops": "IL18R1 - mammalian vulva - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 10.85776, "prob_score": -0.09210301, "relevant": "1", "stops": "IL18R1 - adrenal gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 10.8038, "prob_score": -0.09256364, "relevant": "1", "stops": "IL18R1 - lymphoid tissue - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 10.44386, "prob_score": -0.09574778, "relevant": "1", "stops": "IL18R1 - liver - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 8.9214, "prob_score": -0.11208632, "relevant": "1", "stops": "IL18R1 - decidua - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "481", "sentence": "In <e2> MCF-7 </e2> , an increase in Bad and Bax protein expression and a decrease in <e1> Bcl-x(L) protein </e1> and Bcl-2 protein and mRNA were observed.", "e1": "Bcl-x(L) protein", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 46, "rel_score": 6.00168, "prob_score": -0.16662294, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - endometrium - breast cancer", "reltypes": "INTERACTS_GiG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 5.83635, "prob_score": -0.17134447, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - SLC39A7 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 5.66636, "prob_score": -0.17648008, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - ADGRL3 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 37, "rel_score": 5.58067, "prob_score": -0.17919119, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - ABCB1 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 5.53403, "prob_score": -0.18069568, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - PDE4D - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "482", "sentence": "In prostate cancer <e2> DU-145 </e2> cells, which were transiently transfected with CBP cDNA, hydroxyflutamide enhanced <e1> AR </e1> activity to a greater extent than bicalutamide in the presence of either wild-type or the mutated AR 730 val-->met.", "e1": "AR", "e2": "DU-145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 4.33032, "prob_score": -0.23092677, "relevant": "1", "stops": "ARHGAP15 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 3.94368, "prob_score": -0.25357154, "relevant": "1", "stops": "ARL2BP - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 26, "rel_score": 3.72592, "prob_score": -0.2683865, "relevant": "1", "stops": "ARF4 - EFEMP2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": 3.475, "prob_score": -0.28777036, "relevant": "1", "stops": "ARF4 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 14, "rel_score": 3.40646, "prob_score": -0.2935587, "relevant": "1", "stops": "ARSG - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "483", "sentence": "10(-6) M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and TGFalpha mRNA induction and restored <e1> TGFbeta mRNA </e1> to control levels in T3-treated <e2> MCF-7 </e2> cells.", "e1": "TGFbeta mRNA", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 2.77208, "prob_score": -0.36074367, "relevant": "1", "stops": "TGFBR3L - adipose tissue - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 2.48583, "prob_score": -0.40228364, "relevant": "1", "stops": "TGFBR3L - heart - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 2.40419, "prob_score": -0.41593584, "relevant": "1", "stops": "TGFBR3L - heart - GRIN1 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 2.33721, "prob_score": -0.42786133, "relevant": "1", "stops": "TGFBR3L - heart - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 2.32374, "prob_score": -0.4303438, "relevant": "1", "stops": "TGFBR3L - testis - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "485", "sentence": "The levels of <e1> TAT </e1> and FDP were significantly higher in patients with <e2> ovarian cancer </e2> compared to the control group (both: p less than 0.01), and these levels were higher than in other gynecological malignancies.", "e1": "TAT", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 30, "rel_score": 5.92733, "prob_score": -0.168714, "relevant": "1", "stops": "TATDN1 - female reproductive system - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 5.78402, "prob_score": -0.17289403, "relevant": "1", "stops": "TATDN1 - female gonad - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 5.33589, "prob_score": -0.18741237, "relevant": "1", "stops": "TATDN1 - brain - ID2 - Raloxifene - Ovarian cancer", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 5.30391, "prob_score": -0.188542, "relevant": "1", "stops": "TATDN1 - heart - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 5.04872, "prob_score": -0.19807154, "relevant": "1", "stops": "TATDN1 - brain - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "486", "sentence": "In addition, <e1> Six1 </e1> overexpression renders OCC resistant to tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis, and Six1 knockdown in the TRAIL-resistant <e2> SKOV3 </e2> ovarian carcinoma line dramatically sensitizes the cells to TRAIL.", "e1": "Six1", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 2, "rel_score": -1.66431, "prob_score": -0.6008482, "relevant": "0", "stops": "SIX1 - uterine cervix - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": -1.72357, "prob_score": -0.5801901, "relevant": "0", "stops": "SIX1 - embryo development - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": -1.72933, "prob_score": -0.5782647, "relevant": "0", "stops": "SIX1 - saliva-secreting gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": -1.86036, "prob_score": -0.53753, "relevant": "0", "stops": "SIX1 - embryonic organ development - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": -2.15401, "prob_score": -0.46424645, "relevant": "0", "stops": "SIX1 - positive regulation of cell proliferation - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "487", "sentence": "Conversely, ectopic Pak1 overexpression enhanced <e2> ovarian cancer </e2> cell migration and invasion in a kinase-dependent manner, along with increased <e1> p38 </e1> activation.", "e1": "p38", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 3.77986, "prob_score": -0.26456064, "relevant": "1", "stops": "IPO8 - RUVBL1 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 3.71706, "prob_score": -0.269033, "relevant": "1", "stops": "IPO8 - HSPD1 - Clomifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 3.561, "prob_score": -0.2808229, "relevant": "1", "stops": "IPO8 - HSPD1 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 3.53419, "prob_score": -0.2829522, "relevant": "1", "stops": "IPO8 - myometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": 3.24739, "prob_score": -0.30794144, "relevant": "1", "stops": "IPO8 - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "488", "sentence": "Expression of C2GnT1 is low or absent in around 50% of <e2> breast cancers </e2> , whereas expression of <e1> ST3Gal-I </e1> is consistently increased.", "e1": "ST3Gal-I", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 23, "rel_score": 4.71787, "prob_score": -0.21195717, "relevant": "1", "stops": "ST3GAL6 - tendon - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 4.56621, "prob_score": -0.21900007, "relevant": "1", "stops": "ST3GAL6 - blood - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 4.36948, "prob_score": -0.22885615, "relevant": "1", "stops": "ST3GAL6 - thyroid gland - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 4.01994, "prob_score": -0.24875936, "relevant": "1", "stops": "ST3GAL6 - female reproductive system - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 3.92742, "prob_score": -0.25462484, "relevant": "1", "stops": "ST3GAL6 - adrenal gland - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "489", "sentence": "Elevation of <e1> GC UNC-45 </e1> levels by ectopic expression enhanced the rate of <e2> ovarian cancer </e2> cell proliferation, whereas siRNA knockdown of GC UNC-45 suppressed proliferation without altering myosin II levels.", "e1": "GC UNC-45", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 36, "rel_score": 2.9613, "prob_score": -0.33769304, "relevant": "1", "stops": "GCLC - LAGE3 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 2.81476, "prob_score": -0.35527238, "relevant": "1", "stops": "GCLC - LAGE3 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 2.71643, "prob_score": -0.3681261, "relevant": "1", "stops": "GCLC - SERPINA3 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 2.53338, "prob_score": -0.39473376, "relevant": "1", "stops": "GCLC - SMNDC1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 2.18417, "prob_score": -0.45783752, "relevant": "1", "stops": "GCLC - DLD - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "490", "sentence": "We had reported previously that although both <e2> BT474 </e2> and MKN7 cells overexpress <e1> ErbB2 </e1> , only BT474 cells show an antiproliferative response to mAb 4D5 treatment.", "e1": "ErbB2", "e2": "BT474", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 4.13155, "prob_score": -0.24204232, "relevant": "1", "stops": "ERBB2IP - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 14, "rel_score": 3.53369, "prob_score": -0.28298572, "relevant": "1", "stops": "ERBB2IP - mammary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 48, "rel_score": 3.19744, "prob_score": -0.31274843, "relevant": "1", "stops": "ERBB2 - ST6GALNAC2 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 3.09511, "prob_score": -0.3230931, "relevant": "1", "stops": "ERBB2 - ABCB1 - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 2.7499, "prob_score": -0.36364836, "relevant": "1", "stops": "ERBB2 - MCOLN1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "493", "sentence": "PKC-zeta is required for angiotensin II-induced activation of <e1> ERK </e1> and synthesis of C-FOS in <e2> MCF-7 </e2> cells.", "e1": "ERK", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 37, "rel_score": 12.59605, "prob_score": -0.07938553, "relevant": "1", "stops": "CERK - ARHGEF5 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 12.50313, "prob_score": -0.07998453, "relevant": "1", "stops": "CERK - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 47, "rel_score": 12.2835, "prob_score": -0.0814055, "relevant": "1", "stops": "CERKL - adipose tissue - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 12.108, "prob_score": -0.082590565, "relevant": "1", "stops": "CERK - KDR - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 11, "rel_score": 11.96315, "prob_score": -0.08359302, "relevant": "1", "stops": "CERK - DNAJC1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "494", "sentence": "Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of vascular endothelial growth factor ( <e1> VEGF </e1> ) in <e2> ovarian cancer </e2> cells.", "e1": "VEGF", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 0, "rel_score": 2.9274, "prob_score": -0.3415975, "relevant": "1", "stops": "VEGFA - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "495", "sentence": "This study suggests that the Asn allele in the <e1> SHBG </e1> gene may be related to a reduced risk of <e2> breast cancer </e2> among postmenopausal women by increasing their blood SHBG levels.", "e1": "SHBG", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 41, "rel_score": 11.7096, "prob_score": -0.08540494, "relevant": "1", "stops": "SHBG - Spironolactone - Gynaecomastia - Citalopram - Breast cancer female", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 38, "rel_score": 11.39082, "prob_score": -0.08779172, "relevant": "1", "stops": "SHBG - Estradiol - Gynaecomastia - Escitalopram - Breast cancer female", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 47, "rel_score": 10.41992, "prob_score": -0.095967084, "relevant": "1", "stops": "SHBG - Fluoxymesterone - Gynaecomastia - Citalopram - Breast cancer female", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 48, "rel_score": 9.84349, "prob_score": -0.10158792, "relevant": "1", "stops": "SHBG - Fluoxymesterone - Gynaecomastia - Escitalopram - Breast cancer female", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 30, "rel_score": 9.09504, "prob_score": -0.10994503, "relevant": "1", "stops": "SHBG - Levonorgestrel - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "497", "sentence": "However, in this issue of the JCI, Sharma et al. show that <e1> RB1 </e1> loss is a late event in human <e2> prostate cancer </e2> that is coincident with the emergence of castrate-resistant metastatic disease.", "e1": "RB1", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 24.05002, "prob_score": -0.041581247, "relevant": "1", "stops": "RB1 - MYC - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 23.00966, "prob_score": -0.04345558, "relevant": "1", "stops": "RB1 - CDKN1A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 21.14612, "prob_score": -0.04728583, "relevant": "1", "stops": "RB1 - TOP2A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": 19.23077, "prob_score": -0.05199889, "relevant": "1", "stops": "RB1CC1 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 19.1168, "prob_score": -0.052314818, "relevant": "1", "stops": "RB1CC1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "498", "sentence": "We showed that treatment of <e2> MCF-7 </e2> and triple-negative MDA-MB-231 human breast cancer cells with a GnRH-II antagonist results in apoptotic cell death in vitro via activation of stress-activated MAPK <e1> p38 </e1> and loss of mitochondrial membrane potential.", "e1": "p38", "e2": "MCF-7", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 47, "rel_score": 5.24191, "prob_score": -0.19077116, "relevant": "1", "stops": "IPO8 - AGO2 - Gemcitabine - Breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 5.09814, "prob_score": -0.1961527, "relevant": "1", "stops": "IPO8 - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 27, "rel_score": 4.9373, "prob_score": -0.20254135, "relevant": "1", "stops": "IPO8 - DHCR7 - Clomifene - Breast cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 4.15472, "prob_score": -0.24068803, "relevant": "1", "stops": "IPO8 - OXA1L - Paclitaxel - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 4.08847, "prob_score": -0.2445893, "relevant": "1", "stops": "IPO8 - bone marrow - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "500", "sentence": "The present study showed that <e1> PPAR-gamma </e1> activation can be an important regulator of COX-2 in prostate cells and may be an important target for <e2> prostate cancer </e2> chemoprevention.", "e1": "PPAR-gamma", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 26, "rel_score": -6.57333, "prob_score": -0.15213342, "relevant": "0", "stops": "PPARA - CYTH1 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": -7.04077, "prob_score": -0.14203422, "relevant": "0", "stops": "PPARA - LPIN1 - Paroxetine - Prostate cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": -7.20773, "prob_score": -0.13874298, "relevant": "0", "stops": "PPARA - PFN1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": -7.23851, "prob_score": -0.1381487, "relevant": "0", "stops": "PPARA - IKZF1 - Ropinirole - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": -7.54091, "prob_score": -0.13261048, "relevant": "0", "stops": "PPARA - DECR1 - Ropinirole - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "501", "sentence": "Pak1, p-Pak1 and <e1> p-Pak2 </e1> were overexpressed in <e2> ovarian cancer </e2> cell lines, and clinical samples of ovarian cancers were compared with benign ovarian lesions/inclusion cysts.", "e1": "p-Pak2", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 3.87432, "prob_score": -0.2581096, "relevant": "1", "stops": "PPA2 - vagina - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 24, "rel_score": 3.72315, "prob_score": -0.26858857, "relevant": "1", "stops": "PPA2 - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": 3.64365, "prob_score": -0.27445045, "relevant": "1", "stops": "PPA2 - MSMO1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 3.61585, "prob_score": -0.2765551, "relevant": "1", "stops": "PPA2 - SRM - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 3.59415, "prob_score": -0.27823192, "relevant": "1", "stops": "PPA2 - MSRA - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "502", "sentence": "Transfection of <e1> HER2 </e1> in <e2> MCF7 </e2> breast cancer cells that express HER3 caused a phosphoinoside-3 kinase (PI-3K)-dependent activation of Akt, and was associated with an increased resistance of the cells to multiple chemotherapeutic agents (paclitaxel, doxorubicin, 5-fluorouracil, etoposide, and camptothecin).", "e1": "HER2", "e2": "MCF7", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": -2.01467, "prob_score": -0.49636436, "relevant": "0", "stops": "ERBB2IP - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": -2.2646, "prob_score": -0.4415791, "relevant": "0", "stops": "ERBB2IP - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": -2.83535, "prob_score": -0.35268828, "relevant": "0", "stops": "ERBB2IP - SMAD3 - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 8, "rel_score": -2.95325, "prob_score": -0.33861053, "relevant": "0", "stops": "ERBB2IP - STAT3 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 42, "rel_score": -3.87687, "prob_score": -0.25794366, "relevant": "0", "stops": "ERBB2IP - SDHB - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "503", "sentence": "Loss of <e1> profilin-1 </e1> expression enhances <e2> breast cancer </e2> cell motility by Ena/VASP proteins.", "e1": "profilin-1", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 47, "rel_score": -10.64849, "prob_score": -0.09391026, "relevant": "0", "stops": "PFN1 - TAB2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": -10.74345, "prob_score": -0.093077876, "relevant": "0", "stops": "PFN1 - SQSTM1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 16, "rel_score": -10.9866, "prob_score": -0.09102198, "relevant": "0", "stops": "PFN1 - JUN - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": -11.26253, "prob_score": -0.08879318, "relevant": "0", "stops": "PFN1 - FIGF - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 48, "rel_score": -11.70412, "prob_score": -0.085443206, "relevant": "0", "stops": "PFN1 - Docetaxel - breast cancer", "reltypes": "DOWNREGULATES_CdG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}]}
{"qid": "504", "sentence": "Treatment with cisplatin resulted in more cells accumulating in S phase in <e1> Bcl-2 </e1> -overexpressing <e2> SKOV3 </e2> cells, while the inhibition of Bcl-2 abolished delayed entry into G2M phase without affecting cisplatin-induced apoptosis.", "e1": "Bcl-2", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 13, "rel_score": -4.56892, "prob_score": -0.21887316, "relevant": "0", "stops": "BCL2L15 - digestive system - SATB1 - Estriol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": -4.91497, "prob_score": -0.20346205, "relevant": "0", "stops": "BCL2L15 - renal system - ACADVL - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": -5.13005, "prob_score": -0.19493102, "relevant": "0", "stops": "BCL2L15 - renal system - CCND1 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -5.35332, "prob_score": -0.18679668, "relevant": "0", "stops": "BCL2L15 - renal system - SMARCD2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": -5.51025, "prob_score": -0.18147911, "relevant": "0", "stops": "BCL2L15 - digestive system - P4HTM - Clomifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "505", "sentence": "Transfection of <e1> IGFBP-3 </e1> increased the radiosensitivity of <e2> T47D </e2> and increased IR-induced apoptosis but did not effect a rapid G(1) arrest.", "e1": "IGFBP-3", "e2": "T47D", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 3, "rel_score": -8.17795, "prob_score": -0.12228022, "relevant": "0", "stops": "IGFBP3 - RRP12 - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": -9.14829, "prob_score": -0.10931299, "relevant": "0", "stops": "IGFBP3 - IARS2 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": -11.54335, "prob_score": -0.086630866, "relevant": "0", "stops": "IGFBP3 - Fulvestrant - Breast cancer stage IV", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -13.29787, "prob_score": -0.07519967, "relevant": "0", "stops": "IGFBP3 - bipolar disorder - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_DuG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 2, "rel_score": -13.52082, "prob_score": -0.07396344, "relevant": "0", "stops": "IGFBP3 - bipolar disorder - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_DuG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "506", "sentence": "<e1> SCARA3 mRNA </e1> is overexpressed in ovarian carcinoma compared with <e2> breast carcinoma </e2> effusions.", "e1": "SCARA3 mRNA", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 13.75327, "prob_score": -0.072714664, "relevant": "1", "stops": "SCARA3 - testis - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 12.46572, "prob_score": -0.08022021, "relevant": "1", "stops": "SCARA3 - thyroid gland - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 10.57641, "prob_score": -0.09455274, "relevant": "1", "stops": "SCARA3 - saliva-secreting gland - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 10.47669, "prob_score": -0.095445834, "relevant": "1", "stops": "SCARA3 - trigeminal ganglion - ID2 - Fulvestrant - Breast cancer stage IV", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 9.69838, "prob_score": -0.10311052, "relevant": "1", "stops": "SCARA3 - CYP1A1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "507", "sentence": "Moreover, as observed in the clinical samples, ERG expression was fully restored in the <e2> VCaP </e2> xenografts that relapsed after castration, coincident with <e1> AR </e1> reactivation.", "e1": "AR", "e2": "VCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 16, "rel_score": 1.46304, "prob_score": -0.68351316, "relevant": "1", "stops": "ARHGEF35 - heart - MCM6 - Podofilox - Scab", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 1.4603, "prob_score": -0.6847894, "relevant": "1", "stops": "ARHGEF35 - adipose tissue - MCM6 - Podofilox - Scab", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": -1.44315, "prob_score": -0.6929251, "relevant": "0", "stops": "ARHGEF35 - mammary gland - MCM6 - Podofilox - Scab", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": -1.44682, "prob_score": -0.69117224, "relevant": "0", "stops": "ARHGEF35 - lung - ID2 - Isotretinoin - Scab", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -1.48331, "prob_score": -0.6741672, "relevant": "0", "stops": "ARHGEF35 - female gonad - MCM6 - Podofilox - Scab", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "508", "sentence": "Conversely, <e1> cav-1 </e1> transfection in <e2> IGROV1 </e2> cells led to downregulated alphaFR expression, together with formation of caveolar structures and reduction of growth capability.", "e1": "cav-1", "e2": "IGROV1", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 46, "rel_score": -4.01994, "prob_score": -0.2487636, "relevant": "0", "stops": "CAV1 - TXNRD1 - Estriol - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": -4.49135, "prob_score": -0.22264864, "relevant": "0", "stops": "CAV1 - ILK - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": -4.52489, "prob_score": -0.2209964, "relevant": "0", "stops": "CAV1 - TIMM9 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": -4.53165, "prob_score": -0.22067054, "relevant": "0", "stops": "CAV1 - PGAM1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -5.00325, "prob_score": -0.19986999, "relevant": "0", "stops": "CAV1 - BRCA1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "509", "sentence": "In conclusion, physiological elevation of the <e1> bFGF </e1> during normal menstruation can influence the precise interpretation of the pathological elevation of the bFGF in pre-menopausal <e2> breast cancer </e2> patients.", "e1": "bFGF", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 6.94348, "prob_score": -0.14402479, "relevant": "1", "stops": "FGF16 - regulation of immune response - KCNN4 - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 22, "rel_score": 6.22278, "prob_score": -0.16070075, "relevant": "1", "stops": "FGF16 - RPL27 - EEF1A1 - breast cancer", "reltypes": "COVARIES_GcG - INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 11, "rel_score": 5.93895, "prob_score": -0.16838214, "relevant": "1", "stops": "FGF16 - MAPK cascade - IQGAP3 - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_DuG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 8, "rel_score": 5.66797, "prob_score": -0.17643286, "relevant": "1", "stops": "FGF16 - positive regulation of transferase activity - IQGAP3 - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_DuG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 38, "rel_score": 5.10673, "prob_score": -0.19581866, "relevant": "1", "stops": "FGF16 - positive regulation of MAPK cascade - PTEN - breast cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "510", "sentence": "Heregulin and agonistic anti- <e1> p185 </e1> (c-erbB2) antibodies inhibit proliferation but increase invasiveness of <e2> breast cancer </e2> cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.", "e1": "p185", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 32, "rel_score": 5.89831, "prob_score": -0.16953525, "relevant": "1", "stops": "ERBB2 - Fulvestrant - Breast cancer stage IV", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 5.18699, "prob_score": -0.19279139, "relevant": "1", "stops": "ERBB2IP - MAP4 - Paclitaxel - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 4.80862, "prob_score": -0.20795801, "relevant": "1", "stops": "ERBB2IP - GRIN2B - Memantine - Breast cancer female", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 4.67181, "prob_score": -0.21405458, "relevant": "1", "stops": "ERBB2IP - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 37, "rel_score": 4.32208, "prob_score": -0.23137411, "relevant": "1", "stops": "ERBB2IP - DYRK3 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "511", "sentence": "Runx2 expression in C4-2B PCa cells synergized with AR to promote <e1> PIP </e1> expression, whereas its knockdown in <e2> T47D </e2> BCa cells abrogated basal as well as hormone stimulated PIP expression.", "e1": "PIP", "e2": "T47D", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 44, "rel_score": 5.99988, "prob_score": -0.16666953, "relevant": "1", "stops": "PIPOX - MAL - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 5.81125, "prob_score": -0.17208469, "relevant": "1", "stops": "PIPOX - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 5.63253, "prob_score": -0.17753547, "relevant": "1", "stops": "PIP4K2A - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 42, "rel_score": 5.6281, "prob_score": -0.17768374, "relevant": "1", "stops": "PIPOX - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 5.33106, "prob_score": -0.18757527, "relevant": "1", "stops": "PIP4K2A - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "512", "sentence": "In <e2> T47D </e2> , Bax and <e1> Bad proteins </e1> were up-regulated; Bcl-2 protein is undetectable in these cells.", "e1": "Bad proteins", "e2": "T47D", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": 2.20755, "prob_score": -0.45299485, "relevant": "1", "stops": "BAD - EIF2S2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 2.02832, "prob_score": -0.49301746, "relevant": "1", "stops": "BAD - BAX - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 1.98346, "prob_score": -0.5041689, "relevant": "1", "stops": "BAD - VDR - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 38, "rel_score": 1.92363, "prob_score": -0.5198487, "relevant": "1", "stops": "BAD - PABPC1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": 1.83942, "prob_score": -0.5436497, "relevant": "1", "stops": "BAD - AR - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "513", "sentence": "From a clinical perspective, we suggest that if chemically stable <e1> FASN </e1> inhibitors or cell-selective systems able to deliver RNAi targeting FASN gene demonstrate systemic anticancer effects of FASN inhibition in vivo, additional preclinical studies to characterize their anti- <e2> breast cancer </e2> actions should be of great interest as the specific blockade of FASN activity may also provide a protective means against endometrial carcinoma associated with tamoxifen-based breast cancer therapy.", "e1": "FASN", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 46, "rel_score": -2.86107, "prob_score": -0.34951946, "relevant": "0", "stops": "FASN - Mycophenolate mofetil - Gynaecomastia - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 5, "rel_score": -3.48165, "prob_score": -0.2872216, "relevant": "0", "stops": "FASN - Mycophenolic acid - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 3, "rel_score": -3.75009, "prob_score": -0.26666218, "relevant": "0", "stops": "FASN - Sorafenib - Pancreatitis - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 17, "rel_score": -3.91435, "prob_score": -0.25547254, "relevant": "0", "stops": "FASN - Nilotinib - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 10, "rel_score": -4.65311, "prob_score": -0.21491277, "relevant": "0", "stops": "FASN - Sirolimus - Pancreatitis - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "514", "sentence": "On the contrary, transfection with <e1> GID5-6 </e1> to downregulate GSK-3beta activity decreased the BrdU incorporation in <e2> SKOV3 </e2> cells, compared with that in GID5-6LP, which is a control vector of GID5-6.", "e1": "GID5-6", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 11.84975, "prob_score": -0.08438777, "relevant": "1", "stops": "GDF6 - prostate gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 11.73296, "prob_score": -0.08522582, "relevant": "1", "stops": "GDF6 - gonad - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 11.23217, "prob_score": -0.08902904, "relevant": "1", "stops": "GDF6 - nervous system - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 11.19946, "prob_score": -0.08928638, "relevant": "1", "stops": "GDF6 - central nervous system - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 10.37452, "prob_score": -0.096386, "relevant": "1", "stops": "GDF6 - lymph node - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "515", "sentence": "With the treatment of 9-cis RA, the <e1> NKX3.1 promoter </e1> activity was increased in reporter gene assay and NKX3.1 expression was enhanced at both mRNA and protein levels in <e2> LNCaP </e2> cells.", "e1": "NKX3.1 promoter", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 2.86903, "prob_score": -0.34854633, "relevant": "1", "stops": "NKX3-1 - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 5, "rel_score": 2.72391, "prob_score": -0.36711547, "relevant": "1", "stops": "NKX3-1 - hematologic cancer - Ruxolitinib - Prostate cancer", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 2, "rel_score": 2.20551, "prob_score": -0.45340568, "relevant": "1", "stops": "NKX3-1 - MNAT1 - Ruxolitinib - Prostate cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 2.12531, "prob_score": -0.47052136, "relevant": "1", "stops": "NKX3-1 - HIPK2 - Ruxolitinib - Prostate cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 1.94943, "prob_score": -0.51296735, "relevant": "1", "stops": "NKX3-1 - SPDEF - Testosterone Propionate - Prostate cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "516", "sentence": "Here we show that an increase in the level of expression of <e1> Bcl-2 </e1> in the human prostate carcinoma cell line <e2> LNCaP </e2> observed in response to hormone withdrawal is further augmented by TNF-alpha treatment, and this effect is abated by inhibitors of NF-kappa B.", "e1": "Bcl-2", "e2": "LNCaP", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": -1.94212, "prob_score": -0.51489943, "relevant": "0", "stops": "BCL2L2-PABPN1 - MKNK2 - epithelium - prostate cancer", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 45, "rel_score": -2.02065, "prob_score": -0.49488816, "relevant": "0", "stops": "BCL2L2-PABPN1 - UBC - urethra - prostate cancer", "reltypes": "INTERACTS_GiG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": -2.06135, "prob_score": -0.48511526, "relevant": "0", "stops": "BCL2L2-PABPN1 - RGMA - urethra - prostate cancer", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 10, "rel_score": -2.2887, "prob_score": -0.43693325, "relevant": "0", "stops": "BCL2L2-PABPN1 - UBC - CTSB - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 12, "rel_score": -2.42465, "prob_score": -0.4124279, "relevant": "0", "stops": "BCL2L2-PABPN1 - HOOK2 - MIF - prostate cancer", "reltypes": "COVARIES_GcG - REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "517", "sentence": "The frequencies of loss for areas known to be frequently deleted in <e2> prostate cancer </e2> , such as <e1> 6q </e1> , 8p, or 13q, were not different between the two groups.", "e1": "6q", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 30.84516, "prob_score": -0.032422237, "relevant": "1", "stops": "CPQ - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": 28.33664, "prob_score": -0.03528772, "relevant": "1", "stops": "CPQ - retina - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 28.15315, "prob_score": -0.03551714, "relevant": "1", "stops": "CPQ - prostate gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 27.38976, "prob_score": -0.036514733, "relevant": "1", "stops": "CPQ - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "rel_score": 25.82645, "prob_score": -0.03872304, "relevant": "1", "stops": "CPQ - central nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "518", "sentence": "Several of the analogues elicit stronger growth inhibitory activity against prostate (PC-3) and breast ( <e2> MDA-MB-468 </e2> ) carcinoma cells, which contain elevated basal <e1> IKK </e1> activity; this antiproliferative activity correlates with increased inhibition of recombinant IKKbeta in vitro, suggesting that the anticancer activities of these AdArs might be related to the inhibition of IKK/NFkappaB signaling.", "e1": "IKK", "e2": "MDA-MB-468", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 41, "rel_score": 7.68699, "prob_score": -0.13009429, "relevant": "1", "stops": "IKBKE - LRRC59 - breast cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 27, "rel_score": 7.62893, "prob_score": -0.13107923, "relevant": "1", "stops": "IKBKE - Toremifene - breast cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 47, "rel_score": 7.57978, "prob_score": -0.13193335, "relevant": "1", "stops": "IKBKE - COTL1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 26, "rel_score": 7.03581, "prob_score": -0.14213042, "relevant": "1", "stops": "IKBKE - CDH1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": 6.81153, "prob_score": -0.14681463, "relevant": "1", "stops": "IKBKE - AR - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "520", "sentence": "Finally, ErbB2-amplified <e2> breast cancer </e2> cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of <e1> Erk </e1> and Akt signaling in vivo.", "e1": "Erk", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 3.29794, "prob_score": -0.3032154, "relevant": "1", "stops": "CERK - TFAP2A - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 14, "rel_score": 3.19479, "prob_score": -0.31300753, "relevant": "1", "stops": "CERK - NFKBIA - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 24, "rel_score": 3.14465, "prob_score": -0.31799865, "relevant": "1", "stops": "CERK - Estradiol - breast cancer", "reltypes": "DOWNREGULATES_CdG - PALLIATES_CpD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 1, "rel_score": 3.13519, "prob_score": -0.318963, "relevant": "1", "stops": "CERK - AHR - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 20, "rel_score": 3.07654, "prob_score": -0.32503983, "relevant": "1", "stops": "CERK - ALDOA - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "523", "sentence": "Loss of <e1> BRCA2 </e1> promotes <e2> prostate cancer </e2> cell invasion through up-regulation of matrix metalloproteinase-9.", "e1": "BRCA2", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 29, "rel_score": 28.49815, "prob_score": -0.035085265, "relevant": "1", "stops": "BRCA2 - CCNA2 - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 27.64722, "prob_score": -0.03617023, "relevant": "1", "stops": "BRCA2 - testis - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 27.01242, "prob_score": -0.037018605, "relevant": "1", "stops": "BRCA2 - RRAGA - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 22.82063, "prob_score": -0.04381836, "relevant": "1", "stops": "BRCA2 - pancreas - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 21.51463, "prob_score": -0.046479616, "relevant": "1", "stops": "BRCA2 - lymph node - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "524", "sentence": "Transfection with <e1> GSK-3betaS9A </e1> to upregulate the GSK-3beta activity resulted in the increase of BrdU incorporation in <e2> SKOV3 </e2> cells compared with that in the control vector.", "e1": "GSK-3betaS9A", "e2": "SKOV3", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": -1.46002, "prob_score": -0.6849212, "relevant": "0", "stops": "GSK3A - MTHFD2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": -1.46148, "prob_score": -0.6842426, "relevant": "0", "stops": "GSK3A - DNAJA3 - Tolcapone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -1.5964, "prob_score": -0.62641215, "relevant": "0", "stops": "GSK3A - RPS4Y1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": -1.63311, "prob_score": -0.612332, "relevant": "0", "stops": "GSK3A - DNAJA3 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": -1.64026, "prob_score": -0.60965836, "relevant": "0", "stops": "GSK3A - DNAJA3 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "525", "sentence": "Angiopoietin-1 and <e1> Ang-2 </e1> levels were significantly elevated in serum samples of patients with <e2> ovarian carcinoma </e2> compared with healthy controls (P = 0.0005 and P < 0.0005, respectively).", "e1": "Ang-2", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 5.13163, "prob_score": -0.19487213, "relevant": "1", "stops": "ANGPTL6 - endocrine gland - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 5.01454, "prob_score": -0.19942097, "relevant": "1", "stops": "ANGPTL6 - testis - ST6GALNAC2 - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 4.90052, "prob_score": -0.20405544, "relevant": "1", "stops": "ANGPTL6 - heart - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 4.73642, "prob_score": -0.21113035, "relevant": "1", "stops": "ANGPTL6 - bone marrow - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 4.66701, "prob_score": -0.2142673, "relevant": "1", "stops": "ANGPTL6 - lymph node - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "UPREGULATES_AuG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "526", "sentence": "Antisense bcl-2 oligodeoxynucleotides decreased <e1> Bcl-2 protein </e1> levels and significantly inhibited <e2> PC-3 </e2> cell growth in a dose dependent manner.", "e1": "Bcl-2 protein", "e2": "PC-3", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 10, "rel_score": -27.27769, "prob_score": -0.036659114, "relevant": "0", "stops": "BCL2L2-PABPN1 - UBC - CTSB - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 8, "rel_score": -28.41716, "prob_score": -0.035188045, "relevant": "0", "stops": "BCL2L2-PABPN1 - UBC - ADAM9 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 3, "rel_score": -28.71913, "prob_score": -0.03481684, "relevant": "0", "stops": "BCL2L2-PABPN1 - UBC - MTAP - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 41, "rel_score": -37.53754, "prob_score": -0.026641222, "relevant": "0", "stops": "BCL2L2-PABPN1 - ZNF580 - urethra - prostate cancer", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": -41.47656, "prob_score": -0.024114685, "relevant": "0", "stops": "BCL2L2-PABPN1 - Direct p53 effectors - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - ASSOCIATES_DaG", "nodelabels": "Gene - Pathway - Gene - Disease"}]}
{"qid": "527", "sentence": "The expression of the <e1> p75 neurotrophin receptor </e1> (p75NTR) is diminished in epithelial cells during progression of <e2> prostate cancer </e2> in vivo and in vitro.", "e1": "p75 neurotrophin receptor", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 40, "rel_score": 6.18238, "prob_score": -0.16175498, "relevant": "1", "stops": "GPR75-ASB3 - HSP90AA1 - HSPA1A - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 5.4615, "prob_score": -0.18310228, "relevant": "1", "stops": "GPR75-ASB3 - HSP90AA1 - UROD - prostate cancer", "reltypes": "INTERACTS_GiG - REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 6, "rel_score": 5.34702, "prob_score": -0.18702295, "relevant": "1", "stops": "GPR75-ASB3 - HSP90AA1 - QARS - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 4.88448, "prob_score": -0.20472996, "relevant": "1", "stops": "GPR75-ASB3 - CUL5 - TOP2A - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 17, "rel_score": 4.65875, "prob_score": -0.21465345, "relevant": "1", "stops": "GPR75-ASB3 - HSP90AA1 - STAT3 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "528", "sentence": "Treatment of <e2> HOSE </e2> or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of <e1> PR-A </e1> and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level.", "e1": "PR-A", "e2": "HOSE", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 48, "rel_score": 4.37292, "prob_score": -0.22868212, "relevant": "1", "stops": "PURA - heart - CYP2C9 - Sitaxentan - Gouty tophus", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 4.28339, "prob_score": -0.23346002, "relevant": "1", "stops": "PURA - female reproductive system - CYP3A4 - Sitaxentan - Gouty tophus", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 4.1827, "prob_score": -0.23907992, "relevant": "1", "stops": "PURA - female gonad - EDNRA - Sitaxentan - Gouty tophus", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 3.72024, "prob_score": -0.2688013, "relevant": "1", "stops": "PURA - heart - EDNRA - Sitaxentan - Gouty tophus", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": 3.56265, "prob_score": -0.28069028, "relevant": "1", "stops": "PURA - telencephalon - EDNRB - Sitaxentan - Gouty tophus", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "529", "sentence": "The findings of the present study suggest that <e1> COX-2 </e1> overexpression in lobular and ductal <e2> breast cancers </e2> , which correlates with traditional clinico-pathological parameters, may be considered as a negative prognostic marker.", "e1": "COX-2", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 11.07297, "prob_score": -0.09030745, "relevant": "1", "stops": "COX2 - EGFR - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "rel_score": 10.0553, "prob_score": -0.09944937, "relevant": "1", "stops": "COX2 - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 9.53198, "prob_score": -0.10490668, "relevant": "1", "stops": "COX2 - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 7.30887, "prob_score": -0.1368225, "relevant": "1", "stops": "COX2 - COX4I1 - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": 4.90292, "prob_score": -0.2039628, "relevant": "1", "stops": "COX2 - female reproductive system - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "530", "sentence": "Tight junction proteins claudin-3 and <e1> claudin-4 </e1> are frequently overexpressed in <e2> ovarian cancer </e2> but not in ovarian cystadenomas.", "e1": "claudin-4", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 8.18331, "prob_score": -0.12219871, "relevant": "1", "stops": "CACTIN - female reproductive system - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 8.14797, "prob_score": -0.122725874, "relevant": "1", "stops": "CACTIN - RNPS1 - Estriol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 6.75904, "prob_score": -0.14794703, "relevant": "1", "stops": "CACTIN - decidua - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 6.63922, "prob_score": -0.15062253, "relevant": "1", "stops": "CACTIN - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 6.62383, "prob_score": -0.15096802, "relevant": "1", "stops": "CACTIN - uterus - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "531", "sentence": "More interestingly, however, <e1> MMP-9 </e1> expression and fibronectin concentration were significantly elevated and the activated forms of both MMP-9 and MMP-2 were more frequent in <e2> ovarian cancer </e2> patients who developed recurrent disease.", "e1": "MMP-9", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 8.18532, "prob_score": -0.12216792, "relevant": "1", "stops": "MMP9 - breast cancer - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 9, "rel_score": 7.88146, "prob_score": -0.12688279, "relevant": "1", "stops": "MMP9 - pancreatic cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 7, "rel_score": 7.53523, "prob_score": -0.13271402, "relevant": "1", "stops": "MMP9 - breast cancer - Conjugated Estrogens - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 24, "rel_score": 6.59979, "prob_score": -0.15151575, "relevant": "1", "stops": "MMP9 - LCN2 - Estradiol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 5.76435, "prob_score": -0.17347875, "relevant": "1", "stops": "MMP9 - EPHB2 - Estriol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "532", "sentence": "Accumulation of <e1> p53 protein </e1> in the absence of detectable mutant p53 was recognized more often in <e2> prostate cancer </e2> than in any other tumor examined.", "e1": "p53 protein", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 17, "rel_score": -1.87582, "prob_score": -0.5330976, "relevant": "0", "stops": "TP53RK - ELAC2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 21, "rel_score": -2.02212, "prob_score": -0.49453127, "relevant": "0", "stops": "TP53RK - GDF15 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": -2.19096, "prob_score": -0.45642292, "relevant": "0", "stops": "TP53RK - SMNDC1 - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 24, "rel_score": -2.29684, "prob_score": -0.4353838, "relevant": "0", "stops": "TP53RK - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": -2.3546, "prob_score": -0.42470092, "relevant": "0", "stops": "TP53INP2 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "533", "sentence": "<e1> Maspin </e1> is a noninhibitory member of the serpin family that is down-regulated in <e2> breast carcinoma </e2> but overexpressed in pancreatic carcinoma.", "e1": "Maspin", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 19, "rel_score": 35.26093, "prob_score": -0.028358754, "relevant": "1", "stops": "ASPN - heart - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 34.00204, "prob_score": -0.029413408, "relevant": "1", "stops": "ASPN - bronchus - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 33.50084, "prob_score": -0.02984944, "relevant": "1", "stops": "ASPN - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": 33.0251, "prob_score": -0.03027929, "relevant": "1", "stops": "ASPN - endocrine gland - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 32.29974, "prob_score": -0.030955322, "relevant": "1", "stops": "ASPN - endometrium - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "534", "sentence": "Conversely, ectopic <e1> Pak1 </e1> overexpression enhanced <e2> ovarian cancer </e2> cell migration and invasion in a kinase-dependent manner, along with increased p38 activation.", "e1": "Pak1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 32, "rel_score": -1.46966, "prob_score": -0.6804342, "relevant": "0", "stops": "PAK1 - DNAJA3 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": -1.62214, "prob_score": -0.6164653, "relevant": "0", "stops": "PAK1 - MTHFD2 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": -1.86137, "prob_score": -0.5372363, "relevant": "0", "stops": "PAK1IP1 - TEX10 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -1.94405, "prob_score": -0.51438516, "relevant": "0", "stops": "PAK1IP1 - EBNA1BP2 - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": -2.01939, "prob_score": -0.49520177, "relevant": "0", "stops": "PAK1 - FOXO3 - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "535", "sentence": "A strong association has been observed between reduced expression of the <e1> nm23 gene </e1> and acquisition of metastatic behaviour in some tumour cells, including <e2> breast cancer </e2> and melanoma, but not in others, such as neuroblastoma and colon, cervical and thyroid cancers.", "e1": "nm23 gene", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 27, "rel_score": 9.25326, "prob_score": -0.10806525, "relevant": "1", "stops": "NPM3 - Tamoxifen - Pancreatitis - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 37, "rel_score": 7.39864, "prob_score": -0.1351601, "relevant": "1", "stops": "NPM3 - Paroxetine - Scotoma - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 41, "rel_score": 6.4914, "prob_score": -0.15404685, "relevant": "1", "stops": "NPM3 - Paroxetine - Otitis externa - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 7, "rel_score": 6.27195, "prob_score": -0.15944287, "relevant": "1", "stops": "NPM3 - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 6.25117, "prob_score": -0.15997283, "relevant": "1", "stops": "NPM3 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "538", "sentence": "Cell-surface expression of <e1> galectin-3 </e1> was reduced following treatment of viable <e2> T47D </e2> human breast carcinoma cells with gelatinase A.", "e1": "galectin-3", "e2": "T47D", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 28, "rel_score": 5.46388, "prob_score": -0.18301591, "relevant": "1", "stops": "GALC - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "COVARIES_GcG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 5.02109, "prob_score": -0.199161, "relevant": "1", "stops": "GALC - HSPA8 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 4.9586, "prob_score": -0.20166804, "relevant": "1", "stops": "GALC - RNH1 - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 4.27807, "prob_score": -0.23374633, "relevant": "1", "stops": "GALC - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 26, "rel_score": 4.16979, "prob_score": -0.23981996, "relevant": "1", "stops": "GALC - KAT2B - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "539", "sentence": "The compound investigated is present in a herbal preparation extracted from Boswellia serrata oleo-gum-resin, it inhibits the growth of chemotherapy-resistant human <e2> PC-3 </e2> prostate cancer cells in vitro and induces apoptosis as shown by activation of <e1> caspase 3 </e1> and the induction of DNA fragmentation.", "e1": "caspase 3", "e2": "PC-3", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 49, "rel_score": 10.31779, "prob_score": -0.09691754, "relevant": "1", "stops": "ASPA - Dabrafenib - Alanine aminotransferase increased - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 40, "rel_score": 9.60799, "prob_score": -0.104077645, "relevant": "1", "stops": "ASPA - Dabrafenib - Myalgia - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 9, "rel_score": 7.25216, "prob_score": -0.13788849, "relevant": "1", "stops": "ASPA - renal system - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 6.97593, "prob_score": -0.14335163, "relevant": "1", "stops": "ASPA - nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 6.43791, "prob_score": -0.15533057, "relevant": "1", "stops": "ASPA - central nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "540", "sentence": "Reduction of <e1> AR </e1> expression in the two androgen-sensitive prostate cancer cell lines, LNCaP and <e2> LAPC4 </e2> , significantly decreased AR-mediated transcription and cell growth.", "e1": "AR", "e2": "LAPC4", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 11, "rel_score": 3.79161, "prob_score": -0.26373842, "relevant": "1", "stops": "ARSG - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 36, "rel_score": 3.29045, "prob_score": -0.30391094, "relevant": "1", "stops": "ARF4 - NUCB2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 24, "rel_score": 2.83262, "prob_score": -0.35303354, "relevant": "1", "stops": "ARHGAP15 - TGFBR1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 2.73785, "prob_score": -0.36524883, "relevant": "1", "stops": "ARL2BP - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 2.58813, "prob_score": -0.38638213, "relevant": "1", "stops": "ARL2BP - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "541", "sentence": "Attenuating hypoxia-inducible factor (HIF)-1\u03b1 expression via small interference RNA resulted in a significantly decreased <e1> hCG </e1> expression in <e2> OVCAR-3 </e2> , which indicated that the effect of hypoxia on hCG expression was mediated through HIF-1\u03b1.", "e1": "hCG", "e2": "OVCAR-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 14, "rel_score": 2.85144, "prob_score": -0.35070455, "relevant": "1", "stops": "RHCG - kidney - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 2.68962, "prob_score": -0.37180486, "relevant": "1", "stops": "RHCG - myometrium - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 2.60947, "prob_score": -0.38322017, "relevant": "1", "stops": "RHCG - adrenal cortex - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 2.52928, "prob_score": -0.3953713, "relevant": "1", "stops": "RHCG - lymphoid tissue - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 2.37643, "prob_score": -0.42079657, "relevant": "1", "stops": "RHCG - cerebellum - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "542", "sentence": "All three interferons and TPA enhanced the expression of the Mr 180,000 carcinoembryonic antigen (CEA) and <e1> CEA-related TAA </e1> recognized by monoclonal antibody B1.1 in both <e2> T47D </e2> and MCF-7 human breast carcinoma cell lines.", "e1": "CEA-related TAA", "e2": "T47D", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 5.70939, "prob_score": -0.17514963, "relevant": "1", "stops": "CELA1 - CYP3A4 - Docetaxel - Breast cancer", "reltypes": "COVARIES_GcG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 5.15145, "prob_score": -0.19412443, "relevant": "1", "stops": "CELA1 - pancreatic cancer - Tamoxifen - Breast cancer male", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 15, "rel_score": 4.83582, "prob_score": -0.20679437, "relevant": "1", "stops": "CELA1 - FMO3 - Tamoxifen - Breast cancer male", "reltypes": "COVARIES_GcG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 4.76576, "prob_score": -0.20982806, "relevant": "1", "stops": "CELA1 - CYP3A4 - Progesterone - Breast cancer", "reltypes": "COVARIES_GcG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 4.60045, "prob_score": -0.21736829, "relevant": "1", "stops": "CELA1 - SPRR1A - Gemcitabine - Breast cancer", "reltypes": "COVARIES_GcG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "543", "sentence": "In the present study, we confirmed that the administration of cytostatics used for <e2> breast cancer </e2> treatment, such as taxanes and cyclophosphamide (CPA), up-regulated the tumor level of <e1> dThdPase </e1> in mammary tumor models as well.", "e1": "dThdPase", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 28, "rel_score": 12.25941, "prob_score": -0.08157058, "relevant": "1", "stops": "DHPS - NT5DC2 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 11.90901, "prob_score": -0.083971195, "relevant": "1", "stops": "DHPS - MAN2B2 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 10.86248, "prob_score": -0.09206217, "relevant": "1", "stops": "DHPS - hematologic cancer - Mitoxantrone - Breast cancer stage IV", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 6, "rel_score": 8.19807, "prob_score": -0.121978976, "relevant": "1", "stops": "DHPS - bone marrow - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 18, "rel_score": 7.34376, "prob_score": -0.13616961, "relevant": "1", "stops": "DHPS - AGR2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "545", "sentence": "IL-18 and <e1> FGF-2 proteins </e1> were significantly elevated in tumor tissues (p<0.04) and sera (p<0.05) from patients with <e2> ovarian cancer </e2> .", "e1": "FGF-2 proteins", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 4.39947, "prob_score": -0.22730099, "relevant": "1", "stops": "FGF10 - PCNA - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 4.28982, "prob_score": -0.23310803, "relevant": "1", "stops": "FGF14 - single-organism behavior - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 4.2555, "prob_score": -0.23499203, "relevant": "1", "stops": "FGF10 - breast cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 25, "rel_score": 4.00593, "prob_score": -0.24963422, "relevant": "1", "stops": "FGF10 - USP22 - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 3.34068, "prob_score": -0.29934412, "relevant": "1", "stops": "FGF10 - SERPINA3 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "546", "sentence": "Concomitantly, bcl-2 p2 promoter studies in <e2> LNCaP </e2> cells show a 40-fold increase in promoter activity after stimulation with <e1> TNF-alpha </e1> in the absence of hormone.", "e1": "TNF-alpha", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 35, "rel_score": 3.44175, "prob_score": -0.29054603, "relevant": "1", "stops": "TNFAIP2 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 39, "rel_score": 3.23771, "prob_score": -0.3088636, "relevant": "1", "stops": "TNFAIP2 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": 3.14149, "prob_score": -0.31832227, "relevant": "1", "stops": "TNFRSF1B - HSPA1A - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 2.8632, "prob_score": -0.34926412, "relevant": "1", "stops": "TNFRSF1B - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 20, "rel_score": 2.79431, "prob_score": -0.35786733, "relevant": "1", "stops": "TNFRSF1B - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "547", "sentence": "These results showed fisetin could inhibit the metastatic ability of <e2> PC-3 </e2> by reducing <e1> MMP-2 </e1> and MMP-9 expressions through suppressing phosphoinositide 3-kinase/Akt (PI3K/Akt) and JNK signaling pathways.", "e1": "MMP-2", "e2": "PC-3", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 49, "rel_score": 4.12746, "prob_score": -0.24228126, "relevant": "1", "stops": "MMP20 - lung - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 3.74308, "prob_score": -0.26716173, "relevant": "1", "stops": "MMP25 - testis - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 3.60114, "prob_score": -0.27769235, "relevant": "1", "stops": "MMP20 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 3.44661, "prob_score": -0.2901413, "relevant": "1", "stops": "MMP26 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 44, "rel_score": 3.24907, "prob_score": -0.30777535, "relevant": "1", "stops": "MMP20 - testis - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "548", "sentence": "Dimethyloxalylglycine, a pan-prolyl hydroxylase inhibitor, also induced <e1> Btg2 </e1> and Ndrg1 protein expression in <e2> LNCaP </e2> cells.", "e1": "Btg2", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 30, "rel_score": 19.79414, "prob_score": -0.050518937, "relevant": "1", "stops": "BTG2 - SCAND1 - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 18.15541, "prob_score": -0.055076275, "relevant": "1", "stops": "BTG2 - CASP3 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 36, "rel_score": 17.24435, "prob_score": -0.057985645, "relevant": "1", "stops": "BTG2 - MRPL12 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 16.83218, "prob_score": -0.05941393, "relevant": "1", "stops": "BTG2 - IER3 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 16.45549, "prob_score": -0.060765214, "relevant": "1", "stops": "BTG2 - EDEM1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "549", "sentence": "Increased levels of <e1> plasma haemoxygenase-1 </e1> in <e2> prostate cancer </e2> .", "e1": "plasma haemoxygenase-1", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 7.08516, "prob_score": -0.14113577, "relevant": "1", "stops": "PLAA - Bortezomib - Pancreatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 13, "rel_score": 5.98337, "prob_score": -0.16713212, "relevant": "1", "stops": "PLAA - Bortezomib - Conjunctivitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 31, "rel_score": 5.72377, "prob_score": -0.1747113, "relevant": "1", "stops": "PLAA - kidney - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 5.47885, "prob_score": -0.18251936, "relevant": "1", "stops": "PLAA - urethra - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 5.33191, "prob_score": -0.18755285, "relevant": "1", "stops": "PLAA - Bortezomib - Dermatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "550", "sentence": "Overexpressing <e1> ID2 </e1> in the <e2> MDA-MB-468 </e2> breast cancer cell line generated a marked cytoplasmic localisation of the protein and reduced the invasive capacity of cells.", "e1": "ID2", "e2": "MDA-MB-468", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 39, "rel_score": -1.89656, "prob_score": -0.52726567, "relevant": "0", "stops": "ID2 - UBE2C - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 25, "rel_score": -1.95791, "prob_score": -0.5107451, "relevant": "0", "stops": "ID2 - NME1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 13, "rel_score": -2.07866, "prob_score": -0.48107547, "relevant": "0", "stops": "ID2 - GPER1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 49, "rel_score": -2.30245, "prob_score": -0.43431756, "relevant": "0", "stops": "ID2 - TGFBR2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": -2.36072, "prob_score": -0.42360327, "relevant": "0", "stops": "ID2 - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "551", "sentence": "Experimentally, we found that reducing expression of <e1> SCRIB </e1> by short-hairpin RNAs (shRNAs) reduces the growth of human <e2> breast cancer </e2> cells in xenograft assays.", "e1": "SCRIB", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 14, "rel_score": 55.21811, "prob_score": -0.018105494, "relevant": "1", "stops": "SCRIB - APC - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 20, "rel_score": 54.49591, "prob_score": -0.018350432, "relevant": "1", "stops": "SCRIB - Etidronic acid - Pancytopenia - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 15, "rel_score": 54.14185, "prob_score": -0.018467637, "relevant": "1", "stops": "SCRIB - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 47.96163, "prob_score": -0.020854423, "relevant": "1", "stops": "SCRIB - skin of body - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 24, "rel_score": 39.2773, "prob_score": -0.025458833, "relevant": "1", "stops": "SCRIB - prostate gland - CYP2A6 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "552", "sentence": "Finally, ErbB2-amplified <e2> breast cancer </e2> cells expressing a specific Pak inhibitor showed delayed tumor formation and downregulation of Erk and <e1> Akt </e1> signaling in vivo.", "e1": "Akt", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 48, "rel_score": 1.62093, "prob_score": -0.61693186, "relevant": "1", "stops": "AKT3 - embryo - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 45, "rel_score": 1.5987, "prob_score": -0.62550986, "relevant": "1", "stops": "AKT3 - CDKN1A - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 44, "rel_score": 1.58975, "prob_score": -0.62903214, "relevant": "1", "stops": "AKT3 - NME1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 21, "rel_score": 1.53811, "prob_score": -0.6501525, "relevant": "1", "stops": "AKT3 - MAL - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 1.5187, "prob_score": -0.65846485, "relevant": "1", "stops": "AKT3 - IGFBP7 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "553", "sentence": "IGFBP2 and <e1> IGFBP5 </e1> overexpression correlates with the lymph node metastasis in T1 <e2> breast carcinomas </e2> .", "e1": "IGFBP5", "e2": "breast carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": 15.06705, "prob_score": -0.066369556, "relevant": "1", "stops": "IGFBP5 - POLR2I - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 13.08901, "prob_score": -0.07640467, "relevant": "1", "stops": "IGFBP5 - breast cancer - Mitoxantrone - Breast cancer stage IV", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 15, "rel_score": 12.70164, "prob_score": -0.07872556, "relevant": "1", "stops": "IGFBP5 - breast cancer - Paclitaxel - Breast cancer stage IV", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 37, "rel_score": 12.23691, "prob_score": -0.08172271, "relevant": "1", "stops": "IGFBP5 - PNP - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 12.21896, "prob_score": -0.08184247, "relevant": "1", "stops": "IGFBP5 - CALU - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "554", "sentence": "The epidermal growth factor ( <e1> EGF </e1> ) and EGF receptor (EGFR) family are often overexpressed in various human cancers including <e2> ovarian cancer </e2> .", "e1": "EGF", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 32, "rel_score": 12.282, "prob_score": -0.08141754, "relevant": "1", "stops": "EGFL6 - connective tissue - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 11.81056, "prob_score": -0.08466594, "relevant": "1", "stops": "EGFL6 - female gonad - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 11.64416, "prob_score": -0.085884534, "relevant": "1", "stops": "EGFLAM - breast cancer - Conjugated Estrogens - Ovarian cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 44, "rel_score": 11.55936, "prob_score": -0.08650785, "relevant": "1", "stops": "EGFL6 - heart - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 11.06562, "prob_score": -0.09036506, "relevant": "1", "stops": "EGFL6 - thyroid gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "555", "sentence": "Abdominopelvic tuberculosis simulating disseminated <e2> ovarian carcinoma </e2> with elevated <e1> CA-125 </e1> level: report of two cases.", "e1": "CA-125", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 3.4915, "prob_score": -0.28641054, "relevant": "1", "stops": "CA12 - SLC35B1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 3.29739, "prob_score": -0.3032718, "relevant": "1", "stops": "CA12 - DPH2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 3.26701, "prob_score": -0.30609134, "relevant": "1", "stops": "CA12 - ZDHHC6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 3.11459, "prob_score": -0.32107332, "relevant": "1", "stops": "CA12 - ERBB2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 3.07778, "prob_score": -0.32491225, "relevant": "1", "stops": "CA12 - GNPDA1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "556", "sentence": "We conclude that 13q34 amplification may be of relevance in tumor progression of basal-like <e2> breast cancers </e2> by inducing overexpression of <e1> CUL4A </e1> and TFDP1, which are both important in cell cycle regulation.", "e1": "CUL4A", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 12, "rel_score": -2.10124, "prob_score": -0.47590706, "relevant": "0", "stops": "CUL4A - HSPA1B - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 23, "rel_score": -2.52436, "prob_score": -0.39613965, "relevant": "0", "stops": "CUL4A - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": -2.5391, "prob_score": -0.3938363, "relevant": "0", "stops": "CUL4A - CCNE1 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 24, "rel_score": -2.75505, "prob_score": -0.36296755, "relevant": "0", "stops": "CUL4A - CTNNB1 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 8, "rel_score": -2.90706, "prob_score": -0.3439875, "relevant": "0", "stops": "CUL4A - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "557", "sentence": "Ovarian carcinoma and <e2> breast carcinoma </e2> cells which are multiply drug resistant due to overexpression of <e1> P-glycoprotein </e1> are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol.", "e1": "P-glycoprotein", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 24, "rel_score": -1.65464, "prob_score": -0.6043579, "relevant": "0", "stops": "PCGF5 - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 45, "rel_score": -1.72646, "prob_score": -0.5792211, "relevant": "0", "stops": "PCNX - female gonad - breast cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 31, "rel_score": -2.04578, "prob_score": -0.4888088, "relevant": "0", "stops": "PCGF5 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 49, "rel_score": -2.27739, "prob_score": -0.43910444, "relevant": "0", "stops": "PCDHAC2 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 32, "rel_score": -2.40489, "prob_score": -0.4158235, "relevant": "0", "stops": "PCGF5 - PIN1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "558", "sentence": "These results indicate that long-term NF treatment induces <e2> ovarian tumors </e2> in mice, possibly by continuous stimulation with gonadotropins such as <e1> LH </e1> via a negative-feedback phenomenon secondary to ovarian atrophy (as the tumor-induction mechanism), although we could not completely rule out a genotoxic mechanism.", "e1": "LH", "e2": "ovarian tumors", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 5, "rel_score": 1.58831, "prob_score": -0.62960184, "relevant": "1", "stops": "LHB - vagina - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 1.57532, "prob_score": -0.6347855, "relevant": "1", "stops": "LHB - gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 1.55977, "prob_score": -0.6411241, "relevant": "1", "stops": "LHB - GNAS - Estriol - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": -1.5556, "prob_score": -0.64284205, "relevant": "0", "stops": "LHB - polycystic ovary syndrome - ovarian cancer", "reltypes": "ASSOCIATES_DaG - RESEMBLES_DrD", "nodelabels": "Gene - Disease - Disease"}, {"pathid": 0, "rel_score": -1.64848, "prob_score": -0.6066177, "relevant": "0", "stops": "LHB - C10orf2 - Raloxifene - Ovarian cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "559", "sentence": "<e1> BRCA1 </e1> expression is decreased or absent in a significant proportion of sporadic breast and <e2> ovarian cancers </e2> , suggesting a wider role in these tumor types.", "e1": "BRCA1", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 2.97327, "prob_score": -0.3363345, "relevant": "1", "stops": "BRCA1 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "561", "sentence": "E2 but not ICI stimulated <e1> BMP-6 </e1> reporter activity in <e2> breast cancer </e2> cells, whereas the opposite was observed in osteoblast-like cells, associated with lack of AF-2 dependence of the response, and absent intranuclear localization of ERalpha, suggesting the involvement of a distinct ERalpha-dependent response mechanism in osteoblasts.", "e1": "BMP-6", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 21, "rel_score": 5.09087, "prob_score": -0.1964328, "relevant": "1", "stops": "BMP6 - HDAC6 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 4.67924, "prob_score": -0.21370715, "relevant": "1", "stops": "BMP6 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": 4.27113, "prob_score": -0.23413391, "relevant": "1", "stops": "BMP6 - decidua - PNKP - Tamoxifen - Breast cancer male", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 4.23406, "prob_score": -0.23617958, "relevant": "1", "stops": "BMP6 - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 38, "rel_score": 3.79219, "prob_score": -0.2636988, "relevant": "1", "stops": "BMP6 - lung - PNKP - Tamoxifen - Breast cancer male", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "562", "sentence": "Consequently, <e1> Id-1 </e1> inhibition in the future might be of benefit for patients with <e2> ovarian cancer </e2> .", "e1": "Id-1", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 16, "rel_score": -1.82199, "prob_score": -0.5488544, "relevant": "0", "stops": "ID1 - bone marrow - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 11, "rel_score": -1.94553, "prob_score": -0.51399606, "relevant": "0", "stops": "ID1 - CDC20 - Clomifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": -1.9513, "prob_score": -0.51248336, "relevant": "0", "stops": "ID1 - IKBKG - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 9, "rel_score": -1.96792, "prob_score": -0.5081496, "relevant": "0", "stops": "ID1 - TRAP1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -2.22951, "prob_score": -0.44853243, "relevant": "0", "stops": "ID1 - CPVL - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "563", "sentence": "We have also shown that expression of activated Src in <e2> breast cancer </e2> cells increased the expression of <e1> alpha2-integrin </e1> and that overexpression of alpha2-integrin suppressed FAK-CD-mediated loss of adhesion.", "e1": "alpha2-integrin", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 1.71945, "prob_score": -0.5815785, "relevant": "1", "stops": "ALDH3A2 - breast cancer - Paclitaxel - Breast cancer stage IV", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 30, "rel_score": 1.55519, "prob_score": -0.6430138, "relevant": "1", "stops": "ALDH3A2 - breast cancer - Estradiol valerate/Dienogest - Breast cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 22, "rel_score": 1.50677, "prob_score": -0.6636656, "relevant": "1", "stops": "ALDH3A2 - TRIB3 - Estradiol - Breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 1.47628, "prob_score": -0.67738324, "relevant": "1", "stops": "ALDH3A2 - TRIB3 - Estradiol - Breast cancer invasive NOS", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 1.45575, "prob_score": -0.6869296, "relevant": "1", "stops": "ALDH3A2 - SUPV3L1 - Estradiol - Breast cancer invasive NOS", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "564", "sentence": "<e1> Maspin </e1> is a noninhibitory member of the serpin family that is down-regulated in <e2> breast carcinoma </e2> but overexpressed in pancreatic carcinoma.", "e1": "Maspin", "e2": "breast carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 34.2818, "prob_score": -0.02916645, "relevant": "1", "stops": "ASPN - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 31, "rel_score": 34.02518, "prob_score": -0.029389154, "relevant": "1", "stops": "ASPN - endometrium - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 32.86231, "prob_score": -0.030430382, "relevant": "1", "stops": "ASPN - bronchus - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 31.84713, "prob_score": -0.031403966, "relevant": "1", "stops": "ASPN - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 27.4198, "prob_score": -0.03647225, "relevant": "1", "stops": "ASPN - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "565", "sentence": "In conclusion, three consecutive microarray (CGH, cDNA and tissue) experiments revealed high-level amplification and overexpression of the <e1> FGFR2 </e1> in a <e2> breast cancer </e2> cell line, but only a low frequency of involvement in primary breast tumors.", "e1": "FGFR2", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 11.13586, "prob_score": -0.08979914, "relevant": "1", "stops": "FGFR2 - IFRD2 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 10.005, "prob_score": -0.09994515, "relevant": "1", "stops": "FGFR2 - ADGRG1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 9.85416, "prob_score": -0.1014811, "relevant": "1", "stops": "FGFR2 - TIPARP - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 9.23873, "prob_score": -0.10824059, "relevant": "1", "stops": "FGFR2 - MCOLN1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 8.59402, "prob_score": -0.116364315, "relevant": "1", "stops": "FGFR2 - COTL1 - Citalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "567", "sentence": "We found that the functional disruption of <e1> IGF-1R </e1> markedly influences <e2> breast cancer </e2> metastasis in nude mice by suppressing cellular adhesion, invasion, and metastasis of breast cancer cells to the lung, lymph nodes, and lymph vessels.", "e1": "IGF-1R", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 36, "rel_score": 96.06148, "prob_score": -0.010413743, "relevant": "1", "stops": "IGF1R - CDC20 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 89.76661, "prob_score": -0.011143109, "relevant": "1", "stops": "IGF1R - ITGAE - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 87.41259, "prob_score": -0.011441429, "relevant": "1", "stops": "IGF1R - JMJD6 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 83.05648, "prob_score": -0.012038919, "relevant": "1", "stops": "IGF1R - FOXO4 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 62.93266, "prob_score": -0.01588666, "relevant": "1", "stops": "IGF1R - Mitoxantrone - Breast cancer stage IV", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "570", "sentence": "<e1> Brk </e1> -dependent signaling to p38 MAPK was recapitulated by Brk overexpression in the HC11 murine mammary epithelial cell (MEC) line and human MEC, while Brk knock-down in <e2> breast cancer </e2> cells blocked EGF-stimulated p38 signaling.", "e1": "Brk", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 11, "rel_score": 2.6629, "prob_score": -0.3755314, "relevant": "1", "stops": "BRK1 - blood - alcohol dependence - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 9, "rel_score": 1.90364, "prob_score": -0.52530915, "relevant": "1", "stops": "BRK1 - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 45, "rel_score": 1.65289, "prob_score": -0.6049959, "relevant": "1", "stops": "BRK1 - tendon - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 1.60614, "prob_score": -0.62261313, "relevant": "1", "stops": "BRK1 - tendon - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": -1.43068, "prob_score": -0.6989729, "relevant": "0", "stops": "BRK1 - cortex of kidney - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "571", "sentence": "Our studies implicate that the overexpressed <e1> GRB7 </e1> and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in <e2> ovarian cancer </e2> cells.", "e1": "GRB7", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 13, "rel_score": 5.194, "prob_score": -0.19252588, "relevant": "1", "stops": "GRB7 - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 4.70433, "prob_score": -0.21257156, "relevant": "1", "stops": "GRB7 - SMARCA4 - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 16, "rel_score": 4.68011, "prob_score": -0.21367016, "relevant": "1", "stops": "GRB7 - MSH2 - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 17, "rel_score": 4.61958, "prob_score": -0.21647076, "relevant": "1", "stops": "GRB7 - ZNF548 - ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": 4.59982, "prob_score": -0.217399, "relevant": "1", "stops": "GRB7 - MLH1 - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "572", "sentence": "Elevated serum <e1> chromogranin A </e1> precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced <e2> prostate cancer </e2> .", "e1": "chromogranin A", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 28, "rel_score": 2.22464, "prob_score": -0.44950634, "relevant": "1", "stops": "CHGA - lung - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 2.17505, "prob_score": -0.45976052, "relevant": "1", "stops": "CHGA - respiratory system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 2.09573, "prob_score": -0.4771578, "relevant": "1", "stops": "CHGA - digestive system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 1.92489, "prob_score": -0.5195113, "relevant": "1", "stops": "CHGA - prostate gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 1.86696, "prob_score": -0.53563035, "relevant": "1", "stops": "CHGA - medulla oblongata - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "573", "sentence": "We conclude that elevated expression of <e1> AKR1C3 </e1> is highly associated with <e2> prostate carcinoma </e2> .", "e1": "AKR1C3", "e2": "prostate carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 11.4771, "prob_score": -0.08712816, "relevant": "1", "stops": "AKR1C3 - POP4 - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 11.25619, "prob_score": -0.088840924, "relevant": "1", "stops": "AKR1C3 - PUF60 - Riluzole - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 10.81666, "prob_score": -0.092448145, "relevant": "1", "stops": "AKR1C3 - PUF60 - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 9.91178, "prob_score": -0.1008854, "relevant": "1", "stops": "AKR1C3 - LGMN - Testosterone - Prostate carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 9.72006, "prob_score": -0.10287694, "relevant": "1", "stops": "AKR1C3 - AKR7A2 - Testosterone Propionate - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "574", "sentence": "Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with <e2> prostatic cancer </e2> prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in <e1> alpha 1-globulin </e1> from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.", "e1": "alpha 1-globulin", "e2": "prostatic cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 15.20219, "prob_score": -0.06577615, "relevant": "1", "stops": "APH1A - bone marrow - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 13.98797, "prob_score": -0.07148524, "relevant": "1", "stops": "APH1A - telencephalon - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 13.68363, "prob_score": -0.07308425, "relevant": "1", "stops": "APH1A - testis - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 8.22233, "prob_score": -0.1216233, "relevant": "1", "stops": "APH1A - TNFRSF21 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "rel_score": 8.11557, "prob_score": -0.12321777, "relevant": "1", "stops": "APH1A - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "575", "sentence": "Hepatocyte growth factor up-regulates the expression of the <e1> bone morphogenetic protein (BMP) receptors </e1> , BMPR-IB and BMPR-II, in human <e2> prostate cancer </e2> cells.", "e1": "bone morphogenetic protein (BMP) receptors", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 5.85823, "prob_score": -0.1707006, "relevant": "1", "stops": "GNE - MBOAT7 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 5.74185, "prob_score": -0.17415656, "relevant": "1", "stops": "GNE - ST6GALNAC2 - Riluzole - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": 5.35733, "prob_score": -0.18666427, "relevant": "1", "stops": "GNE - MCOLN1 - Ropinirole - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 5.06868, "prob_score": -0.1972894, "relevant": "1", "stops": "GNE - PCNA - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 4.92684, "prob_score": -0.20296851, "relevant": "1", "stops": "GNE - TPI1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "576", "sentence": "Obesity and <e1> HER 2 </e1> overexpression: a common factor for poor prognosis of <e2> breast cancer </e2> .", "e1": "HER 2", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 21, "rel_score": -1.61967, "prob_score": -0.6174061, "relevant": "0", "stops": "ERBB2IP - ERBB2 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 17, "rel_score": -1.75479, "prob_score": -0.56987023, "relevant": "0", "stops": "ERBB2IP - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "rel_score": -1.81274, "prob_score": -0.5516481, "relevant": "0", "stops": "ERBB2IP - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 38, "rel_score": -1.87045, "prob_score": -0.53462887, "relevant": "0", "stops": "ERBB2IP - ENOPH1 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": -1.94932, "prob_score": -0.51299536, "relevant": "0", "stops": "ERBB2IP - NSDHL - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "577", "sentence": "The oncogene <e1> Bcl-2 </e1> is upregulated frequently in <e2> prostate tumors </e2> following androgen ablation therapy, and Bcl-2 overexpression may contribute to the androgen-refractory relapse of the disease.", "e1": "Bcl-2", "e2": "prostate tumors", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 34, "rel_score": 3.49406, "prob_score": -0.28620392, "relevant": "1", "stops": "BCL2L2-PABPN1 - MKNK2 - epithelium - prostate cancer", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 3.48748, "prob_score": -0.2867376, "relevant": "1", "stops": "BCL2L2-PABPN1 - Direct p53 effectors - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - ASSOCIATES_DaG", "nodelabels": "Gene - Pathway - Gene - Disease"}, {"pathid": 19, "rel_score": 3.46801, "prob_score": -0.2883537, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - SLC39A1 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 12, "rel_score": 3.27043, "prob_score": -0.30576605, "relevant": "1", "stops": "BCL2L2-PABPN1 - HOOK2 - MIF - prostate cancer", "reltypes": "COVARIES_GcG - REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 3.18603, "prob_score": -0.31387192, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - TTC9C - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "579", "sentence": "We have previously shown that <e1> TCEAL7 </e1> (transcription elongation factor A (SII)-like 7) is epigenetically down-regulated in the majority of epithelial <e2> ovarian cancers </e2> .", "e1": "TCEAL7", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 12.22046, "prob_score": -0.08183341, "relevant": "1", "stops": "TCEAL7 - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "rel_score": 12.0919, "prob_score": -0.08270138, "relevant": "1", "stops": "TCEAL7 - testis - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 9, "rel_score": 11.09262, "prob_score": -0.09015056, "relevant": "1", "stops": "TCEAL7 - bone marrow - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 9.52381, "prob_score": -0.1050044, "relevant": "1", "stops": "TCEAL7 - uterine cervix - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 9.51475, "prob_score": -0.105104566, "relevant": "1", "stops": "TCEAL7 - prostate cancer - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "581", "sentence": "Overexpression of <e1> p45-sErbB3 </e1> in the osteolytic prostate cancer cell line <e2> PC-3 </e2> converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice.", "e1": "p45-sErbB3", "e2": "PC-3", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": -39.87241, "prob_score": -0.02508335, "relevant": "0", "stops": "HPS5 - adrenal cortex - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": -39.88831, "prob_score": -0.025066916, "relevant": "0", "stops": "HPS5 - nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": -40.30633, "prob_score": -0.02480631, "relevant": "0", "stops": "HPS5 - mammary gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": -43.74453, "prob_score": -0.022862013, "relevant": "0", "stops": "HPS5 - myocardium - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": -44.82295, "prob_score": -0.022310019, "relevant": "0", "stops": "HPS5 - spinal cord - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "582", "sentence": "Recent studies show that aberrant activation of <e1> Akt </e1> in <e2> breast carcinoma </e2> is associated with a poor prognosis and resistance to endocrine therapy and chemotherapy.", "e1": "Akt", "e2": "breast carcinoma", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 32, "rel_score": 1.46419, "prob_score": -0.6829744, "relevant": "1", "stops": "AKT3 - endometrium - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": -1.67026, "prob_score": -0.598708, "relevant": "0", "stops": "AKT3 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 15, "rel_score": -2.07671, "prob_score": -0.4815344, "relevant": "0", "stops": "AKT3 - MRPS28 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 46, "rel_score": -2.19361, "prob_score": -0.4558747, "relevant": "0", "stops": "AKT3 - GNAI1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": -2.87795, "prob_score": -0.3474689, "relevant": "0", "stops": "AKT3 - HIST1H2BK - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "583", "sentence": "Germline and somatic mutations, loss of heterozygosity (LOH), and epigenetic events such as promoter hypermethylation can lead to decreased expression of <e1> BRCA1/2 </e1> in <e2> ovarian cancers </e2> .", "e1": "BRCA1/2", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 2.78769, "prob_score": -0.3587239, "relevant": "1", "stops": "BRCA1 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "584", "sentence": "These findings support the assumption that induction of <e1> PGR </e1> by estrogen in human <e2> breast cancer </e2> is mediated by a mechanism involving nuclear receptors.", "e1": "PGR", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 39, "rel_score": -1.74691, "prob_score": -0.57244295, "relevant": "0", "stops": "PGRMC1 - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 25, "rel_score": -1.90731, "prob_score": -0.52429736, "relevant": "0", "stops": "PGRMC1 - PPT1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": -1.9978, "prob_score": -0.50055134, "relevant": "0", "stops": "PGRMC1 - RPS6 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 37, "rel_score": -2.00421, "prob_score": -0.49894673, "relevant": "0", "stops": "PGRMC1 - SPRY2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": -2.04148, "prob_score": -0.48984128, "relevant": "0", "stops": "PGRMC1 - WASF2 - breast cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "586", "sentence": "E2, but not ICI, stimulated BMP-6 reporter activity by approximately 100% in <e2> MCF-7 </e2> , T47-D cells, and HepG2 cells when transfected with <e1> ERalpha </e1> .", "e1": "ERalpha", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 7.88146, "prob_score": -0.12687786, "relevant": "1", "stops": "ERAL1 - Everolimus - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 42, "rel_score": 5.62493, "prob_score": -0.17777681, "relevant": "1", "stops": "ERAL1 - vagina - CYP2C19 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 5.44662, "prob_score": -0.18359922, "relevant": "1", "stops": "ERAL1 - vagina - CYP2C19 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 5.20942, "prob_score": -0.19196066, "relevant": "1", "stops": "ERAL1 - cerebellum - CYP2C19 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 5.15597, "prob_score": -0.1939523, "relevant": "1", "stops": "ERAL1 - blood - CYP2C19 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "587", "sentence": "In conclusion, HGF up-regulates the expression of the bone morphogenetic protein receptors, <e1> BMPR-IB </e1> and BMPR-II, in <e2> prostate cancer </e2> cells, both in vitro and in vivo.", "e1": "BMPR-IB", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 6.19579, "prob_score": -0.16140221, "relevant": "1", "stops": "BMPR1B - Pazopanib - Pancreatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 33, "rel_score": 5.81971, "prob_score": -0.17183293, "relevant": "1", "stops": "BMPR1B - head - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 5.74218, "prob_score": -0.17415042, "relevant": "1", "stops": "BMPR1B - Vandetanib - Staphylococcal infection - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 37, "rel_score": 5.24109, "prob_score": -0.1908037, "relevant": "1", "stops": "BMPR1B - brain - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 4.99675, "prob_score": -0.20012847, "relevant": "1", "stops": "BMPR1B - uterus - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "588", "sentence": "Progression of benign <e2> prostate cancer </e2> to malignant metastasis is linked to increased production of basic fibroblast growth factor ( <e1> bFGF </e1> ), a powerful mitogen.", "e1": "bFGF", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": -5.70548, "prob_score": -0.17526694, "relevant": "0", "stops": "FGF16 - epidermal growth factor receptor signaling pathway - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 16, "rel_score": -5.85926, "prob_score": -0.17067242, "relevant": "0", "stops": "FGF16 - positive regulation of MAPK cascade - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 40, "rel_score": -5.98158, "prob_score": -0.16718349, "relevant": "0", "stops": "FGF16 - regulation of MAPK cascade - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 42, "rel_score": -5.98516, "prob_score": -0.167078, "relevant": "0", "stops": "FGF16 - regulation of locomotion - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 43, "rel_score": -7.44269, "prob_score": -0.13435857, "relevant": "0", "stops": "FGF16 - DAP12 interactions - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpPW - PARTICIPATES_GpPW - ASSOCIATES_DaG", "nodelabels": "Gene - Pathway - Gene - Disease"}]}
{"qid": "589", "sentence": "Combined blockade of RANK/RANKL axis and <e1> BMP </e1> pathway resulted in reduced tumor burden and decreased bone loss compared to inhibition of either individual pathway alone in osteolytic <e2> prostate cancer </e2> lesion in bone.", "e1": "BMP", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 4.537, "prob_score": -0.22041003, "relevant": "1", "stops": "BMP1 - TP53 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 3.88546, "prob_score": -0.25737166, "relevant": "1", "stops": "BMP10 - head - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 3.64418, "prob_score": -0.27440837, "relevant": "1", "stops": "BMP10 - brain - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 3.61533, "prob_score": -0.2765994, "relevant": "1", "stops": "BMP10 - heart - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 3.45328, "prob_score": -0.2895849, "relevant": "1", "stops": "BMP10 - heart - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "590", "sentence": "Our findings of increased <e1> HIF-1alpha protein </e1> expression in <e2> BPH </e2> and Pca specimens suggests the potential role of this protein in BPH and Pca.", "e1": "HIF-1alpha protein", "e2": "BPH", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 13.5888, "prob_score": -0.07358535, "relevant": "1", "stops": "HINFP - TP53 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 38, "rel_score": 13.12853, "prob_score": -0.07616673, "relevant": "1", "stops": "HINFP - gonad - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 12.81066, "prob_score": -0.078062706, "relevant": "1", "stops": "HINFP - central nervous system - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 12.52348, "prob_score": -0.07984516, "relevant": "1", "stops": "HINFP - head - PAPD7 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 11.21076, "prob_score": -0.089195535, "relevant": "1", "stops": "HINFP - female reproductive system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "591", "sentence": "Further, treating specific inhibitors for PI3K (Wortmannin) or JNK (SP600125) to <e2> PC-3 </e2> cells could reduce the protein expressions of MMP-2 and <e1> MMP-9 </e1> .", "e1": "MMP-9", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 20, "rel_score": 12.2971, "prob_score": -0.08131687, "relevant": "1", "stops": "MMP9 - Captopril - Hepatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 17, "rel_score": 10.13993, "prob_score": -0.09861642, "relevant": "1", "stops": "MMP9 - PRSS2 - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 10.07861, "prob_score": -0.09921795, "relevant": "1", "stops": "MMP9 - Captopril - Tension - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 11, "rel_score": 9.57213, "prob_score": -0.104472026, "relevant": "1", "stops": "MMP9 - head - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 9.43485, "prob_score": -0.10598858, "relevant": "1", "stops": "MMP9 - Captopril - Pancreatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "592", "sentence": "Lysophosphatidic acid (LPA), at concentrations present in ascitic fluid, indirectly stimulates the growth of malignant ovarian tumors by increasing the expression of <e1> vascular endothelial growth factor </e1> (VEGF) in <e2> ovarian cancer </e2> cells.", "e1": "vascular endothelial growth factor", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 0, "rel_score": -3.13913, "prob_score": -0.31856146, "relevant": "0", "stops": "VEGFA - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "594", "sentence": "Further, treating specific inhibitors for PI3K (Wortmannin) or JNK (SP600125) to <e2> PC-3 </e2> cells could reduce the protein expressions of <e1> MMP-2 </e1> and MMP-9.", "e1": "MMP-2", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 21, "rel_score": 11.9076, "prob_score": -0.08397826, "relevant": "1", "stops": "MMP23B - EP300 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 13, "rel_score": 10.97454, "prob_score": -0.09112191, "relevant": "1", "stops": "MMP25 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 15, "rel_score": 10.23437, "prob_score": -0.097713985, "relevant": "1", "stops": "MMP25 - testis - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 37, "rel_score": 9.74564, "prob_score": -0.10261367, "relevant": "1", "stops": "MMP20 - thyroid gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 9.74564, "prob_score": -0.10260964, "relevant": "1", "stops": "MMP25 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "595", "sentence": "The data also show that LY294002 directly inhibits <e1> vascular endothelial growth factor </e1> (VEGF) protein expression and release from <e2> ovarian carcinoma </e2> and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.", "e1": "vascular endothelial growth factor", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 1.99864, "prob_score": -0.500338, "relevant": "1", "stops": "VEGFA - ZDHHC6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 1.94084, "prob_score": -0.5152449, "relevant": "1", "stops": "VEGFA - JMJD6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 1.8938, "prob_score": -0.5280449, "relevant": "1", "stops": "VEGFA - CCDC86 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 1.89193, "prob_score": -0.5285575, "relevant": "1", "stops": "VEGFA - MSRA - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 1.8091, "prob_score": -0.5527647, "relevant": "1", "stops": "VEGFA - LOXL1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "597", "sentence": "Collagen I, also present in the <e2> ovarian tumours </e2> , then induces these fibroblasts to activate <e1> proMMP-2 </e1> even in the presence of TIMP-2.", "e1": "proMMP-2", "e2": "ovarian tumours", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 40, "rel_score": 3.64511, "prob_score": -0.27434203, "relevant": "1", "stops": "PROM2 - lung - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 3.43171, "prob_score": -0.29139683, "relevant": "1", "stops": "PROM2 - prostate gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 3.29402, "prob_score": -0.30358395, "relevant": "1", "stops": "PROM2 - seminal vesicle - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 3.23311, "prob_score": -0.3093011, "relevant": "1", "stops": "PROM2 - thyroid gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 3.08709, "prob_score": -0.32393405, "relevant": "1", "stops": "PROM2 - saliva-secreting gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "598", "sentence": "Downmodulation of caveolin-1 expression in human <e2> ovarian carcinoma </e2> is directly related to <e1> alpha-folate receptor </e1> overexpression.", "e1": "alpha-folate receptor", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 5.65068, "prob_score": -0.17697158, "relevant": "1", "stops": "APH1A - heart - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 5.28457, "prob_score": -0.18923323, "relevant": "1", "stops": "APH1A - UBC - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 5.11745, "prob_score": -0.19540697, "relevant": "1", "stops": "APH1A - endometrium - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 5.0005, "prob_score": -0.19998062, "relevant": "1", "stops": "APH1A - bronchus - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 4.88162, "prob_score": -0.20485447, "relevant": "1", "stops": "APH1A - vagina - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "599", "sentence": "In this study we show that oestradiol decreased secreted s <e1> VEGF </e1> R-1, increased secreted VEGF, and decreased the ratio of sVEGFR-1/VEGF in <e2> MCF-7 </e2> human breast cancer cells.", "e1": "VEGF", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 16, "rel_score": 9.05223, "prob_score": -0.11047145, "relevant": "1", "stops": "VEGFA - hematologic cancer - Mitoxantrone - Breast cancer stage IV", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 24, "rel_score": 9.04486, "prob_score": -0.11056122, "relevant": "1", "stops": "VEGFA - ASF1B - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 8.95817, "prob_score": -0.11162728, "relevant": "1", "stops": "VEGFA - GPC1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 8.65801, "prob_score": -0.11549586, "relevant": "1", "stops": "VEGFA - ERBB3 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 7.93462, "prob_score": -0.12603019, "relevant": "1", "stops": "VEGFA - LBR - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "600", "sentence": "According to this mechanism the deregulation of the BRCA1 transcription in cancer, resulting in a higher proportion of translationally inhibited transcripts containing 5'-UTRb, contributes to the decrease in the <e1> BRCA1 protein </e1> observed in sporadic breast and <e2> ovarian cancers </e2> .", "e1": "BRCA1 protein", "e2": "ovarian cancers", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": -1.63353, "prob_score": -0.6121653, "relevant": "0", "stops": "BRCA1 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "602", "sentence": "About 50% of <e2> prostate cancers </e2> have TMPRSS2- <e1> ERG </e1> fusions with concurrent ERG overexpression.", "e1": "ERG", "e2": "prostate cancers", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 17, "rel_score": 3.26296, "prob_score": -0.30647248, "relevant": "1", "stops": "ERGIC2 - epithelium - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 14, "rel_score": 1.62075, "prob_score": -0.61700124, "relevant": "1", "stops": "ERGIC2 - TYMS - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": 1.51582, "prob_score": -0.65970576, "relevant": "1", "stops": "ERGIC3 - urethra - prostate cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 35, "rel_score": 1.51053, "prob_score": -0.6620224, "relevant": "1", "stops": "ERGIC3 - SPIN1 - prostate cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 48, "rel_score": -1.45108, "prob_score": -0.6891412, "relevant": "0", "stops": "ERG - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "603", "sentence": "Quantitative PCR revealed decreased <e1> Notch 1 </e1> mRNA in <e2> ovarian adenocarcinomas </e2> compared with adenomas.", "e1": "Notch 1", "e2": "ovarian adenocarcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 12.66143, "prob_score": -0.07897713, "relevant": "1", "stops": "NOTCH1 - MCOLN1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 12.18324, "prob_score": -0.0820765, "relevant": "1", "stops": "NOTCH1 - HMGCS1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 12.15214, "prob_score": -0.08229047, "relevant": "1", "stops": "NOTCH1 - DNTTIP2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 12.0149, "prob_score": -0.08322875, "relevant": "1", "stops": "NOTCH1 - ECH1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 11.93317, "prob_score": -0.08380292, "relevant": "1", "stops": "NOTCH1 - TSC22D3 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "604", "sentence": "These results indicate that DPPIV inhibits the malignant phenotype of <e2> prostate cancer </e2> cells by blocking <e1> bFGF </e1> signaling pathway.", "e1": "bFGF", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 20, "rel_score": 2.30787, "prob_score": -0.43330064, "relevant": "1", "stops": "FGF16 - inositol lipid-mediated signaling - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 13, "rel_score": 1.79733, "prob_score": -0.5563783, "relevant": "1", "stops": "FGF16 - cell-cell signaling - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 33, "rel_score": 1.78763, "prob_score": -0.55939937, "relevant": "1", "stops": "FGF16 - neuron projection morphogenesis - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 5, "rel_score": 1.73265, "prob_score": -0.5771466, "relevant": "1", "stops": "FGF16 - cell projection morphogenesis - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 6, "rel_score": 1.68745, "prob_score": -0.59261453, "relevant": "1", "stops": "FGF16 - regulation of cell migration - PTEN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "605", "sentence": "Concurrently, we demonstrated BN-dependent activation of the <e1> transcription factor Elk-1 </e1> and significant increase of cell proliferation in both <e2> prostate cancer </e2> cell lines.", "e1": "transcription factor Elk-1", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 11, "rel_score": -3.19346, "prob_score": -0.31313747, "relevant": "0", "stops": "ELK1 - SERPINA3 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": -3.26787, "prob_score": -0.3060079, "relevant": "0", "stops": "ELK1 - thyroid gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": -3.51407, "prob_score": -0.28456542, "relevant": "0", "stops": "ELK1 - adipose tissue - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": -3.53744, "prob_score": -0.2826872, "relevant": "0", "stops": "ELK1 - heart - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": -3.61141, "prob_score": -0.27689835, "relevant": "0", "stops": "ELK1 - cerebellum - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "606", "sentence": "These results suggest that TMS may inhibit the cell cycle through induction of p27( <e1> kip1 </e1> ), leading to apoptotic cell death in <e2> PC-3 </e2> prostate cancer cells.", "e1": "kip1", "e2": "PC-3", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 0, "rel_score": 18.457, "prob_score": -0.054178014, "relevant": "1", "stops": "AKIP1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 14.42169, "prob_score": -0.06933982, "relevant": "1", "stops": "AKIP1 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 13.91208, "prob_score": -0.07188452, "relevant": "1", "stops": "AKIP1 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "rel_score": 13.7874, "prob_score": -0.072525434, "relevant": "1", "stops": "AKIP1 - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 13, "rel_score": 3.37405, "prob_score": -0.2963782, "relevant": "1", "stops": "AKIP1 - Alzheimer's disease - Selegiline - Prostate cancer", "reltypes": "UPREGULATES_DuG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "607", "sentence": "Similarly, activation of the <e1> AR </e1> by phosphorylated protein kinase B, Akt, has also been reported in <e2> prostate cancer </e2> .", "e1": "AR", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 32, "rel_score": 1.95614, "prob_score": -0.5112086, "relevant": "1", "stops": "ARF4 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 1.85829, "prob_score": -0.53812504, "relevant": "1", "stops": "ARL2BP - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": 1.75957, "prob_score": -0.5683232, "relevant": "1", "stops": "ARF4 - TERT - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": 1.73653, "prob_score": -0.5758553, "relevant": "1", "stops": "ARF4 - EPCAM - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 44, "rel_score": 1.73301, "prob_score": -0.5770285, "relevant": "1", "stops": "ARF4 - PSAT1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "608", "sentence": "<e1> Trefoil factor 3 </e1> is overexpressed in human <e2> prostate cancer </e2> .", "e1": "Trefoil factor 3", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 21, "rel_score": 8.84173, "prob_score": -0.11309563, "relevant": "1", "stops": "TERF2IP - SERPINA3 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 43, "rel_score": 8.25764, "prob_score": -0.12110132, "relevant": "1", "stops": "TERF2IP - PTPRK - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 8, "rel_score": 7.73096, "prob_score": -0.1293505, "relevant": "1", "stops": "TERF2IP - NAT1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 49, "rel_score": 7.67224, "prob_score": -0.13033833, "relevant": "1", "stops": "TERF2IP - BECN1 - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 23, "rel_score": 7.28916, "prob_score": -0.13718645, "relevant": "1", "stops": "TERF2IP - LPL - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "610", "sentence": "Clinical data showed that the levels of <e1> interleukin-4 </e1> (IL-4) are significantly elevated in serum of patients with ablation resistant <e2> prostate cancer </e2> .", "e1": "interleukin-4", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 10, "rel_score": 11.95029, "prob_score": -0.083676495, "relevant": "1", "stops": "IL4R - Epirubicin - prostate cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 39, "rel_score": 10.61797, "prob_score": -0.09417771, "relevant": "1", "stops": "IL4R - ERG - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 14, "rel_score": 10.0553, "prob_score": -0.09945486, "relevant": "1", "stops": "IL4R - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 9.83188, "prob_score": -0.10170629, "relevant": "1", "stops": "IL4I1 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 40, "rel_score": 9.00009, "prob_score": -0.111112885, "relevant": "1", "stops": "IL4R - JAK2 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "611", "sentence": "Using multiple primer sets and controls, we found that neither mature <e1> BORIS transcripts </e1> nor spliced variants are commonly expressed at detectable levels in malignant breast cells or tissues, although endogenous BORIS transcripts can be induced in <e2> MCF-7 </e2> cells following 5-aza-2'-deoxycytidine treatment.", "e1": "BORIS transcripts", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": 75.64296, "prob_score": -0.0132156955, "relevant": "1", "stops": "CORIN - nipple - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 75.24454, "prob_score": -0.013286132, "relevant": "1", "stops": "CORIN - prostate gland - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 73.80074, "prob_score": -0.013551269, "relevant": "1", "stops": "CORIN - decidua - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 72.09805, "prob_score": -0.0138727045, "relevant": "1", "stops": "CORIN - prostate gland - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 69.8812, "prob_score": -0.014306809, "relevant": "1", "stops": "CORIN - myometrium - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "612", "sentence": "Down-regulation of <e1> ATM protein </e1> sensitizes human <e2> prostate cancer </e2> cells to radiation-induced apoptosis.", "e1": "ATM protein", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 34, "rel_score": 4.77829, "prob_score": -0.20928238, "relevant": "1", "stops": "ATMIN - EBNA1BP2 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 4.22494, "prob_score": -0.23668702, "relevant": "1", "stops": "ATMIN - TLE1 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": 4.13856, "prob_score": -0.24163067, "relevant": "1", "stops": "ATMIN - P4HA2 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 3.50447, "prob_score": -0.28534612, "relevant": "1", "stops": "ATMIN - RRP8 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 2.33956, "prob_score": -0.42743003, "relevant": "1", "stops": "ATMIN - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "614", "sentence": "10(-6) M tamoxifen (TAM) reverted growth stimulation, suppressed progesterone receptor and <e1> TGFalpha mRNA </e1> induction and restored TGFbeta mRNA to control levels in T3-treated <e2> MCF-7 </e2> cells.", "e1": "TGFalpha mRNA", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 35, "rel_score": 7.59474, "prob_score": -0.13167469, "relevant": "1", "stops": "GFAP - Parkinson's disease - Pramipexole - Breast cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 6, "rel_score": 3.45614, "prob_score": -0.28934494, "relevant": "1", "stops": "GFAP - RIBC2 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 16, "rel_score": 3.35312, "prob_score": -0.29823366, "relevant": "1", "stops": "GFAP - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 30, "rel_score": 3.1249, "prob_score": -0.32001254, "relevant": "1", "stops": "GFAP - PDLIM1 - Fulvestrant - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 2.9209, "prob_score": -0.34235877, "relevant": "1", "stops": "GFAP - MAPK14 - Etoricoxib - Breast cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "615", "sentence": "Response to bicalutamide in <e2> LNCaP </e2> cells was represented by downregulation of androgen-regulated genes, activation of the p53 pathway and inhibition of telomerase, which was associated with downregulation of v-myc avian myelocytomatosis viral oncogene homologue ( <e1> MYC </e1> ) and telomerase reverse transcriptase subunit.", "e1": "MYC", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 3.97852, "prob_score": -0.25135383, "relevant": "1", "stops": "MYCN - NGDN - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "rel_score": 3.91328, "prob_score": -0.25553828, "relevant": "1", "stops": "MYCN - TYMS - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 3.60373, "prob_score": -0.27748594, "relevant": "1", "stops": "MYCT1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": 3.55568, "prob_score": -0.28124222, "relevant": "1", "stops": "MYCN - ITGB1 - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 2.87803, "prob_score": -0.3474619, "relevant": "1", "stops": "MYCBP - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "616", "sentence": "These events result in increased accumulation of <e1> AR </e1> and thus enhanced growth of <e2> prostate cancer </e2> cells at low levels of androgen.", "e1": "AR", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 14, "rel_score": 4.62406, "prob_score": -0.21626024, "relevant": "1", "stops": "ARSG - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 27, "rel_score": 4.20539, "prob_score": -0.23778796, "relevant": "1", "stops": "ARF4 - HERPUD1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 4.06802, "prob_score": -0.24581738, "relevant": "1", "stops": "ARL2BP - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 3.49663, "prob_score": -0.28599203, "relevant": "1", "stops": "ARL2BP - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 3.28343, "prob_score": -0.30455852, "relevant": "1", "stops": "ARHGAP15 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "617", "sentence": "We previously showed that the expressing level of <e1> FSH receptor </e1> (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign <e2> ovarian epithelial tumors </e2> (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade.", "e1": "FSH receptor", "e2": "ovarian epithelial tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 48, "rel_score": 8.69112, "prob_score": -0.11506065, "relevant": "1", "stops": "FSHB - brain - MRPL12 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 7.81433, "prob_score": -0.12796661, "relevant": "1", "stops": "FSHB - cerebellum - MRPL12 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 7.75074, "prob_score": -0.1290224, "relevant": "1", "stops": "FSHB - positive regulation of cell proliferation - ID2 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 7.30887, "prob_score": -0.13681996, "relevant": "1", "stops": "FSHB - brain - MTHFD2 - Estradiol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 7.21657, "prob_score": -0.13857007, "relevant": "1", "stops": "FSHB - cellular amide metabolic process - MTHFD2 - Docetaxel - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "618", "sentence": "The same concentration of R1881 resulted in a decrease in intracellular glutathione concentrations and an increase in <e1> gamma-glutamyl transpeptidase </e1> activity in <e2> LNCaP </e2> cells.", "e1": "gamma-glutamyl transpeptidase", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": 11.152, "prob_score": -0.089671485, "relevant": "1", "stops": "GALM - midbrain - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 10.89562, "prob_score": -0.091783255, "relevant": "1", "stops": "GALM - bronchus - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": 10.68148, "prob_score": -0.09362058, "relevant": "1", "stops": "GALM - myocardium - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 8.23927, "prob_score": -0.12137243, "relevant": "1", "stops": "GALM - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 7.7997, "prob_score": -0.12821436, "relevant": "1", "stops": "GALM - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "620", "sentence": "Tight junction proteins <e1> claudin-3 </e1> and claudin-4 are frequently overexpressed in <e2> ovarian cancer </e2> but not in ovarian cystadenomas.", "e1": "claudin-3", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 15.06251, "prob_score": -0.06638505, "relevant": "1", "stops": "CACTIN - RNPS1 - Estriol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 12.36858, "prob_score": -0.0808544, "relevant": "1", "stops": "CACTIN - uterine cervix - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 9, "rel_score": 12.03659, "prob_score": -0.08308469, "relevant": "1", "stops": "CACTIN - decidua - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 8, "rel_score": 11.78967, "prob_score": -0.08481703, "relevant": "1", "stops": "CACTIN - myometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 11.43511, "prob_score": -0.087447636, "relevant": "1", "stops": "CACTIN - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "621", "sentence": "Compared with that of the vector control and na\u00efve <e2> MCF7 </e2> cell group, there was a significant decrease of <e1> BCSG-1 protein </e1> expression in the four experimental groups by immuno-histochemistry staining (P<0.01).", "e1": "BCSG-1 protein", "e2": "MCF7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 10.17191, "prob_score": -0.09831275, "relevant": "1", "stops": "BSG - Doxorubicin - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 37, "rel_score": 7.48839, "prob_score": -0.13353807, "relevant": "1", "stops": "BSG - Mitoxantrone - Rhinitis - Memantine - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 6, "rel_score": 6.12033, "prob_score": -0.16338961, "relevant": "1", "stops": "BSG - Epirubicin - breast cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 14, "rel_score": 5.25735, "prob_score": -0.19021435, "relevant": "1", "stops": "BSG - Mitoxantrone - breast cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 10, "rel_score": 5.05357, "prob_score": -0.19787584, "relevant": "1", "stops": "BSG - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "622", "sentence": "Triple-negative (TN) <e2> breast cancers </e2> lack estrogen receptor (ER), progesterone receptor ( <e1> PR </e1> ), and HER2/neu amplification (HER2).", "e1": "PR", "e2": "breast cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 43, "rel_score": 6.15006, "prob_score": -0.16260344, "relevant": "1", "stops": "PRLH - endocrine gland - GRIN1 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 5.69411, "prob_score": -0.17561843, "relevant": "1", "stops": "PRLH - central nervous system - GRIN1 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 4.66114, "prob_score": -0.2145388, "relevant": "1", "stops": "PRLH - cerebellum - GRIN1 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 4.58001, "prob_score": -0.21833912, "relevant": "1", "stops": "PRLH - brain - GRIN1 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 4.37733, "prob_score": -0.2284496, "relevant": "1", "stops": "PRLHR - PLA2G4A - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "623", "sentence": "Treatment of <e2> HOSE </e2> or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of <e1> PR-A </e1> and PR-B mRNA and protein expression, with the regulation primarily controlled at the transcriptional level.", "e1": "PR-A", "e2": "HOSE", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 32, "rel_score": 4.19006, "prob_score": -0.23865885, "relevant": "1", "stops": "PURA - spinal cord - EDNRB - Sitaxentan - Gouty tophus", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 3.9353, "prob_score": -0.25410718, "relevant": "1", "stops": "PURA - heart - EDNRB - Sitaxentan - Gouty tophus", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 3.8912, "prob_score": -0.2569943, "relevant": "1", "stops": "PURA - central nervous system - CYP3A4 - Sitaxentan - Gouty tophus", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 3.62621, "prob_score": -0.27577227, "relevant": "1", "stops": "PURA - SLC1A4 - Cyclosporine - Gout attack", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 3.47548, "prob_score": -0.28773177, "relevant": "1", "stops": "PURA - KIAA0101 - Cyclosporine - Gout attack", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "624", "sentence": "Expression and overexpression of the <e1> epidermal growth factor receptor </e1> (EGFR) have been described in several solid tumors including bladder, breast, colorectal, NSCLC, prostate, and <e2> ovarian cancers </e2> .", "e1": "epidermal growth factor receptor", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 6.22316, "prob_score": -0.1606857, "relevant": "1", "stops": "EGFR - Docetaxel - Ovarian cancer", "reltypes": "BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "625", "sentence": "Increased expression of <e1> bone morphogenetic protein-7 </e1> in bone metastatic <e2> prostate cancer </e2> .", "e1": "bone morphogenetic protein-7", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 4.89285, "prob_score": -0.20438094, "relevant": "1", "stops": "GNE - PIK3CA - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": 4.40878, "prob_score": -0.22682133, "relevant": "1", "stops": "GNE - EPCAM - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 28, "rel_score": 4.30979, "prob_score": -0.23202561, "relevant": "1", "stops": "GNE - GHR - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "rel_score": 4.15749, "prob_score": -0.24053046, "relevant": "1", "stops": "GNE - MIF - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 3.42888, "prob_score": -0.29164258, "relevant": "1", "stops": "GNE - TMEM109 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "626", "sentence": "In several <e2> breast cancer </e2> cell lines, trichostatin A (TSA), a potent HDAC inhibitor, strongly decreases <e1> ERalpha </e1> expression in a dose-dependent manner.", "e1": "ERalpha", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 2.61958, "prob_score": -0.3817409, "relevant": "1", "stops": "ERAL1 - Everolimus - Pancreatitis - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 31, "rel_score": 2.5999, "prob_score": -0.38463226, "relevant": "1", "stops": "ERAL1 - spinal cord - CYP2C19 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 2.46694, "prob_score": -0.4053621, "relevant": "1", "stops": "ERAL1 - liver - CYP2C19 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 2.09126, "prob_score": -0.47818208, "relevant": "1", "stops": "ERAL1 - Everolimus - Rhinitis - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 6, "rel_score": 1.90273, "prob_score": -0.5255572, "relevant": "1", "stops": "ERAL1 - Everolimus - Rhinitis - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "627", "sentence": "Several of the analogues elicit stronger growth inhibitory activity against prostate (PC-3) and breast ( <e2> MDA-MB-468 </e2> ) carcinoma cells, which contain elevated basal IKK activity; this antiproliferative activity correlates with increased inhibition of recombinant IKKbeta in vitro, suggesting that the anticancer activities of these AdArs might be related to the inhibition of <e1> IKK/NFkappaB </e1> signaling.", "e1": "IKK/NFkappaB", "e2": "MDA-MB-468", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": 6.4156, "prob_score": -0.15586719, "relevant": "1", "stops": "IKBKE - MIF - breast cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": 5.75805, "prob_score": -0.17367494, "relevant": "1", "stops": "IKBKE - AR - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 37, "rel_score": 5.71853, "prob_score": -0.17486645, "relevant": "1", "stops": "IKBKE - FIGF - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 31, "rel_score": 5.53342, "prob_score": -0.18072116, "relevant": "1", "stops": "IKBKE - CCT5 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 46, "rel_score": 4.93364, "prob_score": -0.2026919, "relevant": "1", "stops": "IKBKE - HIF1A - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "628", "sentence": "Basal levels and adrenocorticotropic hormone ( <e1> ACTH </e1> )-induced increments (delta-values) of serum cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS), 4-androstene-3, 17-dione (A4), and 17-hydroxyprogesterone (170HP); basal testosterone (T), luteinizing hormone (LH), serum ASAT, gamma-GT, and albumin were measured in <e2> prostatic cancer </e2> patients before and after 6 months of treatment with LH-RH-agonist, with flutamide, and with LH-RH-agonist + flutamide, respectively.", "e1": "ACTH", "e2": "prostatic cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 32, "rel_score": 6.9541, "prob_score": -0.14380342, "relevant": "1", "stops": "CTHRC1 - female gonad - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 6.36051, "prob_score": -0.15721808, "relevant": "1", "stops": "CTHRC1 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 6.35122, "prob_score": -0.15745342, "relevant": "1", "stops": "CTH - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 23, "rel_score": 6.25195, "prob_score": -0.15995483, "relevant": "1", "stops": "CTHRC1 - urethra - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 5.45108, "prob_score": -0.1834535, "relevant": "1", "stops": "CTH - NUCB2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "629", "sentence": "In <e2> MCF-7 </e2> , an increase in Bad and <e1> Bax protein </e1> expression and a decrease in Bcl-x(L) protein and Bcl-2 protein and mRNA were observed.", "e1": "Bax protein", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 5.42388, "prob_score": -0.18437359, "relevant": "1", "stops": "BAX - SUZ12 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 5.18027, "prob_score": -0.19304365, "relevant": "1", "stops": "BAX - IFRD2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 5.02033, "prob_score": -0.1991942, "relevant": "1", "stops": "BAX - TMEM109 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 4.9456, "prob_score": -0.2022002, "relevant": "1", "stops": "BAX - HAT1 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 4.62235, "prob_score": -0.21634005, "relevant": "1", "stops": "BAX - TXLNA - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "630", "sentence": "Arsenite induces p70S6K1 activation and <e1> HIF-1alpha </e1> expression in <e2> prostate cancer </e2> cells.", "e1": "HIF-1alpha", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 49, "rel_score": 3.27665, "prob_score": -0.30519116, "relevant": "1", "stops": "HIF1AN - MIF - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 3.18066, "prob_score": -0.31439513, "relevant": "1", "stops": "HIF1AN - HDAC2 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 3.17712, "prob_score": -0.31474537, "relevant": "1", "stops": "HIF1AN - DRAP1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 3.07598, "prob_score": -0.32509828, "relevant": "1", "stops": "HIF1AN - SEPT7 - prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 13, "rel_score": 3.00526, "prob_score": -0.3327496, "relevant": "1", "stops": "HIF1AN - GDF15 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "631", "sentence": "Hyperactivation of the <e1> insulin-like growth factor I receptor </e1> (IGF-IR) contributes to primary <e2> breast cancer </e2> development, but the role of the IGF-IR in tumor metastasis is unclear.", "e1": "insulin-like growth factor I receptor", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 32, "rel_score": 1.93102, "prob_score": -0.5178587, "relevant": "1", "stops": "INSL5 - vagina - SF3B4 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_DuG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 3, "rel_score": 1.69612, "prob_score": -0.58957976, "relevant": "1", "stops": "INSL5 - vagina - TK1 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_DuG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 19, "rel_score": 1.66703, "prob_score": -0.59986645, "relevant": "1", "stops": "INSL5 - head - EEF1A1 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_DdG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 13, "rel_score": 1.61825, "prob_score": -0.6179542, "relevant": "1", "stops": "INSL5 - head - KCNN4 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 48, "rel_score": 1.53986, "prob_score": -0.6494065, "relevant": "1", "stops": "INSL5 - head - NBN - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}]}
{"qid": "632", "sentence": "The activation of receptor tyrosine kinases, particularly <e1> ErbB2 </e1> , has an important role in the genesis of <e2> breast cancer </e2> .", "e1": "ErbB2", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 41, "rel_score": 45.43389, "prob_score": -0.022005938, "relevant": "1", "stops": "ERBB2IP - NSDHL - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 42.69855, "prob_score": -0.023420123, "relevant": "1", "stops": "ERBB2IP - MAP4 - Paclitaxel - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": 39.79308, "prob_score": -0.025129767, "relevant": "1", "stops": "ERBB2IP - FOXO3 - Mitoxantrone - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 31.7965, "prob_score": -0.03144876, "relevant": "1", "stops": "ERBB2IP - AGTR2 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "rel_score": 25.29724, "prob_score": -0.039528735, "relevant": "1", "stops": "ERBB2IP - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "633", "sentence": "The authors report one case in a 43-year-old woman, the initial interpretation of which, based on pleural and peritoneal exudate, showed suspected latero-uterine mass and significant elevated serum <e1> CA 125 </e1> level, mimicking disseminated <e2> ovarian carcinoma </e2> .", "e1": "CA 125", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 9, "rel_score": 1.89054, "prob_score": -0.52894914, "relevant": "1", "stops": "CA12 - MRPL12 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 1.88562, "prob_score": -0.5303264, "relevant": "1", "stops": "CA12 - DPH2 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 1.86442, "prob_score": -0.536356, "relevant": "1", "stops": "CA12 - GNPDA1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 1.79414, "prob_score": -0.5573658, "relevant": "1", "stops": "CA12 - PUF60 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 1.71139, "prob_score": -0.58432055, "relevant": "1", "stops": "CA12 - SLC35B1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "634", "sentence": "Transfecting <e2> A2780 </e2> cells with active <e1> Notch 1-IC </e1> resulted in a proliferative and colony formation advantage compared to mock transfected cells.", "e1": "Notch 1-IC", "e2": "A2780", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 15, "rel_score": 2.83102, "prob_score": -0.35322824, "relevant": "1", "stops": "NOTCH1 - MTHFD2 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 2.68377, "prob_score": -0.37260875, "relevant": "1", "stops": "NOTCH1 - TNFRSF21 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 2.34121, "prob_score": -0.42713442, "relevant": "1", "stops": "NOTCH1 - CYTH1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 2.28175, "prob_score": -0.43826357, "relevant": "1", "stops": "NOTCH1 - MCOLN1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 2.21833, "prob_score": -0.4507888, "relevant": "1", "stops": "NOTCH1 - ABCB1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "636", "sentence": "Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of <e2> prostate cancer </e2> cells by up-regulating the expression of <e1> CRABPI </e1> for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.", "e1": "CRABPI", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 9, "rel_score": -3.03887, "prob_score": -0.32907233, "relevant": "0", "stops": "CRABP1 - NFIL3 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": -3.11061, "prob_score": -0.321476, "relevant": "0", "stops": "CRABP1 - CASC3 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": -3.1212, "prob_score": -0.32038864, "relevant": "0", "stops": "CRABP1 - TLE1 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": -3.48129, "prob_score": -0.28724983, "relevant": "0", "stops": "CRABP1 - EIF4EBP1 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": -3.65925, "prob_score": -0.27327833, "relevant": "0", "stops": "CRABP1 - hematologic cancer - Ruxolitinib - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "637", "sentence": "Increased <e1> KLF6-SV1 </e1> expression is associated with poor prognosis in prostate, lung, and <e2> ovarian cancer </e2> .", "e1": "KLF6-SV1", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 10.43841, "prob_score": -0.09579614, "relevant": "1", "stops": "KLF6 - ST6GALNAC2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 10.12966, "prob_score": -0.09871698, "relevant": "1", "stops": "KLF6 - TUBB2A - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 9.92457, "prob_score": -0.10075869, "relevant": "1", "stops": "KLF6 - HMMR - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 9.7924, "prob_score": -0.10212465, "relevant": "1", "stops": "KLF6 - PKIG - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 9.52744, "prob_score": -0.10496442, "relevant": "1", "stops": "KLF6 - CCNB2 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "638", "sentence": "In a murine prostate tumour model, infusion of recombinant HGF resulted in an increase in the levels of both <e1> BMPR-IB </e1> and BMPR-II transcript in <e2> prostate tumours </e2> .", "e1": "BMPR-IB", "e2": "prostate tumours", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 5.58784, "prob_score": -0.17896453, "relevant": "1", "stops": "BMPR1B - Vandetanib - Dysuria - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 10, "rel_score": 5.35475, "prob_score": -0.18675412, "relevant": "1", "stops": "BMPR1B - Dasatinib - Alopecia - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 6, "rel_score": 5.31039, "prob_score": -0.18830925, "relevant": "1", "stops": "BMPR1B - Dasatinib - Gynaecomastia - Lenalidomide - Prostate cancer metastatic", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 26, "rel_score": 5.15251, "prob_score": -0.19408016, "relevant": "1", "stops": "BMPR1B - central nervous system - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 5.02311, "prob_score": -0.19908498, "relevant": "1", "stops": "BMPR1B - thyroid gland - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "639", "sentence": "The data also show that LY294002 directly inhibits vascular endothelial growth factor ( <e1> VEGF </e1> ) protein expression and release from <e2> ovarian carcinoma </e2> and suggest that LY294002 blocks the VEGF signaling pathway involved in angiogenesis and vascular permeability.", "e1": "VEGF", "e2": "ovarian carcinoma", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": -7.10379, "prob_score": -0.14077093, "relevant": "0", "stops": "VEGFA - THAP11 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": -7.1144, "prob_score": -0.14055856, "relevant": "0", "stops": "VEGFA - MSRA - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": -7.13012, "prob_score": -0.14025462, "relevant": "0", "stops": "VEGFA - CCDC86 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": -7.81739, "prob_score": -0.12792443, "relevant": "0", "stops": "VEGFA - ZDHHC6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": -8.04699, "prob_score": -0.12427166, "relevant": "0", "stops": "VEGFA - ALDOC - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "640", "sentence": "We found a correlation between ErbB2 expression and activation of <e1> Pak </e1> in estrogen receptor-positive human <e2> breast tumor </e2> samples and observed that in 3D cultures, activation of Rac-Pak1 pathway by ErbB2 homodimers induced growth factor-independent proliferation and promoted disruption of 3D mammary acinar-like structures through activation of the Erk and Akt pathways.", "e1": "Pak", "e2": "breast tumor", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 47, "rel_score": 2.09056, "prob_score": -0.47834215, "relevant": "1", "stops": "PAK4 - NFKBIA - Memantine - Breast cancer female", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 1.89147, "prob_score": -0.52868855, "relevant": "1", "stops": "PAK4 - SIPA1L3 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": 1.77267, "prob_score": -0.56411904, "relevant": "1", "stops": "PAK4 - NCOA3 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": 1.56284, "prob_score": -0.6398626, "relevant": "1", "stops": "PAK4 - Irinotecan - breast cancer", "reltypes": "DOWNREGULATES_CdG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 10, "rel_score": -1.49631, "prob_score": -0.668312, "relevant": "0", "stops": "PAK4 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "641", "sentence": "We have previously shown that acquisition of cisplatin resistance by OAW42-R <e2> ovarian carcinoma </e2> cells was associated with the loss of <e1> ERK </e1> activation in response to cisplatin.", "e1": "ERK", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 5.00751, "prob_score": -0.1996967, "relevant": "1", "stops": "CERK - PCNA - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 4.8158, "prob_score": -0.207654, "relevant": "1", "stops": "CERK - PHYH - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 4.30867, "prob_score": -0.23208828, "relevant": "1", "stops": "CERK - CTSL - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 4.23693, "prob_score": -0.23601736, "relevant": "1", "stops": "CERKL - SPAG4 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 4.13394, "prob_score": -0.24190237, "relevant": "1", "stops": "CERK - LOXL1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "642", "sentence": "In <e2> MCF-7 </e2> , mimicking E2, T3 stimulated growth in a dose-dependent (10(10) M - 10(-8) M) manner, induced the expression of progesterone receptor and <e1> growth factor TGFalpha mRNAs </e1> and inhibited that of TGFbeta mRNA; T3 also increased progesterone binding and LDH5 isozyme activities.", "e1": "growth factor TGFalpha mRNAs", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 11.01443, "prob_score": -0.090791054, "relevant": "1", "stops": "GOT1L1 - spinal cord - GRIN1 - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 9.34056, "prob_score": -0.10706176, "relevant": "1", "stops": "GOT1L1 - female reproductive system - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 8.34655, "prob_score": -0.1198096, "relevant": "1", "stops": "GOT1 - bone marrow - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 24, "rel_score": 8.30427, "prob_score": -0.120419376, "relevant": "1", "stops": "GOT1 - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 22, "rel_score": 7.95861, "prob_score": -0.12564754, "relevant": "1", "stops": "GOT1 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "643", "sentence": "Overexpression of <e1> PIM-1 </e1> is a potential biomarker in <e2> prostate carcinoma </e2> .", "e1": "PIM-1", "e2": "prostate carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 22.13859, "prob_score": -0.045169756, "relevant": "1", "stops": "PIM1 - HMG20B - Riluzole - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 19.80983, "prob_score": -0.050480742, "relevant": "1", "stops": "PIM1 - POLR2I - Testosterone Propionate - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 19.24187, "prob_score": -0.051969904, "relevant": "1", "stops": "PIM1 - PCNA - Testosterone Propionate - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 18.81468, "prob_score": -0.053152937, "relevant": "1", "stops": "PIM1 - PCNA - Paroxetine - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 18.53568, "prob_score": -0.053946804, "relevant": "1", "stops": "PIM1 - POLR2I - Testosterone - Prostate carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "644", "sentence": "In the CM of <e2> BPH </e2> stromal cells, <e1> IGFBP-2 </e1> levels were dramatically reduced to less than 20% of normal (P &lt; 0.001).", "e1": "IGFBP-2", "e2": "BPH", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 43, "rel_score": 8.371, "prob_score": -0.119461, "relevant": "1", "stops": "IGFBP2 - TMEM50A - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "rel_score": 7.76518, "prob_score": -0.12878066, "relevant": "1", "stops": "IGFBP2 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 31, "rel_score": 6.862, "prob_score": -0.14572622, "relevant": "1", "stops": "IGFBP2 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 25, "rel_score": 6.76544, "prob_score": -0.14781348, "relevant": "1", "stops": "IGFBP2 - SRC - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": 6.18009, "prob_score": -0.16180764, "relevant": "1", "stops": "IGFBP2 - TMEM109 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "645", "sentence": "Immunoblot assays indicated that hypoxia and L-mimosine stabilized hypoxia-inducible factor-1 \u03b1 (HIF-1\u03b1) and induced <e1> Btg2 </e1> and Ndrg1 protein expression, but downregulated protein levels of cyclin A in both <e2> PC-3 </e2> and LNCaP cells.", "e1": "Btg2", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 8.45737, "prob_score": -0.118242666, "relevant": "1", "stops": "BTG2 - NQO1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 7.57117, "prob_score": -0.13208164, "relevant": "1", "stops": "BTG2 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 35, "rel_score": 7.43163, "prob_score": -0.13456431, "relevant": "1", "stops": "BTG2 - MRPL12 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 7.3046, "prob_score": -0.13690038, "relevant": "1", "stops": "BTG2 - EDEM1 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 7.04523, "prob_score": -0.14194253, "relevant": "1", "stops": "BTG2 - GPER1 - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "646", "sentence": "These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the <e1> BRCA1 gene </e1> play an important role in the development of sporadic <e2> ovarian carcinomas </e2> , particularly those of serous histology.", "e1": "BRCA1 gene", "e2": "ovarian carcinomas", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 13, "rel_score": 5.24659, "prob_score": -0.19060051, "relevant": "1", "stops": "BRCA1 - FAM63A - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 5.24439, "prob_score": -0.19068381, "relevant": "1", "stops": "BRCA1 - SPAG4 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 5.04134, "prob_score": -0.19836004, "relevant": "1", "stops": "BRCA1 - CCNB1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 4.62684, "prob_score": -0.21613471, "relevant": "1", "stops": "BRCA1 - RRP12 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 2.87761, "prob_score": -0.34751093, "relevant": "1", "stops": "BRCA1 - Niclosamide - Tolcapone - Ovarian carcinoma", "reltypes": "DOWNREGULATES_CdG - RESEMBLES_CrC - CAUSES_CcSE", "nodelabels": "Gene - Compound - Compound - SideEffect"}]}
{"qid": "647", "sentence": "The down-regulation of <e1> ICAM-1 </e1> by short hairpin RNA in <e2> MCF10A </e2> cells led to the induction of psoriasin, calgranulin-A, calgranulin-B, and MUC1, and we demonstrated that these up-regulations were not ROS dependent.", "e1": "ICAM-1", "e2": "MCF10A", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 1, "rel_score": 8.37872, "prob_score": -0.11935343, "relevant": "1", "stops": "ICAM1 - HEY2 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 8.37311, "prob_score": -0.119430505, "relevant": "1", "stops": "ICAM1 - Mitoxantrone - breast cancer", "reltypes": "UPREGULATES_CuG - TREATS_CtD", "nodelabels": "Gene - Compound - Disease"}, {"pathid": 23, "rel_score": 7.49176, "prob_score": -0.13347767, "relevant": "1", "stops": "ICAM1 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 14, "rel_score": 7.3888, "prob_score": -0.13533778, "relevant": "1", "stops": "ICAM1 - lymph node - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 11, "rel_score": 7.10076, "prob_score": -0.14083064, "relevant": "1", "stops": "ICAM1 - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "648", "sentence": "In the former group, <e1> ErbB2 </e1> overexpression was strongly associated with increased risk of recurrence (RR = 4.7; 95% CI, 2.1-10.4) and <e2> breast cancer </e2> death (RR = 5.4; 95% CI, 2.3-12.6).", "e1": "ErbB2", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": -2.1065, "prob_score": -0.47472218, "relevant": "0", "stops": "ERBB2IP - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": -2.32051, "prob_score": -0.43093786, "relevant": "0", "stops": "ERBB2IP - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 28, "rel_score": -2.36653, "prob_score": -0.42255875, "relevant": "0", "stops": "ERBB2IP - SMAD3 - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 11, "rel_score": -2.49719, "prob_score": -0.40045124, "relevant": "0", "stops": "ERBB2IP - CDH1 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": -3.11818, "prob_score": -0.32069603, "relevant": "0", "stops": "ERBB2IP - ERBB2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "649", "sentence": "These results suggest that <e1> p53 </e1> accumulation occurs more frequently in tumors with aggressive behavior and that p53 immunoreactivity may have a prognostic role in certain subsets of patients with <e2> ovarian carcinoma </e2> .", "e1": "p53", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": 5.29493, "prob_score": -0.18885541, "relevant": "1", "stops": "TP53INP2 - female reproductive system - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 5.24384, "prob_score": -0.19069886, "relevant": "1", "stops": "TP53INP2 - decidua - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": 5.23231, "prob_score": -0.19111764, "relevant": "1", "stops": "TP53INP2 - adrenal cortex - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 5.10308, "prob_score": -0.19596104, "relevant": "1", "stops": "TP53INP2 - adrenal gland - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 4.93803, "prob_score": -0.20251079, "relevant": "1", "stops": "TP53INP2 - islet of Langerhans - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "650", "sentence": "The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the <e1> retinoic acid receptor-beta tumor-suppressor gene </e1> in <e2> breast cancer </e2> cells.", "e1": "retinoic acid receptor-beta tumor-suppressor gene", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 10, "rel_score": -1.49194, "prob_score": -0.6702661, "relevant": "0", "stops": "RETN - endocrine gland - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": -1.58103, "prob_score": -0.6324962, "relevant": "0", "stops": "RETN - respiratory system - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": -1.70888, "prob_score": -0.5851822, "relevant": "0", "stops": "RETN - brain - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": -1.84233, "prob_score": -0.5427912, "relevant": "0", "stops": "RETNLB - adrenal gland - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": -2.09978, "prob_score": -0.47624278, "relevant": "0", "stops": "RETN - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "651", "sentence": "<e1> GRB7 protein </e1> over-expression is an independent adverse prognostic factor in human <e2> breast cancer </e2> .", "e1": "GRB7 protein", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 28, "rel_score": 7.19321, "prob_score": -0.1390187, "relevant": "1", "stops": "GRB7 - CUL7 - Fulvestrant - Breast cancer stage IV", "reltypes": "COVARIES_GcG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 6.69568, "prob_score": -0.14935042, "relevant": "1", "stops": "GRB7 - BRCA1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": 6.35486, "prob_score": -0.15735747, "relevant": "1", "stops": "GRB7 - CSK - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 6.15006, "prob_score": -0.16259892, "relevant": "1", "stops": "GRB7 - TIMM9 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 5.3723, "prob_score": -0.18613958, "relevant": "1", "stops": "GRB7 - OXA1L - Escitalopram - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "652", "sentence": "In addition, the higher <e2> PA1 </e2> cell responsiveness to endogenous compared with exogenous <e1> activin </e1> , suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor.", "e1": "activin", "e2": "PA1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 42, "rel_score": 4.73216, "prob_score": -0.21132314, "relevant": "1", "stops": "ATMIN - RRP8 - Ropinirole - Pain in extremity", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 3.99106, "prob_score": -0.2505645, "relevant": "1", "stops": "ATMIN - AKR7A2 - Docetaxel - Pain localised", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 3.82834, "prob_score": -0.261211, "relevant": "1", "stops": "ATMIN - RRP8 - Bortezomib - Pain in extremity", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 3.44507, "prob_score": -0.29026866, "relevant": "1", "stops": "ATMIN - IRF9 - Pitavastatin - Pain in extremity", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 3.33923, "prob_score": -0.2994654, "relevant": "1", "stops": "ATMIN - CRIP1 - Everolimus - Pain in extremity", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "653", "sentence": "In sum, these findings implicate elevated <e1> GC UNC-45 protein </e1> expression in <e2> ovarian carcinoma </e2> proliferation and metastasis.", "e1": "GC UNC-45 protein", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": 6.05694, "prob_score": -0.1651018, "relevant": "1", "stops": "GCM2 - INSIG1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 5.32907, "prob_score": -0.18764901, "relevant": "1", "stops": "GCNT6 - carbohydrate derivative biosynthetic process - ST6GALNAC2 - Clomifene - Ovarian carcinoma", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 5.2222, "prob_score": -0.19148688, "relevant": "1", "stops": "GCNT6 - glycoprotein biosynthetic process - ST6GALNAC2 - Clomifene - Ovarian carcinoma", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 4.45335, "prob_score": -0.22455168, "relevant": "1", "stops": "GCNT6 - glycosylation - ST6GALNAC2 - Clomifene - Ovarian carcinoma", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 4.37905, "prob_score": -0.22835933, "relevant": "1", "stops": "GCNT6 - Golgi membrane - ST6GALNAC2 - Clomifene - Ovarian carcinoma", "reltypes": "PARTICIPATES_GpCC - PARTICIPATES_GpCC - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - CellularComponent - Gene - Compound - SideEffect"}]}
{"qid": "654", "sentence": "Downmodulation of <e1> caveolin-1 </e1> expression in human <e2> ovarian carcinoma </e2> is directly related to alpha-folate receptor overexpression.", "e1": "caveolin-1", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 11.25112, "prob_score": -0.0888809, "relevant": "1", "stops": "CAV1 - MCOLN1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 11.13834, "prob_score": -0.089775875, "relevant": "1", "stops": "CAV1 - ERBB2 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 10.60558, "prob_score": -0.094285704, "relevant": "1", "stops": "CAV1 - ABCB1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 9.9453, "prob_score": -0.10054586, "relevant": "1", "stops": "CAV1 - PGAM1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 9.78761, "prob_score": -0.10217401, "relevant": "1", "stops": "CAV1 - GRB7 - Tolcapone - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "655", "sentence": "Overexpression of <e1> 12/15-lipoxygenase </e1> , an ortholog of human 15-lipoxygenase-1, in the <e2> prostate tumors </e2> of TRAMP mice.", "e1": "12/15-lipoxygenase", "e2": "prostate tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 40, "rel_score": 2.47231, "prob_score": -0.40447655, "relevant": "1", "stops": "F2RL3 - respiratory system - PTEN - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 29, "rel_score": 1.67311, "prob_score": -0.59768873, "relevant": "1", "stops": "F2RL3 - lung - PLEK2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 15, "rel_score": 1.54667, "prob_score": -0.64655095, "relevant": "1", "stops": "F2R - urethra - prostate cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 8, "rel_score": 1.49914, "prob_score": -0.6670521, "relevant": "1", "stops": "F2 - NUCB2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 25, "rel_score": -1.46269, "prob_score": -0.6836692, "relevant": "0", "stops": "F2R - CSRP1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "656", "sentence": "We have shown that overexpression of an activated form of the <e1> Src tyrosine kinase </e1> suppressed the loss of adhesion induced by dominant-negative; adenoviral FAK-CD and decreased the apoptotic response in <e2> BT474 </e2> and MCF-7 breast cancer cell lines.", "e1": "Src tyrosine kinase", "e2": "BT474", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 49, "rel_score": -3.90946, "prob_score": -0.25579393, "relevant": "0", "stops": "SRCAP - brain - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": -4.3204, "prob_score": -0.23146446, "relevant": "0", "stops": "SRCAP - hematopoietic system - TSPAN4 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": -4.32994, "prob_score": -0.23095019, "relevant": "0", "stops": "SRCAP - head - TSPAN4 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "rel_score": -4.79754, "prob_score": -0.20843598, "relevant": "0", "stops": "SRCAP - head - GRIN1 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": -6.0154, "prob_score": -0.16623518, "relevant": "0", "stops": "SRCIN1 - SRC - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "657", "sentence": "Previous studies have shown that reduction in <e1> BRCA1 mRNA </e1> and protein can result in increased proliferation of <e2> BG-1 </e2> ovarian cancer cells in both in vitro and in vivo conditions, suggesting that BRCA1 may normally act as a growth inhibitor in these cells.", "e1": "BRCA1 mRNA", "e2": "BG-1", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 0, "rel_score": -1.80499, "prob_score": -0.5540221, "relevant": "0", "stops": "BRCA1 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "659", "sentence": "In the parental <e2> HEY </e2> cell line, additional treatment with the PPAR\u03b3 ligands led to an increased protein expression of <e1> DR5 </e1> and a further decline of XIAP expression.", "e1": "DR5", "e2": "HEY", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 46, "rel_score": 4.59559, "prob_score": -0.21760434, "relevant": "1", "stops": "WDR53 - trachea - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": 4.20999, "prob_score": -0.23752746, "relevant": "1", "stops": "WDR5B - ESR1 - Estrone - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 4.13411, "prob_score": -0.24188972, "relevant": "1", "stops": "WDR5B - ESR1 - Conjugated Estrogens - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 4.12575, "prob_score": -0.24238099, "relevant": "1", "stops": "WDR5B - ESR1 - Progesterone - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 3.79694, "prob_score": -0.26337367, "relevant": "1", "stops": "WDR5B - RBM34 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "661", "sentence": "Our findings show, for the first time, that DC is a natural tumor promoter by elevating <e1> Flk-1 </e1> and decreasing ceramide-mediated apoptosis of <e2> breast cancer </e2> progenitor cells.", "e1": "Flk-1", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 19, "rel_score": 1.62124, "prob_score": -0.61680835, "relevant": "1", "stops": "FLOT1 - Benzylpenicillin - Arthropathy - Escitalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 32, "rel_score": 1.4242, "prob_score": -0.7021529, "relevant": "1", "stops": "FLOT1 - adrenal gland - CYP2C19 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": -1.77258, "prob_score": -0.5641515, "relevant": "0", "stops": "FLOT1 - nipple - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": -1.80865, "prob_score": -0.552899, "relevant": "0", "stops": "FLOT1 - blood - CYP2C19 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": -1.891, "prob_score": -0.5288248, "relevant": "0", "stops": "FLOT1 - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "662", "sentence": "[Overexpression of <e1> human tumor metastasis-related gene TMSG-1 </e1> suppresses cell proliferation and invasion of a highly metastatic <e2> prostate cancer </e2> cell line PC-3M-1E8 in vitro].", "e1": "human tumor metastasis-related gene TMSG-1", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 35, "rel_score": -4.01268, "prob_score": -0.24921247, "relevant": "0", "stops": "NUMA1 - lung - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": -4.17362, "prob_score": -0.23960067, "relevant": "0", "stops": "NUMA1 - EZH2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 46, "rel_score": -4.27004, "prob_score": -0.2341902, "relevant": "0", "stops": "NUMA1 - head - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": -4.3956, "prob_score": -0.22750434, "relevant": "0", "stops": "NUMA1 - Dasatinib - Weight increased - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 28, "rel_score": -4.44168, "prob_score": -0.22513753, "relevant": "0", "stops": "NUMA1 - Vincristine - Alopecia - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "663", "sentence": "The <e1> epidermal growth factor </e1> (EGF) and EGF receptor (EGFR) family are often overexpressed in various human cancers including <e2> ovarian cancer </e2> .", "e1": "epidermal growth factor", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 10.6929, "prob_score": -0.09352125, "relevant": "1", "stops": "EGFLAM - breast cancer - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 7, "rel_score": 9.91572, "prob_score": -0.100851834, "relevant": "1", "stops": "EGFLAM - breast cancer - Conjugated Estrogens - Ovarian cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 5, "rel_score": 9.89315, "prob_score": -0.1010807, "relevant": "1", "stops": "EGFLAM - breast cancer - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 22, "rel_score": 9.83768, "prob_score": -0.101645604, "relevant": "1", "stops": "EGFL6 - urethra - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 9.25583, "prob_score": -0.10803991, "relevant": "1", "stops": "EGFL6 - thyroid gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "664", "sentence": "Similarly, activation of the <e1> AR </e1> by phosphorylated protein kinase B, Akt, has also been reported in <e2> prostate cancer </e2> .", "e1": "AR", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 30, "rel_score": 2.0202, "prob_score": -0.4950025, "relevant": "1", "stops": "ARF4 - EGF - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": 1.92012, "prob_score": -0.5207974, "relevant": "1", "stops": "ARF4 - PRKCQ - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 37, "rel_score": 1.86822, "prob_score": -0.5352734, "relevant": "1", "stops": "ARF4 - PCNA - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 1.80102, "prob_score": -0.5552354, "relevant": "1", "stops": "ARL2BP - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 27, "rel_score": 1.6963, "prob_score": -0.5895213, "relevant": "1", "stops": "ARF4 - HERPUD1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "665", "sentence": "Decreased protein expression of the <e1> TSLC1 gene </e1> might be important in conferring a more aggressive behavior in <e2> ovarian carcinoma </e2> .", "e1": "TSLC1 gene", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 7, "rel_score": -18.457, "prob_score": -0.054179985, "relevant": "0", "stops": "TSC1 - ST3GAL5 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": -19.5848, "prob_score": -0.051056135, "relevant": "0", "stops": "TSC1 - PPARG - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": -20.22245, "prob_score": -0.0494539, "relevant": "0", "stops": "TSC1 - RUVBL1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -20.54654, "prob_score": -0.048668988, "relevant": "0", "stops": "TSC1 - FDFT1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": -20.77706, "prob_score": -0.04812929, "relevant": "0", "stops": "TSC1 - CDK1 - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "666", "sentence": "Moreover, as observed in the clinical samples, <e1> ERG </e1> expression was fully restored in the <e2> VCaP </e2> xenografts that relapsed after castration, coincident with AR reactivation.", "e1": "ERG", "e2": "VCaP", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 47, "rel_score": -1.4354, "prob_score": -0.6966744, "relevant": "0", "stops": "ERG - AKT1 - Alitretinoin - Scab", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": -1.46199, "prob_score": -0.6839995, "relevant": "0", "stops": "ERG - PPP2R5A - Isotretinoin - Scab", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 22, "rel_score": -1.5201, "prob_score": -0.65784955, "relevant": "0", "stops": "ERG - ST6GALNAC2 - Tretinoin - Scab", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": -2.0057, "prob_score": -0.4985795, "relevant": "0", "stops": "ERGIC1 - C2CD2 - Imiquimod - Scab", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": -2.06804, "prob_score": -0.48355323, "relevant": "0", "stops": "ERGIC1 - C2CD2 - Isotretinoin - Scab", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "667", "sentence": "<e1> PDLIM4 mRNA </e1> and protein-expression levels were reduced in LNCaP, LAPC4, DU145, CWR22, and <e2> PC3 </e2> prostate cancer cells.", "e1": "PDLIM4 mRNA", "e2": "PC3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 11.19946, "prob_score": -0.08929429, "relevant": "1", "stops": "PDLIM4 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 18, "rel_score": 10.42318, "prob_score": -0.095944755, "relevant": "1", "stops": "PDLIM4 - EDEM1 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 31, "rel_score": 9.89413, "prob_score": -0.101070985, "relevant": "1", "stops": "PDLIM4 - PCNA - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 9.61261, "prob_score": -0.10402919, "relevant": "1", "stops": "PDLIM4 - CASC3 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 9.40115, "prob_score": -0.10636944, "relevant": "1", "stops": "PDLIM4 - CSTA - Testosterone Propionate - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "669", "sentence": "Induction of p27( <e1> kip1 </e1> ) by 2,4,3',5'- tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in <e2> PC-3 </e2> prostate cancer cells.", "e1": "kip1", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 13, "rel_score": 10.13479, "prob_score": -0.09867104, "relevant": "1", "stops": "AKIP1 - Alzheimer's disease - Selegiline - Prostate cancer", "reltypes": "UPREGULATES_DuG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 14, "rel_score": 9.24898, "prob_score": -0.10811756, "relevant": "1", "stops": "AKIP1 - Alzheimer's disease - Ropinirole - Prostate cancer", "reltypes": "UPREGULATES_DuG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 10, "rel_score": 6.76361, "prob_score": -0.14784616, "relevant": "1", "stops": "AKIP1 - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 8, "rel_score": 5.94884, "prob_score": -0.16809638, "relevant": "1", "stops": "AKIP1 - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 5.2499, "prob_score": -0.19048207, "relevant": "1", "stops": "AKIP1 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "670", "sentence": "In a cell line ( <e2> OVCAR-3 </e2> ) where basal phosphorylated Akt levels were high, <e1> XIAP </e1> overexpression failed to increase further the level of this phosphoprotein.", "e1": "XIAP", "e2": "OVCAR-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 18.26818, "prob_score": -0.054736424, "relevant": "1", "stops": "XIAP - PCNA - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 16.82652, "prob_score": -0.05943415, "relevant": "1", "stops": "XIAP - PCNA - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 16.76165, "prob_score": -0.059664726, "relevant": "1", "stops": "XIAP - NUP85 - Progesterone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 13.66867, "prob_score": -0.07315522, "relevant": "1", "stops": "XIAP - ovarian cancer - Altretamine - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 13, "rel_score": 12.6167, "prob_score": -0.079257146, "relevant": "1", "stops": "XIAP - ovarian cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "671", "sentence": "This increased expression of <e1> AR </e1> was followed by 1,25-(OH)2D3-induced inhibition of growth in <e2> LNCaP </e2> cells.", "e1": "AR", "e2": "LNCaP", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 17, "rel_score": -1.72634, "prob_score": -0.57926416, "relevant": "0", "stops": "ARHGAP15 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": -1.85518, "prob_score": -0.5390282, "relevant": "0", "stops": "ARL2BP - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 37, "rel_score": -2.10509, "prob_score": -0.47503597, "relevant": "0", "stops": "ARF4 - PCNA - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": -2.19911, "prob_score": -0.45473006, "relevant": "0", "stops": "ARF4 - PRKCQ - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 27, "rel_score": -2.21558, "prob_score": -0.4513522, "relevant": "0", "stops": "ARF4 - HERPUD1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "672", "sentence": "These findings suggest that inhibition of <e1> COX-2 </e1> development may lead not only to inhibition of the proliferation and metastasis of <e2> prostate carcinoma </e2> but also to the inhibition of prostate carcinogenesis.", "e1": "COX-2", "e2": "prostate carcinoma", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 19, "rel_score": 13.86193, "prob_score": -0.07214326, "relevant": "1", "stops": "COX2 - brain - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 13.21178, "prob_score": -0.0756879, "relevant": "1", "stops": "COX2 - lymphoid tissue - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 13.13025, "prob_score": -0.07615665, "relevant": "1", "stops": "COX2 - gonad - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 11.23343, "prob_score": -0.08902209, "relevant": "1", "stops": "COX2 - head - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 10.71582, "prob_score": -0.09331682, "relevant": "1", "stops": "COX2 - saliva-secreting gland - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "674", "sentence": "In patients with <e2> ovarian cancer </e2> , the increased <e1> leptin </e1> levels were associated with higher circulating follicle-stimulating hormone (FSH).", "e1": "leptin", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 27, "rel_score": 20.80732, "prob_score": -0.04806214, "relevant": "1", "stops": "LEPROT - breast cancer - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 1, "rel_score": 19.92429, "prob_score": -0.05019431, "relevant": "1", "stops": "LEP - osteoporosis - Estradiol - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 9, "rel_score": 19.66955, "prob_score": -0.050843477, "relevant": "1", "stops": "LEP - breast cancer - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 33, "rel_score": 19.29757, "prob_score": -0.051824424, "relevant": "1", "stops": "LEPROTL1 - endometrium - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 19.12046, "prob_score": -0.05229651, "relevant": "1", "stops": "LEP - breast cancer - Estrone - Ovarian cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "675", "sentence": "<e2> Ovarian cancer </e2> patients with elevated <e1> CA 125 </e1> levels after three chemotherapy courses have a poor prognosis.", "e1": "CA 125", "e2": "Ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 25, "rel_score": 9.71628, "prob_score": -0.10292246, "relevant": "1", "stops": "CA12 - CDKN1A - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 8.55286, "prob_score": -0.11691691, "relevant": "1", "stops": "CA12 - PUF60 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 7.78877, "prob_score": -0.12838615, "relevant": "1", "stops": "CA12 - SLC25A46 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 7.72738, "prob_score": -0.12941091, "relevant": "1", "stops": "CA12 - ATP6V0B - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 7.25163, "prob_score": -0.13789798, "relevant": "1", "stops": "CA12 - TBC1D31 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "677", "sentence": "We have previously described the increased expression of two prostate-specific G-protein coupled receptors (PSGR and <e1> PSGR2 </e1> ) in human <e2> prostate cancer </e2> .", "e1": "PSGR2", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 14, "rel_score": 5.61356, "prob_score": -0.17814414, "relevant": "1", "stops": "PSG2 - lymph node - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 4.92611, "prob_score": -0.20299788, "relevant": "1", "stops": "PSG2 - myocardium - IER3 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 4.57268, "prob_score": -0.21869436, "relevant": "1", "stops": "PSG2 - uterus - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 4.37828, "prob_score": -0.22839783, "relevant": "1", "stops": "PSG2 - lung - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 4.29756, "prob_score": -0.23268779, "relevant": "1", "stops": "PSG2 - lung - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "678", "sentence": "The elevated testosterone levels and the increased levels of insulin, IGF-I, and IGF-II that are seen in PCOS and abdominal obesity could favor the development of <e2> breast cancer </e2> in several ways, all of which have been demonstrated experimentally: binding of testosterone to cancer cells bearing testosterone receptors, with direct stimulation; intratissular aromatization of testosterone to estradiol, with stimulation of estrogen-sensitive cells; stimulation of the production of <e1> epithelial growth factor </e1> (EGF) by testosterone, with direct mitogenic effect of EGF on cancer cells; stimulation of aromatase by insulin and IGF-I; direct mitogenic stimulation of cancer cells by insulin, IGF-I, and IGF-II; and stimulation by IGF-I and IGF-II of the intratissular reduction of estrone to estradiol.", "e1": "epithelial growth factor", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 13, "rel_score": -2.77154, "prob_score": -0.36080906, "relevant": "0", "stops": "EGFR - DRAP1 - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 36, "rel_score": -2.78691, "prob_score": -0.3588243, "relevant": "0", "stops": "EGFR - GTPBP8 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": -2.82622, "prob_score": -0.35382602, "relevant": "0", "stops": "EGFR - PTPN6 - Fulvestrant - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": -2.97805, "prob_score": -0.33579177, "relevant": "0", "stops": "EGFR - COX8A - Paclitaxel - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": -3.34169, "prob_score": -0.29924682, "relevant": "0", "stops": "EGFR - MEF2C - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "680", "sentence": "Elucidating the molecular events resulting from loss of <e1> AP-2 </e1> in the prostate epithelium has implications for the understanding and prevention of the onset of <e2> prostate cancer </e2> .", "e1": "AP-2", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 2.15248, "prob_score": -0.4645843, "relevant": "1", "stops": "APC2 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "rel_score": 2.08611, "prob_score": -0.47935683, "relevant": "1", "stops": "APC2 - bone marrow - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 1.91916, "prob_score": -0.52105963, "relevant": "1", "stops": "APC2 - urethra - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 46, "rel_score": 1.8485, "prob_score": -0.54097563, "relevant": "1", "stops": "APC2 - seminal vesicle - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": 1.73515, "prob_score": -0.5763217, "relevant": "1", "stops": "APC2 - medulla oblongata - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "681", "sentence": "(II) Up-regulation of <e1> VDR </e1> in <e2> ovarian carcinomas </e2> is not exclusively induced by an increase of proliferation, but by different unknown mechanisms.", "e1": "VDR", "e2": "ovarian carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 24.47381, "prob_score": -0.040860742, "relevant": "1", "stops": "VDR - ZDHHC6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 24.42599, "prob_score": -0.04093877, "relevant": "1", "stops": "VDR - CDK19 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 23.64066, "prob_score": -0.042295862, "relevant": "1", "stops": "VDR - YME1L1 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 23.0521, "prob_score": -0.043379914, "relevant": "1", "stops": "VDR - SLC2A6 - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 22.79462, "prob_score": -0.043867897, "relevant": "1", "stops": "VDR - MSRA - Clomifene - Ovarian carcinoma", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "682", "sentence": "Northern blot analysis of mRNA from normal and <e2> BPH </e2> stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P &lt; 0.001) and a 4-fold increase in <e1> IGFBP-5 mRNA </e1> (P &lt; 0.01) in BPH compared to normal cells.", "e1": "IGFBP-5 mRNA", "e2": "BPH", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 35, "rel_score": 8.79121, "prob_score": -0.11375189, "relevant": "1", "stops": "IGFBP5 - mammary gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 8.24198, "prob_score": -0.12133343, "relevant": "1", "stops": "IGFBP5 - trachea - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 6.46329, "prob_score": -0.15472037, "relevant": "1", "stops": "IGFBP5 - TYMS - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": 6.33232, "prob_score": -0.1579168, "relevant": "1", "stops": "IGFBP5 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 6.18009, "prob_score": -0.16181464, "relevant": "1", "stops": "IGFBP5 - IGF1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "683", "sentence": "Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of <e1> AKT </e1> and P70S6K1 in human <e2> ovarian cancer </e2> cells.", "e1": "AKT", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 45, "rel_score": 1.95875, "prob_score": -0.5105276, "relevant": "1", "stops": "AKT3 - HIST1H2BK - Progesterone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 1.73828, "prob_score": -0.57527936, "relevant": "1", "stops": "AKT3 - ST3GAL5 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 1.68515, "prob_score": -0.5934157, "relevant": "1", "stops": "AKT3 - VAV3 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 1.63495, "prob_score": -0.6116406, "relevant": "1", "stops": "AKT3 - HIST1H2BK - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 1.57126, "prob_score": -0.6364267, "relevant": "1", "stops": "AKT3 - ALDOC - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "684", "sentence": "In addition, we showed GnRH-II antagonist-induced activation of <e1> caspase-3 </e1> in <e2> MDA-MB-231 </e2> human breast cancer cells.", "e1": "caspase-3", "e2": "MDA-MB-231", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 2.12843, "prob_score": -0.46983302, "relevant": "1", "stops": "ASPA - carboxylic acid metabolic process - CYP2C19 - Escitalopram - Breast cancer female", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 5, "rel_score": 1.72461, "prob_score": -0.57983613, "relevant": "1", "stops": "ASPA - Dabrafenib - Phosphatase alkaline increased - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 34, "rel_score": 1.64756, "prob_score": -0.6069593, "relevant": "1", "stops": "ASPA - brain - HRH1 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 1.61031, "prob_score": -0.6210021, "relevant": "1", "stops": "ASPA - spinal cord - HRH1 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 1.56546, "prob_score": -0.63879484, "relevant": "1", "stops": "ASPA - forebrain - HRH1 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "685", "sentence": "Previous studies by us and others, with androgen-sensitive <e2> prostate cancer </e2> cell lines, have demonstrated that androgen deprivation results in activation/overexpression of Akt, <e1> COX-2 </e1> , and MMP-9 in cells.", "e1": "COX-2", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 7.72559, "prob_score": -0.12944105, "relevant": "1", "stops": "COX2 - EGFR - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 25, "rel_score": 6.14024, "prob_score": -0.16286139, "relevant": "1", "stops": "COX2 - endocrine gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 5.9499, "prob_score": -0.16807476, "relevant": "1", "stops": "COX2 - renal system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 5.4277, "prob_score": -0.18424211, "relevant": "1", "stops": "COX20 - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 34, "rel_score": 5.0355, "prob_score": -0.1985866, "relevant": "1", "stops": "COX2 - prostate gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "686", "sentence": "Conversely, enforced expression of MKP3 in MKP3-deficient <e2> ovarian cancer </e2> cells significantly reduced <e1> ERK1/2 </e1> activity and inhibited cell proliferation, anchorage-independent growth ability and tumor development in nude mice.", "e1": "ERK1/2", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 25, "rel_score": -1.54126, "prob_score": -0.6488246, "relevant": "0", "stops": "ERVV-2 - brain - ABCB1 - Docetaxel - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": -1.56309, "prob_score": -0.6397567, "relevant": "0", "stops": "ERVV-2 - brain - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 29, "rel_score": -1.61925, "prob_score": -0.61757356, "relevant": "0", "stops": "ERVV-2 - brain - ABCB1 - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": -1.63332, "prob_score": -0.61225474, "relevant": "0", "stops": "ERVV-2 - brain - PLOD3 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": -1.68979, "prob_score": -0.591787, "relevant": "0", "stops": "ERVV-2 - brain - MTHFD2 - Docetaxel - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "687", "sentence": "In <e2> MDA-MB-231 </e2> , TGF-beta1 had no effect on cell proliferation but increased <e1> uPA </e1> activity and PAI-1 antigen level; sodium butyrate inhibited both cell proliferation and uPA activity but had no effect on PAI-1 level.", "e1": "uPA", "e2": "MDA-MB-231", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 47, "rel_score": 9.16003, "prob_score": -0.10916876, "relevant": "1", "stops": "LPAR6 - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 45, "rel_score": 8.8881, "prob_score": -0.11251224, "relevant": "1", "stops": "LPAR6 - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "rel_score": 8.47458, "prob_score": -0.11799763, "relevant": "1", "stops": "LPAR5 - SDC1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 32, "rel_score": 8.35213, "prob_score": -0.11973331, "relevant": "1", "stops": "LPAR3 - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 29, "rel_score": 7.57518, "prob_score": -0.13200566, "relevant": "1", "stops": "LPAR3 - HP - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "688", "sentence": "It was found that there were both significant overexpression of <e1> Wnt5A </e1> and underexpression of Wnt10B in the metastasis-derived finite life-span breast cancer cells when they were compared to the finite life-span normal and established normal and <e2> breast tumor </e2> cells.", "e1": "Wnt5A", "e2": "breast tumor", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 5.56421, "prob_score": -0.17972194, "relevant": "1", "stops": "WNT5A - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 13, "rel_score": 5.1701, "prob_score": -0.19342078, "relevant": "1", "stops": "WNT5A - epithelium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 4.83349, "prob_score": -0.2068883, "relevant": "1", "stops": "WNT5A - bone marrow - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 25, "rel_score": 4.74136, "prob_score": -0.21090613, "relevant": "1", "stops": "WNT5A - ADRB2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 4.60024, "prob_score": -0.21737863, "relevant": "1", "stops": "WNT5A - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "692", "sentence": "Stimulation of <e2> SKBR3 </e2> cells and HCII RI#11 mouse mammary epithelial cells expressing the human <e1> erbB-2 </e1> with EGF led to an increase in scFv(FRP5)-ETA activity, showing that the EGF-induced activation of erbB-2 can potentiate the action of the erbB-2-directed toxin.", "e1": "erbB-2", "e2": "SKBR3", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": -1.51382, "prob_score": -0.66058385, "relevant": "0", "stops": "ERBB2IP - nipple - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 25, "rel_score": -1.58331, "prob_score": -0.6315918, "relevant": "0", "stops": "ERBB2IP - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 47, "rel_score": -1.7287, "prob_score": -0.5784684, "relevant": "0", "stops": "ERBB2 - CES1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": -1.75257, "prob_score": -0.5705863, "relevant": "0", "stops": "ERBB2 - ST6GALNAC2 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -1.85808, "prob_score": -0.53818774, "relevant": "0", "stops": "ERBB2 - MCOLN1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "693", "sentence": "Induction of <e1> gamma-glutamyl transpeptidase mRNA </e1> by platinum complexes in a human <e2> ovarian carcinoma </e2> cell line.", "e1": "gamma-glutamyl transpeptidase mRNA", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 2.42919, "prob_score": -0.41166422, "relevant": "1", "stops": "GALM - female reproductive system - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 1.9908, "prob_score": -0.5023145, "relevant": "1", "stops": "GALM - head - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 1.95806, "prob_score": -0.5107099, "relevant": "1", "stops": "GALM - cerebellum - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 1.88232, "prob_score": -0.53125507, "relevant": "1", "stops": "GALM - spinal cord - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": 1.78393, "prob_score": -0.56055796, "relevant": "1", "stops": "GALM - bronchus - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "694", "sentence": "<e2> M12 </e2> cells, like many other human cancer cells, contain constitutively activated signal transducer and activator of transcription 3 ( <e1> STAT3 </e1> ).", "e1": "STAT3", "e2": "M12", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 4.80169, "prob_score": -0.20825855, "relevant": "1", "stops": "STAT3 - brain - Gilles de la Tourette syndrome - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}, {"pathid": 36, "rel_score": 4.68472, "prob_score": -0.2134599, "relevant": "1", "stops": "STAT3 - asthma - Pseudoephedrine - Dextroamphetamine - Tic", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - RESEMBLES_CrC - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - Compound - SideEffect"}, {"pathid": 7, "rel_score": 4.34972, "prob_score": -0.22989668, "relevant": "1", "stops": "STAT3 - nervous system - Gilles de la Tourette syndrome - Tics", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - PRESENTS_DpS", "nodelabels": "Gene - Anatomy - Disease - Symptom"}, {"pathid": 42, "rel_score": 2.68327, "prob_score": -0.37267613, "relevant": "1", "stops": "STAT3 - endometrium - SLC6A2 - Dexmethylphenidate - Tic", "reltypes": "EXPRESSES_AeG - UPREGULATES_AuG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 2.18981, "prob_score": -0.4566612, "relevant": "1", "stops": "STAT3 - endometrium - MAOB - Amphetamine - Tic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "695", "sentence": "Here we demonstrate that arsenite induces the expression of <e1> HIF-1alpha </e1> but not HIF-1beta subunit in <e2> DU145 </e2> human prostate carcinoma cells.", "e1": "HIF-1alpha", "e2": "DU145", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 28, "rel_score": 11.51013, "prob_score": -0.08687871, "relevant": "1", "stops": "HIF1AN - PARP1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 8, "rel_score": 11.37139, "prob_score": -0.087943345, "relevant": "1", "stops": "HIF1AN - COX6A1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 39, "rel_score": 10.91941, "prob_score": -0.091580585, "relevant": "1", "stops": "HIF1AN - MAP7 - Riluzole - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 10.13993, "prob_score": -0.09862108, "relevant": "1", "stops": "HIF1AN - MIF - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": 9.87459, "prob_score": -0.10126807, "relevant": "1", "stops": "HIF1AN - DRAP1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "696", "sentence": "Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins ( <e1> albumin </e1> , alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with <e2> prostatic cancer </e2> prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.", "e1": "albumin", "e2": "prostatic cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 30, "rel_score": 11.65637, "prob_score": -0.08578529, "relevant": "1", "stops": "ATMIN - EBNA1BP2 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 9.92556, "prob_score": -0.10074926, "relevant": "1", "stops": "ATMIN - RRP8 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 9.64227, "prob_score": -0.103712805, "relevant": "1", "stops": "ATMIN - POLR2I - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 9.40557, "prob_score": -0.10632347, "relevant": "1", "stops": "ATMIN - P4HA2 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 8.86368, "prob_score": -0.112815216, "relevant": "1", "stops": "ATMIN - BAZ2A - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "697", "sentence": "We present here for the first time that <e1> signal transducers and activators of transcription 3 </e1> (Stat3), which is constitutively activated in a wide variety of human cancers, including <e2> prostate cancer </e2> , interacts with PKCepsilon.", "e1": "signal transducers and activators of transcription 3", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": -1.48471, "prob_score": -0.6735301, "relevant": "0", "stops": "GNAL - BNIP3 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "rel_score": -1.53718, "prob_score": -0.65054196, "relevant": "0", "stops": "GNAL - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 18, "rel_score": -1.9375, "prob_score": -0.5161271, "relevant": "0", "stops": "GNAL - brain - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": -1.96021, "prob_score": -0.51015335, "relevant": "0", "stops": "GNAL - adrenal gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": -2.03211, "prob_score": -0.49209675, "relevant": "0", "stops": "GNAL - urethra - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "698", "sentence": "Functional ablation of pRb activates <e1> Cdk2 </e1> and causes antiestrogen resistance in human <e2> breast cancer </e2> cells.", "e1": "Cdk2", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 31, "rel_score": -12.36094, "prob_score": -0.080904394, "relevant": "0", "stops": "CDK20 - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": -13.98797, "prob_score": -0.0714938, "relevant": "0", "stops": "CDK2AP2 - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": -14.80823, "prob_score": -0.06753339, "relevant": "0", "stops": "CDK2AP2 - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 45, "rel_score": -19.37234, "prob_score": -0.0516188, "relevant": "0", "stops": "CDK2 - VAT1 - Escitalopram - Breast cancer female", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": -22.12389, "prob_score": -0.045201715, "relevant": "0", "stops": "CDK2 - GDF15 - Memantine - Breast cancer female", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "700", "sentence": "The overexpression of the colony-stimulating factor-1( <e1> CSF-1 </e1> ) by epithelial <e2> ovarian cancer </e2> cells enhances invasiveness and metastatic properties, contributing to the poor prognosis of the patients.", "e1": "CSF-1", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 1, "rel_score": 14.34309, "prob_score": -0.06971636, "relevant": "1", "stops": "CSF1R - CEBPB - Estriol - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 13.47164, "prob_score": -0.074233614, "relevant": "1", "stops": "CSF1R - LCN2 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 13.21353, "prob_score": -0.07567708, "relevant": "1", "stops": "CSF1R - RPS4Y1 - Estrone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 12.85843, "prob_score": -0.07776757, "relevant": "1", "stops": "CSF1R - CCNB2 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 10.58873, "prob_score": -0.094442606, "relevant": "1", "stops": "CSF1R - breast cancer - Estradiol - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "701", "sentence": "Overexpression of <e1> c-erbB-2 oncoprotein </e1> was found in seven (21.9%) of 32 epithelial <e2> ovarian cancers </e2> .", "e1": "c-erbB-2 oncoprotein", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 4.03991, "prob_score": -0.24752825, "relevant": "1", "stops": "CPOX - STAMBP - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 3.08594, "prob_score": -0.32404906, "relevant": "1", "stops": "CPEB3 - telencephalon - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 2.7274, "prob_score": -0.3666479, "relevant": "1", "stops": "CPEB3 - parotid gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 2.4817, "prob_score": -0.40294728, "relevant": "1", "stops": "CPEB3 - forebrain - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 43, "rel_score": 2.1588, "prob_score": -0.46322405, "relevant": "1", "stops": "CPEB3 - prostate gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "702", "sentence": "In keeping with our clinical data, activation of AR by dihydrotestosterone (DHT) potently activated <e1> GRP78 </e1> expression in both <e2> LNCaP </e2> and LNCaP-CR cells.", "e1": "GRP78", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 9.53289, "prob_score": -0.10489696, "relevant": "1", "stops": "GPR78 - PRKCQ - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": 8.83002, "prob_score": -0.1132455, "relevant": "1", "stops": "GPR78 - HSPE1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 25, "rel_score": 6.00637, "prob_score": -0.16649391, "relevant": "1", "stops": "GPR78 - CES1 - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": 5.81429, "prob_score": -0.1719943, "relevant": "1", "stops": "GPR78 - CCL2 - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 5.7323, "prob_score": -0.17445032, "relevant": "1", "stops": "GPR78 - STUB1 - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}]}
{"qid": "703", "sentence": "Oestradiol acutely increases PI3-kinase and <e1> Akt </e1> activities in <e2> MCF-7 </e2> cells.", "e1": "Akt", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 37, "rel_score": 8.79817, "prob_score": -0.113664076, "relevant": "1", "stops": "AKT3 - bone marrow - breast cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 23, "rel_score": 8.32362, "prob_score": -0.120141685, "relevant": "1", "stops": "AKT3 - ADRB2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 9, "rel_score": 8.1248, "prob_score": -0.12307873, "relevant": "1", "stops": "AKT3 - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 15, "rel_score": 7.39919, "prob_score": -0.13515428, "relevant": "1", "stops": "AKT3 - MRPS28 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": 7.15973, "prob_score": -0.13967207, "relevant": "1", "stops": "AKT3 - RPL22 - breast cancer", "reltypes": "COVARIES_GcG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "704", "sentence": "From a clinical perspective, we suggest that if chemically stable <e1> FASN </e1> inhibitors or cell-selective systems able to deliver RNAi targeting FASN gene demonstrate systemic anticancer effects of FASN inhibition in vivo, additional preclinical studies to characterize their anti- <e2> breast cancer </e2> actions should be of great interest as the specific blockade of FASN activity may also provide a protective means against endometrial carcinoma associated with tamoxifen-based breast cancer therapy.", "e1": "FASN", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 35, "rel_score": -2.40171, "prob_score": -0.41637063, "relevant": "0", "stops": "FASN - Mycophenolate mofetil - Rhinitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 45, "rel_score": -3.06908, "prob_score": -0.32583192, "relevant": "0", "stops": "FASN - Mycophenolate mofetil - Gynaecomastia - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 31, "rel_score": -3.32579, "prob_score": -0.30067563, "relevant": "0", "stops": "FASN - Sirolimus - Rhinitis - Memantine - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 21, "rel_score": -3.44721, "prob_score": -0.29008636, "relevant": "0", "stops": "FASN - Orlistat - Pancreatitis - Escitalopram - Breast cancer female", "reltypes": "BINDS_CbG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 44, "rel_score": -3.8072, "prob_score": -0.26266336, "relevant": "0", "stops": "FASN - Sorafenib - Gynaecomastia - Escitalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "705", "sentence": "In general, IFN-gamma was more effective than IFN-alpha, IFN-beta or TPA in augmenting the expression of TAA, CEA and BCA-225, and <e1> HLA-DR </e1> expression in <e2> T47D </e2> and MCF-7 cells.", "e1": "HLA-DR", "e2": "T47D", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 46, "rel_score": 5.86063, "prob_score": -0.17062727, "relevant": "1", "stops": "HLA-DRA - TGFBR2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 22, "rel_score": 5.29942, "prob_score": -0.18869992, "relevant": "1", "stops": "HLA-DRA - pituitary gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 43, "rel_score": 5.27899, "prob_score": -0.18942551, "relevant": "1", "stops": "HLA-DRA - TSTA3 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 9, "rel_score": 5.21975, "prob_score": -0.1915805, "relevant": "1", "stops": "HLA-DRA - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 31, "rel_score": 4.93632, "prob_score": -0.20258425, "relevant": "1", "stops": "HLA-DRA - AHR - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "706", "sentence": "We propose that, in the <e2> ovarian tumour </e2> microenvironment, interaction between tumour cells and fibroblasts may enhance fibroblast production of the <e1> proMMP-2 </e1> and TIMP-2.", "e1": "proMMP-2", "e2": "ovarian tumour", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 29, "rel_score": 8.06712, "prob_score": -0.123963825, "relevant": "1", "stops": "MMP20 - female gonad - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 7.62777, "prob_score": -0.131098, "relevant": "1", "stops": "MMP20 - adrenal gland - ID2 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 41, "rel_score": 6.32111, "prob_score": -0.15819784, "relevant": "1", "stops": "MMP20 - embryo - SATB1 - Estriol - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 6.13234, "prob_score": -0.16307345, "relevant": "1", "stops": "MMP20 - adrenal gland - CYP2C19 - Progesterone - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 6.01685, "prob_score": -0.16619967, "relevant": "1", "stops": "MMP20 - testis - CYP2C19 - Progesterone - Ovarian cancer", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "708", "sentence": "Resveratrol- and EGCG-induced apoptosis is associated with a significant down-regulation of <e1> CK2 </e1> activity and protein expression in both the ALVA-41 and <e2> PC-3 </e2> cells.", "e1": "CK2", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 23, "rel_score": 9.19794, "prob_score": -0.10872384, "relevant": "1", "stops": "CDK2 - HSP90B1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": 8.51281, "prob_score": -0.11746947, "relevant": "1", "stops": "CDK2 - PARP1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 21, "rel_score": 8.22098, "prob_score": -0.12163615, "relevant": "1", "stops": "CDK2 - NRP1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 29, "rel_score": 7.88955, "prob_score": -0.12674598, "relevant": "1", "stops": "CDK2 - RPL14 - prostate cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 42, "rel_score": 7.83453, "prob_score": -0.12764452, "relevant": "1", "stops": "CDK2 - RPS19 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "709", "sentence": "Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and <e1> ERK1/2 </e1> activation and subsequently reduces <e2> ovarian cancer </e2> cell growth, invasion and metastasis.", "e1": "ERK1/2", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": -1.48289, "prob_score": -0.67436177, "relevant": "0", "stops": "ERVV-2 - brain - MRPL12 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": -1.57958, "prob_score": -0.6330814, "relevant": "0", "stops": "ERVV-2 - brain - ZWINT - Docetaxel - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": -1.60321, "prob_score": -0.62374806, "relevant": "0", "stops": "ERVV-2 - brain - PLOD3 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": -1.61439, "prob_score": -0.6194332, "relevant": "0", "stops": "ERVV-2 - brain - CAPNS1 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": -1.71409, "prob_score": -0.58340335, "relevant": "0", "stops": "ERVV-2 - brain - ATF6 - Estriol - Ovarian cancer", "reltypes": "DOWNREGULATES_AdG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "710", "sentence": "Hyperactivation of the insulin-like growth factor I receptor ( <e1> IGF-IR </e1> ) contributes to primary <e2> breast cancer </e2> development, but the role of the IGF-IR in tumor metastasis is unclear.", "e1": "IGF-IR", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 42, "rel_score": 2.91002, "prob_score": -0.3436363, "relevant": "1", "stops": "IGF1R - SPON2 - Estradiol - Breast cancer invasive NOS", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 2.72013, "prob_score": -0.3676293, "relevant": "1", "stops": "IGF1R - ST3GAL5 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 2.64124, "prob_score": -0.37860966, "relevant": "1", "stops": "IGF1R - RBM34 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 2.38663, "prob_score": -0.4189955, "relevant": "1", "stops": "IGF1R - CCNB1 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 2.27905, "prob_score": -0.43877834, "relevant": "1", "stops": "IGF1R - SRC - Tamoxifen - Breast cancer male", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "711", "sentence": "Importantly, this signaling circuit is manifest in human cancer cells and in a mouse model of ErbB2-driven <e2> breast cancer </e2> , where <e1> IL6 </e1> loss significantly impairs tumorigenesis.", "e1": "IL6", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 6, "rel_score": 17.12915, "prob_score": -0.058383875, "relevant": "1", "stops": "IL6ST - LIFR - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": 16.70007, "prob_score": -0.059884097, "relevant": "1", "stops": "IL6ST - CDC20 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": 15.29286, "prob_score": -0.065390855, "relevant": "1", "stops": "IL6ST - GPER1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 24, "rel_score": 14.03312, "prob_score": -0.07125699, "relevant": "1", "stops": "IL6ST - adrenal gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 30, "rel_score": 13.47527, "prob_score": -0.07421127, "relevant": "1", "stops": "IL6ST - TYMS - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "712", "sentence": "Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with <e2> prostatic cancer </e2> prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of alpha 2- and beta-globulin and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in <e1> alpha 1- and gamma-globulin </e1> from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.", "e1": "alpha 1- and gamma-globulin", "e2": "prostatic cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 11.44034, "prob_score": -0.087413445, "relevant": "1", "stops": "APH1A - uterus - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 10.92777, "prob_score": -0.09151423, "relevant": "1", "stops": "APH1A - endometrium - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 10.41667, "prob_score": -0.095995575, "relevant": "1", "stops": "APH1A - urethra - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 7.54774, "prob_score": -0.13248755, "relevant": "1", "stops": "APH1A - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 7.12352, "prob_score": -0.14038333, "relevant": "1", "stops": "APH1A - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "713", "sentence": "We also found that: (1) luciferase activity mediated by the <e1> VEGF </e1> reporter containing a mutation of the HIF-1 binding site was much lower than that of the reporter containing a wild-type HIF-1 binding site in <e2> ovarian cancer </e2> cells, thus confirming that HIF-1 is a major transcriptional regulator of VEGF expression; and that (2) CDDP greatly inhibited VEGF reporter activity containing the wild-type but not the mutant HIF-1 binding site.", "e1": "VEGF", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 5.98659, "prob_score": -0.16703576, "relevant": "1", "stops": "VEGFA - Estradiol - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "714", "sentence": "<e2> SKOV3 </e2> , but not two alphaFR-negative non-ovarian cell lines, exhibited down-regulation of <e1> cav-1 </e1> expression following stable alphaFR cDNA transfection.", "e1": "cav-1", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 4.94633, "prob_score": -0.20216566, "relevant": "1", "stops": "CAV1 - KLHL21 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 4.59855, "prob_score": -0.21745607, "relevant": "1", "stops": "CAV1 - ADI1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 4.57122, "prob_score": -0.21875547, "relevant": "1", "stops": "CAV1 - SATB1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 39, "rel_score": 4.02236, "prob_score": -0.24860941, "relevant": "1", "stops": "CAV1 - ovarian cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 43, "rel_score": 3.93144, "prob_score": -0.25436035, "relevant": "1", "stops": "CAV1 - STUB1 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "715", "sentence": "Despite these differences, <e2> ovarian carcinoma </e2> cells show substantial accumulation of <e1> araCTP from extracellular araC </e1> .", "e1": "araCTP from extracellular araC", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 5.25265, "prob_score": -0.19038339, "relevant": "1", "stops": "ARC - nervous system - PHYH - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 5.16236, "prob_score": -0.19371223, "relevant": "1", "stops": "ARC - nervous system - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 5.14668, "prob_score": -0.1942953, "relevant": "1", "stops": "ARC - thyroid gland - PHYH - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 4.40199, "prob_score": -0.22717111, "relevant": "1", "stops": "ARC - trigeminal ganglion - ST6GALNAC2 - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 4.13856, "prob_score": -0.24163014, "relevant": "1", "stops": "ARC - seminal vesicle - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "717", "sentence": "We further demonstrate that <e1> Pfn1 </e1> downregulation results in a hyper-motile phenotype of <e2> MDA-MB-231 </e2> cells in an Ena/VASP-dependent mechanism.", "e1": "Pfn1", "e2": "MDA-MB-231", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 16, "rel_score": -1.98039, "prob_score": -0.50494677, "relevant": "0", "stops": "PFN1 - JUN - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 43, "rel_score": -2.0016, "prob_score": -0.49959645, "relevant": "0", "stops": "PFN1 - SPRY2 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 46, "rel_score": -2.0279, "prob_score": -0.4931173, "relevant": "0", "stops": "PFN1 - NR3C1 - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": -2.0324, "prob_score": -0.49203157, "relevant": "0", "stops": "PFN1 - STMN1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 20, "rel_score": -2.5705, "prob_score": -0.38903472, "relevant": "0", "stops": "PFN1 - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "718", "sentence": "Accordingly, a meta-analysis of available microarray data shows that <e1> CLU mRNA </e1> is significantly downregulated in <e2> prostate cancer </e2> tissue compared to normal prostate in 14 out of 15 independent studies.", "e1": "CLU mRNA", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 14.01738, "prob_score": -0.071344875, "relevant": "1", "stops": "CLMN - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 22, "rel_score": 10.50641, "prob_score": -0.09517906, "relevant": "1", "stops": "CLMN - islet of Langerhans - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": 9.14829, "prob_score": -0.10930858, "relevant": "1", "stops": "CLMN - telencephalon - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 8.38715, "prob_score": -0.11922798, "relevant": "1", "stops": "CLMN - female reproductive system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 6.53851, "prob_score": -0.15293555, "relevant": "1", "stops": "CLMN - vagina - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "719", "sentence": "The butyrate-induced apoptosis in <e2> MCF-7 </e2> cells was closely linked with the down-regulation of expression of <e1> Bcl-2 mRNA </e1> and Bcl-2 protein, a gene product known to be involved in the regulation of apoptosis in mammalian cells.", "e1": "Bcl-2 mRNA", "e2": "MCF-7", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": -6.66045, "prob_score": -0.15013592, "relevant": "0", "stops": "BCL2L2-PABPN1 - UBC - CTSB - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 16, "rel_score": -6.95459, "prob_score": -0.14379048, "relevant": "0", "stops": "BCL2L2-PABPN1 - UBC - RB1 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 3, "rel_score": -7.12099, "prob_score": -0.14042751, "relevant": "0", "stops": "BCL2L2-PABPN1 - UBC - KCNN4 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 20, "rel_score": -7.17463, "prob_score": -0.13937742, "relevant": "0", "stops": "BCL2L2-PABPN1 - MLST8 - MIF - breast cancer", "reltypes": "COVARIES_GcG - REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 4, "rel_score": -7.57518, "prob_score": -0.13201046, "relevant": "0", "stops": "BCL2L2-PABPN1 - UBC - EEF1A1 - breast cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "720", "sentence": "We previously reported that <e1> LTBP-1L </e1> is overexpressed in some patients with <e2> ovarian cancer </e2> .", "e1": "LTBP-1L", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 14.85001, "prob_score": -0.067341596, "relevant": "1", "stops": "LTBP1 - CEBPD - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 14.06668, "prob_score": -0.071085684, "relevant": "1", "stops": "LTBP1 - endometrium - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 12, "rel_score": 13.89275, "prob_score": -0.0719849, "relevant": "1", "stops": "LTBP1 - lymph node - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "rel_score": 13.72872, "prob_score": -0.072843656, "relevant": "1", "stops": "LTBP1 - IGFBP3 - Estradiol - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 13.59804, "prob_score": -0.0735426, "relevant": "1", "stops": "LTBP1 - vagina - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "721", "sentence": "<e1> miR-9 </e1> is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, <e2> breast cancer </e2> and Hodgkin lymphoma (HL).", "e1": "miR-9", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": 4.11117, "prob_score": -0.24324012, "relevant": "1", "stops": "IRF9 - KRAS - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 21, "rel_score": 3.747, "prob_score": -0.26687568, "relevant": "1", "stops": "IRF9 - PHB - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 46, "rel_score": 3.58102, "prob_score": -0.2792532, "relevant": "1", "stops": "IRF9 - Mycophenolic acid - Pancreatitis - Memantine - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 35, "rel_score": 3.42185, "prob_score": -0.29223922, "relevant": "1", "stops": "IRF9 - Irinotecan - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 47, "rel_score": 3.33356, "prob_score": -0.2999798, "relevant": "1", "stops": "IRF9 - Mycophenolic acid - Pancreatitis - Citalopram - Breast cancer female", "reltypes": "UPREGULATES_CuG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "722", "sentence": "Here, we demonstrate that the EGFR inhibitor PD153035 specifically induces <e1> RAR-beta2 </e1> , but not the other two isoforms (RAR-beta1, RAR-beta4) in MDA-MB-468 and <e2> MDA-MB-453 </e2> human breast cancer cells.", "e1": "RAR-beta2", "e2": "MDA-MB-453", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 46, "rel_score": 5.99018, "prob_score": -0.16694495, "relevant": "1", "stops": "RARA - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "rel_score": 5.41741, "prob_score": -0.18458776, "relevant": "1", "stops": "RARA - CTSB - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 25, "rel_score": 5.05919, "prob_score": -0.19766067, "relevant": "1", "stops": "RARA - LDHB - breast cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 5.03905, "prob_score": -0.19844598, "relevant": "1", "stops": "RARA - NCOA1 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 48, "rel_score": 4.60193, "prob_score": -0.2173009, "relevant": "1", "stops": "RARA - HIST1H1C - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "723", "sentence": "The oncogene <e1> Bcl-2 </e1> is upregulated frequently in <e2> prostate tumors </e2> following androgen ablation therapy, and Bcl-2 overexpression may contribute to the androgen-refractory relapse of the disease.", "e1": "Bcl-2", "e2": "prostate tumors", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 11, "rel_score": 3.31093, "prob_score": -0.30203062, "relevant": "1", "stops": "BCL2L2-PABPN1 - MLST8 - MIF - prostate cancer", "reltypes": "COVARIES_GcG - REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 16, "rel_score": 3.18086, "prob_score": -0.3143771, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - PDE4D - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 3.11042, "prob_score": -0.32150155, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - CDH1 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 37, "rel_score": 3.04859, "prob_score": -0.32802466, "relevant": "1", "stops": "BCL2L2-PABPN1 - UBC - PTRH2 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 46, "rel_score": 2.90563, "prob_score": -0.34415838, "relevant": "1", "stops": "BCL2L2-PABPN1 - RGMA - urethra - prostate cancer", "reltypes": "COVARIES_GcG - EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Gene - Anatomy - Disease"}]}
{"qid": "724", "sentence": "PKC isozyme analysis revealed that chronic PDBu treatment caused downregulation of <e1> PKC-alpha and -epsilon </e1> in <e2> DU-145 </e2> cells.", "e1": "PKC-alpha and -epsilon", "e2": "DU-145", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 18, "rel_score": -1.67543, "prob_score": -0.5968597, "relevant": "0", "stops": "PRKCA - NFE2L2 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 15, "rel_score": -1.68421, "prob_score": -0.59375274, "relevant": "0", "stops": "PRKCA - PRKCZ - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": -1.91512, "prob_score": -0.52215743, "relevant": "0", "stops": "PRKCA - CASP3 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 35, "rel_score": -2.14532, "prob_score": -0.46613386, "relevant": "0", "stops": "PRKCA - regulation of inflammatory response - IER3 - Lenalidomide - Prostate cancer metastatic", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 45, "rel_score": -2.35921, "prob_score": -0.4238689, "relevant": "0", "stops": "PRKCA - cardiovascular system - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "725", "sentence": "Intriguingly, the loss of <e1> MKP3 protein </e1> was associated with ubiquitination/proteosome degradation mediated by high intracellular reactive oxygen species (ROS) accumulation such as hydrogen peroxide in <e2> ovarian cancer </e2> cells.", "e1": "MKP3 protein", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": 3.57411, "prob_score": -0.27979496, "relevant": "1", "stops": "PKP3 - prostate cancer - Docetaxel - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 10, "rel_score": 3.23813, "prob_score": -0.30882138, "relevant": "1", "stops": "PKP3 - uterine cervix - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 16, "rel_score": 3.09329, "prob_score": -0.32328096, "relevant": "1", "stops": "PKP3 - decidua - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 2.87695, "prob_score": -0.34758875, "relevant": "1", "stops": "PKP3 - NSDHL - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 2.70834, "prob_score": -0.3692341, "relevant": "1", "stops": "PKP3 - RNH1 - Estrone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "728", "sentence": "Evaluation of alterations in the level of the five major electrophoretic fractions of serum proteins (albumin, alpha 1-, alpha 2-, beta- and gamma-globulin) in 18 patients with <e2> prostatic cancer </e2> prior to and following cryoprostatectomy disclosed: (i) a progressive increase in the level of <e1> alpha 2- and beta-globulin </e1> and the incidence of patients possessing statistically significant (p less than 0.05) elevations in these proteins with a progression of the stage of their malignancy; (ii) a significant decrease in albumin, alpha 2- and beta-globulin and increase in alpha 1- and gamma-globulin from their preoperative levels following cryoprostatectomy in patients with metastatic disease (stage III) in association with a favorable clinical response; (iii) an overall significant decrease in albumin and alpha 2-globulin and increase in alpha 1-globulin from their preoperative levels and (iv) a general association of decreases in albumin (83% of the patients) and alpha 2-globulin (92%) and gamma-globulin (75%) with a favorable clinical response following cryoprostatectomy.", "e1": "alpha 2- and beta-globulin", "e2": "prostatic cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": 8.84564, "prob_score": -0.11304793, "relevant": "1", "stops": "APH1A - liver - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 8.18398, "prob_score": -0.1221889, "relevant": "1", "stops": "APH1A - cerebellum - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 7.47719, "prob_score": -0.1337438, "relevant": "1", "stops": "APH1A - uterine cervix - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 6.96427, "prob_score": -0.14359413, "relevant": "1", "stops": "APH1A - telencephalon - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "rel_score": 5.05459, "prob_score": -0.19783543, "relevant": "1", "stops": "APH1A - TNFRSF21 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "729", "sentence": "The most prominent of these progressive changes is the up-regulation of <e1> AR </e1> that occurs in &gt;90% <e2> of prostate canc </e2> ers.", "e1": "AR", "e2": "of prostate canc", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 1.72816, "prob_score": -0.57865316, "relevant": "1", "stops": "ARF4 - NUCB2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 41, "rel_score": 1.7138, "prob_score": -0.58350325, "relevant": "1", "stops": "ARF4 - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 29, "rel_score": 1.69059, "prob_score": -0.5915104, "relevant": "1", "stops": "ARF4 - EPCAM - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 42, "rel_score": 1.67538, "prob_score": -0.5968775, "relevant": "1", "stops": "ARF4 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 14, "rel_score": 1.53584, "prob_score": -0.6511134, "relevant": "1", "stops": "ARSG - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "730", "sentence": "The synergistic action of unopposed oestrogen and leptin, compounded by increasing <e1> insulin </e1> , cortisol and xeno-oestrogen exposure directly initiate, promote and exacerbate obesity, type 2 diabetes, uterine overgrowth, prostatic enlargement, prostate cancer and <e2> breast cancer </e2> .", "e1": "insulin", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 28, "rel_score": -7.92581, "prob_score": -0.12616804, "relevant": "0", "stops": "INSL5 - head - PTEN - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 44, "rel_score": -8.10701, "prob_score": -0.12334899, "relevant": "0", "stops": "INSL5 - central nervous system - NBN - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 20, "rel_score": -8.28912, "prob_score": -0.120636426, "relevant": "0", "stops": "INSL5 - digestive system - EEF1A1 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_DdG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 11, "rel_score": -8.56531, "prob_score": -0.11674764, "relevant": "0", "stops": "INSL5 - vagina - KCNN4 - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 47, "rel_score": -8.69112, "prob_score": -0.11505951, "relevant": "0", "stops": "INSL5 - vagina - NBN - breast cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}]}
{"qid": "732", "sentence": "Coexistence of Graves' disease and benign <e2> struma ovarii </e2> in a patient with marked ascites and elevated <e1> CA-125 </e1> levels.", "e1": "CA-125", "e2": "struma ovarii", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 41, "rel_score": 5.60381, "prob_score": -0.17845212, "relevant": "1", "stops": "CA12 - TIMM9 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 10, "rel_score": 5.48908, "prob_score": -0.18218164, "relevant": "1", "stops": "CA12 - GNPDA1 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 17, "rel_score": 5.32028, "prob_score": -0.18795612, "relevant": "1", "stops": "CA12 - PNP - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 5.30532, "prob_score": -0.18849167, "relevant": "1", "stops": "CA12 - TPI1 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 4.59749, "prob_score": -0.21751228, "relevant": "1", "stops": "CA12 - FABP5 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "733", "sentence": "Quantitative reverse transcription-PCR and Western blot analyses showed that <e1> GRB7 </e1> and GRB7v were frequently upregulated in <e2> ovarian cancer </e2> samples.", "e1": "GRB7", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 23.55713, "prob_score": -0.042453643, "relevant": "1", "stops": "GRB7 - MET - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 13, "rel_score": 21.79599, "prob_score": -0.045879126, "relevant": "1", "stops": "GRB7 - female gonad - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 22, "rel_score": 21.66847, "prob_score": -0.046150275, "relevant": "1", "stops": "GRB7 - ZBTB18 - ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "rel_score": 21.64034, "prob_score": -0.0462143, "relevant": "1", "stops": "GRB7 - BRCA1 - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 14, "rel_score": 20.72969, "prob_score": -0.048243236, "relevant": "1", "stops": "GRB7 - SPARC - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "734", "sentence": "We also found that the expression of tumour necrosis factor receptor 2 and death receptor 3 (DR3) was increased in <e2> PC3 </e2> cells, and the expression of <e1> FAS </e1> and DR3 was increased in SW620 cells by co-culture with NK-92 cells.", "e1": "FAS", "e2": "PC3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 21, "rel_score": 9.00658, "prob_score": -0.11102795, "relevant": "1", "stops": "FASTKD5 - TMEM50A - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 47, "rel_score": 8.58664, "prob_score": -0.11646263, "relevant": "1", "stops": "FASTKD2 - female reproductive system - EFEMP2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 33, "rel_score": 7.95355, "prob_score": -0.125731, "relevant": "1", "stops": "FASTKD2 - endocrine gland - PLEK2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 18, "rel_score": 6.80596, "prob_score": -0.14693093, "relevant": "1", "stops": "FASTKD5 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 25, "rel_score": 6.64055, "prob_score": -0.15058681, "relevant": "1", "stops": "FASTKD3 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "736", "sentence": "<e2> Prostate cancer </e2> bony metastases show increased expression of the PTH receptor ( <e1> PTH-IR </e1> ) and PTH promotes the growth and invasiveness of prostate cancer cells in bone.", "e1": "PTH-IR", "e2": "Prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 4, "rel_score": 37.60812, "prob_score": -0.026590906, "relevant": "1", "stops": "PTH - testis - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 20, "rel_score": 32.5839, "prob_score": -0.0306913, "relevant": "1", "stops": "PTH2 - brain - EFEMP2 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 0, "rel_score": 30.9119, "prob_score": -0.032348067, "relevant": "1", "stops": "PTH - prostate gland - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 47, "rel_score": 28.79355, "prob_score": -0.034727998, "relevant": "1", "stops": "PTH2 - central nervous system - NBN - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}, {"pathid": 38, "rel_score": 27.43484, "prob_score": -0.03645385, "relevant": "1", "stops": "PTH2 - nervous system - ADAM9 - prostate cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - ASSOCIATES_DaG", "nodelabels": "Gene - Anatomy - Gene - Disease"}]}
{"qid": "738", "sentence": "Quinazoline-based alpha 1-adrenoceptor antagonists induce <e2> prostate cancer </e2> cell apoptosis via TGF-beta signalling and <e1> I kappa B alpha </e1> induction.", "e1": "I kappa B alpha", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 48, "rel_score": 4.39812, "prob_score": -0.22736539, "relevant": "1", "stops": "IKBKE - PHGDH - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 17, "rel_score": 4.25967, "prob_score": -0.23475742, "relevant": "1", "stops": "IKBKE - SSBP2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "rel_score": 3.96385, "prob_score": -0.2522807, "relevant": "1", "stops": "IKBKE - PFDN5 - prostate cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 45, "rel_score": 3.58654, "prob_score": -0.27882197, "relevant": "1", "stops": "IKBKE - CHEK2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 3.37792, "prob_score": -0.29603666, "relevant": "1", "stops": "IKZF2 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "739", "sentence": "<e1> Neurofibromin 1 </e1> (NF1) defects are common in human <e2> ovarian serous carcinomas </e2> and co-occur with TP53 mutations.", "e1": "Neurofibromin 1", "e2": "ovarian serous carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 36, "rel_score": 3.80185, "prob_score": -0.26302996, "relevant": "1", "stops": "NF1 - PLS1 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 46, "rel_score": 3.69918, "prob_score": -0.2703323, "relevant": "1", "stops": "NF1 - PGM1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 3.56494, "prob_score": -0.28050658, "relevant": "1", "stops": "NF1 - FAM57A - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 3.55809, "prob_score": -0.28105444, "relevant": "1", "stops": "NF1 - ST6GALNAC2 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 3.11129, "prob_score": -0.32141095, "relevant": "1", "stops": "NF1 - TXNRD1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "740", "sentence": "Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and <e1> BMPR-II </e1> , in human <e2> prostate cancer </e2> cells.", "e1": "BMPR-II", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 6, "rel_score": 8.0032, "prob_score": -0.12494709, "relevant": "1", "stops": "MPRIP - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 35, "rel_score": 6.92137, "prob_score": -0.14448078, "relevant": "1", "stops": "MPRIP - hematopoietic system - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Disease - Compound - SideEffect"}, {"pathid": 44, "rel_score": 6.41108, "prob_score": -0.15597712, "relevant": "1", "stops": "MPRIP - Afatinib - Infestation - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 41, "rel_score": 6.32831, "prob_score": -0.15801899, "relevant": "1", "stops": "MPRIP - GRB2 - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Gene - Disease - Compound - SideEffect"}, {"pathid": 43, "rel_score": 5.85446, "prob_score": -0.17080608, "relevant": "1", "stops": "MPRIP - Afatinib - Unspecified disorder of skin and subcutaneous tissue - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "741", "sentence": "Overexpression of <e1> HER2 </e1> has independent prognostic significance in early <e2> breast cancer </e2> and may also predict response to hormonal and cytotoxic therapies, although this latter role is less well studied.", "e1": "HER2", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 12, "rel_score": 2.03318, "prob_score": -0.4918352, "relevant": "1", "stops": "ERBB2IP - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 39, "rel_score": 1.94314, "prob_score": -0.5146295, "relevant": "1", "stops": "ERBB2IP - ERBB2 - Fulvestrant - Breast cancer stage IV", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 1.92289, "prob_score": -0.52005476, "relevant": "1", "stops": "ERBB2IP - ERBB2 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 9, "rel_score": 1.74773, "prob_score": -0.57217157, "relevant": "1", "stops": "ERBB2IP - uterus - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 48, "rel_score": 1.63637, "prob_score": -0.61110955, "relevant": "1", "stops": "ERBB2 - ST6GALNAC2 - Tamoxifen - Breast cancer male", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "742", "sentence": "The overexpression of Bax inhibitor-1 ( <e1> BI-1 </e1> ) in <e2> prostate carcinoma </e2> and prostate cancer cell lines was confirmed by using Northern blot and Western blot analyses.", "e1": "BI-1", "e2": "prostate carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 6.19118, "prob_score": -0.16152193, "relevant": "1", "stops": "ABI1 - HSPA8 - Paroxetine - Prostate carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 5.392, "prob_score": -0.18545932, "relevant": "1", "stops": "ABI1 - CACNA1A - Pregabalin - Prostate carcinoma", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 5.2173, "prob_score": -0.19167466, "relevant": "1", "stops": "ABI1 - CDK6 - Testosterone - Prostate carcinoma", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "743", "sentence": "Compared with primary <e2> prostate tumors </e2> , castration-resistant metastases displayed alterations in genes encoding steroidogenic enzymes, including up-regulated expression of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and <e1> UGT2B17 </e1> and down-regulated expression of SRD5A2 (P < 0.001 for all).", "e1": "UGT2B17", "e2": "prostate tumors", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 9.08018, "prob_score": -0.110126324, "relevant": "1", "stops": "UGT2B17 - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 1, "rel_score": 8.96941, "prob_score": -0.1114856, "relevant": "1", "stops": "UGT2B17 - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 3, "rel_score": 8.58443, "prob_score": -0.11649067, "relevant": "1", "stops": "UGT2B17 - hematologic cancer - Ruxolitinib - Prostate cancer", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "744", "sentence": "These compounds decreased <e1> ERalpha </e1> in <e2> MCF-7 </e2> cells at both mRNA and protein levels, and suppressed estrogen-stimulated genes.", "e1": "ERalpha", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 10, "rel_score": 8.13339, "prob_score": -0.12294751, "relevant": "1", "stops": "ERAL1 - blood - CYP2C19 - Memantine - Breast cancer female", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "rel_score": 7.80823, "prob_score": -0.12806931, "relevant": "1", "stops": "ERAL1 - Everolimus - Conjunctivitis - Citalopram - Breast cancer female", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}, {"pathid": 23, "rel_score": 6.73537, "prob_score": -0.14847068, "relevant": "1", "stops": "ERAL1 - telencephalon - CYP2C19 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 6.57376, "prob_score": -0.15212049, "relevant": "1", "stops": "ERAL1 - telencephalon - CYP2C19 - Escitalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 6.45619, "prob_score": -0.15489332, "relevant": "1", "stops": "ERAL1 - cerebellum - CYP2C19 - Citalopram - Breast cancer female", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "745", "sentence": "This study showed that <e1> IL-18 </e1> serum levels were elevated in <e2> ovarian cancer </e2> patients and were correlated with overall survival, although they were shown not to be an independent prognostic factor.", "e1": "IL-18", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 34, "rel_score": 38.74467, "prob_score": -0.025810098, "relevant": "1", "stops": "IL18R1 - heart - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 48, "rel_score": 36.50968, "prob_score": -0.027387798, "relevant": "1", "stops": "IL18R1 - brain - ID2 - Raloxifene - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 36.08805, "prob_score": -0.027706424, "relevant": "1", "stops": "IL18R1 - adrenal gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 35.29827, "prob_score": -0.028328452, "relevant": "1", "stops": "IL18R1 - prostate gland - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 35.06311, "prob_score": -0.028523669, "relevant": "1", "stops": "IL18R1 - lymph node - MCM6 - Docetaxel - Ovarian cancer", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "746", "sentence": "Immunoblot assays indicated that hypoxia and L-mimosine stabilized hypoxia-inducible factor-1 \u03b1 (HIF-1\u03b1) and induced <e1> Btg2 </e1> and Ndrg1 protein expression, but downregulated protein levels of cyclin A in both <e2> PC-3 </e2> and LNCaP cells.", "e1": "Btg2", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 8.50774, "prob_score": -0.117537275, "relevant": "1", "stops": "BTG2 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 43, "rel_score": 7.40851, "prob_score": -0.13498399, "relevant": "1", "stops": "BTG2 - AKT1 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 7.25268, "prob_score": -0.13787523, "relevant": "1", "stops": "BTG2 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 34, "rel_score": 6.42839, "prob_score": -0.15555964, "relevant": "1", "stops": "BTG2 - MRPL12 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": 6.39591, "prob_score": -0.15635288, "relevant": "1", "stops": "BTG2 - EDEM1 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "748", "sentence": "<e1> p53 </e1> overexpression has been correlated with poor outcome for women with <e2> ovarian cancer </e2> in some studies.", "e1": "p53", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 7.84929, "prob_score": -0.12740226, "relevant": "1", "stops": "TP53RK - PUF60 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 7.25479, "prob_score": -0.13783905, "relevant": "1", "stops": "TP53RK - MCOLN1 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 6.86012, "prob_score": -0.14577161, "relevant": "1", "stops": "TP53RK - CXCL2 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 28, "rel_score": 6.77231, "prob_score": -0.14765832, "relevant": "1", "stops": "TP53RK - PSMG1 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 49, "rel_score": 6.62515, "prob_score": -0.15094306, "relevant": "1", "stops": "TP53RK - AKR7A2 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "749", "sentence": "This decrease in the <e1> UTP </e1> and CTP pools promoted a fivefold increase in the incorporation of [3H]BrdUrd into the DNA of <e2> BG-1 </e2> cells.", "e1": "UTP", "e2": "BG-1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 7.63126, "prob_score": -0.13104361, "relevant": "1", "stops": "UTP6 - CDKN1A - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 7.04424, "prob_score": -0.14196196, "relevant": "1", "stops": "UTP6 - GRN - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 6.61901, "prob_score": -0.15107818, "relevant": "1", "stops": "UTP6 - GRN - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "rel_score": 6.12858, "prob_score": -0.16317344, "relevant": "1", "stops": "UTP6 - TP53 - ovarian cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "rel_score": 4.37484, "prob_score": -0.22858413, "relevant": "1", "stops": "UTP6 - female reproductive system - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "750", "sentence": "The epidermal growth factor (EGF) and EGF receptor ( <e1> EGFR </e1> ) family are often overexpressed in various human cancers including <e2> ovarian cancer </e2> .", "e1": "EGFR", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 11.60901, "prob_score": -0.08613599, "relevant": "1", "stops": "EGFR - Docetaxel - Ovarian cancer", "reltypes": "BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "751", "sentence": "Many advanced human tumors including <e2> breast cancer </e2> overproduce <e1> plasmin </e1> that is known to promote angiogenesis and metastasis.", "e1": "plasmin", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 8, "rel_score": -3.10001, "prob_score": -0.32258436, "relevant": "0", "stops": "ATMIN - PYCR1 - breast cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 12, "rel_score": -3.24118, "prob_score": -0.3085301, "relevant": "0", "stops": "ATMIN - female reproductive system - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 20, "rel_score": -3.40646, "prob_score": -0.29356205, "relevant": "0", "stops": "ATMIN - endocrine gland - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 48, "rel_score": -3.42243, "prob_score": -0.292186, "relevant": "0", "stops": "ATMIN - CCNE2 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": -3.51074, "prob_score": -0.28484115, "relevant": "0", "stops": "ATMIN - adipose tissue - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "752", "sentence": "<e1> Cdc25B </e1> is frequently overexpressed in human <e2> prostate cancer </e2> tissues (29 of 30; 97%).", "e1": "Cdc25B", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 14, "rel_score": 6.03136, "prob_score": -0.16579862, "relevant": "1", "stops": "CDC25B - DIABLO - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 19, "rel_score": 5.97407, "prob_score": -0.16739312, "relevant": "1", "stops": "CDC25B - MYC - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 24, "rel_score": 5.65579, "prob_score": -0.17681019, "relevant": "1", "stops": "CDC25B - AR - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 43, "rel_score": 5.48306, "prob_score": -0.18237607, "relevant": "1", "stops": "CDC25B - P4HB - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "rel_score": 4.99326, "prob_score": -0.20027158, "relevant": "1", "stops": "CDC25B - SDF2L1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "753", "sentence": "These observations suggest that <e1> U19 </e1> is growth inhibitory and tumor suppressive and that the disruption of androgen-dependent growth inhibition via U19 down-regulation is commonly associated with <e2> prostate cancer </e2> progression.", "e1": "U19", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 25, "rel_score": 2.07172, "prob_score": -0.48268571, "relevant": "1", "stops": "SP9 - appendage morphogenesis - BMPR1B - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 4, "rel_score": 2.03099, "prob_score": -0.49236664, "relevant": "1", "stops": "SP9 - embryonic appendage morphogenesis - TBX5 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 32, "rel_score": 1.86804, "prob_score": -0.5353203, "relevant": "1", "stops": "SP9 - appendage morphogenesis - SOX9 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 15, "rel_score": 1.70923, "prob_score": -0.5850617, "relevant": "1", "stops": "SP9 - embryo development - NBN - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}, {"pathid": 30, "rel_score": 1.59274, "prob_score": -0.6278465, "relevant": "1", "stops": "SP9 - limb development - SOX9 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - ASSOCIATES_DaG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "754", "sentence": "The accumulation of <e1> p53 protein </e1> was analysed immunohistochemically in <e2> ovarian cancer </e2> and correlated with clinical data to further clarify the role of p53 mutations for prognosis in these patients.", "e1": "p53 protein", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 41, "rel_score": -1.8159, "prob_score": -0.55068535, "relevant": "0", "stops": "TP53RK - ITGAE - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": -1.91644, "prob_score": -0.5218006, "relevant": "0", "stops": "TP53RK - AKR7A2 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": -2.00196, "prob_score": -0.49950787, "relevant": "0", "stops": "TP53RK - MTHFD2 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 16, "rel_score": -2.17434, "prob_score": -0.45991227, "relevant": "0", "stops": "TP53RK - DNAJA3 - Tolcapone - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": -2.26511, "prob_score": -0.44148415, "relevant": "0", "stops": "TP53RK - SATB1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "755", "sentence": "Although expressed at low levels in some normal human tissues, including the ovary, <e1> CLDN3 </e1> and CLDN4 are highly up-regulated in epithelial <e2> ovarian cancers </e2> of all subtypes.", "e1": "CLDN3", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 5, "rel_score": 4.42635, "prob_score": -0.22592023, "relevant": "1", "stops": "CLDN3 - prostate cancer - Conjugated Estrogens - Ovarian cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 10, "rel_score": 3.5466, "prob_score": -0.28195676, "relevant": "1", "stops": "CLDN3 - uterine cervix - ovarian cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 3.01878, "prob_score": -0.33125633, "relevant": "1", "stops": "CLDN34 - azoospermia - DNAJC19 - ovarian cancer", "reltypes": "DOWNREGULATES_DdG - UPREGULATES_DuG - UPREGULATES_DuG", "nodelabels": "Gene - Disease - Gene - Disease"}, {"pathid": 16, "rel_score": 3.01486, "prob_score": -0.3316858, "relevant": "1", "stops": "CLDN34 - cell-cell junction - AQP3 - ovarian cancer", "reltypes": "PARTICIPATES_GpCC - PARTICIPATES_GpCC - ASSOCIATES_DaG", "nodelabels": "Gene - CellularComponent - Gene - Disease"}, {"pathid": 41, "rel_score": 2.70621, "prob_score": -0.36951622, "relevant": "1", "stops": "CLDN34 - azoospermia - testicular cancer - ovarian cancer", "reltypes": "DOWNREGULATES_DdG - RESEMBLES_DrD - RESEMBLES_DrD", "nodelabels": "Gene - Disease - Disease - Disease"}]}
{"qid": "756", "sentence": "We have shown previously that although <e1> AP-2 </e1> is expressed highly in normal prostatic epithelium, its expression is lost in high-grade prostatic intraepithelial neoplasia and <e2> prostate cancer </e2> , suggesting that loss of AP-2 plays a role in prostate cancer development.", "e1": "AP-2", "e2": "prostate cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 17, "rel_score": 21.88663, "prob_score": -0.045689855, "relevant": "1", "stops": "APC2 - spinal cord - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 18.53568, "prob_score": -0.05394771, "relevant": "1", "stops": "APC2 - central nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 16.592, "prob_score": -0.060270637, "relevant": "1", "stops": "APC2 - pituitary gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 21, "rel_score": 16.49621, "prob_score": -0.060624056, "relevant": "1", "stops": "APC2 - adrenal cortex - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 10.49759, "prob_score": -0.095261626, "relevant": "1", "stops": "APC2 - bone marrow - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "757", "sentence": "Knockdown of <e1> TRAIL receptor 4 </e1> by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of <e2> ovarian cancer </e2> .", "e1": "TRAIL receptor 4", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "1", "metapaths": [{"pathid": 18, "rel_score": -3.7896, "prob_score": -0.26387927, "relevant": "0", "stops": "TRIL - positive regulation of immune system process - DNAJA3 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": -4.15248, "prob_score": -0.2408231, "relevant": "0", "stops": "TRIL - regulation of immune response - DNAJA3 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 9, "rel_score": -4.45315, "prob_score": -0.22456118, "relevant": "0", "stops": "TRIL - regulation of innate immune response - DNAJA3 - Tolcapone - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": -4.59728, "prob_score": -0.21752225, "relevant": "0", "stops": "TRIL - activation of innate immune response - PSMB10 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": -4.68669, "prob_score": -0.2133698, "relevant": "0", "stops": "TRIL - activation of immune response - PSMB10 - Raloxifene - Ovarian cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - BiologicalProcess - Gene - Compound - SideEffect"}]}
{"qid": "758", "sentence": "Enhanced <e1> Ha-ras </e1> expression was documented in 66% of breast and 100% of colon carcinomas as compared with their normal counterparts, with levels in <e2> breast carcinomas </e2> ranging from 10.1 to 50.4 pg ras p21/micrograms protein and those in colon carcinomas ranging from 18.4 to 51.7 pg ras p21/micrograms protein.", "e1": "Ha-ras", "e2": "breast carcinomas", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 15, "rel_score": 7.84129, "prob_score": -0.12752768, "relevant": "1", "stops": "HARS - PCNA - breast cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "rel_score": 6.68315, "prob_score": -0.14962983, "relevant": "1", "stops": "HARS - MCM4 - breast cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 28, "rel_score": 6.44538, "prob_score": -0.1551481, "relevant": "1", "stops": "HARS - RPS8 - breast cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 18, "rel_score": 6.22781, "prob_score": -0.16056663, "relevant": "1", "stops": "HARS - DNMT1 - breast cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": 5.46597, "prob_score": -0.18295461, "relevant": "1", "stops": "HARS - RPS14 - breast cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "759", "sentence": "<e2> Prostate cancer </e2> cells transfected with <e1> EP4-siRNA </e1> and treatments with EP4 antagonist suggest a link between EP4, and Snail activation, potentially via p-Akt.", "e1": "EP4-siRNA", "e2": "Prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 10.83072, "prob_score": -0.092327565, "relevant": "1", "stops": "ELP4 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "rel_score": 10.23227, "prob_score": -0.09772689, "relevant": "1", "stops": "ELP4 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 19, "rel_score": 9.94233, "prob_score": -0.100578494, "relevant": "1", "stops": "ELP4 - nervous system - ABCB1 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 9.89413, "prob_score": -0.101074815, "relevant": "1", "stops": "ELP4 - UBC - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": 9.59325, "prob_score": -0.10423957, "relevant": "1", "stops": "ELP4 - Irinotecan - Bradycardia - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "760", "sentence": "Transfection with <e1> GSK-3beta </e1> S9A to upregulate the GSK-3beta activity resulted in the increase of BrdU incorporation in <e2> SKOV3 </e2> cells compared with that in the control vector.", "e1": "GSK-3beta", "e2": "SKOV3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 38, "rel_score": 2.30187, "prob_score": -0.43443283, "relevant": "1", "stops": "GSK3B - SNCA - Raloxifene - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 1.85905, "prob_score": -0.5379083, "relevant": "1", "stops": "GSK3B - SQSTM1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 11, "rel_score": 1.73641, "prob_score": -0.57589763, "relevant": "1", "stops": "GSK3B - SATB1 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 19, "rel_score": 1.66739, "prob_score": -0.5997394, "relevant": "1", "stops": "GSK3B - SLC7A5 - Raloxifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "rel_score": 1.53657, "prob_score": -0.65080065, "relevant": "1", "stops": "GSK3B - FKBP14 - Estradiol - Ovarian cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "761", "sentence": "MonoHER suppressed DOX-dependent activation of the mitochondrial apoptotic pathway in normal and <e2> A2780 </e2> cells as illustrated by <e1> p53 </e1> accumulation and activation of caspase-9 and -3 cleavage.", "e1": "p53", "e2": "A2780", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 22, "rel_score": -2.28061, "prob_score": -0.4384821, "relevant": "0", "stops": "TP53RK - MRPL12 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": -2.28906, "prob_score": -0.43685627, "relevant": "0", "stops": "TP53RK - ABCE1 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 35, "rel_score": -2.33111, "prob_score": -0.42897868, "relevant": "0", "stops": "TP53RK - MCM3 - Docetaxel - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 12, "rel_score": -2.39843, "prob_score": -0.41693938, "relevant": "0", "stops": "TP53RK - MTHFD2 - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": -2.54933, "prob_score": -0.39226457, "relevant": "0", "stops": "TP53RK - MRPS16 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "762", "sentence": "Androgen-sensitive <e2> LNCaP </e2> prostate cancer cells engineered to stably overexpress <e1> CDK6 </e1> display increased expression of the prostate-specific antigen and enhanced growth in the presence of dihydrotestosterone.", "e1": "CDK6", "e2": "LNCaP", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 35, "rel_score": 9.72668, "prob_score": -0.10281374, "relevant": "1", "stops": "CDK6 - GRB7 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 33, "rel_score": 9.10001, "prob_score": -0.10989089, "relevant": "1", "stops": "CDK6 - AGR2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 9, "rel_score": 8.86446, "prob_score": -0.11280889, "relevant": "1", "stops": "CDK6 - CCND1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 10, "rel_score": 8.72296, "prob_score": -0.114641696, "relevant": "1", "stops": "CDK6 - SPON2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 34, "rel_score": 7.48447, "prob_score": -0.13360894, "relevant": "1", "stops": "CDK6 - ANXA3 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "763", "sentence": "Induction of <e1> MDR1-gene </e1> expression by antineoplastic agents in <e2> ovarian cancer </e2> cell lines.", "e1": "MDR1-gene", "e2": "ovarian cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 7, "rel_score": 2.38186, "prob_score": -0.41983777, "relevant": "1", "stops": "DR1 - SPAG4 - Clomifene - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 2.26331, "prob_score": -0.4418322, "relevant": "1", "stops": "DR1 - PDIA5 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 2.02581, "prob_score": -0.4936285, "relevant": "1", "stops": "DR1 - DRAP1 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 44, "rel_score": 2.01792, "prob_score": -0.49555683, "relevant": "1", "stops": "DR1 - CDCA4 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 24, "rel_score": 1.82239, "prob_score": -0.54873353, "relevant": "1", "stops": "DR1 - PPP2R5E - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "764", "sentence": "In this study we show that oestradiol decreased secreted <e1> sVEGFR-1 </e1> , increased secreted VEGF, and decreased the ratio of sVEGFR-1/VEGF in <e2> MCF-7 </e2> human breast cancer cells.", "e1": "sVEGFR-1", "e2": "MCF-7", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 24, "rel_score": 16.2022, "prob_score": -0.061716475, "relevant": "1", "stops": "EGFR - AKT1 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 47, "rel_score": 15.75548, "prob_score": -0.063474596, "relevant": "1", "stops": "EGFR - JMJD6 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 15.02404, "prob_score": -0.06655679, "relevant": "1", "stops": "EGFR - DYRK3 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 40, "rel_score": 14.89647, "prob_score": -0.067132905, "relevant": "1", "stops": "EGFR - SCPEP1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 14.32459, "prob_score": -0.0698064, "relevant": "1", "stops": "EGFR - ICAM1 - Mitoxantrone - Breast cancer stage IV", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "765", "sentence": "Antisense blocking of <e1> BRCA1 </e1> enhances sensitivity to plumbagin but not tamoxifen in <e2> BG-1 </e2> ovarian cancer cells.", "e1": "BRCA1", "e2": "BG-1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 34.9895, "prob_score": -0.02858493, "relevant": "1", "stops": "BRCA1 - Raloxifene - Ovarian cancer", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}]}
{"qid": "766", "sentence": "<e1> Six1 </e1> overexpression in <e2> ovarian carcinoma </e2> causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.", "e1": "Six1", "e2": "ovarian carcinoma", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 45, "rel_score": 24.22481, "prob_score": -0.041277852, "relevant": "1", "stops": "SIX1 - kidney - PHYH - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 34, "rel_score": 22.27668, "prob_score": -0.044891484, "relevant": "1", "stops": "SIX1 - uterus - ABCE1 - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "rel_score": 20.04811, "prob_score": -0.049879756, "relevant": "1", "stops": "SIX1 - brain - PNKP - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 17.00391, "prob_score": -0.05880823, "relevant": "1", "stops": "SIX1 - female reproductive system - PHYH - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "rel_score": 15.08068, "prob_score": -0.06631416, "relevant": "1", "stops": "SIX1 - female reproductive system - ST6GALNAC2 - Clomifene - Ovarian carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "768", "sentence": "Induction of <e1> p27 </e1> (kip1) by 2,4,3',5'- tetramethoxystilbene is regulated by protein phosphatase 2A-dependent Akt dephosphorylation in <e2> PC-3 </e2> prostate cancer cells.", "e1": "p27", "e2": "PC-3", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 8, "rel_score": 3.99473, "prob_score": -0.25032663, "relevant": "1", "stops": "USP27X - peptidase activity - ADAM9 - prostate cancer", "reltypes": "PARTICIPATES_GpMF - PARTICIPATES_GpMF - ASSOCIATES_DaG", "nodelabels": "Gene - MolecularFunction - Gene - Disease"}, {"pathid": 10, "rel_score": 3.97283, "prob_score": -0.25170547, "relevant": "1", "stops": "USP27X - peptidase activity - KLK5 - prostate cancer", "reltypes": "PARTICIPATES_GpMF - PARTICIPATES_GpMF - ASSOCIATES_DaG", "nodelabels": "Gene - MolecularFunction - Gene - Disease"}, {"pathid": 2, "rel_score": 3.85743, "prob_score": -0.25924182, "relevant": "1", "stops": "USP27X - transferase complex - CCND1 - prostate cancer", "reltypes": "PARTICIPATES_GpCC - PARTICIPATES_GpCC - ASSOCIATES_DaG", "nodelabels": "Gene - CellularComponent - Gene - Disease"}, {"pathid": 9, "rel_score": 3.75601, "prob_score": -0.2662374, "relevant": "1", "stops": "USP27X - peptidase activity, acting on L-amino acid peptides - ADAM9 - prostate cancer", "reltypes": "PARTICIPATES_GpMF - PARTICIPATES_GpMF - ASSOCIATES_DaG", "nodelabels": "Gene - MolecularFunction - Gene - Disease"}, {"pathid": 41, "rel_score": 3.26456, "prob_score": -0.30632457, "relevant": "1", "stops": "USP27X - cellular macromolecule catabolic process - KLHL3 - prostate cancer", "reltypes": "PARTICIPATES_GpBP - PARTICIPATES_GpBP - UPREGULATES_DuG", "nodelabels": "Gene - BiologicalProcess - Gene - Disease"}]}
{"qid": "769", "sentence": "Both obesity and over-expression of <e1> HER II </e1> are associated with poor prognosis of <e2> breast cancer </e2> .", "e1": "HER II", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 4, "rel_score": 4.99775, "prob_score": -0.20008539, "relevant": "1", "stops": "ERBB2IP - female gonad - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 17, "rel_score": 4.75602, "prob_score": -0.21025999, "relevant": "1", "stops": "ERBB2IP - endometrium - breast cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 33, "rel_score": 4.55851, "prob_score": -0.21936649, "relevant": "1", "stops": "ERBB2 - Mitoxantrone - Breast cancer stage IV", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 3.71996, "prob_score": -0.2688246, "relevant": "1", "stops": "ERBB2IP - ENOPH1 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 42, "rel_score": 3.41087, "prob_score": -0.29318497, "relevant": "1", "stops": "ERBB2IP - SDHB - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "770", "sentence": "Thus, <e1> ING1 </e1> mutation is very rare in breast or <e2> ovarian cancers </e2> , however, repression of ING1 expression frequently accompanies tumour development of breast cancer.", "e1": "ING1", "e2": "ovarian cancers", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 17, "rel_score": 9.8561, "prob_score": -0.10146081, "relevant": "1", "stops": "ING1 - ESR1 - Estrone - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 8.87705, "prob_score": -0.11265218, "relevant": "1", "stops": "ING1 - ESR1 - Medroxyprogesterone Acetate - Ovarian cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "rel_score": 8.71992, "prob_score": -0.11468409, "relevant": "1", "stops": "ING1 - SPON2 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 30, "rel_score": 7.21293, "prob_score": -0.13863829, "relevant": "1", "stops": "ING1 - SMARCA4 - ovarian cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 39, "rel_score": 6.31832, "prob_score": -0.15826525, "relevant": "1", "stops": "ING1 - decidua - ovarian cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "771", "sentence": "In summary, the <e2> LNCaP </e2> xenograft model of human prostate cancer as well as clinical specimens of prostate cancer demonstrated an up-regulation of <e1> SREBPs </e1> and their downstream effector genes during progression to androgen independence.", "e1": "SREBPs", "e2": "LNCaP", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 26, "rel_score": 3.72162, "prob_score": -0.2686978, "relevant": "1", "stops": "EBPL - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "rel_score": 3.6527, "prob_score": -0.27376574, "relevant": "1", "stops": "EBP - CBR1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 30, "rel_score": 3.37314, "prob_score": -0.2964592, "relevant": "1", "stops": "EBPL - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "rel_score": 3.34493, "prob_score": -0.29896128, "relevant": "1", "stops": "EBP - IRS1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 40, "rel_score": 2.86017, "prob_score": -0.34963432, "relevant": "1", "stops": "EBP - Anagrelide - Pancreatitis - Lenalidomide - Prostate cancer metastatic", "reltypes": "DOWNREGULATES_CdG - CAUSES_CcSE - CAUSES_CcSE - CAUSES_CcSE", "nodelabels": "Gene - Compound - SideEffect - Compound - SideEffect"}]}
{"qid": "773", "sentence": "Isosilybin B (10-90 microM) treatment decreased the <e1> AR </e1> and prostate specific antigen (PSA) levels in LNCaP, <e2> 22Rv1 </e2> and LAPC4 cells, but not in non-neoplastic human prostate epithelial PWR-1E cells.", "e1": "AR", "e2": "22Rv1", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 2, "rel_score": 5.99233, "prob_score": -0.16688392, "relevant": "1", "stops": "ARL2BP - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 27, "rel_score": 5.87406, "prob_score": -0.1702357, "relevant": "1", "stops": "ARF4 - HERPUD1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "rel_score": 5.76037, "prob_score": -0.1735954, "relevant": "1", "stops": "ARL2BP - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 8, "rel_score": 5.67795, "prob_score": -0.17612466, "relevant": "1", "stops": "ARHGEF35 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 42, "rel_score": 5.66861, "prob_score": -0.17640562, "relevant": "1", "stops": "ARF4 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "774", "sentence": "Angiogenic cytokines such as vascular endothelial growth factor ( <e1> VEGF </e1> ) have been identified in <e2> prostate cancer </e2> cells and tumours, and androgens appear to stimulate VEGF.", "e1": "VEGF", "e2": "prostate cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 27, "rel_score": 2.62096, "prob_score": -0.38154194, "relevant": "1", "stops": "VEGFA - LGMN - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 32, "rel_score": 2.43061, "prob_score": -0.411424, "relevant": "1", "stops": "VEGFA - ORM1 - Imatinib - Prostate cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 33, "rel_score": 2.34604, "prob_score": -0.42624584, "relevant": "1", "stops": "VEGFA - SYK - Riluzole - Prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 14, "rel_score": 2.03745, "prob_score": -0.49081254, "relevant": "1", "stops": "VEGFA - breast cancer - Testosterone Propionate - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 6, "rel_score": 1.88925, "prob_score": -0.5293101, "relevant": "1", "stops": "VEGFA - RPS4Y1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "775", "sentence": "Decreased expression of miR-342 in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated <e1> miR-520g </e1> in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis <e2> breast cancer </e2> , but that it could also present an attractive target for therapeutic intervention.", "e1": "miR-520g", "e2": "breast cancer", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 33, "rel_score": 7.83515, "prob_score": -0.1276318, "relevant": "1", "stops": "MIR205HG - amyotrophic lateral sclerosis - VCP - breast cancer", "reltypes": "DOWNREGULATES_DdG - ASSOCIATES_DaG - ASSOCIATES_DaG", "nodelabels": "Gene - Disease - Gene - Disease"}, {"pathid": 15, "rel_score": 7.7006, "prob_score": -0.12986223, "relevant": "1", "stops": "MIR205HG - amyotrophic lateral sclerosis - MMP9 - breast cancer", "reltypes": "DOWNREGULATES_DdG - ASSOCIATES_DaG - ASSOCIATES_DaG", "nodelabels": "Gene - Disease - Gene - Disease"}, {"pathid": 41, "rel_score": 7.47999, "prob_score": -0.13369134, "relevant": "1", "stops": "MIR205HG - amyotrophic lateral sclerosis - Anoxia - breast cancer", "reltypes": "DOWNREGULATES_DdG - PRESENTS_DpS - PRESENTS_DpS", "nodelabels": "Gene - Disease - Symptom - Disease"}, {"pathid": 39, "rel_score": 7.34161, "prob_score": -0.13621247, "relevant": "1", "stops": "MIR205HG - amyotrophic lateral sclerosis - LEF1 - breast cancer", "reltypes": "DOWNREGULATES_DdG - UPREGULATES_DuG - UPREGULATES_DuG", "nodelabels": "Gene - Disease - Gene - Disease"}, {"pathid": 21, "rel_score": 7.17566, "prob_score": -0.13936423, "relevant": "1", "stops": "MIR205HG - amyotrophic lateral sclerosis - GSTP1 - breast cancer", "reltypes": "DOWNREGULATES_DdG - ASSOCIATES_DaG - ASSOCIATES_DaG", "nodelabels": "Gene - Disease - Gene - Disease"}]}
{"qid": "776", "sentence": "Treatment of <e2> HOSE </e2> or OCa cells with estrone or 17beta-estradiol at 10(-8) M for a period of 72 h induced significant loss of PR-A and <e1> PR-B mRNA </e1> and protein expression, with the regulation primarily controlled at the transcriptional level.", "e1": "PR-B mRNA", "e2": "HOSE", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 26, "rel_score": 6.94059, "prob_score": -0.14407742, "relevant": "1", "stops": "PRLH - central nervous system - EED - Cyclosporine - Gout attack", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 0, "rel_score": 6.67824, "prob_score": -0.14974321, "relevant": "1", "stops": "PRLH - nervous system - MCM6 - Cyclosporine - Gout attack", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 18, "rel_score": 6.39632, "prob_score": -0.15633965, "relevant": "1", "stops": "PRLH - endocrine gland - TK1 - Cyclosporine - Gout attack", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "rel_score": 6.11098, "prob_score": -0.16364004, "relevant": "1", "stops": "PRLH - medulla oblongata - MCM6 - Cyclosporine - Gout attack", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 27, "rel_score": 5.99448, "prob_score": -0.1668214, "relevant": "1", "stops": "PRLH - medulla oblongata - EED - Cyclosporine - Gout attack", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "777", "sentence": "Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial <e2> ovarian carcinoma </e2> : evidence of up-regulated Tn and <e1> Sialyl Tn antigen </e1> expression in effusions.", "e1": "Sialyl Tn antigen", "e2": "ovarian carcinoma", "llm_pred": "0", "ground_truth": "0", "metapaths": [{"pathid": 0, "rel_score": 2.88234, "prob_score": -0.34694368, "relevant": "1", "stops": "RALYL - BYSL - Clomifene - Ovarian carcinoma", "reltypes": "INTERACTS_GiG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "778", "sentence": "Activated Src increases adhesion, survival and <e1> alpha2-integrin </e1> expression in human <e2> breast cancer </e2> cells.", "e1": "alpha2-integrin", "e2": "breast cancer", "llm_pred": "1", "ground_truth": "0", "metapaths": [{"pathid": 3, "rel_score": -1.90161, "prob_score": -0.52586836, "relevant": "0", "stops": "ALDH3A2 - JMJD6 - Fulvestrant - Breast cancer stage IV", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 26, "rel_score": -1.93641, "prob_score": -0.51641893, "relevant": "0", "stops": "ALDH3A2 - breast cancer - Docetaxel - Breast cancer", "reltypes": "DOWNREGULATES_DdG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 41, "rel_score": -2.01548, "prob_score": -0.49615806, "relevant": "0", "stops": "ALDH3A2 - TRIB3 - Estradiol - Breast cancer invasive NOS", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 25, "rel_score": -2.51351, "prob_score": -0.39784858, "relevant": "0", "stops": "ALDH3A2 - breast cancer - Medroxyprogesterone Acetate - Breast cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 24, "rel_score": -2.84236, "prob_score": -0.3518165, "relevant": "0", "stops": "ALDH3A2 - rheumatoid arthritis - Gabapentin - Breast cancer", "reltypes": "DOWNREGULATES_DdG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "779", "sentence": "Knockdown of <e1> GC UNC-45 </e1> reduced the spreading ability of <e2> ovarian cancer </e2> cells whereas it was enhanced by GC UNC-45 overexpression.", "e1": "GC UNC-45", "e2": "ovarian cancer", "llm_pred": "1", "ground_truth": "1", "metapaths": [{"pathid": 48, "rel_score": 2.79197, "prob_score": -0.3581694, "relevant": "1", "stops": "GCLC - SNX6 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 23, "rel_score": 2.66099, "prob_score": -0.3758019, "relevant": "1", "stops": "GCLC - PCM1 - Estradiol valerate/Dienogest - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 20, "rel_score": 2.31675, "prob_score": -0.43163538, "relevant": "1", "stops": "GCLC - DLD - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 37, "rel_score": 2.19529, "prob_score": -0.45552316, "relevant": "1", "stops": "GCLC - LAGE3 - Estradiol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 38, "rel_score": 2.13033, "prob_score": -0.46941486, "relevant": "1", "stops": "GCLC - SERPINA3 - Estriol - Ovarian cancer", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
